Macrocyclic picolinamides as fungicides

Abstract
The invention relates to macrocyclic picolinamides of Formula I and their use as fungicides.
Description
BACKGROUND & SUMMARY

Fungicides are compounds, of natural or synthetic origin, which act to protect and/or cure plants against damage caused by agriculturally relevant fungi. Generally, no single fungicide is useful in all situations. Consequently, research is ongoing to produce fungicides that may have better performance, are easier to use, and cost less.


The present disclosure relates to macrocyclic picolinamides and their use as fungicides. The compounds of the present disclosure may offer protection against ascomycetes, basidiomycetes, deuteromycetes and oomycetes.


One embodiment of the present disclosure may include compounds of Formula I:




embedded image


R is H or C(O)R6;


R1 is H, C(O)R6, or Q;


Q is




embedded image


R2 is independently H, alkyl, alkenyl, aryl, heterocyclyl, each substituted with 0, 1 or multiple R5, or —C(O)R5;


R3 is independently H, alkyl, or alkenyl, each substituted with 0, 1 or multiple R5;


R4 is independently alkyl or alkoxy, substituted with 0, 1, or multiple R5;


R5 is alkyl, alkenyl, halo, haloalkyl, alkoxy, haloalkoxy, C(O)R8, arylalkoxy, or aryl;


R6 is alkoxy or benzyloxy;


R7 is H, —C(O)R4, or —CH2OC(O)R4; and


R8 is H, alkyl, alkenyl, halo, haloalkyl, alkoxy, haloalkoxy, arylalkoxy, or aryl.


Another embodiment of the present disclosure may include a fungicidal composition for the control or prevention of fungal attack comprising the compounds described above and a phytologically acceptable carrier material.


Yet another embodiment of the present disclosure may include a method for the control or prevention of fungal attack on a plant, the method including the steps of applying a fungicidally effective amount of one or more of the compounds described above to at least one of the fungus, the plant, and an area adjacent to the plant.


It will be understood by the those skilled in the art that the following terms may include generic “R”-groups within their definitions, e.g., “the term alkoxy refers to an —OR substituent”. It is also understood that within the definitions for the following terms, these “R” groups are included for illustration purposes and should not be construed as limiting or being limited by substitutions about Formula I.


The term “alkyl” refers to a branched, unbranched, or saturated cyclic carbon chain, including, but not limited to, methyl, ethyl, propyl, butyl, isopropyl, isobutyl, tertiary butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like.


The term “alkenyl” refers to a branched, unbranched or cyclic carbon chain containing one or more double bonds including, but not limited to, ethenyl, propenyl, butenyl, isopropenyl, isobutenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, and the like.


The term “alkynyl” refers to a branched or unbranched carbon chain containing one or more triple bonds including, but not limited to, propynyl, butynyl and the like.


The term “aryl” refers to any aromatic, mono- or bi-cyclic, containing 0 heteroatoms.


The term “heterocycle” refers to any aromatic or non-aromatic ring, mono- or bi-cyclic, containing one or more heteroatoms


The term “alkoxy” refers to an —OR substituent.


The term “cyano” refers to a —C≡N substituent.


The term “hydroxyl” refers to an —OH substituent.


The term “amino” refers to a —NH2 substituent.


The term “arylalkoxy” refers to —O(CH2)nAr where n is an integer selected from the list 1, 2, 3, 4, 5, or 6.


The term “haloalkoxy” refers to an —OR—X substituent, wherein X is Cl, F, Br, or I, or any combination thereof.


The term “haloalkyl” refers to an alkyl, which is substituted with Cl, F, I, or Br or any combination thereof.


The term “halogen” or “halo” refers to one or more halogen atoms, defined as F, Cl, Br, and I.


The term “nitro” refers to a —NO2 substituent.


Throughout the disclosure, reference to the compounds of Formula I is read as also including diastereomers, enantiomers, and mixtures thereof. In another embodiment, Formula (I) is read as also including salts or hydrates thereof. Exemplary salts include, but are not limited to: hydrochloride, hydrobromide, and hydroiodide.


It is also understood by those skilled in the art that additional substitution is allowable, unless otherwise noted, as long as the rules of chemical bonding and strain energy are satisfied and the product still exhibits fungicidal activity.


Another embodiment of the present disclosure is a use of a compound of Formula I, for protection of a plant against attack by a phytopathogenic organism or the treatment of a plant infested by a phytopathogenic organism, comprising the application of a compound of Formula I, or a composition comprising the compound to soil, a plant, a part of a plant, foliage, and/or roots.


Additionally, another embodiment of the present disclosure is a composition useful for protecting a plant against attack by a phytopathogenic organism and/or treatment of a plant infested by a phytopathogenic organism comprising a compound of Formula I and a phytologically acceptable carrier material.







DETAILED DESCRIPTION

The compounds of the present disclosure may be applied by any of a variety of known techniques, either as the compounds or as formulations comprising the compounds. For example, the compounds may be applied to the roots or foliage of plants for the control of various fungi, without damaging the commercial value of the plants. The materials may be applied in the form of any of the generally used formulation types, for example, as solutions, dusts, wettable powders, flowable concentrate, or emulsifiable concentrates.


Preferably, the compounds of the present disclosure are applied in the form of a formulation, comprising one or more of the compounds of Formula I with a phytologically acceptable carrier. Concentrated formulations may be dispersed in water, or other liquids, for application, or formulations may be dust-like or granular, which may then be applied without further treatment. The formulations can be prepared according to procedures that are conventional in the agricultural chemical art.


The present disclosure contemplates all vehicles by which one or more of the compounds may be formulated for delivery and use as a fungicide. Typically, formulations are applied as aqueous suspensions or emulsions. Such suspensions or emulsions may be produced from water-soluble, water-suspendible, or emulsifiable formulations which are solids, usually known as wettable powders; or liquids, usually known as emulsifiable concentrates, aqueous suspensions, or suspension concentrates. As will be readily appreciated, any material to which these compounds may be added may be used, provided it yields the desired utility without significant interference with the activity of these compounds as antifungal agents.


Wettable powders, which may be compacted to form water-dispersible granules, comprise an intimate mixture of one or more of the compounds of Formula I, an inert carrier and surfactants. The concentration of the compound in the wettable powder may be from about 10 percent to about 90 percent by weight based on the total weight of the wettable powder, more preferably about 25 weight percent to about 75 weight percent. In the preparation of wettable powder formulations, the compounds may be compounded with any finely divided solid, such as prophyllite, talc, chalk, gypsum, Fuller's earth, bentonite, attapulgite, starch, casein, gluten, montmorillonite clays, diatomaceous earths, purified silicates or the like. In such operations, the finely divided carrier and surfactants are typically blended with the compound(s) and milled.


Emulsifiable concentrates of the compounds of Formula I may comprise a convenient concentration, such as from about 1 weight percent to about 50 weight percent of the compound, in a suitable liquid, based on the total weight of the concentrate. The compounds may be dissolved in an inert carrier, which is either a water-miscible solvent or a mixture of water-immiscible organic solvents, and emulsifiers. The concentrates may be diluted with water and oil to form spray mixtures in the form of oil-in-water emulsions. Useful organic solvents include aromatics, especially the high-boiling naphthalenic and olefinic portions of petroleum such as heavy aromatic naphtha. Other organic solvents may also be used, for example, terpenic solvents, including rosin derivatives, aliphatic ketones, such as cyclohexanone, and complex alcohols, such as 2-ethoxyethanol.


Emulsifiers which may be advantageously employed herein may be readily determined by those skilled in the art and include various nonionic, anionic, cationic and amphoteric emulsifiers, or a blend of two or more emulsifiers. Examples of nonionic emulsifiers useful in preparing the emulsifiable concentrates include the polyalkylene glycol ethers and condensation products of alkyl and aryl phenols, aliphatic alcohols, aliphatic amines or fatty acids with ethylene oxide, propylene oxides such as the ethoxylated alkyl phenols and carboxylic esters solubilized with the polyol or polyoxyalkylene. Cationic emulsifiers include quaternary ammonium compounds and fatty amine salts. Anionic emulsifiers include the oil-soluble salts (e.g., calcium) of alkylaryl sulphonic acids, oil-soluble salts or sulfated polyglycol ethers and appropriate salts of phosphated polyglycol ether.


Representative organic liquids which may be employed in preparing the emulsifiable concentrates of the compounds of the present disclosure are the aromatic liquids such as xylene, propyl benzene fractions; or mixed naphthalene fractions, mineral oils, substituted aromatic organic liquids such as dioctyl phthalate; kerosene; dialkyl amides of various fatty acids, particularly the dimethyl amides of fatty glycols and glycol derivatives such as the n-butyl ether, ethyl ether or methyl ether of diethylene glycol, the methyl ether of triethylene glycol, petroleum fractions or hydrocarbons such as mineral oil, aromatic solvents, paraffinic oils, and the like; vegetable oils such as soy bean oil, rape seed oil, olive oil, castor oil, sunflower seed oil, coconut oil, corn oil, cotton seed oil, linseed oil, palm oil, peanut oil, safflower oil, sesame oil, tung oil and the like; esters of the above vegetable oils; and the like. Mixtures of two or more organic liquids may also be employed in the preparation of the emulsifiable concentrate. Organic liquids include xylene, and propyl benzene fractions, with xylene being most preferred in some cases. Surface-active dispersing agents are typically employed in liquid formulations and in an amount of from 0.1 to 20 percent by weight based on the combined weight of the dispersing agent with one or more of the compounds. The formulations can also contain other compatible additives, for example, plant growth regulators and other biologically active compounds used in agriculture.


Aqueous suspensions comprise suspensions of one or more water-insoluble compounds of Formula I, dispersed in an aqueous vehicle at a concentration in the range from about 1 to about 50 weight percent, based on the total weight of the aqueous suspension. Suspensions are prepared by finely grinding one or more of the compounds, and vigorously mixing the ground material into a vehicle comprised of water and surfactants chosen from the same types discussed above. Other components, such as inorganic salts and synthetic or natural gums, may also be added to increase the density and viscosity of the aqueous vehicle.


The compounds of Formula I can also be applied as granular formulations, which are particularly useful for applications to the soil. Granular formulations generally contain from about 0.5 to about 10 weight percent, based on the total weight of the granular formulation of the compound(s), dispersed in an inert carrier which consists entirely or in large part of coarsely divided inert material such as attapulgite, bentonite, diatomite, clay or a similar inexpensive substance. Such formulations are usually prepared by dissolving the compounds in a suitable solvent and applying it to a granular carrier which has been preformed to the appropriate particle size, in the range of from about 0.5 to about 3 mm. A suitable solvent is a solvent in which the compound is substantially or completely soluble. Such formulations may also be prepared by making a dough or paste of the carrier and the compound and solvent, and crushing and drying to obtain the desired granular particle.


Dusts containing the compounds of Formula I may be prepared by intimately mixing one or more of the compounds in powdered form with a suitable dusty agricultural carrier, such as, for example, kaolin clay, ground volcanic rock, and the like. Dusts can suitably contain from about 1 to about 10 weight percent of the compounds, based on the total weight of the dust.


The formulations may additionally contain adjuvant surfactants to enhance deposition, wetting and penetration of the compounds onto the target crop and organism. These adjuvant surfactants may optionally be employed as a component of the formulation or as a tank mix. The amount of adjuvant surfactant will typically vary from 0.01 to 1.0 percent by volume, based on a spray-volume of water, preferably 0.05 to 0.5 volume percent. Suitable adjuvant surfactants include, but are not limited to ethoxylated nonyl phenols, ethoxylated synthetic or natural alcohols, salts of the esters or sulphosuccinic acids, ethoxylated organosilicones, ethoxylated fatty amines, blends of surfactants with mineral or vegetable oils, crop oil concentrate (mineral oil (85%)+emulsifiers (15%)); nonylphenol ethoxylate; benzylcocoalkyldimethyl quaternary ammonium salt; blend of petroleum hydrocarbon, alkyl esters, organic acid, and anionic surfactant; C9-C11 alkylpolyglycoside; phosphated alcohol ethoxylate; natural primary alcohol (C12-C16) ethoxylate; di-sec-butylphenol EO-PO block copolymer; polysiloxane-methyl cap; nonylphenol ethoxylate+urea ammonium nitrate; emulsified methylated seed oil; tridecyl alcohol (synthetic) ethoxylate (8EO); tallow amine ethoxylate (15 EO); PEG(400) dioleate-99. The formulations may also include oil-in-water emulsions such as those disclosed in U.S. patent application Ser. No. 11/495,228, the disclosure of which is expressly incorporated by reference herein.


The formulations may optionally include combinations that contain other pesticidal compounds. Such additional pesticidal compounds may be fungicides, insecticides, herbicides, nematocides, miticides, arthropodicides, bactericides or combinations thereof that are compatible with the compounds of the present disclosure in the medium selected for application, and not antagonistic to the activity of the present compounds. Accordingly, in such embodiments, the other pesticidal compound is employed as a supplemental toxicant for the same or for a different pesticidal use. The compounds of Formula I and the pesticidal compound in the combination can generally be present in a weight ratio of from 1:100 to 100:1.


The compounds of the present disclosure may also be combined with other fungicides to form fungicidal mixtures and synergistic mixtures thereof. The fungicidal compounds of the present disclosure are often applied in conjunction with one or more other fungicides to control a wider variety of undesirable diseases. When used in conjunction with other fungicide(s), the presently claimed compounds may be formulated with the other fungicide(s), tank-mixed with the other fungicide(s) or applied sequentially with the other fungicide(s). Such other fungicides may include 2-(thiocyanatomethylthio)-benzothiazole, 2-phenylphenol, 8-hydroxyquinoline sulfate, ametoctradin, amisulbrom, antimycin, Ampelomyces quisqualis, azaconazole, azoxystrobin, Bacillus subtilis, Bacillus subtilis strain QST713, benalaxyl, benomyl, benthiavalicarb-isopropyl, benzylaminobenzene-sulfonate (BABS) salt, bicarbonates, biphenyl, bismerthiazol, bitertanol, bixafen, blasticidin-S, borax, Bordeaux mixture, boscalid, bromuconazole, bupirimate, calcium polysulfide, captafol, captan, carbendazim, carboxin, carpropamid, carvone, chlazafenone, chloroneb, chlorothalonil, chlozolinate, Coniothyrium minitans, copper hydroxide, copper octanoate, copper oxychloride, copper sulfate, copper sulfate (tribasic), cuprous oxide, cyazofamid, cyflufenamid, cymoxanil, cyproconazole, cyprodinil, dazomet, debacarb, diammonium ethylenebis-(dithiocarbamate), dichlofluanid, dichlorophen, diclocymet, diclomezine, dichloran, diethofencarb, difenoconazole, difenzoquat ion, diflumetorim, dimethomorph, dimoxystrobin, diniconazole, diniconazole-M, dinobuton, dinocap, diphenylamine, dithianon, dodemorph, dodemorph acetate, dodine, dodine free base, edifenphos, enestrobin, enestroburin, epoxiconazole, ethaboxam, ethoxyquin, etridiazole, famoxadone, fenamidone, fenarimol, fenbuconazole, fenfuram, fenhexamid, fenoxanil, fenpiclonil, fenpropidin, fenpropimorph, fenpyrazamine, fentin, fentin acetate, fentin hydroxide, ferbam, ferimzone, fluazinam, fludioxonil, flumorph, fluopicolide, fluopyram, fluoroimide, fluoxastrobin, fluquinconazole, flusilazole, flusulfamide, flutianil, flutolanil, flutriafol, fluxapyroxad, folpet, formaldehyde, fosetyl, fosetyl-aluminium, fuberidazole, furalaxyl, furametpyr, guazatine, guazatine acetates, GY-81, hexachlorobenzene, hexaconazole, hymexazol, imazalil, imazalil sulfate, imibenconazole, iminoctadine, iminoctadine triacetate, iminoctadine tris(albesilate), iodocarb, ipconazole, ipfenpyrazolone, iprobenfos, iprodione, iprovalicarb, isoprothiolane, isopyrazam, isotianil, kasugamycin, kasugamycin hydrochloride hydrate, kresoxim-methyl, laminarin, mancopper, mancozeb, mandipropamid, maneb, mefenoxam, mepanipyrim, mepronil, meptyl-dinocap, mercuric chloride, mercuric oxide, mercurous chloride, metalaxyl, metalaxyl-M, metam, metam-ammonium, metam-potassium, metam-sodium, metconazole, methasulfocarb, methyl iodide, methyl isothiocyanate, metiram, metominostrobin, metrafenone, mildiomycin, myclobutanil, nabam, nitrothal-isopropyl, nuarimol, octhilinone, ofurace, oleic acid (fatty acids), orysastrobin, oxadixyl, oxine-copper, oxpoconazole fumarate, oxycarboxin, pefurazoate, penconazole, pencycuron, penflufen, pentachlorophenol, pentachlorophenyl laurate, penthiopyrad, phenylmercury acetate, phosphonic acid, phthalide, picoxystrobin, polyoxin B, polyoxins, polyoxorim, potassium bicarbonate, potassium hydroxyquinoline sulfate, probenazole, prochloraz, procymidone, propamocarb, propamocarb hydrochloride, propiconazole, propineb, proquinazid, prothioconazole, pyraclostrobin, pyrametostrobin, pyraoxystrobin, pyrazophos, pyribencarb, pyributicarb, pyrifenox, pyrimethanil, pyriofenone, pyroquilon, quinoclamine, quinoxyfen, quintozene, Reynoutria sachalinensis extract, sedaxane, silthiofam, simeconazole, sodium 2-phenylphenoxide, sodium bicarbonate, sodium pentachlorophenoxide, spiroxamine, sulfur, SYP-Z048, tar oils, tebuconazole, tebufloquin, tecnazene, tetraconazole, thiabendazole, thifluzamide, thiophanate-methyl, thiram, tiadinil, tolclofos-methyl, tolylfluanid, triadimefon, triadimenol, triazoxide, tricyclazole, tridemorph, trifloxystrobin, triflumizole, triforine, triticonazole, validamycin, valifenalate, valiphenal, vinclozolin, zineb, ziram, zoxamide, Candida oleophila, Fusarium oxysporum, Gliocladium spp., Phlebiopsis gigantea, Streptomyces griseoviridis, Trichoderma spp., (RS)—N-(3,5-dichlorophenyl)-2-(methoxymethyl)-succinimide, 1,2-dichloropropane, 1,3-dichloro-1,1,3,3-tetrafluoroacetone hydrate, 1-chloro-2,4-dinitronaphthalene, 1-chloro-2-nitropropane, 2-(2-heptadecyl-2-imidazolin-1-yl)ethanol, 2,3-dihydro-5-phenyl-1,4-dithiine 1,1,4,4-tetraoxide, 2-methoxyethylmercury acetate, 2-methoxyethylmercury chloride, 2-methoxyethylmercury silicate, 3-(4-chlorophenyl)-5-methylrhodanine, 4-(2-nitroprop-1-enyl)phenyl thiocyanateme, ampropylfos, anilazine, azithiram, barium polysulfide, Bayer 32394, benodanil, benquinox, bentaluron, benzamacril; benzamacril-isobutyl, benzamorf, binapacryl, bis(methylmercury) sulfate, bis(tributyltin) oxide, buthiobate, cadmium calcium copper zinc chromate sulfate, carbamorph, CECA, chlobenthiazone, chloraniformethan, chlorfenazole, chlorquinox, climbazole, copper bis(3-phenylsalicylate), copper zinc chromate, cufraneb, cupric hydrazinium sulfate, cuprobam, cyclafuramid, cypendazole, cyprofuram, decafentin, dichlone, dichlozoline, diclobutrazol, dimethirimol, dinocton, dinosulfon, dinoterbon, dipyrithione, ditalimfos, dodicin, drazoxolon, EBP, ESBP, etaconazole, etem, ethirim, fenaminosulf, fenapanil, fenitropan, fluotrimazole, furcarbanil, furconazole, furconazole-cis, furmecyclox, furophanate, glyodine, griseofulvin, halacrinate, Hercules 3944, hexylthiofos, ICIA0858, isopamphos, isovaledione, mebenil, mecarbinzid, metazoxolon, methfuroxam, methylmercury dicyandiamide, metsulfovax, milneb, mucochloric anhydride, myclozolin, N-3,5-dichlorophenyl-succinimide, N-3-nitrophenylitaconimide, natamycin, N-ethylmercurio-4-toluenesulfonanilide, nickel bis(dimethyldithiocarbamate), OCH, phenylmercury dimethyldithiocarbamate, phenylmercury nitrate, phosdiphen, prothiocarb; prothiocarb hydrochloride, pyracarbolid, pyridinitril, pyroxychlor, pyroxyfur, quinacetol; quinacetol sulfate, quinazamid, quinconazole, rabenzazole, salicylanilide, SSF-109, sultropen, tecoram, thiadifluor, thicyofen, thiochlorfenphim, thiophanate, thioquinox, tioxymid, triamiphos, triarimol, triazbutil, trichlamide, urbacid, zarilamid, and any combinations thereof.


Additionally, the compounds described herein may be combined with other pesticides, including insecticides, nematocides, miticides, arthropodicides, bactericides or combinations thereof that are compatible with the compounds of the present disclosure in the medium selected for application, and not antagonistic to the activity of the present compounds to form pesticidal mixtures and synergistic mixtures thereof. The fungicidal compounds of the present disclosure may be applied in conjunction with one or more other pesticides to control a wider variety of undesirable pests. When used in conjunction with other pesticides, the presently claimed compounds may be formulated with the other pesticide(s), tank-mixed with the other pesticide(s) or applied sequentially with the other pesticide(s). Typical insecticides include, but are not limited to: 1,2-dichloropropane, abamectin, acephate, acetamiprid, acethion, acetoprole, acrinathrin, acrylonitrile, alanycarb, aldicarb, aldoxycarb, aldrin, allethrin, allosamidin, allyxycarb, alpha-cypermethrin, alpha-ecdysone, alpha-endosulfan, amidithion, aminocarb, amiton, amiton oxalate, amitraz, anabasine, athidathion, azadirachtin, azamethiphos, azinphos-ethyl, azinphos-methyl, azothoate, barium hexafluorosilicate, barthrin, bendiocarb, benfuracarb, bensultap, beta-cyfluthrin, beta-cypermethrin, bifenthrin, bioallethrin, bioethanomethrin, biopermethrin, bistrifluoron, borax, boric acid, bromfenvinfos, bromocyclen, bromo-DDT, bromophos, bromophos-ethyl, bufencarb, buprofezin, butacarb, butathiofos, butocarboxim, butonate, butoxycarboxim, cadusafos, calcium arsenate, calcium polysulfide, camphechlor, carbanolate, carbaryl, carbofuran, carbon disulfide, carbon tetrachloride, carbophenothion, carbosulfan, cartap, cartap hydrochloride, chlorantraniliprole, chlorbicyclen, chlordane, chlordecone, chlordimeform, chlordimeform hydrochloride, chlorethoxyfos, chlorfenapyr, chlorfenvinphos, chlorfluazuron, chlormephos, chloroform, chloropicrin, chlorphoxim, chlorprazophos, chlorpyrifos, chlorpyrifos-methyl, chlorthiophos, chromafenozide, cinerin I, cinerin II, cinerins, cismethrin, cloethocarb, closantel, clothianidin, copper acetoarsenite, copper arsenate, copper naphthenate, copper oleate, coumaphos, coumithoate, crotamiton, crotoxyphos, crufomate, cryolite, cyanofenphos, cyanophos, cyanthoate, cyantraniliprole, cyclethrin, cycloprothrin, cyfluthrin, cyhalothrin, cypermethrin, cyphenothrin, cyromazine, cythioate, DDT, decarbofuran, deltamethrin, demephion, demephion-O, demephion-S, demeton, demeton-methyl, demeton-O, demeton-O-methyl, demeton-S, demeton-S-methyl, demeton-S-methylsulphon, diafenthiuron, dialifos, diatomaceous earth, diazinon, dicapthon, dichlofenthion, dichlorvos, dicresyl, dicrotophos, dicyclanil, dieldrin, diflubenzuron, dilor, dimefluthrin, dimefox, dimetan, dimethoate, dimethrin, dimethylvinphos, dimetilan, dinex, dinex-diclexine, dinoprop, dinosam, dinotefuran, diofenolan, dioxabenzofos, dioxacarb, dioxathion, disulfoton, dithicrofos, d-limonene, DNOC, DNOC-ammonium, DNOC-potassium, DNOC-sodium, doramectin, ecdysterone, emamectin, emamectin benzoate, EMPC, empenthrin, endosulfan, endothion, endrin, EPN, epofenonane, eprinomectin, esdepalléthrine, esfenvalerate, etaphos, ethiofencarb, ethion, ethiprole, ethoate-methyl, ethoprophos, ethyl formate, ethyl-DDD, ethylene dibromide, ethylene dichloride, ethylene oxide, etofenprox, etrimfos, EXD, famphur, fenamiphos, fenazaflor, fenchlorphos, fenethacarb, fenfluthrin, fenitrothion, fenobucarb, fenoxacrim, fenoxycarb, fenpirithrin, fenpropathrin, fensulfothion, fenthion, fenthion-ethyl, fenvalerate, fipronil, flonicamid, flubendiamide, flucofuron, flucycloxuron, flucythrinate, flufenerim, flufenoxuron, flufenprox, fluvalinate, fonofos, formetanate, formetanate hydrochloride, formothion, formparanate, formparanate hydrochloride, fosmethilan, fospirate, fosthietan, furathiocarb, furethrin, gamma-cyhalothrin, gamma-HCH, halfenprox, halofenozide, HCH, HEOD, heptachlor, heptenophos, heterophos, hexaflumuron, HHDN, hydramethylnon, hydrogen cyanide, hydroprene, hyquincarb, imidacloprid, imiprothrin, indoxacarb, iodomethane, IPSP, isazofos, isobenzan, isocarbophos, isodrin, isofenphos, isofenphos-methyl, isoprocarb, isoprothiolane, isothioate, isoxathion, ivermectin, jasmolin I, jasmolin II, jodfenphos, juvenile hormone I, juvenile hormone II, juvenile hormone III, kelevan, kinoprene, lambda-cyhalothrin, lead arsenate, lepimectin, leptophos, lindane, lirimfos, lufenuron, lythidathion, malathion, malonoben, mazidox, mecarbam, mecarphon, menazon, mephosfolan, mercurous chloride, mesulfenfos, metaflumizone, methacrifos, methamidophos, methidathion, methiocarb, methocrotophos, methomyl, methoprene, methoxychlor, methoxyfenozide, methyl bromide, methyl isothiocyanate, methylchloroform, methylene chloride, metofluthrin, metolcarb, metoxadiazone, mevinphos, mexacarbate, milbemectin, milbemycin oxime, mipafox, mirex, molosultap, monocrotophos, monomehypo, monosultap, morphothion, moxidectin, naftalofos, naled, naphthalene, nicotine, nifluridide, nitenpyram, nithiazine, nitrilacarb, novaluron, noviflumuron, omethoate, oxamyl, oxydemeton-methyl, oxydeprofos, oxydisulfoton, para-dichlorobenzene, parathion, parathion-methyl, penfluoron, pentachlorophenol, permethrin, phenkapton, phenothrin, phenthoate, phorate, phosalone, phosfolan, phosmet, phosnichlor, phosphamidon, phosphine, phoxim, phoxim-methyl, pirimetaphos, pirimicarb, pirimiphos-ethyl, pirimiphos-methyl, potassium arsenite, potassium thiocyanate, pp′-DDT, prallethrin, precocene I, precocene II, precocene III, primidophos, profenofos, profluralin, promacyl, promecarb, propaphos, propetamphos, propoxur, prothidathion, prothiofos, prothoate, protrifenbute, pyraclofos, pyrafluprole, pyrazophos, pyresmethrin, pyrethrin I, pyrethrin II, pyrethrins, pyridaben, pyridalyl, pyridaphenthion, pyrifluquinazon, pyrimidifen, pyrimitate, pyriprole, pyriproxyfen, quassia, quinalphos, quinalphos-methyl, quinothion, rafoxanide, resmethrin, rotenone, ryania, sabadilla, schradan, selamectin, silafluofen, silica gel, sodium arsenite, sodium fluoride, sodium hexafluorosilicate, sodium thiocyanate, sophamide, spinetoram, spinosad, spiromesifen, spirotetramat, sulcofuron, sulcofuron-sodium, sulfluramid, sulfotep, sulfoxaflor, sulfuryl fluoride, sulprofos, tau-fluvalinate, tazimcarb, TDE, tebufenozide, tebufenpyrad, tebupirimfos, teflubenzuron, tefluthrin, temephos, TEPP, terallethrin, terbufos, tetrachloroethane, tetrachlorvinphos, tetramethrin, tetramethylfluthrin, theta-cypermethrin, thiacloprid, thiamethoxam, thicrofos, thiocarboxime, thiocyclam, thiocyclam oxalate, thiodicarb, thiofanox, thiometon, thiosultap, thiosultap-disodium, thiosultap-monosodium, thuringiensin, tolfenpyrad, tralomethrin, transfluthrin, transpermethrin, triarathene, triazamate, triazophos, trichlorfon, trichlormetaphos-3, trichloronat, trifenofos, triflumuron, trimethacarb, triprene, vamidothion, vaniliprole, XMC, xylylcarb, zeta-cypermethrin, zolaprofos, and any combinations thereof.


Additionally, the compounds described herein may be combined with herbicides that are compatible with the compounds of the present disclosure in the medium selected for application, and not antagonistic to the activity of the present compounds to form pesticidal mixtures and synergistic mixtures thereof. The fungicidal compounds of the present disclosure may be applied in conjunction with one or more herbicides to control a wide variety of undesirable plants. When used in conjunction with herbicides, the presently claimed compounds may be formulated with the herbicide(s), tank-mixed with the herbicide(s) or applied sequentially with the herbicide(s). Typical herbicides include, but are not limited to: 4-CPA; 4-CPB; 4-CPP; 2,4-D; 3,4-DA; 2,4-DB; 3,4-DB; 2,4-DEB; 2,4-DEP; 3,4-DP; 2,3,6-TBA; 2,4,5-T; 2,4,5-TB; acetochlor, acifluorfen, aclonifen, acrolein, alachlor, allidochlor, alloxydim, allyl alcohol, alorac, ametridione, ametryn, amibuzin, amicarbazone, amidosulfuron, aminocyclopyrachlor, aminopyralid, amiprofos-methyl, amitrole, ammonium sulfamate, anilofos, anisuron, asulam, atraton, atrazine, azafenidin, azimsulfuron, aziprotryne, barban, BCPC, beflubutamid, benazolin, bencarbazone, benfluralin, benfuresate, bensulfuron, bensulide, bentazone, benzadox, benzfendizone, benzipram, benzobicyclon, benzofenap, benzofluor, benzoylprop, benzthiazuron, bicyclopyrone, bifenox, bilanafos, bispyribac, borax, bromacil, bromobonil, bromobutide, bromofenoxim, bromoxynil, brompyrazon, butachlor, butafenacil, butamifos, butenachlor, buthidazole, buthiuron, butralin, butroxydim, buturon, butylate, cacodylic acid, cafenstrole, calcium chlorate, calcium cyanamide, cambendichlor, carbasulam, carbetamide, carboxazole chlorprocarb, carfentrazone, CDEA, CEPC, chlomethoxyfen, chloramben, chloranocryl, chlorazifop, chlorazine, chlorbromuron, chlorbufam, chloreturon, chlorfenac, chlorfenprop, chlorflurazole, chlorflurenol, chloridazon, chlorimuron, chlomitrofen, chloropon, chlorotoluron, chloroxuron, chloroxynil, chlorpropham, chlorsulfuron, chlorthal, chlorthiamid, cinidon-ethyl, cinmethylin, cinosulfuron, cisanilide, clethodim, cliodinate, clodinafop, clofop, clomazone, clomeprop, cloprop, cloproxydim, clopyralid, cloransulam, CMA, copper sulfate, CPMF, CPPC, credazine, cresol, cumyluron, cyanatryn, cyanazine, cycloate, cyclosulfamuron, cycloxydim, cycluron, cyhalofop, cyperquat, cyprazine, cyprazole, cypromid, daimuron, dalapon, dazomet, delachlor, desmedipham, desmetryn, di-allate, dicamba, dichlobenil, dichloralurea, dichlormate, dichlorprop, dichlorprop-P, diclofop, diclosulam, diethamquat, diethatyl, difenopenten, difenoxuron, difenzoquat, diflufenican, diflufenzopyr, dimefuron, dimepiperate, dimethachlor, dimethametryn, dimethenamid, dimethenamid-P, dimexano, dimidazon, dinitramine, dinofenate, dinoprop, dinosam, dinoseb, dinoterb, diphenamid, dipropetryn, diquat, disul, dithiopyr, diuron, DMPA, DNOC, DSMA, EBEP, eglinazine, endothal, epronaz, EPTC, erbon, esprocarb, ethalfluralin, ethametsulfuron, ethidimuron, ethiolate, ethofumesate, ethoxyfen, ethoxysulfuron, etinofen, etnipromid, etobenzanid, EXD, fenasulam, fenoprop, fenoxaprop, fenoxaprop-P, fenoxasulfone, fenteracol, fenthiaprop, fentrazamide, fenuron, ferrous sulfate, flamprop, flamprop-M, flazasulfuron, florasulam, fluazifop, fluazifop-P, fluazolate, flucarbazone, flucetosulfuron, fluchloralin, flufenacet, flufenican, flufenpyr, flumetsulam, flumezin, flumiclorac, flumioxazin, flumipropyn, fluometuron, fluorodifen, fluoroglycofen, fluoromidine, fluoronitrofen, fluothiuron, flupoxam, flupropacil, flupropanate, flupyrsulfuron, fluridone, fluorochloridone, fluoroxypyr, flurtamone, fluthiacet, fomesafen, foramsulfuron, fosamine, furyloxyfen, glufosinate, glufosinate-P, glyphosate, halosafen, halosulfuron, haloxydine, haloxyfop, haloxyfop-P, hexachloroacetone, hexaflurate, hexazinone, imazamethabenz, imazamox, imazapic, imazapyr, imazaquin, imazethapyr, imazosulfuron, indanofan, indaziflam, iodobonil, iodomethane, iodosulfuron, ioxynil, ipazine, ipfencarbazone, iprymidam, isocarbamid, isocil, isomethiozin, isonoruron, isopolinate, isopropalin, isoproturon, isouron, isoxaben, isoxachlortole, isoxaflutole, isoxapyrifop, karbutilate, ketospiradox, lactofen, lenacil, linuron, MAA, MAMA, MCPA, MCPA-thioethyl, MCPB, mecoprop, mecoprop-P, medinoterb, mefenacet, mefluidide, mesoprazine, mesosulfuron, mesotrione, metam, metamifop, metamitron, metazachlor, metazosulfuron, metflurazon, methabenzthiazuron, methalpropalin, methazole, methiobencarb, methiozolin, methiuron, methometon, methoprotryne, methyl bromide, methyl isothiocyanate, methyldymron, metobenzuron, metobromuron, metolachlor, metosulam, metoxuron, metribuzin, metsulfuron, molinate, monalide, monisouron, monochloroacetic acid, monolinuron, monuron, morfamquat, MSMA, naproanilide, napropamide, naptalam, neburon, nicosulfuron, nipyraclofen, nitralin, nitrofen, nitrofluorfen, norflurazon, noruron, OCH, orbencarb, ortho-dichlorobenzene, orthosulfamuron, oryzalin, oxadiargyl, oxadiazon, oxapyrazon, oxasulfuron, oxaziclomefone, oxyfluorfen, parafluoron, paraquat, pebulate, pelargonic acid, pendimethalin, penoxsulam, pentachlorophenol, pentanochlor, pentoxazone, perfluidone, pethoxamid, phenisopham, phenmedipham, phenmedipham-ethyl, phenobenzuron, phenylmercury acetate, picloram, picolinafen, pinoxaden, piperophos, potassium arsenite, potassium azide, potassium cyanate, pretilachlor, primisulfuron, procyazine, prodiamine, profluazol, profluralin, profoxydim, proglinazine, prometon, prometryn, propachlor, propanil, propaquizafop, propazine, propham, propisochlor, propoxycarbazone, propyrisulfuron, propyzamide, prosulfalin, prosulfocarb, prosulfuron, proxan, prynachlor, pydanon, pyraclonil, pyraflufen, pyrasulfotole, pyrazolynate, pyrazosulfuron, pyrazoxyfen, pyribenzoxim, pyributicarb, pyriclor, pyridafol, pyridate, pyriftalid, pyriminobac, pyrimisulfan, pyrithiobac, pyroxasulfone, pyroxsulam, quinclorac, quinmerac, quinoclamine, quinonamid, quizalofop, quizalofop-P, rhodethanil, rimsulfuron, saflufenacil, S-metolachlor, sebuthylazine, secbumeton, sethoxydim, siduron, simazine, simeton, simetryn, SMA, sodium arsenite, sodium azide, sodium chlorate, sulcotrione, sulfallate, sulfentrazone, sulfometuron, sulfosulfuron, sulfuric acid, sulglycapin, swep, TCA, tebutam, tebuthiuron, tefuryltrione, tembotrione, tepraloxydim, terbacil, terbucarb, terbuchlor, terbumeton, terbuthylazine, terbutryn, tetrafluoron, thenylchlor, thiazafluoron, thiazopyr, thidiazimin, thidiazuron, thiencarbazone-methyl, thifensulfuron, thiobencarb, tiocarbazil, tioclorim, topramezone, tralkoxydim, triafamone, tri-allate, triasulfuron, triaziflam, tribenuron, tricamba, triclopyr, tridiphane, trietazine, trifloxysulfuron, trifluralin, triflusulfuron, trifop, trifopsime, trihydroxytriazine, trimeturon, tripropindan, tritac, tritosulfuron, vemolate, and xylachlor.


Another embodiment of the present disclosure is a method for the control or prevention of fungal attack. This method comprises applying to the soil, plant, roots, foliage, or locus of the fungus, or to a locus in which the infestation is to be prevented (for example applying to cereal or grape plants), a fungicidally effective amount of one or more of the compounds of Formula I. The compounds are suitable for treatment of various plants at fungicidal levels, while exhibiting low phytotoxicity. The compounds may be useful both in a protectant and/or an eradicant fashion.


The compounds have been found to have significant fungicidal effect particularly for agricultural use. Many of the compounds are particularly effective for use with agricultural crops and horticultural plants.


It will be understood by those in the art that the efficacy of the compound for the foregoing fungi establishes the general utility of the compounds as fungicides.


The compounds have broad ranges of activity against fungal pathogens. Exemplary pathogens may include, but are not limited to, causing agent of wheat leaf blotch (Mycosphaerella graminicola; impect stage: Septoria tritici), wheat brown rust (Puccinia triticina), wheat stripe rust (Puccinia striiformis), scab of apple (Venturia inaequalis), powdery mildew of grapevine (Uncinula necator), barley scald (Rhynchosporium secalis), blast of rice (Magnaporthe grisea), rust of soybean (Phakopsora pachyrhizi), glume blotch of wheat (Leptosphaeria nodorum), powdery mildew of wheat (Blumeria graminis f. sp. tritici), powdery mildew of barley (Blumeria graminis f. sp. hordei), powdery mildew of cucurbits (Erysiphe cichoracearum), anthracnose of cucurbits (Glomerella lagenarium), leaf spot of beet (Cercospora beticola), early blight of tomato (Alternaria solani), and spot blotch of barley (Cochliobolus sativus). The exact amount of the active material to be applied is dependent not only on the specific active material being applied, but also on the particular action desired, the fungal species to be controlled, and the stage of growth thereof, as well as the part of the plant or other product to be contacted with the compound. Thus, all the compounds, and formulations containing the same, may not be equally effective at similar concentrations or against the same fungal species.


The compounds are effective in use with plants in a disease-inhibiting and phytologically acceptable amount. The term “disease-inhibiting and phytologically acceptable amount” refers to an amount of a compound that kills or inhibits the plant disease for which control is desired, but is not significantly toxic to the plant. This amount will generally be from about 0.1 to about 1000 ppm (parts per million), with 1 to 500 ppm being preferred. The exact concentration of compound required varies with the fungal disease to be controlled, the type of formulation employed, the method of application, the particular plant species, climate conditions, and the like. A suitable application rate is typically in the range from about 0.10 to about 4 pounds/acre (about 0.01 to 0.45 grams per square meter, g/m2).


Any range or desired value given herein may be extended or altered without losing the effects sought, as is apparent to the skilled person for an understanding of the teachings herein.


The compounds of Formula I may be made using well-known chemical procedures. Intermediates not specifically mentioned in this disclosure are either commercially available, may be made by routes disclosed in the chemical literature, or may be readily synthesized from commercial starting materials utilizing standard procedures.


General Schemes


The following schemes illustrate approaches to generating picolinamide compounds of Formula (I). It may be understood by those skilled in the art that each R2 may be differentially substituted. The following descriptions and examples are provided for illustrative purposes and should not be construed as limiting in terms of substituents or substitution patterns.


In Scheme I, a mixture of compounds of Formula III, IV and V can be formed from compound of Formula II using an alkyl halide such as benzyl bromide (BnBr) and a quaternary amine salt such as tetrabutylammonium iodide ((Bu)4N+I) and a base such as sodium hydroxide (NaOH) in an aprotic solvent such as dichloromethane (DCM, CH2Cl2). Compounds of Formula VI and VII, where R2 is alkyl can be formed from compounds of Formula III and IV, respectively, using a base such as sodium hydride (NaH) and an alkyl halide such as butyl iodide (BuI), in an aprotic solvent such N,N-dimethylformamide (DMF). Compounds of Formula VIII and IX, where R2 is alkyl, can be prepared from compounds of Formula VI and VII, respectively, by treatment with ozone in the presence of sodium bicarbonate (NaHCO3) in a solvent mixture such as DCM/methanol (MeOH), with subsequent quenching of the reaction using a reducing agent such as sodium borohydride (NaBH4) and a salt such as sodium acetate (NaOAc) in a solvent such as water (H2O).




embedded image


In Scheme II, compounds of Formula XI, where R2 is alkenyl, can be prepared from compounds of Formula X by treatment with an allyl carbonate such as bis(2-methylallyl)carbonate, in the presence of a catalyst such as tetrakis(triphenylphosphine)-palladium(0) (Pd(PPh3)4) in an aprotic solvent such as tetrahydrofuran (THF) at an elevated temperature. Compounds of Formula XII, where R2 is alkenyl, can be prepared from compounds of Formula XI by treatment with a reducing agent, such as lithium aluminum hydride (LAH) in an aprotic solvent such as THF.




embedded image


In Scheme III, compounds of Formula XIV, where R2 is alkenyl can be prepared from compounds of Formula XIII by treatment with an allyl carbonate such as bis(2-methylallyl)carbonate, in the presence of a catalyst such as Pd(PPh3)4 in an aprotic solvent such as THF at an elevated temperature. Compounds of Formula XV, where R2 is alkenyl, can be prepared from compounds of Formula XIV by treatment with a reducing agent, such as LAH in an aprotic solvent such as THF.




embedded image


In Scheme IV, compounds of Formula XVII, where R2 is a substituted alkyl or alkenyl can be prepared from compounds of Formula XVI by treatment with a base such as NaH and an alkyl halide such as benzyl halide or 3-bromo-2-methylpropene in an aprotic solvent such as DMF. Compounds of Formula XVIII, where R2 is as above, can be prepared from compounds of Formula XVII by treatment with a reducing agent, such as LAH in an aprotic solvent such as THF.




embedded image


In Scheme V, compounds of Formula XX, where R2 is alkyl or alkenyl, PG is Cbz or Boc, and R3 is as originally defined, can be prepared from compounds of Formula XIX, where R2 is substituted alkyl or alkenyl, and R3 is as originally defined, by treatment with a protected aziridine, such as (S)-1-tert-butyl 2-methyl aziridine-1,2-dicarboxylate in the presence of a Lewis acid such as boron trifluoride diethyl etherate (BF3-Et2O), in an aprotic solvent such as DCM.




embedded image


In Scheme VI, compounds of Formula XXII, where R2 and PG are as defined above and R3 is as originally defined, can be prepared from compounds of Formula XXI, where R2 and PG are as defined above and R3 is as originally defined, by treatment with an oxidizing agent, such as sulfur trioxide pyridine complex, in the presence of an organic amine base such as, for example, triethylamine (TEA) in a solvent mixture such as DCM/dimethylsulfoxide (DMSO). Compounds of Formula XXIIIa and XXIVa, where R2 and PG are as defined above, R3 is as originally defined and R9 is alkyl can be prepared from compounds of Formula XXII by treatment with an organometallic reagent such as methylmagnesium bromide in an aprotic solvent such as THF.




embedded image


In Scheme VII, compounds of Formula XXV, where R2, R3 and PG are as defined above, can be prepared from compounds of Formula XXIIIb, where R2, R3 and PG are as defined above, by treatment with a base such as lithium hydroxide (LiOH) in a solvent mixture such as THF/H2O. Compounds of Formula Ia, where R2, R3 and PG are as defined above, can be prepared from compounds of Formula XXV by treatment with an activating reagent, such as 2-methyl-6-nitrobenzoic anhydride (MNBA) in the presence of a base such as 4-dimethylaminopyridine (DMAP) in a solvent such as toluene.




embedded image


In Scheme VIII, compounds of Formula XXVI, where R2, R3 and PG are as defined above, can be prepared from compounds of Formula XXIVb, where R2, R3 and PG are as defined above, by treatment with a base such as LiOH in a solvent mixture such as THF/H2O. Diastereomers of Formula Ib and Ic, where R2, R3 and PG are as defined above, can be prepared from compounds of Formula XXVI by treatment with an activating reagent, such as MBNA in the presence of a base such as DMAP in a solvent such as toluene under high dilution.




embedded image


In Scheme IX, compounds of Formula Ie, where R2 is alkyl or alkenyl, can be prepared from compounds of Formula Id, where R2 is alkyl or alkenyl, by treatment with a protecting group such as di-tert-butyl dicarbonate in the presence of a base such as DMAP in an aprotic solvent such as acetonitrile (CH3CN). Compounds of Formula If, where R2 is as defined above, can be prepared from compounds of Formula Ie by treatment with hydrogen in the presence of a catalyst such as palladium on carbon (Pd/C) in a solvent such as ethyl acetate (EtOAc). Compounds of Formula Ig, where R2 is as defined above and R10 is acyl, can be prepared from compounds of Formula Id, where R2 is as defined above, by treatment with hydrogen in the presence of a catalyst such as Pd/C in a solvent such as EtOAc, followed by treatment with an acyl halide such as isobutyryl chloride in the presence of a base such as DMAP in an aprotic solvent such as pyridine. Compounds of Formula Ih, where R2 is as defined above and R10 is alkyl or alkenyl, can be prepared from compounds of Formula If, where R2 is as defined above, by treatment with an alkylating reagent such as trimethyloxonium tetrafluoroborate in the presence of an amine such as N,N,N′,N′-tetramethyl-1,8-naphthalenediamine (Proton-Sponge™) in an aprotic solvent such as DCM. Alternatively, compounds of Formula Ih can be prepared from compounds of Formula If by treatment with an allyl carbonate such as bis(2-methylallyl)carbonate, in the presence of a catalyst such as tris(dibenzylideneacetone)dipalladium(0) (Pd2(dba)3) and a ligand such as 1,1′-bis(diphenylphosphino)ferrocene (dppf) in an aprotic solvent such as THF at an elevated temperature, such as 60° C.




embedded image


In Scheme X, compounds of Formula Ij, where R2 is alkyl, can be prepared from compounds of Formula II, where R2 is alkyl, by treatment with ozone in the presence of sodium bicarbonate (NaHCO3) in a solvent mixture such as DCM/MeOH, with subsequent quenching of the reaction using a reducing agent such as dimethyl sulfide ((CH3)2S, DMS). Compounds of Formula Ik, where R2 is alkyl, can be prepared from compounds of Formula Ij by treatment with a fluorinating agent such as Deoxo-Fluor® in a solvent such as DCM. Compounds of Formula II, where R2 is alkyl, can be prepared from compounds of Formula II by treatment with ozone in the presence of NaHCO3 in a solvent mixture such as DCM/MeOH, with subsequent quenching of the reaction using a reducing agent such as sodium borohydride (NaBH4) and a salt such as sodium acetate (NaOAc) in a solvent such as H2O. Compounds of Formula Im, where R2 is alkyl, can be prepared from compounds of Formula II by treatment with an alkylating agent such as trimethyloxonium tetrafluoroborate in the presence of an amine base, such as Proton-Sponge™, in a solvent such as DCM.




embedded image


In Scheme XI, compounds of Formula Io can be prepared from compounds of Formula In by treatment with a protecting group such as di-tert-butyl dicarbonate in the presence of a base such as DMAP in an aprotic solvent such as CH3CN. Compounds of Formula Ip can be prepared from compounds of Formula Io by treatment with hydrogen in the presence of a catalyst such as Pd/C in a solvent such as EtOAc. Compounds of Formula Iq can be prepared from compounds of Formula Ip by treatment with an alkylating reagent such as trimethyloxonium tetrafluoroborate in the presence of an amine such as Proton-Sponge™ in an aprotic solvent such as DCM. Alternatively, compounds of Formula Iq can be prepared from compounds of Formula Ip by treatment with an allyl carbonate such as bis(2-methylallyl)carbonate, in the presence of a catalyst such as Pd2(dba)3 and a ligand such as dppf in an aprotic solvent such as THF at an elevated temperature. Alternatively, compounds of Formula Iq can be prepared from compounds of Formula Ip by treatment with an organometallic species such as bis(acetato-O)triphenylbismuth(V) in the presence of a catalyst such as copper(II) acetate in a solvent such as DCM. Alternatively, compounds of Formula Iq can be prepared from compounds of Formula Ip by treatment with an acyl halide such as isobutyryl chloride in the presence of a base such as DMAP in an aprotic solvent such as pyridine.




embedded image


In Scheme XII, compounds of Formula Iu, where R2 and R3 are as originally defined, can be prepared from compounds of Formula Ir or compounds of Formula Is, where R2 and R3 are as originally defined, by treatment with an acid such as a 4.0 M hydrogen chloride (HCl) solution in dioxane in a solvent such as DCM. Alternatively, compounds of Formula Iu, where R2 and R3 are as originally defined, can be prepared from compounds of Formula Ir or compounds of Formula Is, where R2 and R3 are as originally defined, by treatment with trimethylsilyl trifluoromethanesulfonate in the presence of a base such 2,6-lutidine in an aprotic solvent such as DCM, followed by treatment with a protic solvent such as MeOH. Alternatively, compounds of Formula Iu, where R2 and R3 are as originally defined, can be prepared from compounds of Formula It, where R2 and R3 are as originally defined, by treatment with hydrogen in the presence of a catalyst such as Pd/C in a solvent such as EtOAc. Compounds of Formula Iv, where R2 and R3 are as originally defined, can be prepared from compounds of Formula Iu, where R2 and R3 are as originally defined, by treatment with 3-hydroxy-4-methoxypicolinic acid in the presence of a base such as 4-methylmorpholine and a peptide coupling reagent such as O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (HATU) and benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate (PyBOP) in an aprotic solvent such as DCM.




embedded image


In Scheme XIII, compounds of Formula Ix, where R2, R3 and R7 are as originally defined, can be prepared from compound of Formula Iw, where R2 and R3 are as originally defined, by treatment with the appropriate alkyl halide in the presence of a reagent such as sodium iodide (NaI) and a base such as sodium carbonate (Na2CO3) in a solvent such as acetone or an acyl halide in the presence of an amine base, such as pyridine or triethylamine, in an aprotic solvent such as DCM.




embedded image


The following examples are presented to illustrate the various aspects of the compounds of the present disclosure and should not be construed as limitations to the claims.


EXAMPLES
Example 1
Step 1: Preparation of (3R,4S,5S)-5-methyl-3,4-bis(2-methylallyloxy)dihydrofuran-2(3H)-one



embedded image


To a stirred solution of (3R,4R,5S)-3,4-dihydroxy-5-methyldihydrofuran-2(3H)-one (1.3 grams (g), 9.84 millimole (mmol)) and Pd(Ph3P)4 (0.569 g, 0.492 mmol) in anhydrous THF (9 milliliters (mL)) under nitrogen (N2) was added bis(2-methylallyl)carbonate. After stirring the solution at 60° C. for 1 hour (h) (CO2 evolution ceased), the reaction mixture was cooled and the solvent was evaporated. The crude product was purified by flash chromatography (silica gel (SiO2)) to yield the title compound as a colorless oil (2.3 g, 97%): 1H NMR (400 MHz, CDCl3) δ 5.04 (dd, J=1.9, 0.9 Hz, 1H), 5.00-4.98 (m, 1H), 4.97-4.93 (m, 2H), 4.47-4.38 (m, 1H), 4.36-4.27 (m, 1H), 4.23-4.00 (m, 4H), 3.82 (t, J=7.2 Hz, 1H), 1.78 (s, 3H), 1.75 (s, 3H), 1.48 (d, J=6.3 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 172.65, 141.07, 140.92, 113.54, 113.14, 84.19, 79.31, 76.57, 74.53, 74.51, 19.48, 19.35, 19.00; EIMS m/z 240 [M+].


Example 1
Step 2: Preparation of (2S,3S,4S)-2,3-bis(2-methylallyloxy)pentane-1,4-diol



embedded image


To a solution of (3R,4S,5S)-5-methyl-3,4-bis(2-methylallyloxy)dihydrofuran-2(3H)-one (1 g, 4.16 mmol) in THF (10 mL) at 0° C. was added 1.0 M LAH (9.57 mL, 9.57 mmol) in THF over 15 min. The mixture was warmed to room temperature and stirred for 2 h, then carefully added dropwise to an ice cold saturated aqueous ammonium chloride (NH4Cl) solution (100 mL). The phases were separated and the aqueous layer was extracted with DCM. The combined organic layers were dried over sodium sulfate (Na2SO4), filtered, and the filtrate was concentrated. Purification by flash chromatography (SiO2) afforded the title compound as a colorless oil (920 mg, 90%): 1H NMR (400 MHz, CDCl3) δ 4.99 (d, J=7.8 Hz, 2H), 4.91 (d, J=8.9 Hz, 2H), 4.09-3.92 (m, 5H), 3.93-3.83 (m, 1H), 3.82-3.73 (m, 1H), 3.70 (q, J=4.7 Hz, 1H), 3.39 (dd, J=6.0, 5.0 Hz, 1H), 3.14 (s, 1H), 2.46 (s, 1H), 1.77 (s, 3H), 1.76 (s, 3H), 1.26 (d, J=6.3 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 141.95, 141.75, 112.99, 112.79, 81.57, 79.41, 75.52, 74.57, 67.60, 61.33, 19.67, 19.63, 19.61.


Example 1
Step 3: Preparation of(S)-methyl 2-(benzyloxycarbonylamino)-3-((2S,3S,4S)-4-hydroxy-2,3-bis(2-methylallyloxy)pentyloxy)propanoate and (S)-methyl 2-(benzyloxycarbonylamino)-3-((2S,3S,4S)-5-hydroxy-3,4-bis(2-methylallyloxy)pentan-2-yloxy)propanoate



embedded image


To a solution of (2S,3S,4S)-2,3-bis(2-methylallyloxy)pentane-1,4-diol (920 milligrams (mg), 3.77 mmol) and (S)-1-benzyl 2-methyl aziridine-1,2-dicarboxylate (0.739 mL, 3.74 mmol) in anhydrous chloroform (CHCl3; 5 mL) was added BF3-Et2O (26 microliters (μL) 0.55 mmol) at 0° C. and the solution was stirred at 0° C. for 3 h. The crude reaction mixture was concentrated and purified by flash chromatography (SiO2) to furnish (S)-methyl 2-(benzyloxycarbonylamino)-3-((2S,3S,4S)-4-hydroxy-2,3-bis(2-methylallyloxy)-pentyloxy)-propanoate as a colorless oil (620 mg, 35%) and (S)-methyl 2-(benzyloxycarbonylamino)-3-((2S,3S,4S)-5-hydroxy-3,4-bis(2-methylallyloxy)pentan-2-yloxy)propanoate as a colorless oil (300 mg, 17%).


(S)-methyl 2-(benzyloxycarbonylamino)-3-((2S,3S,4S)-4-hydroxy-2,3-bis(2-methylallyloxy)-pentyloxy)propanoate: 1H NMR (400 MHz, CDCl3) δ 7.43-7.29 (m, 5H), 5.75 (d, J=8.7 Hz, 1H), 5.17-5.07 (m, 2H), 5.01-4.91 (m, 2H), 4.87 (t, J=5.3 Hz, 2H), 4.51 (dt, J=8.7, 3.0 Hz, 1H), 4.07-3.90 (m, 5H), 3.90-3.79 (m, 1H), 3.75 (s, 2H), 3.74-3.61 (m, 5H), 3.29-3.18 (m, 1H), 3.11 (d, J=4.0 Hz, 1H), 1.78-1.68 (m, 6H), 1.21 (d, J=6.3 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 170.66, 156.01, 142.04, 141.83, 136.25, 128.52, 128.17, 128.08, 112.79, 112.65, 81.18, 78.26, 75.51, 74.77, 71.42, 70.68, 67.74, 67.05, 54.43, 52.57, 19.91, 19.66, 19.55; ESIMS m/z 502.4 ([M+Na]+).


(S)-methyl 2-(benzyloxycarbonylamino)-3-((2S,3S,4S)-5-hydroxy-3,4-bis(2-methylallyloxy)pentan-2-yloxy)propanoate: 1H NMR (400 MHz, CDCl3) δ 7.41-7.28 (m, 5H), 5.69 (d, J=8.5 Hz, 1H), 5.18-5.08 (m, 2H), 5.04-4.93 (m, 2H), 4.92-4.80 (m, 2H), 4.48 (dt, J=8.7, 3.3 Hz, 1H), 4.07-3.93 (m, 5H), 3.87 (dd, J=9.3, 3.1 Hz, 1H), 3.78-3.66 (m, 5H), 3.65-3.53 (m, 2H), 3.48-3.40 (m, 2H), 1.84-1.64 (m, 6H), 1.19 (d, J=6.3 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 170.82, 156.04, 142.39, 142.34, 136.24, 128.51, 128.47, 128.17, 128.09, 128.04, 112.12, 112.05, 81.47, 79.72, 76.63, 76.14, 74.82, 68.72, 67.04, 61.85, 54.45, 52.53, 19.68, 19.61, 15.33; ESIMS m/z 502.4 ([M+Na]+).


Example 1
Step 4: Preparation of benzyl (3S,7S,8S,9S)-9-methyl-7,8-bis(2-methylallyloxy)-2-oxo-1,5-dioxonan-3-ylcarbamate (compound 126)



embedded image


To a solution of (S)-methyl 2-(benzyloxycarbonylamino)-3-((2S,3S,4S)-4-hydroxy-2,3-bis(2-methylallyloxy)pentyloxy)propanoate (480 mg, 1.001 mmol) in THF/H2O (18 mL, 2:1 ratio) was added LiOH (71.9 mg, 3.00 mmol) and the solution was allowed to stir for 40 minutes (min) at ambient temperature. The crude reaction mixture was diluted with EtOAc and washed with 1 Normal (N) aqueous HCl. The phases were separated and the aqueous phase was extracted with EtOAc (3×20 mL). The combined organic layers were dried over Na2SO4, filtered, and concentrated to furnish the intermediate acid as a colorless oil which was dissolved in anhydrous toluene (50 mL) and added to a solution of MNBA (521 mg, 1.512 mmol) and DMAP (693 mg, 5.67 mmol) in toluene (180 mL) over the course of 3 h via syringe pump. After the addition was completed the reaction mixture was stirred for 1 h, concentrated, and purified by flash chromatography (SiO2) to afford the title compound as a white foam (281 mg, 62%): 1H NMR (400 MHz, CDCl3) δ 7.40-7.28 (m, 5H), 5.55 (d, J=7.7 Hz, 1H), 5.10 (s, 2H), 5.01-4.91 (m, 3H), 4.85 (d, J=1.2 Hz, 2H), 4.69 (dd, J=12.1, 6.7 Hz, 1H), 4.32 (d, J=11.7 Hz, 1H), 3.99-3.89 (m, 4H), 3.85 (d, J=11.3 Hz, 1H), 3.74 (dd, J=11.9, 4.5 Hz, 1H), 3.60-3.51 (m, 1H), 3.33-3.23 (m, 2H), 1.72 (d, J=6.2 Hz, 6H), 1.44 (d, J=6.3 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 170.85, 155.71, 142.26, 142.02, 136.10, 128.57, 128.25, 128.11, 112.33, 112.02, 84.95, 83.01, 77.63, 75.87, 74.89, 74.66, 72.86, 67.14, 54.26, 19.81, 19.66, 18.63; ESIMS m/z 470.3 ([M+Na]+).


Compound 127 was prepared in a similar manner as described in example 1, step 4 starting from (S)-methyl 2-(benzyloxycarbonylamino)-3-((2S,3S,4S)-5-hydroxy-3,4-bis(2-methylallyloxy)pentan-2-yloxy)propanoate.


Compound 157 was prepared in a similar manner as described in example 1, steps 3 and 4 starting from 1,6-dideoxy-3,4-O-isopropylidene-D-mannitol. 1,6-Dideoxy-3,4-O-isopropylidene-D-mannitol was made using the procedures disclosed in Heterocycles, 2007, 74, 983-989.


Example 1
Step 5: Preparation of (3S,7S,8S,9S)-3-amino-7,8-diisobutoxy-9-methyl-1,5-dioxonan-2-one (compound 160)



embedded image


Benzyl (3S,7S,8S,9S)-9-methyl-7,8-bis(2-methylallyloxy)-2-oxo-1,5-dioxonan-3-ylcarbamate (265 mg, 0.592 mmol) was dissolved in EtOAc (8 mL) in a 50 mL high pressure reactor with a stir bar and Pd/C (5%, 30 mg) was added. The reactor was sealed and purged with H2 (4×), then charged to ˜600 pounds per square inch (psi) with H2. The reactor was warmed to 50° C. and stirred at 50° C. for 12 h. The reaction mixture was filtered through a pad of Celite® and the filtrate was concentrated to afford the title compound as a white solid (170 mg, 91%): mp 144-146° C.; 1H NMR (400 MHz, CDCl3) δ 4.82 (dq, J=8.5, 6.3 Hz, 1H), 3.97-3.84 (m, 1H), 3.78 (t, J=7.0 Hz, 1H), 3.72-3.53 (m, 3H), 3.44-3.29 (m, 2H), 3.29-3.12 (m, 4H), 1.82 (ttd, J=13.4, 6.5, 2.5 Hz, 2H), 1.42 (d, J=6.3 Hz, 3H), 0.99-0.78 (m, 12H); 13C NMR (101 MHz, CDCl3) δ 175.66, 84.70, 83.85, 80.55, 77.57, 74.90, 72.72, 72.70, 29.11, 28.87, 19.58, 19.48, 19.45, 19.38, 18.61; ESIMS m/z 318.8 ([M+H]+).


Compound 132 and 162 were prepared in a similar manner as described in example 1, step 5.


Example 1
Step 6: Preparation of N-((3S,7S,8S,9S)-7,8-diisobutoxy-9-methyl-2-oxo-1,5-dioxonan-3-yl)-3-hydroxy-4-methoxypicolinamide (compound 1)



embedded image


To a mixture of (3S,7S,8S,9S)-3-amino-7,8-diisobutoxy-9-methyl-1,5-dioxonan-2-one (170 mg, 0.536 mmol), 3-hydroxy-4-methoxypicolinic acid (136 mg, 0.803 mmol) and HATU (336 mg, 0.857 mmol) in a vial was added CH2Cl2 (3 mL), followed by 4-methylmorpholine (0.353 mL, 3.21 mmol), and the resulting suspension was stirred at room temperature for 3 h. The resulting orange solution was directly purified by flash chromatography (SiO2) to afford the title compound as a white solid (176 mg, 70%): 1H NMR (400 MHz, CDCl3) δ 11.95 (s, 1H), 8.68 (d, J=8.0 Hz, 1H), 8.00 (d, J=5.2 Hz, 1H), 6.87 (d, J=5.2 Hz, 1H), 5.10-5.00 (m, 1H), 4.97 (dt, J=12.6, 6.3 Hz, 1H), 4.10-4.01 (m, 1H), 3.94 (s, 3H), 3.87-3.78 (m, 2H), 3.71 (dd, J=8.4, 6.1 Hz, 1H), 3.66-3.57 (m, 1H), 3.38-3.28 (m, 2H), 3.28-3.17 (m, 3H), 1.90-1.76 (m, 2H), 1.45 (t, J=5.8 Hz, 3H), 0.98-0.88 (m, 12H); 13C NMR (101 MHz, CDCl3) δ 170.33, 168.95, 155.38, 148.76, 140.66, 130.23, 109.58, 84.84, 83.75, 80.60, 77.74, 75.32, 73.97, 73.23, 56.11, 52.19, 29.13, 28.89, 19.60, 19.48, 19.47, 19.39, 18.66; ESIMS m/z 469.4 ([M+H]+).


Compounds 4 and 27 were prepared in a similar manner as described in example 1, step 6.


Example 2
Step 1: Preparation of (S)-methyl 2-(benzyloxycarbonylamino)-3-((2S,3S)-2,3-bis(benzyloxy)-4-hydroxybutoxy)propanoate



embedded image


To a solution of (2S,3S)-2,3-bis(benzyloxy)butane-1,4-diol (283 mg, 0.935 mmol), prepared as disclosed in Journal of Organic Chemistry 1991, 56(3), 1321-1322, and (S)-1-benzyl 2-methyl aziridine-1,2-dicarboxylate (110 mg, 0.468 mmol) in CH2Cl2 (1.5 mL) at −78° C. was added BF3-OEt2 (10 μL, 0.081 mmol), and the reaction mixture was stirred at −78° C. for 1 h, slowly warmed to 0° C., and then stirred at 0° C. for 3 h. The reaction mixture was directly purified by flash chromatography (SiO2) to afford the title compound as a colorless oil (208 mg, 83%): 1H NMR (400 MHz, CDCl3) δ 7.45-7.20 (m, 16H), 5.70 (d, J=8.5 Hz, 1H), 4.70-4.54 (m, 6H), 4.53-4.46 (m, 1H), 3.93 (dd, J=9.5, 3.2 Hz, 1H), 3.80-3.53 (m, 9H), 2.09-1.96 (m, 1H); 13C NMR (101 MHz, CDCl3) δ 170.72, 156.04, 138.16, 138.08, 136.24, 128.54, 128.49, 128.47, 128.20, 128.13, 127.99, 127.91, 127.89, 127.86, 79.03, 78.10, 73.09, 72.88, 71.40, 71.08, 67.08, 61.40, 54.46, 52.60; ESIMS m/z 538.4 ([M+H]+).


Example 2
Step 2: Preparation of (S)-methyl 2-(benzyloxycarbonylamino)-3-((2S,3S)-2,3-bis(benzyloxy)-4-hydroxybutoxy)propanoate (compound 128)



embedded image


Compound 128 was prepared in a similar manner as described in Example 1, Step 4 starting from (S)-methyl 2-(benzyloxycarbonylamino)-3-((2S,3S)-2,3-bis(benzyloxy)-4-hydroxybutoxy)propanoate: 1H NMR (400 MHz, CDCl3) δ 7.37-7.24 (m, 15H), 5.54 (d, J=8.0 Hz, 1H), 5.11 (s, 2H), 4.80-4.61 (m, 6H), 4.09 (dd, J=11.5, 3.9 Hz, 1H), 3.99 (dd, J=11.5, 6.7 Hz, 1H), 3.78 (dt, J=8.4, 3.8 Hz, 2H), 3.72-3.63 (m, 1H), 3.56 (dd, J=11.5, 6.0 Hz, 1H), 3.49-3.39 (m, 1H); 13C NMR (101 MHz, CDCl3) δ 171.66, 155.61, 138.01, 137.98, 136.10, 128.59, 128.50, 128.45, 128.28, 128.15, 127.91, 127.89, 127.82, 81.63, 79.43, 73.96, 73.80, 73.26, 72.96, 67.17, 63.80, 54.10; ESIMS m/z 506.3 ([M+H]+).


Compound 186 was prepared in the same manner as described in Example 2, Step 2 using (S)-methyl 2-(((benzyloxy)carbonyl)amino)-3-((2S,3S)-4-hydroxy-2,3-bis((2-methylallyl)oxy)butoxy)propanoate as starting material.


Compound 187 was prepared in two steps from (2S,3S)-2,3-bis((2-methylallyl)oxy)butane-1,4-diol: Step 1 was performed in a similar manner as described in Example 2, Step 1 but using (R)-1-tert-butyl 2-methyl aziridine-1,2-dicarboxylate instead of the corresponding (S)-enantiomer; Step 2 was performed in the same manner as described in Example 2, Step 2.


Example 2
Step 3: Preparation of (3S,7S,8S)-3-amino-7,8-bis(benzyloxy)-1,5-dioxonan-2-one (compound 129)



embedded image


Benzyl (3S,7S,8S)-7,8-bis(benzyloxy)-2-oxo-1,5-dioxonan-3-ylcarbamate (71 mg, 0.140 mmol) was dissolved in MeOH (1 mL) and EtOAc (1 mL) and 2.0 molar (M) ammonia in ethanol (EtOH) (35 μL, 0.070 mmol) and 5% Pd/C (10 mass wt. %) were added. The air was removed by two cycles of evacuating the flask under vacuum and backfilling with H2. The reaction mixture was placed under an atmosphere of H2 (balloon, ˜1 atmosphere) and stirred at room temperature for 2 h. The reaction mixture was filtered through Celite®, and the filtrate was concentrated to afford the title compound as an off-white solid (47 mg, 91%): 1H NMR (400 MHz, CDCl3) δ 7.79-6.92 (m, 10H), 4.79-4.53 (m, 6H), 4.14 (dd, J=11.4, 3.6 Hz, 1H), 3.97 (dd, J=11.4, 7.2 Hz, 1H), 3.87-3.74 (m, 3H), 3.73-3.56 (m, 2H), 3.45 (ddd, J=7.8, 6.0, 1.8 Hz, 1H), 3.25 (dd, J=11.5, 7.9 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ 175.95, 138.09, 138.04, 128.46, 128.40, 128.00, 127.88, 127.85, 127.74, 81.49, 79.46, 75.01, 73.66, 72.75, 71.53, 63.47, 54.33; ESIMS m/z 372.9 ([M+H]+).


Compound 170 was prepared from compound 186 in a similar manner as described in Example 2, Step 3 but in the absence of ammonia (see also Example 1, Step 5).


Example 2
Step 4: Preparation of N-((3S,7S,8S)-7,8-bis(benzyloxy)-2-oxo-1,5-dioxonan-3-yl)-3-hydroxy-4-methoxypicolinamide (compound 5)



embedded image


To a mixture of (3S,7S,8S)-3-amino-7,8-bis(benzyloxy)-1,5-dioxonan-2-one (47 mg, 0.127 mmol), 3-hydroxy-4-methoxypicolinic acid (32.1 mg, 0.190 mmol) and HATU (80 mg, 0.202 mmol) in a vial were added CH2Cl2 (1.5 mL), followed by 4-methylmorpholine (0.083 mL, 0.759 mmol), and the resulting suspension was stirred at room temperature for 12 h. The resulting orange solution was directly purified by flash chromatography (SiO2) to afford the title compound as a white foam (32 mg, 48%): 1H NMR (400 MHz, CDCl3) δ 11.90 (d, J=0.6 Hz, 1H), 8.61 (d, J=8.2 Hz, 1H), 8.49 (d, J=5.2 Hz, 1H), 7.43-7.24 (m, 11H), 6.86 (d, J=5.2 Hz, 1H), 5.03 (ddd, J=8.2, 6.8, 6.0 Hz, 1H), 4.80-4.62 (m, 5H), 4.21-4.07 (m, 2H), 3.93 (s, 3H), 3.85 (s, 1H), 3.79-3.65 (m, 2H), 3.55-3.47 (m, 1H); 13C NMR (101 MHz, CDCl3) δ 170.83, 168.92, 155.37, 148.76, 140.66, 137.97, 137.94, 130.17, 128.48, 128.43, 127.91, 127.89, 127.87, 127.81, 109.61, 81.52, 79.29, 73.80, 73.44, 73.24, 72.97, 63.91, 56.10, 52.25; ESIMS m/z 524.1 ([M+H]+).


Compound 8 was prepared in the same manner as described in Example 2, Step 4 using compound 170 as starting material.


Example 3
Step 1: Preparation of (2R,3R)-dimethyl 2,3-bis((2-methylallyl)oxy)succinate



embedded image


To a cooled (−10° C.) suspension of NaH (60% dispersion in mineral oil, 6.73 g, 168 mmol) in DMF (240 mL) was added dropwise a solution of (+)-dimethyl L-tartrate (15.0 g, 84.0 mmol) in DMF (40 mL) over a period of 30 min. After the addition was complete, the mixture was stirred for another 30 min at −10° C., and then 3-bromo-2-methylpropene (25.5 mL, 253 mmol) was added while maintaining the reaction temperature below 0° C. The mixture was stirred for 1.5 h at −10° C., quenched with H2O and saturated aqueous sodium chloride (NaCl, brine), and extracted with EtOAc. The phases were separated and the aqueous phase was further extracted with EtOAc. The combined organic phases were washed with brine, dried over magnesium sulfate (MgSO4), filtered, and concentrated to yield a yellow oil. Purification by flash chromatography (SiO2, hexanes/EtOAc gradient) yielded the title compound as a colorless oil (17.05 g, 71%): IR (neat) 2953, 1758, 1435, 1270, 1203, 1106 cm−1; 1H NMR (400 MHz, CDCl3) δ 4.92-4.86 (m, 4H), 4.37 (s, 2H), 4.19 (d, J=12.3 Hz, 2H), 3.82 (d, J=12.3 Hz, 2H), 3.77 (s, 6H), 1.68 (s, 6H); 13C NMR (101 MHz, CDCl3) δ 169.84, 141.04, 114.10, 78.60, 75.66, 52.22, 19.52; HRMS-ESI (m/z) [M]+ calcd for C14H22O6, 286.1416; found, 286.1417.


Example 3
Step 2: Preparation of (2S,3S)-2,3-bis((2-methylallyl)oxy)butane-1,4-diol



embedded image


To a solution of (2R,3R)-dimethyl 2,3-bis((2-methylallyl)oxy)succinate (14.7 g, 51.3 mmol) in THF (130 mL) at 0° C. was added slowly a 1.0 M solution of LAH in THF (257 mL, 257 mmol). The mixture was warmed to room temperature and stirred for 2 h, carefully quenched by the addition of EtOAc at 0° C., and then treated with a saturated aqueous solution of potassium sodium tartrate (Rochelle's salt). The phases were separated and the aqueous layer was extracted with EtOAc. The combined organic phases were washed with brine, dried over Na2SO4, filtered, and concentrated. The residue was purified by flash chromatography (SiO2, hexanes/EtOAc gradient) to yield the title compound as a colorless oil (10.87 g, 92%): IR (neat) 3388, 2918, 2880, 1656, 1452, 1046 cm−1; 1H NMR (400 MHz, CDCl3) δ 4.98 (s, 2H), 4.90 (s, 2H), 4.03 (s, 4H), 3.81 (d, J=11.7 Hz, 2H), 3.71 (d, J=11.9 Hz, 2H), 3.64-3.59 (m, 2H), 2.57-2.47 (m, 2H), 1.75 (s, 6H); 13C NMR (101 MHz, CDCl3) δ 142.16, 112.85, 78.75, 74.52, 60.85, 19.68; HRMS-ESI (m/z) [M]+ calcd for C12H22O4, 230.1518; found, 230.1519.


Example 3
Step 3: Preparation of (S)-methyl 2-(((benzyloxy)carbonyl)amino)-3-((2S,3S)-4-hydroxy-2,3-bis((2-methylallyl)oxy)butoxy)propanoate



embedded image


The title compound was prepared in the same manner as described in Example 2, Step 1 to give a colorless oil (6.14 g, 62%): 1H NMR (400 MHz, CDCl3) δ 7.34 (dt, J=12.4, 4.7 Hz, 5H), 5.73 (d, J=8.5 Hz, 1H), 5.13 (s, 2H), 4.96 (dd, J=2.3, 1.0 Hz, 2H), 4.88 (d, J=8.5 Hz, 2H), 4.49 (dt, J=8.6, 3.1 Hz, 1H), 4.04-3.91 (m, 5H), 3.75 (s, 3H), 3.73-3.46 (m, 7H), 1.73 (d, J=6.3 Hz, 6H); 13C NMR (101 MHz, CDCl3) δ 170.69, 156.01, 142.12, 136.23, 128.51, 128.16, 128.07, 112.58, 78.57, 78.19, 74.92, 74.65, 71.41, 70.89, 67.04, 61.38, 54.44, 52.58, 19.55; ESIMS m/z 488.3 ([M+Na]+).


Example 3
Step 4: Preparation of (S)-methyl 2-(((benzyloxy)carbonyl)amino)-3-((2S,3R)-2,3-bis((2-methylallyl)oxy)-4-oxobutoxy)propanoate



embedded image


To a solution of (S)-methyl 2-(((benzyloxy)carbonyl)amino)-3-((2S,3S)-4-hydroxy-2,3-bis((2-methylallyl)oxy)butoxy)propanoate (3.96 g, 8.51 mmol) in CH2Cl2/DMSO (56.7 mL, ratio: 5/1) at 0° C. was added TEA (5.93 ml, 42.5 mmol) followed by sulfur trioxide pyridine complex (4.06 g, 25.5 mmol) and the reaction was slowly warmed to room temperature and stirred for 2 h. The reaction mixture was quenched with saturated aqueous NH4Cl and extracted with EtOAc. The combined organic phases were washed with H2O and brine, dried over MgSO4, filtered, and the filtrate was concentrated. The crude residue was purified by flash chromatography (SiO2, hexanes/EtOAc gradient) to provide the title compound as a colorless oil (3.26 g, 83% yield): IR (neat) 3360, 2951, 1721, 1512, 1209, 1053 cm−1; 1H NMR (400 MHz, CDCl3) δ 9.69 (d, J=1.0 Hz, 1H), 7.41-7.27 (m, 5H), 5.65 (d, J=8.7 Hz, 1H), 5.17-5.08 (m, 2H), 4.96-4.92 (m, 2H), 4.90 (d, J=14.8 Hz, 2H), 4.47 (dt, J=8.7, 2.9 Hz, 1H), 4.10 (d, J=12.4 Hz, 1H), 3.97-3.88 (m, 4H), 3.85-3.78 (m, 2H), 3.75 (s, 3H), 3.65 (dd, J=9.5, 3.2 Hz, 1H), 3.62 (d, J=4.5 Hz, 2H), 1.74 (s, 3H), 1.69 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 202.61, 170.65, 156.16, 141.73, 141.27, 136.42, 128.63, 128.26, 128.17, 113.83, 113.23, 82.49, 78.16, 75.45, 75.01, 71.55, 69.39, 67.16, 54.49, 52.70, 19.62, 19.55; ESIMS m/z 486.2 ([M+Na]+).


Example 3
Step 5: Preparation of (S)-methyl 2-(((benzyloxy)carbonyl)amino)-3-(((2S,3S,4S)-4-hydroxy-2,3-bis((2-methylallyl)oxy)hexyl)oxy)propanoate and (S)-methyl 2-(((benzyloxy)carbonyl)amino)-3-(((2S,3S,4R)-4-hydroxy-2,3-bis((2-methylallyl)oxy)hexyl)-oxy)propanoate



embedded image


A 1.0 M solution of ethylmagnesium bromide in tert-butyl methyl ether (1.804 ml, 1.804 mmol) was added slowly to a solution of (S)-methyl 2-(((benzyloxy)carbonyl)amino)-3-((2S,3R)-2,3-bis((2-methylallyl)oxy)-4-oxobutoxy)propanoate (0.400 g, 0.863 mmol) in THF (6.0 ml) at −78° C. and the reaction was stirred for 30 min at −78° C., then warmed to −40° C. and stirred for 2 h at −40° C., and warmed to 0° C. over a 2 h period. The reaction was quenched at 0° C. with saturated aqueous NH4Cl and extracted with EtOAc. The combined organic phases were washed with brine, dried over MgSO4, filtered, and concentrated. The crude residue was purified by flash chromatography on (SiO2, hexanes/EtOAc gradient) to provide the title compounds as colorless oils.


(S)-methyl 2-(((benzyloxy)carbonyl)amino)-3-(((2S,3S,4S)-4-hydroxy-2,3-bis((2-methylallyl)oxy)hexyl)oxy)propanoate (35.0 mg, 8%): IR (neat) 3443, 2919, 1272, 1509, 1454, 1209, 1084 cm−1; 1H NMR (400 MHz, CDCl3) δ 7.39-7.23 (m, 5H), 5.76 (d, J=8.7 Hz, 1H), 5.11 (s, 2H), 4.97-4.91 (m, 2H), 4.86 (s, 2H), 4.50 (dt, J=8.3, 2.9 Hz, 1H), 4.05-3.88 (m, 4H), 3.77-3.57 (m, 5H), 3.73 (s, 3H), 3.27 (dd, J=7.1, 3.6 Hz, 1H), 3.14 (d, J=3.9 Hz, 1H), 1.77-1.60 (m, 8H), 1.49-1.36 (m, 1H), 0.97 (t, J=7.4 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 170.72, 156.09, 142.05, 141.86, 136.30, 128.54, 128.19, 128.13, 112.82, 112.70, 79.63, 78.22, 75.23, 74.79, 72.79, 71.40, 70.68, 67.09, 54.50, 52.59, 26.71, 19.72, 19.61, 10.0; ESIMS m/z 494.3 ([M+H]+).


(S)-methyl 2-(((benzyloxy)carbonyl)amino)-3-(((2S,3S,4R)-4-hydroxy-2,3-bis((2-methylallyl)oxy)hexyl)oxy)propanoate (150 mg, 35%): IR (neat) 3355, 2936, 1719, 1513, 1455, 1210, 1056 cm−1; 1H NMR (400 MHz, CDCl3) δ 7.40-7.26 (m, 5H), 5.74 (d, J=8.7 Hz, 1H), 5.12 (s, 2H), 4.97-4.92 (m, 2H), 4.87 (s, 2H), 4.51 (dt, J=8.7, 3.0 Hz, 1H), 4.05-3.89 (m, 4H), 3.77-3.57 (m, 5H), 3.74 (s, 3H), 3.28 (dd, J=7.1, 3.7 Hz, 1H), 3.14 (d, J=3.6 Hz, 1H), 1.73 (s, 3H), 1.72 (s, 3H), 1.72-1.58 (m, 2H), 1.48-1.35 (m, 1H), 0.97 (t, J=7.4 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 170.80, 156.12, 142.39, 142.27, 136.36, 128.56, 128.20, 128.11, 112.51, 112.34, 80.58, 78.66, 76.51, 74.98, 72.04, 71.42, 71.39, 67.07, 54.57, 52.60, 27.65, 19.77, 19.63, 10.42; ESIMS m/z 516.3 ([M+Na]+).


Example 3
Step 6: Preparation of benzyl ((3S,7S,8S,9S)-9-ethyl-7,8-bis((2-methylallyl)oxy)-2-oxo-1,5-dioxonan-3-yl)carbamate (compound 88)



embedded image


Compound 88 was prepared in a similar manner as described in Example 1, Step 4 using CH2Cl2 instead of toluene as the reaction solvent in the cyclization step, to afford the title compound as a white solid (82.1 mg, 45%): mp 108-110° C.; IR (neat) 3288, 2925, 2879, 1752, 1689, 1555, 1330, 1197 cm−1; 1H NMR (400 MHz, CDCl3) δ 7.41-7.27 (m, 5H), 5.60 (d, J=7.5 Hz, 1H), 5.10 (s, 2H), 4.98-4.88 (m, 3H), 4.88-4.81 (m, 2H) 4.74-4.64 (m, 1H), 4.33 (d, J=11.8 Hz, 1H), 3.96 (s, 2H), 3.95-3.80 (m, 4H), 3.53 (dd, J=11.9, 6.0 Hz, 1H), 3.38-3.25 (m, 2H), 2.07-1.95 (m, 1H), 1.72 (d, J=4.7 Hz, 6H), 1.72-1.61 (m, 1H), 0.96 (t, J=7.4 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 171.00, 155.85, 142.43, 142.12, 136.25, 128.69, 128.36, 128.23, 112.41, 112.00, 83.44, 83.36, 75.92, 74.66, 67.24, 54.84, 25.32, 19.91, 19.78, 9.61; ESIMS m/z 462.3 ([M+H]+).


Compound 89 was prepared in a two step sequence from (S)-methyl 2-(((benzyloxy)carbonyl)amino)-3-((2S,3R)-2,3-bis((2-methylallyl)oxy)-4-oxobutoxy)propanoate, in a similar manner as described in Example 3, Step 5 using a 2.9 M solution of isopropylmagnesium bromide in 2-methyltetrahydrofuran instead of a 1.0 M solution of ethylmagnesium bromide in tert-butyl methyl ether, followed by a saponification-cyclization as described in Example 3, Step 6.


Compound 155 was prepared in the same manner as described in Example 3, Steps 4 to 6, starting from (S)-methyl 2-(benzyloxycarbonylamino)-3-((2S,3S,4S)-5-hydroxy-3,4-bis(2-methylallyloxy)pentan-2-yloxy)propanoate (see Example 1, Step 3).


Compound 156 was prepared in the same manner as described in Example 3, Steps 4 to 6, starting from (S)-methyl 3-(((2S,3S,4S)-3,4-bis(benzyloxy)-5-hydroxypentan-2-yl)oxy)-2-((tert-butoxycarbonyl)amino)propanoate (see Example 8, Step 2).


Example 3
Step 7: Preparation of (3S,7S,8S,9S)-3-amino-9-ethyl-7,8-diisobutoxy-1,5-dioxonan-2-one (compound 121)



embedded image


Compound 121 was prepared in the same manner as described in Example 1, Step 5 to give the title compound as a colorless oil (71.2 mg, 93%): IR (neat) 3364, 2954, 2873, 1742, 1467, 1183, 1094 cm−1; 1H NMR (400 MHz, CDCl3) δ 4.79 (td, J=8.8, 3.1 Hz, 1H), 3.92 (dd, J=11.7, 6.8 Hz, 1H), 3.78 (t, J=6.4 Hz, 1H), 3.68 (dd, J=8.4, 6.1 Hz, 1H), 3.62 (d, J=3.7 Hz, 2H), 3.45 (dd, J=11.7, 6.0 Hz, 1H), 3.36-3.13 (m, 5H), 2.08-1.95 (m, 1H), 1.88-1.74 (m, 2H), 1.72-1.58 (m, 3H), 0.97 (t, J=7.4 Hz, 3H), 0.92-0.86 (m, 12H); HRMS-ESI (m/z) [M]+ calcd for C17H33NO5, 331.2359; found, 331.2350.


Compound 161 was prepared in a similar manner as described in Example 3, Step 7.


Example 3
Step 8: Preparation of N-((3S,7S,8S,9S)-9-ethyl-7,8-diisobutoxy-2-oxo-1,5-dioxonan-3-yl)-3-hydroxy-4-methoxypicolinamide (compound 21)



embedded image


Compound 21 was prepared in the same manner as described in Example 1, Step 6 to give the title compound as a white solid (60.50 mg, 62%): mp 119-121° C.; 1H NMR (400 MHz, CDCl3) δ 11.95 (s, 1H), 8.73 (d, J=8.0 Hz, 1H), 8.00 (d, J=5.2 Hz, 1H), 6.86 (d, J=5.2 Hz, 1H), 5.03 (ddd, J=8.0, 6.3, 4.2 Hz, 1H), 4.93 (td, J=8.8, 2.9 Hz, 1H), 4.04 (dd, J=12.0, 6.3 Hz, 1H), 3.94 (s, 3H), 3.89 (dd, J=12.0, 4.0 Hz, 1H), 3.85 (d, J=12.0 Hz, 1H), 3.71 (dd, J=8.4, 6.2 Hz, 1H), 3.58 (dd, J=11.6, 6.0 Hz, 1H), 3.37-3.14 (m, 5H), 2.03 (dqd, J=14.9, 7.5, 2.9 Hz, 1H), 1.81 (dp, J=13.2, 6.6 Hz, 2H), 1.72-1.59 (m, 1H), 0.97 (t, J=7.4 Hz, 3H), 0.93-0.86 (m, 12H); 13C NMR (151 MHz, CDCl3) δ 170.53, 169.10, 155.49, 148.90, 140.81, 130.47, 109.71, 84.19, 83.34, 80.50, 77.84, 77.76, 76.80, 74.99, 56.23, 52.79, 29.26, 29.01, 25.30, 19.72, 19.62, 19.60, 19.53, 9.64; HRMS-ESI (m/z) [M]+ calcd for C24H38N2O8, 482.2628; found, 482.2647.


Compounds 25 and 26 were prepared in a similar manner as described in Example 3, Step 8.


Example 4
Step 1: Preparation of benzyl ((3S,7S,8S,9R)-9-ethyl-7,8-bis((2-methylallyl)oxy)-2-oxo-1,5-dioxonan-3-yl)carbamate (compound 90) and benzyl ((3R,7S,8S,9R)-9-ethyl-7,8-bis((2-methylallyl)oxy)-2-oxo-1,5-dioxonan-3-yl)carbamate (compound 91)



embedded image


Compounds 90 and 91 were prepared in the same manner as described in Example 3, Step 6 to give the title compounds as pale yellow oils.


Benzyl ((3R,7S,8S,9R)-9-ethyl-7,8-bis((2-methylallyl)oxy)-2-oxo-1,5-dioxonan-3-yl)carbamate (compound 91) (32.0 mg, 33%): IR (neat) 3320, 2969, 2935, 1754, 1722, 1506, 1455, 1200 cm−1; 1H NMR (400 MHz, CDCl3) δ 7.41-7.26 (m, 5H), 5.74 (d, J=7.5 Hz, 1H), 5.10 (s, 2H), 5.10-5.03 (m, 1H), 4.96 (dd, J=7.9, 0.8 Hz, 2H), 4.89 (d, J=7.8 Hz, 2H), 4.72 (t, J=6.0 Hz, 1H), 4.67-4.63 (m, 1H), 4.08-3.79 (m, 7H), 3.78-3.67 (m, 2H), 3.62 (d, J=12.1 Hz, 1H), 3.45 (ddd, J=6.9, 3.9, 1.4 Hz, 1H), 1.74 (s, 3H), 1.72 (s, 3H), 1.00 (t, J=7.4 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 170.76, 155.95, 142.30, 142.06, 136.40, 128.66, 128.27, 128.15, 113.07, 112.78, 78.09, 76.25, 75.88, 73.94, 71.73, 67.09, 55.51, 22.72, 19.76, 19.67, 10.73; ESIMS m/z 462.2 ([M+H]+).


Benzyl ((3R,7S,8S,9R)-9-ethyl-7,8-bis((2-methylallyl)oxy)-2-oxo-1,5-dioxonan-3-yl)carbamate (compound 91) (34.8 mg, 36%): 1H NMR (400 MHz, CDCl3) 7.42-7.28 (m, 5H), 5.52-5.37 (m, 1H), 5.11 (s, 2H), 5.01 (ddd, J=9.2, 4.8, 2.8 Hz, 1H), 4.98-4.93 (m, 2H), 4.88 (s, 2H), 4.53 (bs, 1H), 4.16-4.09 (m, 1H), 4.04 (d, J=21.7 Hz, 1H), 4.01 (d, J=22.0 Hz, 1H), 3.93 (dd, J=12.2, 3.3 HZ, 2H), 3.87 (dd, J=11.7, 4.1 Hz, 1H) 3.76 (dd, J=11.8, 1.7 Hz, 1H), 3.70 (dd, J=6.4, 2.7 Hz, 1H), 3.55-3.45 (m, 2H), 1.86-1.74 (m, 2H), 1.74 (s, 3H), 1.72 (s, 3H), 0.98 (t, J=7.4 Hz, 3H); ESIMS m/z 462.2 ([M+H]+).


Example 4
Step 2: Preparation of (3S,7S,8S,9R)-3-amino-9-ethyl-7,8-diisobutoxy-1,5-dioxonan-2-one (compound 122)



embedded image


Compound 122 was prepared in the same manner as described in Example 1, Step 5 to give the title compound as a light yellow oil (177 mg, 93%): IR (neat) 2955, 2872, 1745, 1467, 1180, 1081 cm−1; 1H NMR (400 MHz, CDCl3) δ 4.96 (dt, J=10.1, 3.6 Hz, 1H), 4.07 (dd, J=11.7, 3.5 Hz, 1H), 3.90-3.77 (m, 3H), 3.68 (dd, J=7.1, 3.0 Hz, 1H), 3.63 (dd, J=11.7, 1.7 Hz, 1H), 3.42-3.25 (m, 4H), 3.20 (dd, J=8.8, 6.8 Hz, 1H), 1.91-1.76 (m, 3H), 1.76-1.59 (m, 3H), 1.00 (t, J=7.4 Hz, 3H), 0.89 (ddd, J=6.9, 4.0, 1.6 Hz, 12H); HRMS-ESI (m/z) [M]+ calcd for C17H33NO5, 331.2359; found, 331.2373.


Compound 123 was prepared in the same manner as described in Example 4, Step 2 using compound 91 as starting material.


Example 4
Step 3: Preparation of N-((3S,7S,8S,9R)-9-ethyl-7,8-diisobutoxy-2-oxo-1,5-dioxonan-3-yl)-3-hydroxy-4-methoxypicolinamide (compound 19)



embedded image


Compound 19 was prepared in the same manner as described in Example 1, Step 6 to give the title compound as a colorless oil (170 mg, 67%): IR (neat) 3369, 2956, 1751, 1650, 1528, 1242, 1082 cm−1; 1H NMR (400 MHz, CDCl3) δ 12.02 (s, 1H), 8.86 (d, J=8.0 Hz, 1H), 8.00 (d, J=5.2 Hz, 1H), 6.86 (d, J=5.2 Hz, 1H), 5.11-5.02 (m, 2H), 4.17 (dd, J=11.9, 3.6 Hz, 1H), 4.14 (dd, J=11.7, 1.6 Hz, 1H), 3.97 (dd, J=11.7, 5.9 Hz, 1H), 3.94 (s, 3H), 3.78-3.68 (m, 1H), 3.64 (dd, J=11.8, 1.5 Hz, 1H), 3.35 (dtd, J=26.6, 8.9, 6.6 Hz, 4H), 3.21 (dd, J=8.7, 6.8 Hz, 1H), 1.93-1.79 (m, 3H), 1.78-1.65 (m, 1H), 1.02 (t, J=7.4 Hz, 3H), 0.94-0.88 (m, 12H); 13C NMR (101 MHz, CDCl3) δ 170.17, 169.05, 155.37, 148.79, 140.78, 130.57, 109.59, 79.37, 78.70, 78.33, 75.53, 72.63, 56.19, 53.59, 29.03, 28.85, 22.50, 19.60, 19.53, 19.51, 10.85; HRMS-ESI (m/z) [M]+ calcd for C24H38N2O8, 482.2628; found, 482.2642.


Compound 22 was prepared in the same manner as described in Example 4, Step 3 using compound 123 as starting material.


Example 5
Steps 1 to 4: Preparation of (S)-methyl 3-((2S,3R)-2,3-bis(benzyloxy)-4-oxobutoxy)-2-((tert-butoxycarbonyl)amino)propanoate



embedded image


The title compound was prepared in the same manner as described in Example 3, Steps 1 to 4 to give a pale yellow oil (4.85 g, 35% overall yield over four steps): IR (neat) 3380, 2931, 1713, 1498, 1367, 1163 cm−1; 1H NMR (400 MHz, CDCl3) δ 9.64 (d, J=0.8 Hz, 1H), 7.39-7.22 (m, 10H), 5.34 (d, J=8.7 Hz, 1H), 4.73 (d, J=11.9 Hz, 1H), 4.63-4.49 (m, 3H), 4.46-4.37 (m, 1H), 3.99-3.82 (m, 3H), 3.70 (s, 3H), 3.67-3.57 (m, 3H), 1.46 (s, 9H); 13C NMR (101 MHz, CDCl3) δ 202.49, 171.05, 155.60, 137.66, 137.20, 128.68, 128.56, 128.32, 128.08, 82.83, 80.18, 78.00, 73.57, 73.09, 71.73, 69.63, 54.06, 52.60, 28.46; HRMS-ESI (m/z) [M]+ calcd for C27H35NO8, 501.2363; found, 501.2364.


Example 5
Step 5: Preparation of (S)-methyl 3-(((2S,3S,4R)-2,3-bis(benzyloxy)-4-hydroxypentyl)oxy)-2-((tert-butoxycarbonyl)amino)propanoate



embedded image


To a solution of (S)-methyl 3-((2S,3R)-2,3-bis(benzyloxy)-4-oxobutoxy)-2-((tert-butoxycarbonyl)amino)propanoate (0.980 g, 1.95 mmol) in DCM (18.61 ml) at −78° C. was added a 3.0 M solution of methylmagnesium bromide in diethyl ether (Et2O) (1.30 ml, 3.91 mmol) and the reaction was stirred at −70° C. for 1 h, warmed slowly to −20° C. over 2 h, and then quenched at −20° C. with H2O. The organic layer was separated and the aqueous layer was extracted with EtOAc. The combined organic phases were washed with brine, dried over MgSO4, filtered, and the filtrate was concentrated and purified by flash chromatography (SiO2, hexanes/EtOAc gradient) to yield the title compound as a colorless oil (0.475 g, 47%): 1H NMR (400 MHz, CDCl3) δ 7.37-7.27 (m, 10H), 5.43 (d, J=8.6 Hz, 1H), 4.71 (d, J=14.0 Hz, 1H), 4.69 (d, J=14.4 Hz, 1H), 4.55 (dd, J=11.5, 2.6 Hz, 2H), 4.49-4.41 (m, 1H), 3.96-3.84 (m, 2H), 3.75 (dd, J=10.1, 5.0 Hz, 1H), 3.72 (s, 3H), 3.71-3.63 (m, 3H), 3.32-3.29 (m, 1H), 2.26 (d, J=6.3 Hz, 1H), 1.45 (s, 9H), 1.14 (d, J=6.4 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 171.20, 155.58, 138.36, 138.21, 128.59, 128.53, 128.21, 128.07, 128.05, 127.89, 82.88, 80.16, 78.55, 74.94, 73.18, 71.71, 71.34, 67.04, 54.16, 52.58, 28.46, 20.30; ESIMS m/z 516.3 ([M−H]).


Example 5
Step 6: Preparation of tert-butyl ((3R,7S,8S,9R)-7,8-bis(benzyloxy)-9-methyl-2-oxo-1,5-dioxonan-3-yl)carbamate (compound 172) and tert-butyl ((3S,7S,8S,9R)-7,8-bis(benzyloxy)-9-methyl-2-oxo-1,5-dioxonan-3-yl)carbamate (compound 92)



embedded image


Compounds 172 and 92 were prepared in the same manner as described in Example 3, Step 6 to give the title compounds as colorless oils.


tert-Butyl ((3R,7S,8S,9R)-7,8-bis(benzyloxy)-9-methyl-2-oxo-1,5-dioxonan-3-yl)carbamate (compound 172) (104.0 mg, 36%): ESIMS m/z 386.2 ([M-Boc(C5H9O2)+2H]+).


tert-Butyl ((3S,7S,8S,9R)-7,8-bis(benzyloxy)-9-methyl-2-oxo-1,5-dioxonan-3-yl)carbamate (compound 92) (89.7 mg, 31%): 1H NMR (400 MHz, CDCl3) δ 7.42-7.19 (m, 10H), 5.31-5.19 (m, 1H), 5.18-5.02 (m, 1H), 4.67 (dd, J=16.0, 11.7 Hz, 2H), 4.60-4.52 (m, 1H), 4.51-4.40 (m, 1H), 4.18-4.08 (m, 2H), 3.92 (dd, J=11.7, 3.9 Hz, 1H), 3.85-3.75 (m, 2H), 3.59-3.53 (m, 1H), 3.43 (dd, J=11.5, 5.5 Hz, 1H), 1.44 (s, 9H), 1.36 (d, J=6.8 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 169.03, 154.68, 138.23, 138.17, 128.54, 128.53, 128.12, 128.00, 127.97, 127.85, 77.97, 74.40, 73.44, 72.31, 72.14, 71.61, 28.43, 15.64; ESIMS m/z 484.3 ([M−H]).


Compounds 130 and 131 were prepared in the same manner as described in Example 5, Steps 1 to 6 using (−)-dimethyl D-tartrate as starting material.


Example 5
Step 7: Preparation of (3R,7S,8S,9R)-3-amino-7,8-bis(benzyloxy)-9-methyl-1,5-dioxonan-2-one hydrochloride (compound 124)



embedded image


To a solution of tert-butyl ((3R,7S,8S,9R)-7,8-bis(benzyloxy)-9-methyl-2-oxo-1,5-dioxonan-3-yl)carbamate (104.0 mg, 0.214 mmol) in DCM (1.20 mL) was added a 4.0 M solution of HCl in dioxane (1.07 mL, 4.28 mmol) and the reaction was stirred at room temperature for 2 h. The solvent was removed under vacuum and the residue was dried under high vacuum to yield the title compound as an off-white oil (85.0 mg, 94%): IR (neat) 3365, 1636, 1235, 1063 cm−1; 1H NMR (400 MHz, CDCl3) δ 8.76 (bs, 2H), 7.35-7.20 (m, 10H), 5.30 (s, 1H), 4.69-4.45 (m, 5H), 4.20 (d, J=9.1 Hz, 2H), 3.89-3.75 (m, 2H), 3.59 (d, J=11.1 Hz, 1H), 3.47 (d, J=7.1 Hz, 1H), 1.32 (d, J=6.8 Hz, 3H); HRMS-ESI (m/z) [M]+ calcd for C22H27NO5, 385.1889; found, 385.1890.


Compound 173 was prepared in the same manner as described in Example 5, Step 7 using compound 92 as starting material.


Compounds 188 was prepared in a similar manner as described in Example 5, Step 7 using compound 156 as starting material.


Compounds 133 and 134 were prepared in the same manner as described in Example 5, Step 7 using compounds 130 and 131, respectively as starting materials.


Compound 272 was prepared in the same manner as described in Example 5, Step 7 using compound 241 as starting material.


Example 5
Step 8: Preparation of N-((3R,7S,8S,9R)-7,8-bis(benzyloxy)-9-methyl-2-oxo-1,5-dioxonan-3-yl)-3-hydroxy-4-methoxypicolinamide (compound 30)



embedded image


To a mixture of (3R,7S,8S,9R)-3-amino-7,8-bis(benzyloxy)-9-methyl-1,5-dioxonan-2-one hydrochloride (85.0 mg, 0.2015 mmol) and 3-hydroxy-4-methoxypicolinic acid (54.0 mg, 0.321 mmol) in DCM (1.20 mL) was added 4-methylmorpholine (0.141 mL, 1.29 mmol) followed by HATU (135.0 mg, 0.343 mmol) and the mixture was stirred at room temperature for 4 h. The reaction mixture was directly purified by flash chromatography (SiO2, hexanes/EtOAc gradient) to yield the title compound as a colorless oil (65.4 mg, 61%): IR (neat) 3368, 2933, 1748, 1648, 1527, 1242, 1066 cm−1; 1H NMR (400 MHz, CDCl3) δ 11.98 (s, 1H), 8.86 (d, J=8.0 Hz, 1H), 8.01 (d, J=5.2 Hz, 1H), 7.41-7.27 (m, 10H), 6.86 (d, J=5.2 Hz, 1H), 5.36 (qd, J=6.7, 3.1 Hz, 1H), 5.06 (ddd, J=8.0, 6.1, 1.9 Hz, 1H), 4.71 (d, J=11.4 Hz, 1H), 4.68 (d, J=11.8 Hz, 1H), 4.60 (d, J=11.3 Hz, 1H), 4.58 (d, J=11.8 Hz, 1H), 4.16 (dd, J=12.2, 3.6 Hz, 1H), 4.12 (dd, J=9.4, 2.2 Hz, 2H), 3.98 (dd, J=11.7, 6.1 Hz, 1H), 3.94 (s, 3H), 3.71 (dd, J=11.9, 1.7 Hz, 1H), 3.57-3.50 (m, 1H), 1.38 (d, J=6.8 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 169.86, 169.07, 155.41, 148.82, 140.81, 138.27, 138.10, 130.51, 128.58, 128.54, 128.14, 128.05, 128.00, 127.85, 109.64, 78.70, 75.15, 74.37, 72.35, 71.55, 56.21, 53.37, 15.28; HRMS-ESI (m/z) [M]+ calcd for C29H32N2O8, 536.2159; found, 536.2162.


Compound 49 was prepared in the same manner as described in Example 5, Step 8 using compound 173 as starting material.


Compounds 38 and 39 were prepared in the same manner as described in Example 5, Step 8 using compounds 133 and 134, respectively, as starting materials.


Example 6
Step 1 to 3: Preparation of (S)-methyl 2-(((benzyloxy)carbonyl)-amino)-3-(((2S,3S,4R)-4-hydroxy-2,3,5-tris((2 methylallyl)oxy)pentyl)oxy)propanoate



embedded image


(S)-methyl 2-(((benzyloxy)carbonyl)amino)-3-(((2S,3S,4R)-4-hydroxy-2,3,5-tris((2 methylallyl)oxy)pentyl)oxy)propanoate was prepared starting from D-xylono-1,4-lactone as described in Example 1, Steps 1 to 3: 1H NMR (400 MHz, CDCl3) δ 7.42-7.26 (m, 5H), 5.92-5.76 (d, J=8.8 Hz, 1H), 5.22-5.01 (s, 2H), 5.01-4.79 (m, 6H), 4.54-4.43 (m, 1H), 4.10-4.06 (m, 1H), 4.00-3.83 (m, 6H), 3.77-3.72 (s, 3H), 3.72-3.59 (m, 5H), 3.56-3.52 (dd, J=5.2, 2.8 Hz, 1H), 3.47-3.41 (dd, J=6.2, 1.4 Hz, 2H), 2.53-2.43 (d, J=6.8 Hz, 1H), 1.75-1.73 (s, 3H), 1.73-1.70 (s, 6H); 13C NMR (101 MHz, CDCl3) δ 170.70, 156.09, 142.27, 142.13, 141.96, 136.30, 128.48, 128.45, 128.11, 128.05, 112.52, 112.28, 78.33, 77.76, 76.40, 75.16, 74.75, 71.41, 71.21, 71.11, 69.25, 67.00, 54.50, 52.51, 19.68, 19.54, 19.46; ESIMS m/z 550.3 ([M+H]+).


Example 6
Step 4: Preparation of benzyl (3S,7S,8R,9R)-7,8-bis(2-methylallyloxy)-9-((2-methylallyloxy)methyl)-2-oxo-1,5-dioxonan-3-ylcarbamate (compound 153) and (3R,7S,8R,9R)-7,8-bis(2-methylallyloxy)-9-((2-methylallyloxy)methyl)-2-oxo-1,5-dioxonan-3-ylcarbamate (compound 154)



embedded image


A solution of (S)-2-(benzyloxycarbonylamino)-3-((2S,3S,4R)-4-hydroxy-2,3,5-tris(2-methylallyloxy)pentyloxy)propanoic acid (400 mg, 0.747 mmol) in anhydrous toluene (400 mL) was added to a solution of MNBA (411 mg, 1.195 mmol) and DMAP (547 mg, 4.48 mmol) in toluene (1600 mL) over the course of 3 h via syringe pump. After the addition was complete, the reaction mixture was stirred for 1 h, concentrated, and the residue purified by flash chromatography (SiO2, 200 EtOAc/hexanes) to furnish benzyl (3S,7S,8R,9R)-7,8-bis(2-methylallyloxy)-9-((2-methylallyloxy)methyl)-2-oxo-1,5-dioxonan-3-ylcarbamate (140 mg, 36%) and (3R,7S,8R,9R)-7,8-bis(2-methylallyloxy)-9-((2-methylallyloxy)methyl)-2-oxo-1,5-dioxonan-3-ylcarbamate as white foams (140 mg, 36%).


For (3S,7S,8R,9R)-7,8-bis(2-methylallyloxy)-9-((2-methylallyloxy)methyl)-2-oxo-1,5-dioxonan-3-ylcarbamate (compound 153): 1H NMR (400 MHz, CDCl3) δ 7.42-7.27 (m, 6H), 5.74 (d, J=7.7 Hz, 1H), 5.36-5.25 (m, 1H), 5.10 (d, J=1.6 Hz, 2H), 5.00-4.84 (m, 6H), 4.80-4.71 (m, 1H), 4.12 (dd, J=12.0, 3.5 Hz, 1H), 4.09-3.78 (m, 9H), 3.77-3.65 (m, 2H), 3.57-3.45 (m, 1H), 1.78-1.68 (m, 9H); 13C NMR (101 MHz, CDCl3) δ 170.29, 155.78, 142.14, 141.92, 141.86, 141.74, 136.23, 128.56, 128.51, 128.14, 128.00, 112.95, 112.71, 112.41, 77.22, 76.30, 76.19, 75.77, 75.19, 75.22, 73.82, 67.08, 66.96, 55.29, 19.61, 19.52, 19.45; ESIMS m/z 541.3 ([M+Na]+).


For (3R,7S,8R,9R)-7,8-bis(2-methylallyloxy)-9-((2-methylallyloxy)methyl)-2-oxo-1,5-dioxonan-3-ylcarbamate (compound 154): 1H NMR (400 MHz, CDCl3) δ 7.44-7.28 (m, 6H), 5.49 (d, J=9.0 Hz, 1H), 5.24 (td, J=5.7, 3.2 Hz, 1H), 5.09 (s, 2H), 5.00-4.83 (m, 6H), 4.60-4.52 (m, 1H), 4.19 (dd, J=11.6, 6.0 Hz, 1H), 4.04 (t, J=12.7 Hz, 1H), 4.00-3.85 (m, 6H), 3.83-3.77 (m, 1H), 3.76-3.61 (m, 2H), 3.55 (ddd, J=7.0, 3.9, 1.6 Hz, 1H), 3.51-3.38 (m, 1H), 1.74-1.72 (m, 9H). ESIMS m/z 541.2 ([M+Na]+).


Example 6
Step 5: Preparation of (3S,7S,8R,9R)-3-amino-7,8-diisobutoxy-9 (isobutoxy-methyl)-1,5-dioxonan-2-one (compound 189)



embedded image


Compound 189 was prepared in the same manner as described in Example 1, step 5 from compound 153 to give a white foam: 1H NMR (400 MHz, CDCl3) δ 5.18 (td, J=5.5, 3.3 Hz, 1H), 4.14-4.05 (m, 1H), 3.92-3.80 (m, 2H), 3.76-3.66 (m, 3H), 3.46-3.30 (m, 4H), 3.25 (d, J=6.6 Hz, 2H), 3.23-3.14 (m, 2H), 1.93-1.77 (m, 4H), 0.97-0.83 (m, 19H).


Compound 190 was prepared in the manner as described in Example 6, step 5 starting from compound 154.


Example 6
Step 6: Preparation of N-((3S,7S,8R,9R)-7,8-diisobutoxy-9-(isobutoxymethyl)-2-oxo-1,5-dioxonan-3-yl)-3-hydroxy-4-methoxypicolinamide (compound 15)



embedded image


Compound 15 was prepared as described in Example 1, Step 6 starting from compound 189: 1H NMR (400 MHz, CDCl3) δ 12.00 (d, J=0.7 Hz, 1H), 8.86 (d, J=8.1 Hz, 1H), 8.01 (d, J=5.2 Hz, 1H), 6.87 (dd, J=5.2, 0.6 Hz, 1H), 5.33-5.23 (m, 1H), 5.09 (ddd, J=7.9, 6.0, 1.7 Hz, 1H), 4.24-4.07 (m, 2H), 3.99 (dd, J=11.7, 6.1 Hz, 1H), 3.93 (s, 3H), 3.92-3.86 (m, 1H), 3.82-3.67 (m, 3H), 3.46-3.39 (m, 2H), 3.34 (td, J=9.1, 6.5 Hz, 2H), 3.27 (d, J=6.6 Hz, 2H), 3.20 (dd, J=8.9, 6.9 Hz, 1H), 1.97-1.79 (m, 3H), 0.96-0.87 (m, 18H); 13C NMR (101 MHz, CDCl3) δ 169.72, 168.89, 155.24, 148.66, 140.64, 130.39, 109.47, 79.21, 78.31, 76.84, 75.42, 73.40, 72.61, 67.95, 56.05, 53.39, 28.84, 28.70, 28.47, 19.49, 19.39; ESIMS m/z 541.4 ([M+H]+).


Compound 16 was prepared in the same manner as described in Example 6, Step 6 from compound 190.


Example 7
Step 1: Preparation of (S)-methyl 3-(((2S,3S,4S)-2,3-bis(benzyloxy)-4-hydroxypentyl)oxy)-2-((tert-butoxycarbonyl)amino)propanoate



embedded image


To a solution of (S)-methyl 3-((2S,3R)-2,3-bis(benzyloxy)-4-oxobutoxy)-2-((tert-butoxycarbonyl)amino)propanoate (7.55 g, 15.05 mmol) in DCM (30 ml) and THF (30 ml) at −78° C. was added triisopropoxy(methyl)titanium, 1.0 M in THF (31.6 ml, 31.6 mmol) and the reaction was stirred at −78° C. for 2 h, warmed to −20° C., and stored at −20° C. overnight. The reaction was warmed to 0° C., stirred for 4 h between 0° C. and −10° C., and then quenched at this temperature with saturated aqueous NH4Cl. The reaction mixture was extracted with EtOAc, and the combined extracts were washed with brine, dried over MgSO4, filtered, and concentrated. The crude residue was purified by flash chromatography (SiO2, hexanes/EtOAc) to yield the title compound as a colorless oil (4.59 g, 59%, diastereomer selectivity=6:1): 1H NMR (400 MHz, CDCl3) δ 7.45-7.14 (m, 11H), 5.45 (d, J=8.8 Hz, 1H), 4.67 (d, J=11.6 Hz, 1H), 4.61-4.51 (m, 3H), 4.50-4.41 (m, 1H), 3.90 (dd, J=9.4, 3.0 Hz, 1H), 3.84-3.78 (m, 1H), 3.74-3.61 (m, 6H), 3.31 (dd, J=6.8, 4.0 Hz, 1H), 2.85 (d, J=4.5 Hz, 1H), 1.45 (s, 9H), 1.20 (d, J=6.2 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 171.04, 155.45, 137.99, 137.76, 128.51, 128.44, 128.12, 128.00, 127.97, 127.87, 81.43, 80.05, 77.91, 73.55, 72.88, 71.60, 70.91, 67.53, 54.00, 52.47, 28.34, 19.89; ESIMS m/z 540.6 ([M+Na]+).


Example 7
Step 2: Preparation of tert-butyl ((3S,7S,8S,9S)-7,8-bis(benzyloxy)-9-methyl-2-oxo-1,5-dioxonan-3-yl)carbamate (compound 93)



embedded image


Compound 93 was prepared in the same manner as described in Example 1, Step 4 to give the title compound as an off-white solid (74.5 mg, 73%): mp 69-71° C.; IR (neat) 3349, 2978, 2933, 2876, 1753, 1710, 1497, 1367, 1249, 1161, 1074, 734, 697 cm−1; 1H NMR (400 MHz, CDCl3) δ 7.38-7.19 (m, 11H), 5.38-5.20 (d, J=7.9 Hz, 1H), 5.08-4.96 (dq, J=8.2, 6.1 Hz, 1H), 4.96-4.88 (d, J=10.8 Hz, 1H), 4.76-4.48 (m, 3H), 4.02-3.85 (dd, J=11.8, 6.3 Hz, 2H), 3.77-3.55 (m, 2H), 3.52-3.34 (m, 2H), 1.48-1.36 (s, 12H); 13C NMR (101 MHz, CDCl3) δ 171.24, 155.11, 138.11, 137.93, 128.40, 128.38, 127.94, 127.86, 127.74, 84.76, 83.57, 80.17, 75.79, 75.50, 74.90, 72.94, 72.70, 53.72, 28.28, 18.69; ESIMS m/z 508.6 ([M+Na]+).


Example 7
Step 3: Preparation of tert-butyl N-tert-butoxycarbonyl-N-[(3S,7S,8S,9S)-7,8-dibenzyloxy-9-methyl-2-oxo-1,5-dioxonan-3-yl]carbamate (compound 192)



embedded image


To a solution of tert-butyl ((3S,7S,8S,9S)-7,8-bis(benzyloxy)-9-methyl-2-oxo-1,5-dioxonan-3-yl)carbamate (6.65 g, 13.70 mmol) in anhydrous CH3CN (62 mL) was added DMAP (0.837 g, 6.85 mmol) followed by di-tertibutyl dicarbonate (6.36 ml, 27.4 mmol) at room temperature, and the mixture was stirred overnight at room temperature. The crude residue was purified by flash chromatography (SiO2, hexanes/EtOAc) to yield the title compound as a colorless oil (7.10 g, 89%): 1H NMR (400 MHz, CDCl3) δ 7.38-7.23 (m, 10H), 5.24 (dd, J=8.9, 3.9 Hz, 1H), 4.98-4.82 (m, 2H), 4.70-4.54 (m, 3H), 4.26 (dd, J=12.2, 3.9 Hz, 1H), 4.03-3.88 (m, 2H), 3.63 (dd, J=10.9, 7.2 Hz, 1H), 3.58-3.50 (m, 1H), 3.50-3.42 (m, 1H), 1.50 (s, 18H), 1.43 (d, J=6.3 Hz, 3H); ESIMS m/z 609.6 ([M+Na]+).


Example 7
Step 4: Preparation of tert-butyl N-tert-butoxycarbonyl-N-[(3S,7S,8R,9S)-7,8-dihydroxy-9-methyl-2-oxo-1,5-dioxonan-3-yl]carbamate (compound 191)



embedded image


To a solution of tert-butyl N-tert-butoxycarbonyl-N-[(3S,7S,8S,9S)-7,8-dibenzyloxy-9-methyl-2-oxo-1,5-dioxonan-3-yl]carbamate (3.8 g, 6.49 mmol) in EtOAc (10 mL) in a 50 mL high pressure reactor with a stir bar was added 5% Pd/C (500 mg, 0.235 mmol). After the reactor was sealed, it was evacuated and purged with H2 (4×), and then charged to ˜600 psi of H2 at room temperature. The reaction mixture was warmed to 45° C. and stirred for 5 h. The reaction mixture was filtered through a pad of Celite® and the filtrate concentrated to yield the title compound as a white foam (2.63 g, 100%): 1H NMR (400 MHz, CDCl3) δ 5.25 (dd, J=8.7, 2.8 Hz, 1H), 4.94-4.76 (m, 1H), 4.26 (dd, J=12.3, 2.9 Hz, 1H), 4.06 (dd, J=10.7, 1.3 Hz, 1H), 3.91 (dd, J=12.3, 8.7 Hz, 1H), 3.62-3.54 (m, 1H), 3.54-3.38 (m, 2H), 3.15 (d, J=4.0 Hz, 1H), 2.96 (d, J=3.5 Hz, 1H), 1.51 (s, 18H), 1.46 (d, J=6.3 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 168.63, 152.70, 83.18, 79.34, 77.96, 74.40, 74.25, 73.02, 58.54, 27.98, 18.60; ESIMS m/z 428.5 ([M+Na]+).


Example 7
Step 5: Preparation of tert-butyl N-tert-butoxycarbonyl-N-[(3S,7S,8S,9S)-7,8-diallyloxy-9-methyl-2-oxo-1,5-dioxonan-3-yl]carbamate (compound 94)



embedded image


To a stirred solution of tert-butyl N-tert-butoxycarbonyl-N-[(3S,7S,8R,9S)-7,8-dihydroxy-9-methyl-2-oxo-1,5-dioxonan-3-yl]carbamate (170 mg, 0.419 mmol), Pd2(dba)3 (38.4 mg, 0.042 mmol) and dppf (46.5 mg, 0.084 mmol) in anhydrous THF (4.0 mL) was added allyl tert-butyl carbonate (332 mg, 2.096 mmol) and the resulting mixture was warmed to 60° C. and stirred for 1 h. The reaction was concentrated and the residue purified by flash chromatography (SiO2, EtOAc/hexanes) to yield the title compound as a light yellow oil (170 mg, 83%): 1H NMR (400 MHz, CDCl3) δ 6.02-5.78 (m, 2H), 5.30-5.10 (m, 5H), 4.81 (dq, J=9.5, 6.3 Hz, 1H), 4.38 (ddd, J=12.2, 5.5, 1.4 Hz, 1H), 4.24 (dd, J=12.1, 4.1 Hz, 1H), 4.17-4.02 (m, 3H), 3.95-3.81 (m, 2H), 3.54 (dd, J=10.9, 7.2 Hz, 1H), 3.41-3.21 (m, 2H), 1.50 (s, 18H), 1.42 (d, J=6.3 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 169.00, 152.64, 134.93, 134.80, 116.95, 116.78, 84.63, 83.06, 82.84, 75.93, 74.68, 72.85, 72.62, 71.85, 57.94, 27.97, 18.74; ESIMS m/z 509.2 ([M+Na]+).


Compounds 97, 135 and 136 were prepared in the same manner as described in Example 7, Step 5.


Example 7
Step 6: Preparation of tert-butyl N-tert-butoxycarbonyl-N-[(3S,7S,8S,9S)-9-methyl-2-oxo-7,8-dipropoxy-1,5-dioxonan-3-yl]carbamate (compound 137)



embedded image


To a solution of tert-butyl N-tert-butoxycarbonyl-N-[(3S,7S,8S,9S)-7,8-diallyloxy-9-methyl-2-oxo-1,5-dioxonan-3-yl]carbamate (170 mg, 0.350 mmol) in EtOAc (3 mL) in a 50 mL high pressure reactor with a stir bar was added 5% Pd/C (20.0 mg, 9.40 μmol). After the reactor was sealed, it was purged with H2 (4×), and charged to ˜600 psi with H2 at room temperature. The reaction mixture was warmed to 40° C. and stirred for 2 h. The reaction mixture was filtered through a pad of Celite® and the filtrate concentrated to provide the title compound as a colorless oil (170 mg, 99%): 1H NMR (400 MHz, CDCl3) δ 5.21 (dd, J=8.9, 4.2 Hz, 1H), 4.77 (dq, J=9.3, 6.2 Hz, 1H), 4.26 (dd, J=12.1, 4.2 Hz, 1H), 3.92 (dd, J=12.1, 8.9 Hz, 1H), 3.86-3.77 (m, 2H), 3.60-3.41 (m, 4H), 3.29-3.12 (m, 2H), 1.67-1.52 (m, 2H), 1.49 (s, 19H), 1.42 (d, J=6.4 Hz, 3H), 0.92 (td, J=7.4, 2.8 Hz, 7H); 13C NMR (101 MHz, CDCl3) δ 169.04, 152.59, 84.88, 83.40, 82.95, 75.71, 75.41, 72.78, 72.65, 72.55, 57.88, 27.91, 23.48, 23.27, 18.62, 10.59, 10.57; ESIMS m/z 513.3 ([M+Na]+).


Compounds 98, 138, 141, and 189 were prepared in the same manner as described in Example 7, Step 6.


Compound 240 was prepared in the same manner as described in Example 7, Step 6.


Example 7
Step 7: Preparation of (3S,7S,8S,9S)-9-methyl-2-oxo-7,8-dipropoxy-1,5-dioxonan-3-aminium chloride (compound 139)



embedded image


Compound 139 was prepared as described in example 5, step 7: 1H NMR (400 MHz, CDCl3) δ 8.67 (s, 3H), 4.91 (dq, J=8.7, 6.2 Hz, 1H), 4.55 (dd, J=6.7, 4.1 Hz, 1H), 4.28 (dd, J=12.8, 4.1 Hz, 1H), 4.05 (dd, J=12.8, 6.7 Hz, 1H), 3.90-3.73 (m, 2H), 3.58-3.38 (m, 4H), 3.23-3.09 (m, 2H), 1.56 (dddd, J=8.6, 7.0, 5.2, 2.4 Hz, 4H), 1.44 (d, J=6.3 Hz, 3H), 0.91 (td, J=7.4, 1.6 Hz, 6H); 13C NMR (101 MHz, CDCl3) δ 168.56, 84.88, 83.28, 76.08, 75.58, 73.93, 72.69, 70.96, 53.41, 23.50, 23.31, 18.50, 10.63; ESIMS m/z 290.7 ([M+H]+).


Compounds 140, 143 and 175 were prepared in the same manner as described in Example 7, Step 7.


Example 7
Step 8: Preparation of 3-hydroxy-4-methoxy-N-((3S,7S,8S,9S)-9-methyl-2-oxo-7,8-dipropoxy-1,5-dioxonan-3-yl)picolinamide (compound 58)



embedded image


Compound 58 was prepared in the same manner as described in Example 5, Step 8: 1H NMR (400 MHz, CDCl3) δ 11.92 (s, 1H), 8.56 (d, J=8.2 Hz, 1H), 8.00 (d, J=5.2 Hz, 1H), 6.87 (d, J=5.2 Hz, 1H), 5.03 (ddd, J=8.2, 6.8, 5.1 Hz, 1H), 4.99-4.89 (m, 1H), 4.07 (dd, J=11.9, 6.8 Hz, 1H), 3.94 (s, 3H), 3.88-3.76 (m, 3H), 3.65-3.43 (m, 4H), 3.26-3.14 (m, 2H), 1.67-1.53 (m, 4H), 1.46 (d, J=6.3 Hz, 3H), 0.92 (td, J=7.4, 3.1 Hz, 6H); 13C NMR (101 MHz, CDCl3) δ 170.33, 168.99, 155.38, 148.79, 140.66, 130.30, 109.60, 85.00, 83.58, 75.59, 75.38, 73.96, 73.23, 72.74, 56.09, 52.17, 23.53, 23.30, 18.60, 10.65, 10.62; ESIMS m/z 442.1 ([M+H]+).


Compounds 59, 62 and 67 were prepared in the same manner as described in Example 7, Step 8.


Example 8
Step 1: Preparation of (2S,3S,4S)-2,3-bis(benzyloxy)pentane-1,4-diol



embedded image


A mixture of (2S,3S,4S)-3,4-bis(benzyloxy)-2-methyl-3,4-dihydro-2H-pyran (0.621 g, 2.00 mmol) and NaHCO3 (17.0 mg, 0.200 mmol) in MeOH (0.22 ml) and DCM (7 mL) was treated with ozone at −78° C. until the solution became light blue in color. The mixture was purged with nitrogen until colorless, diluted with MeOH (7 mL), and treated with a solution of NaBH4 (0.454 g, 12.0 mmol) and NaOAc (0.335 g, 4.08 mmol) in H2O (7 mL). The mixture was slowly warmed to room temperature and stirred for 12 h. The mixture was diluted with EtOAc and washed with H2O. The organic layer was separated and the aqueous layer was extracted with EtOAc. The combined organic phases were washed with brine, dried over MgSO4, filtered, and the filtrate concentrated. The crude residue was purified by flash chromatography (SiO2, hexanes/EtOAc gradient) to yield the title compound as a colorless oil (0.590 g, 93%): IR (neat) 3389, 2876, 1453, 1064, 733, 696 cm−1; 1H NMR (400 MHz, CDCl3) δ 7.39-7.27 (m, 10H), 4.64 (s, 2H), 4.63 (s, 2H), 4.06-3.97 (m, 1H), 3.92-3.83 (m, 1H), 3.80-3.73 (m, 2H), 3.47 (dd, J=6.2, 4.3 Hz, 1H), 2.92 (d, J=4.9 Hz, 1H), 2.23 (dd, J=6.9, 4.9 Hz, 1H), 1.24 (d, J=6.4 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 137.91, 137.71, 128.69, 128.62, 128.23, 128.19, 128.09, 81.72, 79.53, 73.63, 72.78, 67.66, 61.45, 19.74; ESIMS m/z 339.2 ([M+Na]+).


Example 8
Step 2: Preparation of (S)-methyl 3-(((2S,3S,4S)-2,3-bis(benzyloxy)-4-hydroxypentyl)oxy)-2-((tert-butoxycarbonyl)amino)propanoate and (S)-methyl 3-(((2S,3S,4S)-3,4-bis(benzyloxy)-5-hydroxypentan-2-yl)oxy)-2-((tert-butoxycarbonyl)amino)propanoate



embedded image


The title compounds were prepared in a similar manner as described in Example 1, Step 3 to give colorless oils.


(S)-Methyl 3-(((2S,3S,4S)-2,3-bis(benzyloxy)-4-hydroxypentyl)oxy)-2-((tert-butoxycarbonyl)amino)propanoate: See Example 7, Step 1


(S)-methyl 3-(((2S,3S,4S)-3,4-bis(benzyloxy)-5-hydroxypentan-2-yl)oxy)-2-((tert-butoxycarbonyl)amino)propanoate: IR (neat) 3439, 2977, 1707, 1497, 1367, 1161, 1062, 734, 698 cm−1; 1H NMR (400 MHz, CDCl3) δ 7.38-7.24 (m, 10H), 5.36 (d, J=8.6 Hz, 1H), 4.70-4.55 (m, 4H), 4.47-4.36 (m, 1H), 3.80-3.53 (m, 7H), 3.67 (s, 3H), 2.10-2.00 (m, 1H), 1.46 (s, 9H), 1.25 (d, J=6.0 Hz, 3H); ESIMS m/z 540.3 ([M+Na]+).


Example 8
Steps 3 to 5: Preparation of N-((3S,7S,8S,9S)-7,8-bis(benzyloxy)-9-methyl-2-oxo-1,5-dioxonan-3-yl)-3-hydroxy-4-methoxypicolinamide (compound 11)



embedded image


Compound 11 was prepared in three steps: Step 3 was performed in the same manner as described in Example 1, Step 4 to give compound 93 (see Example 7, Step 2); Step 4 was performed in the same manner as described in Example 5, Step 7 to give compound 174; Step 5 was performed in the same manner as described in Example 5, Step 8 to give the title compound as a white solid (137.0 mg, 45% overall yield over three steps): mp 144-146° C.; IR (neat) 3363, 2935, 1749, 1648, 1527, 1263, 1076 cm−1; 1H NMR (400 MHz, CDCl3) δ 11.93 (s, 1H), 8.69 (d, J=8.1 Hz, 1H), 8.00 (d, J=5.2 Hz, 1H), 7.37-7.25 (m, 10H), 6.87 (d, J=5.2 Hz, 1H), 5.13-5.02 (m, 2H), 4.95 (d, J=10.8 Hz, 1H), 4.70-4.61 (m, 2H), 4.62 (d, J=10.8 Hz, 1H), 4.07 (dd, J=11.9, 6.7 Hz, 1H), 4.02-3.96 (m, 1H), 3.94 (s, 3H), 3.87 (dd, J=11.9, 4.8 Hz, 1H), 3.70 (dd, J=11.3, 6.6 Hz, 1H), 3.56-3.45 (m, 2H), 1.46 (d, J=6.3 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 170.31, 169.11, 155.47, 148.87, 140.82, 138.23, 138.06, 130.35, 128.56, 128.54, 128.11, 128.01, 127.91, 109.72, 84.84, 83.68, 75.95, 75.78, 74.38, 73.14, 73.12, 56.23, 52.40, 18.85; ESIMS m/z 537 ([M+H]+); HRMS-ESI (m/z) [M]+ calcd for C29H32N2O8, 536.2159; found, 536.2150.


Example 9
Step 1: Preparation of (2S,3S,4S)-4-(benzyloxy)-2-methyl-3,4-dihydro-2H-pyran-3-ol and (2S,3R,4S)-3-(benzyloxy)-2-methyl-3,4-dihydro-2H-pyran-4-ol



embedded image


To a stirred solution of (2S,3S,4S)-2-methyl-3,4-dihydro-2H-pyran-3,4-diyl diacetate (20.0 g, 93.0 mmol) in DCM (934 ml) were added (bromomethyl)benzene (11.6 ml, 98.0 mmol), tetrabutylammonium iodide (17.2 g, 46.7 mmol) and a 50% aqueous NaOH solution (49.3 ml, 934 mmol). The resulting mixture was stirred at room temperature for 16 h and then diluted with H2O. The organic phase was separated and the aqueous layer was extracted with DCM. The combined organic phases were washed with H2O and brine, dried over Na2SO4, filtered, and concentrated to give a colorless oil, which was dissolved in MeOH (150 mL) and treated with potassium carbonate (K2CO3; 1.29 g, 9.34 mmol). The reaction mixture was stirred at room temperature for 16 h, concentrated and filtered through a shourt plug of SiO2 (EtOAc as eluent) to give a pale-yellow filtrate, from which some tetrabutylammonium iodide precipitated out during the filtration. The precipitate was removed by a second filtration and the filtrate was concentrated and purified by flash chromatography (SiO2, hexanes/EtOAc gradient) to yield the title compounds.


(2S,3S,4S)-4-(Benzyloxy)-2-methyl-3,4-dihydro-2H-pyran-3-ol (0.932 g, 5%) as a light yellow oil: IR (neat) 3416, 2933, 1722, 1645, 1453, 1267, 1049, 735, 698 cm−1; 1H NMR (400 MHz, CDCl3) δ 7.42-7.24 (m, 5H), 6.35 (dd, J=6.1, 1.4 Hz, 1H), 4.85 (dd, J=6.2, 2.2 Hz, 1H), 4.70 (d, J=11.7 Hz, 1H), 4.55 (d, J=11.7 Hz, 1H), 4.05 (dt, J=7.0, 1.9 Hz, 1H), 3.89 (dq, J=9.3, 6.3 Hz, 1H), 3.65-3.58 (m, 1H), 2.31 (bs, 1H), 1.38 (d, J=6.4 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 145.12, 138.42, 128.68, 127.98, 127.96, 99.83, 77.00, 74.59, 72.85, 70.63, 17.29.


(2S,3R,4S)-3-(Benzyloxy)-2-methyl-3,4-dihydro-2H-pyran-4-ol (6.82 g, 33%) as a white solid.


Example 9
Step 2: Preparation of (2S,3S,4S)-4-(benzyloxy)-3-butoxy-2-methyl-3,4-dihydro-2H-pyran



embedded image


To a solution of (2S,3S,4S)-4-(benzyloxy)-2-methyl-3,4-dihydro-2H-pyran-3-ol (0.100 g, 0.454 mmol) in DMF (2.67 ml) at 0° C. was added NaH (45.0 mg, 1.13 mmol, 60% dispersion in mineral oil) and the reaction was stirred for 20 min at 0° C. Tetrabutylammonium iodide (34.0 mg, 0.091 mmol) and 1-iodobutane (0.20 mL, 1.76 mmol) were added and the reaction was stirred at room temperature for 18 h. The reaction was cooled to 0° C., additional NaH in (23.0 mg, 0.575 mmol) and 1-iodobutane (0.10 mL, 0.879 mmol) were added, and the reaction was warmed to 70° C. and stirred for 4 h. The reaction was cooled to room temperature, quenched with H2O, and extracted with EtOAc. The organic layer was separated and the aqueous layer was further extracted with EtOAc. The combined organic phases were washed with brine, dried over MgSO4, filtered, and concentrated to yield a pale-yellow oil. Purification of the crude oil by flash chromatography (SiO2, hexanes/EtOAc gradient) yielded the title compound as a colorless oil (93.0 mg, 74%): IR (neat) 2933, 2871, 1646, 1453, 1239, 1107, 1056, 734, 697 cm−1; 1H NMR (400 MHz, CDCl3) δ 7.41-7.24 (m, 5H), 6.34 (dd, J=6.1, 1.3 Hz, 1H), 4.83 (dd, J=6.1, 2.5 Hz, 1H), 4.67 (d, J=11.7 Hz, 1H), 4.59 (d, J=11.7 Hz, 1H), 4.11 (ddd, J=6.5, 2.2, 1.6 Hz, 1H), 3.89 (ddd, J=13.5, 9.3, 6.7 Hz, 1H), 3.83 (dt, J=9.2, 6.5 Hz, 1H), 3.63 (dt, J=9.2, 6.6 Hz, 1H), 3.30 (dd, J=9.0, 6.6 Hz, 1H), 1.64-1.51 (m, 2H), 1.44-1.33 (m, 2H), 1.38 (d, J=6.4 Hz, 3H), 0.92 (t, J=7.4 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 144.82, 138.69, 128.49, 127.81, 127.69, 100.49, 80.35, 76.53, 74.29, 72.32, 70.83, 32.52, 19.47, 17.53, 14.06; HRMS-ESI (m/z) [M]+ calcd for C17H24O3, 276.1725; found, 276.1710.


Example 9
Steps 3 to 5: Preparation of tert-butyl ((3S,7S,8S,9S)-7-(benzyloxy)-8-butoxy-9-methyl-2-oxo-1,5-dioxonan-3-yl)carbamate (compound 99)



embedded image


Compound 99 was prepared in three steps: Step 3 was performed in the same manner as described in Example 8, Step 1; Step 4 was performed in the same manner as described in Example 2, Step 1; Step 5 was performed in the same manner as described in Example 1, Step 4 to give the title compound as a white solid (138 mg, 9.6% overall yield over three steps): mp 51-54° C.; 1H NMR (400 MHz, CDCl3) δ 7.36-7.25 (m, 5H), 5.32-5.21 (m, 1H), 4.91 (dq, J=9.5, 6.3 Hz, 1H), 4.68-4.60 (m, 1H), 4.62 (s, 2H), 3.96-3.81 (m, 3H), 3.67 (dd, J=11.6, 4.8 Hz, 1H), 3.58 (dd, J=10.8, 7.3 Hz, 1H), 3.50 (dd, J=15.5, 6.9 Hz, 1H), 3.36 (dd, J=12.0, 4.8 Hz, 1H), 3.23 (t, J=9.1 Hz, 1H), 1.60-1.44 (m, 2H), 1.44 (d, J=5.8 Hz, 3H), 1.43 (s, 9H), 1.41-1.22 (m, 2H), 0.88 (t, J=7.3 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 171.47, 155.24, 138.27, 128.50, 127.88, 127.81, 85.31, 83.48, 80.28, 75.53, 74.86, 74.01, 73.14, 73.03, 53.77, 32.60, 28.42, 19.49, 18.71, 14.11; ESIMS m/z 452.3 ([M+H]+).


Example 9
Steps 6 and 7: Preparation of N-((3S,7S,8S,9S)-7-(benzyloxy)-8-butoxy-9-methyl-2-oxo-1,5-dioxonan-3-yl)-3-hydroxy-4-methoxypicolinamide (compound 32)



embedded image


Compound 32 was prepared in two steps: Step 6 was performed in the same manner as described in Example 5, Step 7 to give compound 176; Step 7 was performed in the same manner as described in Example 5, Step 8, to give the title compound as a white solid (84.8 mg, 55% overall yield over two steps): mp 105-107° C.; IR (neat) 3347, 2957, 1732, 1642, 1540, 1435, 1285, 1261, 1206, 1081 cm−1; 1H NMR (400 MHz, CDCl3) δ 12.00-11.55 (m, 1H), 8.67 (d, J=8.1 Hz, 1H), 8.00 (d, J=5.2 Hz, 1H), 7.39-7.27 (m, 5H), 6.87 (d, J=5.2 Hz, 1H), 5.04 (ddd, J=8.1, 6.8, 5.0 Hz, 1H), 4.99 (ddd, J=15.8, 7.8, 4.6 Hz, 1H), 4.64 (s, 2H), 4.05 (dd, J=11.9, 6.8 Hz, 1H), 3.94 (s, 3H), 3.94-3.84 (m, 2H), 3.83 (dd, J=11.9, 5.0 Hz, 1H), 3.65 (dd, J=11.2, 7.1 Hz, 1H), 3.52 (dt, J=8.8, 6.8 Hz, 1H), 3.42 (ddd, J=8.4, 7.1, 1.3 Hz, 1H), 3.27 (t, J=9.1 Hz, 1H), 1.59-1.49 (m, 2H), 1.47 (d, J=6.3 Hz, 3H), 1.41-1.27 (m, 2H), 0.89 (t, J=7.4 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 170.40, 169.09, 155.47, 148.87, 140.81, 138.25, 130.36, 128.52, 127.89, 127.84, 109.71, 85.27, 83.44, 75.66, 74.20, 74.04, 73.32, 73.19, 56.23, 52.31, 32.61, 19.50, 18.72, 14.12; HRMS-ESI (m/z) [M]+ calcd for C26H34N2O8, 502.2315; found, 502.2324.


Example 10
Steps 1 to 4: Preparation of tert-butyl ((3S,7S,8S,9S)-8-(benzyloxy)-7-butoxy-9-methyl-2-oxo-1,5-dioxonan-3-yl)carbamate (compound 100)



embedded image


Compound 100 was prepared in four steps: Step 1 was performed in the same manner as described in Example 9, Step 2; Step 2 was performed in the same manner as described in Example 8, Step 1; Step 3 was performed in the same manner as described in Example 2, Step 1, and Step 4 was performed in the same manner as described in Example 1, Step 4 to give the title compound as a colorless oil (1.052 g, 18% overall yield over four steps): IR (neat) 3347, 2932, 1754, 1714, 1498, 1367, 1163, 1094 cm−1; 1H NMR (400 MHz, CDCl3) δ 7.38-7.24 (m, 5H), 5.34-5.23 (m, 1H), 5.02-4.91 (m, 1H), 4.93 (d, J=10.8 Hz, 1H), 4.68-4.60 (m, 1H), 4.59 (d, J=10.9 Hz, 1H), 3.92 (dd, J=11.8, 6.7 Hz, 1H), 3.81 (d, J=11.1 Hz, 1H), 3.68 (dd, J=11.7, 4.9 Hz, 1H), 3.60 (t, J=6.7 Hz, 1H), 3.58 (t, J=6.8 Hz, 1H), 3.51 (dt, J=9.1, 6.6 Hz, 1H), 3.37 (t, J=9.0 Hz, 1H), 3.26 (t, J=7.4 Hz, 1H), 1.59-1.49 (m, 2H), 1.43 (s, 9H), 1.41 (d, J=6.3 Hz, 3H), 1.40-1.30 (m, 2H), 0.88 (t, J=7.4 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 171.43, 155.22, 138.42, 128.49, 128.04, 127.83, 84.76, 83.99, 80.24, 75.84, 75.35, 74.81, 72.82, 70.78, 53.76, 32.31, 28.40, 19.47, 18.82, 14.02; HRMS-ESI (m/z) [M]+ calcd for C24H37NO7, 451.2570; found, 451.2560.


Example 10
Step 5: Preparation of (3S,7S,8S,9S)-3-amino-8-(benzyloxy)-7-butoxy-9-methyl-1,5-dioxonan-2-one hydrochloride (compound 125)



embedded image


Compound 125 was prepared in the same manner as described in Example 5, Step 7 to give the title compound as a white solid (107.2 mg, quantitative): mp 174-177° C.; 1H NMR (400 MHz, CDCl3) δ 8.71 (bs, 1H), 7.36-7.25 (m, 5H), 5.04-4.90 (m, 1H), 4.92 (d, J=10.8 Hz, 1H), 4.63-4.47 (m, 2H), 4.39-4.21 (m, 1H), 4.16-3.97 (m, 1H), 3.94-3.79 (m, 1H), 3.64-3.42 (m, 3H), 3.40-3.22 (m, 2H), 1.57-1.45 (m, 2H), 1.44-1.21 (m, 7H), 0.86 (t, J=7.3 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 168.62, 138.39, 128.50, 128.06, 127.85, 84.55, 83.65, 76.01, 75.84, 73.82, 71.16, 70.82, 53.59, 32.36, 19.50, 18.76, 14.08; ESIMS m/z 352.2 ([M+H]+).


Example 10
Step 6: Preparation of N-((3S,7S,8S,9S)-8-(benzyloxy)-7-butoxy-9-methyl-2-oxo-1,5-dioxonan-3-yl)-3-hydroxy-4-methoxypicolinamide (compound 33)



embedded image


Compound 33 was prepared in the same manner as described in Example 5, Step 8 to give the title compound as a white solid (95.7 mg, 69%): mp 117-119° C.; IR (neat) 3363, 2933, 1749, 1648, 1528, 1243, 1091 cm−1; 1H NMR (400 MHz, CDCl3) δ 11.93 (s, 1H), 8.67 (d, J=8.1 Hz, 1H), 8.00 (d, J=5.2 Hz, 1H), 7.42-7.26 (m, 5H), 6.87 (d, J=5.2 Hz, 1H), 5.07-4.98 (m, 2H), 4.95 (d, J=10.9 Hz, 1H), 4.61 (d, J=10.9 Hz, 1H), 4.06 (dd, J=11.9, 6.8 Hz, 1H), 3.94 (s, 3H), 3.90-3.79 (m, 2H), 3.69-3.49 (m, 3H), 3.41 (t, J=9.0 Hz, 1H), 3.32 (ddd, J=8.4, 6.9, 1.2 Hz, 1H), 1.59-1.50 (m, 2H), 1.44 (d, J=6.3 Hz, 3H), 1.41-1.29 (m, 2H), 0.89 (t, J=7.4 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 170.38, 169.10, 155.47, 148.87, 140.80, 138.40, 130.35, 128.53, 128.09, 127.89, 109.71, 84.72, 83.97, 75.89, 75.51, 74.18, 73.12, 70.86, 56.23, 52.32, 32.34, 19.50, 18.86, 14.05; HRMS-ESI (m/z) [M]+ calcd for C26H34N2O8, 502.2315; found, 502.2324.


Example 11
Step 1: Preparation of tert-butyl ((3S,7S,8R,9S)-7,8-dihydroxy-9-methyl-2-oxo-1,5-dioxonan-3-yl)carbamate (compound 102)



embedded image


Compound 102 was prepared in the same manner as described in Example 7, Step 4 to give the title compound as a white solid (290 mg, quantitative): IR (neat) 3357, 2979, 1751, 1691, 1523, 1368, 1163, 1047 cm−1; 1H NMR (400 MHz, CDCl3) δ 5.52 (d, J=7.9 Hz, 1H), 5.02 (dq, J=12.7, 6.3 Hz, 1H), 4.67-4.58 (m, 1H), 4.10-4.01 (m, 1H), 3.93 (dd, J=11.7, 2.6 Hz, 1H), 3.84 (dd, J=11.7, 5.8 Hz, 1H), 3.52-3.36 (m, 3H), 3.08 (bs, 1H), 2.90 (bs, 1H), 1.47 (d, J=6.3 Hz, 3H), 1.43 (s, 9H); 13C NMR (101 MHz, CDCl3) δ 171.04, 155.49, 80.40, 79.61, 78.32, 76.66, 74.59, 73.06, 54.80, 28.44, 18.74; ESIMS m/z 304.2 ([M−H]).


Example 11
Step 2: Preparation of (3S,7S,8S,9S)-3-((tert-butoxycarbonyl)amino)-9-methyl-2-oxo-1,5-dioxonane-7,8-diyl bis(2-methylpropanoate) (compound 103)



embedded image


To a solution of tert-butyl ((3S,7S,8R,9S)-7,8-dihydroxy-9-methyl-2-oxo-1,5-dioxonan-3-yl)carbamate (115.0 mg, 0.245 mmol) in pyridine (1.75 mL) was added DMAP (6.40 mg, 0.0520 mmol) followed by isobutyryl chloride (0.10 mL, 0.956 mmol) at 0° C. and the reaction was slowly warmed to room temperature and stirred for 16 h. The reaction mixture was quenched with H2O and the reaction was stirred at room temperature for 30 min and then extracted with Et2O. The phases were separated and the aqueous phase was further extracted with Et2O. The combined organic phases were washed with brine, dried over MgSO4, filtered, and the filtrate was concentrated and purified by flash chromatography (SiO2, hexanes/EtOAc gradient) to yield the title compound as a colorless, thick oil (115 mg, 94%): IR (neat) 3353, 2976, 1742, 1519, 1368, 1251, 1155 cm−1; 1H NMR (400 MHz, CDCl3) δ 5.41 (d, J=8.2 Hz, 1H), 5.21-5.12 (m, 1H), 5.12-5.04 (m, 1H), 4.92-4.83 (m, 1H), 4.74 (dd, J=13.4, 6.9 Hz, 1H), 3.95 (dd, J=11.7, 7.0 Hz, 1H), 3.80-3.65 (m, 3H), 2.64-2.41 (m, 2H), 1.44 (s, 9H), 1.32 (d, J=6.2 Hz, 3H), 1.20 (d, J=7.0 Hz, 3H), 1.16 (d, J=7.0 Hz, 3H), 1.14 (d, J=7.0 Hz, 3H), 1.10 (d, J=7.0 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 175.57, 175.47, 171.37, 155.18, 80.34, 74.52, 74.30, 74.15, 73.35, 71.34, 34.01, 33.91, 28.30, 19.01, 18.88, 18.74, 18.71, 18.03; HRMS-ESI (m/z) [M]+ calcd for C21H35NO9, 445.2312; found, 445.2322.


Compound 261 was prepared in the same manner as described in Example 11, Step 2 starting from compound 256.


Compound 262 was prepared in the same manner as described in Example 11, Step 2 starting from compound 257.


Example 11
Step 3: Preparation of (3S,7S,8S,9S)-3-amino-9-methyl-2-oxo-1,5-dioxonane-7,8-diyl bis(2-methylpropanoate) hydrochloride (compound 177)



embedded image


Compound 177 was prepared in the same manner as described in Example 5, Step 7 to give the title compound as a light yellow solid (97.0 mg, quantitative): 1H NMR (400 MHz, CDCl3) δ 8.83 (bs, 1H), 5.24-5.12 (m, 2H), 4.88-4.80 (m, 1H), 4.71-4.63 (m, 1H), 4.45 (dd, J=12.9, 3.3 Hz, 1H), 4.12 (dd, J=12.7, 6.5 Hz, 1H), 3.85 (d, J=10.8 Hz, 1H), 3.73 (dd, J=11.9, 7.9 Hz, 1H), 2.57-2.39 (m, 2H), 1.82-1.52 (m, 2 H), 1.35 (d, J=5.7 Hz, 3H), 1.16 (d, J=7.0 Hz, 3H), 1.13 (d, J=7.0 Hz, 3H), 1.10 (d, J=7.0 Hz, 3H), 1.09 (d, J=7.0 Hz, 3H); ESIMS m/z 346.7 ([M+H]+).


Example 11
Step 4: Preparation of (3S,7S,8S,9S)-3-(3-hydroxy-4-methoxypicolinamido)-9-methyl-2-oxo-1,5-dioxonane-7,8-diyl bis(2-methylpropanoate) (compound 56)



embedded image


Compound 56 was prepared in the same manner as described in Example 5, Step 8 to give the title compound as a white solid (70.0 mg, 56%): mp 111-113° C.; IR (neat) 3364, 2974, 1738, 1649, 1529, 1242, 1140 cm−1; 1H NMR (400 MHz, CDCl3) δ 11.85 (s, 1H), 8.64 (d, J=8.3 Hz, 1H), 7.98 (d, J=5.2 Hz, 1H), 6.86 (d, J=5.2 Hz, 1H), 5.22-5.12 (m, 2H), 5.10 (ddd, J=8.2, 7.0, 5.4 Hz, 1H), 4.90 (ddd, J=8.9, 6.5, 2.6 Hz, 1H), 4.07 (dd, J=11.9, 6.9 Hz, 1H), 3.92 (s, 3H), 3.83 (dd, J=11.9, 5.2 Hz, 1H), 3.81-3.72 (m, 2H), 2.57-2.39 (m, 2H), 1.33 (d, J=5.9 Hz, 3H), 1.15 (d, J=7.0 Hz, 3H), 1.13 (d, J=7.0 Hz, 3H), 1.10 (d, J=7.0 Hz, 3H), 1.09 (d, J=7.0 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 175.60, 175.50, 170.26, 169.09, 155.46, 148.85, 140.83, 130.20, 109.76, 74.87, 74.19, 73.95, 73.35, 71.71, 56.21, 52.03, 34.08, 33.99, 19.09, 18.98, 18.81, 18.79, 18.11; HRMS-ESI (m/z) [M]+ calcd for C23H32N2O10, 496.2057; found, 496.2063.


Example 12
Step 1: Preparation of tert-butyl N-tert-butoxycarbonyl-N-[(3S,7S,8S,9S)-7,8-dimethoxy-9-methyl-2-oxo-1,5-dioxonan-3-yl]carbamate (compound 104)



embedded image


To solution of tert-butyl N-tert-butoxycarbonyl-N-[(3S,7S,8R,9S)-7,8-dihydroxy-9-methyl-2-oxo-1,5-dioxonan-3-yl]carbamate (0.220 g, 0.543 mmol) and Na2SO4 (500 mg) in CH2Cl2 (5.4 mL) at 0° C. was added Proton-Sponge™ (1.63 g, 7.60 mmol) and trimethyloxonium tetrafluoroborate (0.562 g, 3.80 mmol). The reaction mixture was slowly warmed to room temperature and stirred overnight. The reaction mixture was diluted with EtOAc and filtered. The organic layer was washed successively with H2O, 1 M aqueous NaHSO4, and saturated aqueous NaHCO3. The organic layer was dried over MgSO4, filtered, and the filtrate was concentrated and purified by flash chromatography (SiO2, hexanes/EtOAc gradient) to yield the title compound as a colorless oil (133 mg, 57%): IR (neat) 2980, 2935, 1746, 1707, 1367, 1254, 1106 cm−1; 1H NMR (400 MHz, CDCl3) δ 5.19 (dd, J=8.9, 4.2 Hz, 1H), 4.75 (dq, J=9.4, 6.3 Hz, 1H), 4.23 (dd, J=12.1, 4.2 Hz, 1H), 3.89 (dd, J=12.1, 9.0 Hz, 1H), 3.80 (d, J=10.6 Hz, 1H), 3.56-3.48 (m, 1H), 3.52 (s, 3H), 3.42 (s, 3H), 3.17-3.11 (m, 1H), 3.06 (t, J=9.0 Hz, 1H), 1.48 (s, 18H), 1.40 (d, J=6.3 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 169.10, 152.73, 86.77, 85.12, 83.13, 75.07, 72.76, 72.52, 61.21, 58.43, 57.94, 28.03, 18.65; HRMS-ESI (m/z) [M]+ calcd for C20H35NO9, 433.2312; found, 433.2317.


Example 12
Steps 2 and 3: Preparation of N-((3S,7S,8S,9S)-7,8-dimethoxy-9-methyl-2-oxo-1,5-dioxonan-3-yl)-3-hydroxy-4-methoxypicolinamide (compound 63)



embedded image


Compound 63 was prepared in two steps: Step 2 was performed in the same manner as described in Example 5, Step 7 to give compound 178; Step 3 was performed in the same manner as described in Example 5, Step 8, to give the title compound as a white solid (82.6 mg, 72%): mp 165-167° C.; IR (neat) 3365, 2982, 1733, 1643, 1535, 1285, 1091 cm−1; 1H NMR (400 MHz, CDCl3) δ 11.91 (s, 1H), 8.64 (s, 1H), 7.98 (d, J=5.2 Hz, 1H), 6.86 (d, J=5.2 Hz, 1H), 5.02 (ddd, J=8.1, 6.8, 5.1 Hz, 1H), 4.94 (dq, J=8.7, 6.3 Hz, 1H), 4.05 (dd, J=11.9, 6.8 Hz, 1H), 3.92 (s, 3H), 3.81 (d, J=11.8 Hz, 1H), 3.80 (d, J=11.9 Hz, 1H), 3.62-3.57 (m, 1H), 3.55 (s, 3H), 3.44 (s, 3H), 3.16-3.07 (m, 2H), 1.44 (d, J=6.3 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 170.38, 169.06, 155.43, 148.82, 140.78, 130.29, 109.69, 86.83, 85.33, 74.75, 74.06, 72.92, 61.35, 58.47, 56.20, 52.23, 18.61; HRMS-ESI (m/z) [M]+ calcd for C17H24N2O8, 384.1533; found, 384.1532.


Example 13
Step 1: Preparation of tert-butyl N-tert-butoxycarbonyl-N-[(3S,7S,8R,9S)-8-(1,1-dimethylallyloxy)-7-hydroxy-9-methyl-2-oxo-1,5-dioxonan-3-yl]carbamate (compound 105) and tert-butyl N-tert-butoxycarbonyl-N-[(3S,7S,8S,9S)-7-(1,1-dimethylallyloxy)-8-hydroxy-9-methyl-2-oxo-1,5-dioxonan-3-yl]carbamate (compound 106)



embedded image


Compounds 105 and 106 were prepared in the same manner as described in Example 7, Step 5 to give the title compounds as pale yellow oils.


tert-Butyl N-tert-butoxycarbonyl-N-[(3S,7S,8R,9S)-8-(1,1-dimethylallyloxy)-7-hydroxy-9-methyl-2-oxo-1,5-dioxonan-3-yl]carbamate (compound 105) (140 mg, 30%): 1H NMR (400 MHz, CDCl3) δ 5.81 (dd, J=17.7, 10.6 Hz, 1H), 5.17-5.14 (m, 1H), 4.99-4.86 (m, 2H), 4.19 (dd, J=11.6, 9.1 Hz, 1H), 4.13-4.02 (m, 2H), 3.83-3.71 (m, 2H), 3.55-3.47 (m, 2H), 2.78 (d, J=5.3 Hz, 1H), 1.48 (s, 18H), 1.38 (d, J=6.8 Hz, 3H), 1.27 (s, 3H), 1.23 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 169.43, 152.53, 143.20, 115.09, 83.16, 77.26, 76.60, 75.75, 74.16, 73.32, 71.73, 58.07, 28.00, 26.74, 26.30, 19.31; ESIMS m/z 496.7 ([M+Na]+).


tert-Butyl N-tert-butoxycarbonyl-N-[(3S,7S,8S,9S)-7-(1,1-dimethylallyloxy)-8-hydroxy-9-methyl-2-oxo-1,5-dioxonan-3-yl]carbamate (compound 106) (200 mg, 43%): 1H NMR (400 MHz, CDCl3) δ 5.79 (dd, J=17.8, 10.5 Hz, 1H), 5.18 (dd, J=8.2, 3.4 Hz, 1H), 5.15 (s, 1H), 5.11 (dd, J=5.6, 0.7 Hz, 1H), 4.95 (dq, J=12.9, 6.4 Hz, 1H), 4.14 (dd, J=12.4, 3.4 Hz, 1H), 3.96-3.84 (m, 2H), 3.45 (dd, J=10.6, 7.6 Hz, 1H), 3.41-3.32 (m, 2H), 3.05 (d, J=1.3 Hz, 1H), 1.47 (s, 18H), 1.42 (d, J=6.4 Hz, 3H), 1.29 (s, 3H), 1.26 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 169.01, 152.64, 142.56, 115.33, 83.07, 79.83, 77.47, 76.46, 74.46, 74.35, 74.01, 58.56, 28.04, 26.82, 25.82, 18.56; ESIMS m/z 496.7 ([M+Na]+).


Example 13
Step 2: Preparation of tert-butyl N-tert-butoxycarbonyl-N-[(3S,7S,8S,9S)-7-(1,1-dimethylallyloxy)-9-methyl-8-(2-methylallyloxy)-2-oxo-1,5-dioxonan-3-yl]carbamate (compound 107)



embedded image


Compound 107 was prepared in the same manner as described in Example 7, Step 5 to give the title compound as a pale yellow oil (210 mg, 59%): 1H NMR (400 MHz, CDCl3) δ 5.90 (dd, J=17.9, 10.5 Hz, 1H), 5.17 (dd, J=8.6, 4.1 Hz, 1H), 5.07-5.05 (m, 1H) 5.03 (dd, J=4.9, 1.1 Hz, 1H), 4.96-4.89 (m, 1H), 4.85-4.77 (m, 2H), 4.33 (d, J=12.1 Hz, 1H), 4.13 (dd, J=12.2, 4.1 Hz, 1H), 3.86 (dd, J=12.3, 8.6 Hz, 1H), 3.81 (t, J=11.8 Hz, 2H), 3.48 (dd, J=10.7, 7.2 Hz, 1H), 3.41 (t, J=7.5 Hz, 1H), 3.11 (t, J=8.8 Hz, 1H), 1.70 (s, 3H), 1.46 (s, 18H), 1.38 (d, J=6.3 Hz, 3H), 1.26 (s, 3H), 1.22 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 169.08, 152.57, 144.07, 142.26, 114.06, 111.66, 84.32, 83.01, 79.73, 77.43, 77.12, 76.01, 73.04, 72.85, 58.13, 28.01, 27.04, 25.68, 19.95, 18.83; ESIMS m/z 550.8 ([M+Na]+).


Compound 109 was prepared in the same manner as described in Example 13, Step 2 using compound 105 as starting material.


Compounds 142 and 144 were prepared in the same manner as described in Example 13, Steps 1 and 2.


Example 13
Step 3: Preparation of tert-butyl N-tert-butoxycarbonyl-N-[(3S,7S,8S,9S)-7-(1,1-dimethylpropoxy)-8-isobutoxy-9-methyl-2-oxo-1,5-dioxonan-3-yl]carbamate (compound 108)



embedded image


Compound 108 was prepared in the same manner as described in Example 7, Step 6 to give the title compound as a colorless oil (218 mg, 82%): 1H NMR (400 MHz, CDCl3) δ 5.18 (dd, J=8.6, 3.8 Hz, 1H), 4.87-4.77 (m, 1H), 4.15 (dd, J=12.3, 3.9 Hz, 1H), 3.87 (dd, J=12.3, 8.6 Hz, 1H), 3.81 (dd, J=10.0, 4.3 Hz, 1H), 3.75 (dd, J=8.5, 5.6 Hz, 1H), 3.54-3.43 (m, 2H), 3.10-2.99 (m, 2H), 1.91-1.72 (m, 1H), 1.48 (s, 18H), 1.47-1.41 (m, 2H), 1.39 (d, J=6.3 Hz, 3H), 1.13 (s, 3H), 1.10 (s, 3H), 0.90 (d, J=6.6 Hz, 3H), 0.85 (t, J=7.5 Hz, 3H), 0.84 (d, J=6.7 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 169.10, 152.63, 84.90, 83.01, 81.02, 80.20, 77.56, 75.09, 73.14, 73.07, 58.27, 35.03, 29.04, 28.04, 25.12, 25.00, 19.89, 19.53, 18.97, 9.00; ESIMS m/z 553.4 ([M+Na]+).


Compound 110 was prepared in the same manner as described in Example 13, Step 3 using compound 109 as starting material.


Compounds 145 and 146 were prepared in the same manner as described in Example 13, Step 3.


Example 13
Steps 4 and 5, Method A: Preparation of 3-hydroxy-N-((3S,7S,8S,9S)-8-isobutoxy-9-methyl-2-oxo-7-(tert-pentyloxy)-1,5-dioxonan-3-yl)-4-methoxypicolinamide (compound 71)



embedded image


Step 4: To a solution of tert-butyl N-tert-butoxycarbonyl-N-[(3S,7S,8S,9S)-7-(1,1-dimethylpropoxy)-8-isobutoxy-9-methyl-2-oxo-1,5-dioxonan-3-yl]carbamate (165.0 mg, 0.310 mmol) in CH2Cl2 (4.3 mL) was added 2,6-lutidine (0.108 mL, 0.931 mmol) and trimethylsilyl trifluoromethanesulfonate (0.140 mL, 0.776 mmol) and the resulting solution was stirred at room temperature for 2 h. The reaction was treated with MeOH (2 mL), stirred at room temperature overnight, concentrated, and dried under high vacuum to give, (3S,7S,8S,9S)-3-amino-7-(1,1-dimethylpropoxy)-8-isobutoxy-9-methyl-1,5-dioxonan-2-one (Compound 179) as a colorless oil, which was used directly for the coupling reaction.


Step 5: To a mixture of (3S,7S,8S,9S)-3-amino-7-(1,1-dimethylpropoxy)-8-isobutoxy-9-methyl-1,5-dioxonan-2-one and 3-hydroxy-4-methoxypicolinic acid (79.0 mg, 0.466 mmol) in DCM (2.0 mL) were added 4-methylmorpholine (0.205 mL, 1.86 mmol) followed by HATU (189 mg, 0.497 mmol) and the mixture was stirred at room temperature for 16 h. The reaction mixture was directly purified by flash chromatography (SiO2, hexanes/EtOAc gradient) to yield the title compound as a white solid (50.0 mg, 42%): mp 138-140° C.; IR (neat) 3370, 2926, 1750, 1650, 1529, 1243, 1085 cm−1; 1H NMR (400 MHz, CDCl3) δ 11.98 (s, 1H), 8.73 (d, J=8.0 Hz, 1H), 8.01 (d, J=5.2 Hz, 1H), 6.87 (d, J=5.2 Hz, 1H), 5.08 (dq, J=9.1, 6.3 Hz, 1H), 5.00 (ddd, J=8.1, 6.1, 3.8 Hz, 1H), 4.00 (dd, J=12.1, 6.1 Hz, 1H), 3.94 (s, 3H), 3.95-3.89 (m, 2H), 3.79 (dd, J=8.6, 5.6 Hz, 1H), 3.56-3.45 (m, 2H), 3.07 (dt, J=12.6, 8.4 Hz, 2H), 1.90-1.78 (m, 1H), 1.56-1.43 (m, 2H), 1.45 (d, J=6.4 Hz, 3H), 1.15 (s, 3H), 1.14 (s, 3H), 0.93 (d, J=6.6 Hz, 3H), 0.91-0.85 (m, 6H); 13C NMR (101 MHz, CDCl3) δ 170.17, 169.09, 155.47, 148.89, 140.79, 130.47, 109.68, 85.26, 81.29, 81.18, 77.82, 75.32, 75.19, 73.37, 56.23, 53.07, 35.01, 29.10, 25.16, 25.08, 19.95, 19.60, 18.97, 9.06; HRMS-ESI (m/z) [M]+ calcd for C24H38N2O8, 482.2628; found, 482.2631.


Compound 193 was prepared in the same manner as described in Example 13, Step 4 using compound 110 as starting material.


Compound 79 was prepared in the same manner as described in Example 13, Step 5 using compound 193 as starting material.


Example 13
Steps 4 and 5, Method B: Preparation of 3-hydroxy-N-((3S,7S,8R,9S)-7-hydroxy-8-isobutoxy-9-methyl-2-oxo-1,5-dioxonan-3-yl)-4-methoxypicolinamide (compound 72)



embedded image


Compound 72 was prepared in the same manner as described in Example 5, Steps 7 and 8 using compound 108 as starting material: 1H NMR (400 MHz, CDCl3) δ 11.92 (d, J=0.7 Hz, 1H), 8.75 (d, J=8.2 Hz, 1H), 7.98 (d, J=5.2 Hz, 1H), 6.86 (d, J=5.2 Hz, 1H), 5.12 (dq, J=9.4, 6.4 Hz, 1H), 5.01 (ddd, J=8.2, 5.4, 3.5 Hz, 1H), 4.12 (d, J=11.0 Hz, 1H), 4.07-3.97 (m, 2H), 3.94 (s, 3H), 3.60-3.48 (m, 2H), 3.47-3.43 (m, 2H), 3.14 (dd, J=9.4, 8.4 Hz, 1H), 2.02-1.81 (m, 2H), 1.47 (d, J=6.4 Hz, 3H), 0.97 (dd, J=6.7, 4.0 Hz, 6H); 13C NMR (101 MHz, CDCl3) δ 169.65, 168.98, 155.31, 148.70, 140.69, 130.23, 109.57, 86.44, 80.31, 79.27, 75.77, 74.17, 72.70, 56.07, 53.09, 29.04, 19.31, 19.21, 18.68; ESIMS m/z 413.1 ([M+H]+).


Compound 74 was prepared in the same manner as described in Example 13, Steps 4 and 5, Method B.


Compound 165 was prepared in the same manner as described in Example 13, Step 4, Method B starting from compound 146.


Compound 166 was prepared in the same manner as described in Example 13, Step 4, Method B starting from compound 145.


Compound 73 was prepared in the same manner as described in Example 13, Step 5, Method B using compound 166 as starting material.


Compound 75 was prepared in the same manner as described in Example 13, Step 5, method B using compound 165 as starting material


Compound 70 was prepared in the same manner as described in Example 13, Steps 4 and 5, Method B starting from compound 110.


Compound 211 was prepared in the same manner as described in Example 13, Steps 4 and 5, Method B starting from Compound 239 (by-product).


Example 14
Step 1: Preparation of tert-butyl N-tert-butoxycarbonyl-N-[(3S,7S,8R,9S)-7-hydroxy-9-methyl-2-oxo-8-phenoxy-1,5-dioxonan-3-yl]carbamate (Compound 249) and tert-butyl N-tert-butoxycarbonyl-N-[(3S,7S,8S,9S)-8-hydroxy-9-methyl-2-oxo-7-phenoxy-1,5-dioxonan-3-yl]carbamate (Compound 250)



embedded image


To a stirred solution of tert-butyl N-tert-butoxycarbonyl-N-[(3S,7S,8R,9S)-7,8-dihydroxy-9-methyl-2-oxo-1,5-dioxonan-3-yl]carbamate (484 mg, 1.194 mmol) in DCM (10 ml) was added bis(acetato-O)triphenylbismuth(V) (667 mg, 1.194 mmol) and diacetoxycopper (21.68 mg, 0.119 mmol) in a round bottom flask. The reaction mixture was stirred at room temperature overnight, then purified by flash chromatography (SiO2; EtOAc/hexanes) to provide the title compounds as colorless oils.


tert-Butyl N-tert-butoxycarbonyl-N-[(3S,7S,8R,9S)-7-hydroxy-9-methyl-2-oxo-8-phenoxy-1,5-dioxonan-3-yl]carbamate was isolated as a colorless oil (Compound 249) (380 mg, 66%): 1H NMR (400 MHz, CDCl3) δ 7.36-7.20 (m, 2H), 7.05-6.93 (m, 3H), 5.36-5.17 (m, 1H), 5.16-5.00 (m, 1H), 4.34-4.21 (m, 2H), 4.17-4.08 (m, 1H), 3.99 (dd, J=12.2, 8.5 Hz, 1H), 3.93-3.83 (m, 1H), 3.68 (dd, J=11.0, 7.4 Hz, 1H), 2.46 (d, J=3.1 Hz, 1H), 1.51 (s, 18H), 1.34 (d, J=6.4 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 168.72, 158.92, 152.61, 129.77, 122.15, 116.26, 84.59, 83.18, 77.53, 73.89, 72.19, 58.22, 27.96, 18.98; ESIMS m/z 505.3 ([M+Na]+).


tert-Butyl N-tert-butoxycarbonyl-N-[(3S,7S,8S,9S)-8-hydroxy-9-methyl-2-oxo-7-phenoxy-1,5-dioxonan-3-yl]carbamate was isolated as a colorless oil (Compound 250) (160 mg, 27.8%): 1H NMR (400 MHz, CDCl3) δ 7.33-7.22 (m, 2H), 7.05-6.88 (m, 3H), 5.33 (dd, J=8.7, 2.5 Hz, 1H), 5.03 (dq, J=9.0, 6.3 Hz, 1H), 4.29 (dd, J=12.6, 2.4 Hz, 1H), 4.19 (ddd, J=8.7, 7.6, 1.3 Hz, 1H), 4.11 (dd, J=11.0, 1.3 Hz, 1H), 3.93 (dd, J=12.6, 8.7 Hz, 1H), 3.77 (td, J=8.8, 2.0 Hz, 1H), 3.59 (dd, J=11.0, 7.7 Hz, 1H), 2.99 (d, J=2.1 Hz, 1H), 1.57-1.47 (m, 21H); 13C NMR (101 MHz, CDCl3) δ 168.42, 156.60, 152.60, 129.73, 121.88, 115.83, 83.19, 80.38, 76.32, 75.91, 74.23, 73.40, 58.41, 27.99, 18.71; ESIMS m/z 505.2 ([M+Na]+).


Compounds 243 and 244 were prepared in the same manner as described in Example 14, Step 1, using tri(4-fluorophenyl)bismuth diacetate.


Compounds 247 and 248 were prepared in the same manner as described in Example 14, Step 1, using tri(4-methylphenyl)bismuth diacetate.


Compounds 249 and 250 were prepared in Example 14, Step 1.


Compounds 256 and 257 were prepared in the same manner as described in Example 14, Step 1, using tri(4-methoxylphenyl)bismuth diacetate.


Example 14
Step 2: Preparation of tert-butyl N-tert-butoxycarbonyl-N-[(3S,7S,8S,9S)-9-methyl-7-(2-methylallyloxy)-2-oxo-8-phenoxy-1,5-dioxonan-3-yl]carbamate (compound 159)



embedded image


Compound 159 was prepared as described in Example 7, Step 5: 1H NMR (400 MHz, CDCl3) δ 7.31-7.19 (m, 2H), 7.05-6.97 (m, 2H), 6.93 (tt, J=7.4, 1.1 Hz, 1H), 5.27 (dd, J=8.9, 4.1 Hz, 1H), 5.04 (dq, J=9.5, 6.3 Hz, 1H), 4.79-4.69 (m, 2H), 4.37-4.24 (m, 2H), 4.03-3.82 (m, 4H), 3.68 (dd, J=11.0, 7.3 Hz, 1H), 3.51 (ddd, J=8.7, 7.3, 1.4 Hz, 1H), 1.52 (s, 18H), 1.49 (s, 3H), 1.37 (d, J=6.3 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 169.03, 159.37, 152.63, 141.86, 129.29, 121.18, 116.06, 112.66, 83.15, 83.03, 81.47, 75.52, 74.93, 72.82, 72.46, 57.86, 27.96, 19.41, 18.80; ESIMS m/z 559.4 ([M+Na]+).


Compound 158 was prepared in the same manner as described in Example 14, Step 2 starting from tert-butyl N-tert-butoxycarbonyl-N-[(3S,7S,8S,9S)-8-hydroxy-9-methyl-2-oxo-7-phenoxy-1,5-dioxonan-3-yl]carbamate.


Compound 239 was prepared in the same manner as described in Example 14, Step 2 starting from tert-butyl N-tert-butoxycarbonyl-N-[(3S,7S,8S,9S)-8-hydroxy-9-methyl-2-oxo-7-phenoxy-1,5-dioxonan-3-yl]carbamate.


Example 14
Step 3: Preparation of tert-butyl N-tert-butoxycarbonyl-N-[(3S,7S,8S,9S)-7-isobutoxy-9-methyl-2-oxo-8-phenoxy-1,5-dioxonan-3-yl]carbamate (compound 148)



embedded image


Compound 148 was prepared as described in Example 7, Step 6: 1H NMR (400 MHz, CDCl3) δ 7.30-7.18 (m, 2H), 6.99 (dt, J=7.9, 1.0 Hz, 2H), 6.96-6.87 (m, 1H), 5.27 (dd, J=9.0, 4.1 Hz, 1H), 5.10-4.93 (m, 1H), 4.37-4.21 (m, 2H), 4.05-3.88 (m, 2H), 3.64 (dd, J=10.9, 7.5 Hz, 1H), 3.41 (ddd, J=8.9, 7.4, 1.5 Hz, 1H), 3.32-3.23 (m, 1H), 3.23-3.12 (m, 1H), 1.60-1.51 (m, 1H), 1.52 (s, 18H), 1.37 (d, J=6.3 Hz, 3H), 0.66 (dd, J=21.7, 6.7 Hz, 6H); 13C NMR (101 MHz, CDCl3) δ 169.05, 159.48, 152.64, 129.18, 121.04, 116.07, 83.12, 83.01, 82.48, 78.05, 75.56, 72.81, 72.45, 57.89, 28.61, 27.96, 19.19, 19.07, 18.81; ESIMS m/z 538.8 ([M+H]+).


Compound 149 was prepared in the same manner as described in Example 14, Step 3 starting from compound 158.


Compound 246 was prepared in the same manner as described in Example 14, Steps 2 and 3, starting from compound 243.


Compound 252 was prepared in the same manner as described in Example 14, Steps 2 and 3, starting from compound 250 using tert-butyl cyclopent-2-en-1-yl carbonate.


Compound 253 was prepared in the same manner as described in Example 14, Steps 2 and 3, starting from compound 249 using tert-butyl cyclopent-2-en-1-yl carbonate.


Compound 254 was prepared in the same manner as described in Example 14, Steps 2 and 3, starting from compound 250 using allyl tert-butyl carbonate.


Compound 255 was prepared in the same manner as described in Example 14, Steps 2 and 3, starting from compound 249 using allyl tert-butyl carbonate.


Compound 264 was prepared in the same manner as described in Example 14, Steps 2 and 3, starting from compound 259 using allyl tert-butyl carbonate.


Compound 265 was prepared in the same manner as described in Example 14, Steps 2 and 3, starting from compound 260 using allyl tert-butyl carbonate.


Compound 266 was prepared in the same manner as described in Example 14, Steps 2 and 3, starting from compound 260.


Compound 269 was prepared in the same manner as described in Example 14, Steps 2 and 3, starting from compound 267


Example 14
Step 4: Preparation of (3S,7S,8S,9S)-7-isobutoxy-9-methyl-2-oxo-8-phenoxy-1,5-dioxonan-3-aminium chloride (compound 151)



embedded image


Compound 151 was prepared in the same manner as described in Example 5, Step 7: 1H NMR (400 MHz, CDCl3) δ 8.73 (s, 3H), 7.28-7.16 (m, 2H), 7.01-6.87 (m, 3H), 5.17 (dt, J=15.8, 6.2 Hz, 1H), 4.67 (t, J=5.3 Hz, 1H), 4.44-4.31 (m, 1H), 4.27 (t, J=9.0 Hz, 1H), 4.22-4.07 (m, 1H), 3.97 (d, J=10.8 Hz, 1H), 3.70-3.58 (m, 1H), 3.40 (t, J=8.2 Hz, 1H), 3.27 (dd, J=8.8, 6.3 Hz, 1H), 3.16 (dd, J=8.8, 6.3 Hz, 1H), 1.54 (dt, J=13.1, 6.6 Hz, 1H), 1.41 (d, J=6.3 Hz, 3H), 0.67 (d, J=6.7 Hz, 3H), 0.61 (d, J=6.7 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 168.69, 159.26, 129.25, 121.24, 115.99, 82.76, 82.29, 78.11, 75.46, 73.58, 70.86, 53.43, 28.60, 19.18, 19.05, 18.67; ESIMS m/z 338.9 ([M+H]+).


Compound 152 was prepared in the same manner as described in Example 14, Step 4.


Compound 275 was prepared in the same manner as described in Example 14, Step 4, starting from compound 246.


Compound 277 was prepared in the same manner as described in Example 14, Step 4, starting from compound 252.


Compound 278 was prepared in the same manner as described in Example 14, Step 4, starting from compound 253.


Compound 279 was prepared in the same manner as described in Example 14, Step 4, starting from compound 254.


Compound 280 was prepared in the same manner as described in Example 14, Step 4, starting from compound 255.


Compound 282 was prepared in the same manner as described in Example 14, Step 4, starting from compound 261.


Compound 283 was prepared in the same manner as described in Example 14, Step 4, starting from compound 262.


Compound 285 was prepared in the same manner as described in Example 14, Step 4, starting from compound 264.


Compound 286 was prepared in the same manner as described in Example 14, Step 4, starting from compound 265.


Compound 287 was prepared in the same manner as described in Example 14, Step 4, starting from compound 266.


Compound 288 was prepared in the same manner as described in Example 14, Step 4, starting from compound 269.


Compound 271 was prepared in the same manner as described in Example 14, Step 4, starting from compound 239.


Example 14
Step 5: Preparation of 3-hydroxy-N-((3S,7S,8S,9S)-7-isobutoxy-9-methyl-2-oxo-8-phenoxy-1,5-dioxonan-3-yl)-4-methoxypicolinamide (compound 82)



embedded image


Compound 82 was prepared in the same manner as described in Example 5, Step 8: 1H NMR (400 MHz, CDCl3) δ 12.13-11.57 (m, 1H), 8.69 (d, J=8.2 Hz, 1H), 8.00 (d, J=5.2 Hz, 1H), 7.41-7.11 (m, 2H), 7.06-6.97 (m, 2H), 6.97-6.90 (m, 1H), 6.87 (d, J=5.2 Hz, 1H), 5.19 (dq, J=9.4, 6.3 Hz, 1H), 5.10 (ddd, J=8.2, 6.9, 5.2 Hz, 1H), 4.31 (t, J=9.1 Hz, 1H), 4.11 (dd, J=11.9, 6.9 Hz, 1H), 3.94 (s, 3H), 3.91 (d, J=1.6 Hz, 1H), 3.86 (dd, J=11.8, 5.2 Hz, 1H), 3.74 (dd, J=11.1, 7.3 Hz, 1H), 3.40 (ddd, J=8.7, 7.2, 1.6 Hz, 1H), 3.34-3.24 (m, 1H), 3.19 (dd, J=8.9, 6.4 Hz, 1H), 1.59 (dp, J=13.3, 6.6 Hz, 1H), 1.41 (d, J=6.4 Hz, 3H), 0.70 (d, J=6.7 Hz, 3H), 0.65 (d, J=6.7 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 170.37, 168.98, 159.41, 155.35, 148.74, 140.70, 130.16, 129.24, 121.20, 116.06, 109.62, 83.01, 82.67, 78.15, 74.80, 73.81, 72.86, 56.09, 52.05, 28.60, 19.19, 19.07, 18.74; ESIMS m/z 489.4 ([M+H]+).


Compound 83 was prepared in the same manner as described in Example 14, Step 5.


Example 15
Step 1: Preparation of tert-butyl N-tert-butoxycarbonyl-N-[(3S,7S,8S,9S)-9-methyl-2-oxo-7,8-diphenoxy-1,5-dioxonan-3-yl]carbamate (compound 147)



embedded image


To a solution of tert-butyl N-tert-butoxycarbonyl-N-[(3S,7S,8R,9S)-7-hydroxy-9-methyl-2-oxo-8-phenoxy-1,5-dioxonan-3-yl]carbamate (102 mg, 0.212 mmol) in toluene (1 mL) was added fluorotetraphenylbismuth (227 mg, 0.424 mmol, prepared according to the procedure disclosed in J. Am. Chem. Soc. 2003, 125, 10494-10495), diacetoxycopper (7.69 mg, 0.042 mmol) and N-cyclohexyl-N-methylcyclohexanamine (83 mg, 0.424 mmol). The reaction solution was heated to 40° C. for 6 h and then stirred at room temperature overnight. The reaction mixture was purified by flash chromatography (SiO2, hexanes/EtOAc gradient) to yield the title compound as a white solid (95 mg, 80%): 1H NMR (400 MHz, CDCl3) δ 7.31-7.20 (m, 2H), 7.20-7.12 (m, 2H), 7.02-6.81 (m, 4H), 6.73 (dt, J=7.8, 1.1 Hz, 2H), 5.34 (dd, J=9.0, 3.6 Hz, 1H), 5.16 (dq, J=9.4, 6.3 Hz, 1H), 4.58-4.45 (m, 1H), 4.41 (ddd, J=8.7, 7.3, 1.3 Hz, 1H), 4.32 (dd, J=12.3, 3.6 Hz, 1H), 4.08 (dd, J=11.1, 1.3 Hz, 1H), 3.98 (dd, J=12.4, 8.9 Hz, 1H), 3.77 (dd, J=11.1, 7.3 Hz, 1H), 1.54 (s, 18H), 1.46 (d, J=6.3 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 168.79, 159.50, 157.39, 152.59, 129.37, 129.24, 121.47, 121.23, 116.49, 115.72, 83.25, 82.80, 80.62, 75.45, 73.18, 72.36, 57.95, 28.00, 18.97; ESIMS m/z 559.0 ([M+H]+).


Compound 245 was prepared in the same manner as described in Example 15, Step 1, starting from compound 244 and using tri(4-fluorophenyl)bismuth diacetate.


Compound 251 was prepared in the same manner as described in Example 15, Step 1, starting from compound 247 and using tri(4-methylphenyl)bismuth diacetate.


Compound 258 was prepared in the same manner as described in Example 15, Step 1, starting from compound 257 and using tri(4-methoxyphenyl)bismuth diacetate.


Compound 263 was prepared in two steps from compound 191. Step 1 was performed in the same manner as Example 14, Step 1 using tri(3,5-dimethylphenyl)bismuth diacetate; Step 2 was performed in the same manner as Example 15, Step 1, using tri(3,5-dimethylphenyl)bismuth diacetate.


Example 15
Step 2: Preparation of (3S,7S,8S,9S)-9-methyl-2-oxo-7,8-diphenoxy-1,5-dioxonan-3-aminium chloride (compound 150)



embedded image


Compound 150 was prepared in a similar manner as described in Example 5, Step 7 to give the title compound as a white solid: mp 227-229° C.; 1H NMR (400 MHz, MeOD) δ 7.30-7.21 (m, 2H), 7.21-7.12 (m, 2H), 7.04-6.84 (m, 4H), 6.67 (dt, J=7.8, 1.0 Hz, 2H), 5.53-5.32 (m, 1H), 4.70 (t, J=9.2 Hz, 1H), 4.55 (dd, J=4.2, 3.1 Hz, 1H), 4.29 (ddd, J=9.1, 6.7, 1.0 Hz, 1H), 4.20-4.09 (m, 3H), 4.01-3.83 (m, 1H), 1.50 (d, J=6.3 Hz, 3H); ESIMS m/z 358.7 ([M+H]+).


Compound 274 was prepared in the same manner as described in Example 15, Step 2, starting from compound 245.


Compound 276 was prepared in the same manner as described in Example 15, Step 2, starting from compound 251.


Compound 281 was prepared in the same manner as described in Example 15, Step 2, starting from compound 258.


Compound 284 was prepared in the same manner as described in Example 15, Step 2, starting from compound 263.


Example 15
Step 3: Preparation of 3-hydroxy-4-methoxy-N-((3S,7S,8S,9S)-9-methyl-2-oxo-7,8-diphenoxy-1,5-dioxonan-3-yl)picolinamide (compound 81)



embedded image


Compound 81 was prepared as described in Example 5, Step 8: 1H NMR (400 MHz, CDCl3) δ 11.92 (s, 1H), 8.76 (d, J=8.1 Hz, 1H), 8.02 (d, J=5.2 Hz, 1H), 7.43-7.08 (m, 5H), 7.08-6.80 (m, 5H), 6.73 (dt, J=7.8, 1.1 Hz, 2H), 5.56-5.24 (m, 1H), 5.16 (ddd, J=8.1, 6.6, 4.5 Hz, 1H), 4.70-4.46 (m, 1H), 4.38 (ddd, J=8.7, 7.2, 1.3 Hz, 1H), 4.17-4.03 (m, 1H), 4.02-3.95 (m, 1H), 3.93 (s, 3H), 3.83 (dd, J=11.3, 7.2 Hz, 1H), 1.50 (d, J=6.3 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 170.04, 169.04, 159.45, 157.21, 155.39, 148.79, 140.77, 130.15, 129.49, 129.31, 121.62, 121.38, 116.49, 115.59, 109.68, 82.87, 80.51, 75.06, 74.46, 72.54, 56.11, 52.37, 18.88; ESIMS m/z 510.1 ([M+H]+).


Example 16
Step 1: Preparation of tert-butyl ((3S,7S,8S,9S)-7-butoxy-8-hydroxy-9-methyl-2-oxo-1,5-dioxonan-3-yl)carbamate (compound III)



embedded image


Compound III was prepared in the same manner as described in Example 7, Step 4 to give the title compound as a colorless oil (176 mg, quantitative): IR (neat) 3323, 2960, 2933, 2874, 1755, 1710, 1521, 1367, 1248, 1164, 1084 cm−1; 1H NMR (400 MHz, CDCl3) δ 5.41 (d, J=7.1 Hz, 1H), 5.08 (dq, J=9.3, 6.3 Hz, 1H), 4.66-4.56 (m, 1H), 4.07 (d, J=12.0 Hz, 1H), 4.02 (d, J=13.5 Hz, 1H), 3.81 (dd, J=11.9, 5.6 Hz, 1H), 3.65 (dt, J=9.3, 6.6 Hz, 1H), 3.44-3.34 (m, 3H), 3.17 (s, 1H), 3.08-3.01 (m, 1H), 1.59-1.49 (m, 2H), 1.46 (d, J=6.3 Hz, 3H), 1.44 (s, 9H), 1.41-1.31 (m, 2H), 0.91 (t, J=7.4 Hz, 3H); HRMS-ESI (m/z) [M]+ calcd for C17H31NO7, 361.2101; found, 361.2107.


Example 16
Step 2: Preparation of (3S,6S,7S,8S)-8-butoxy-3-((tert-butoxycarbonyl)amino)-6-methyl-4-oxo-1,5-dioxonan-7-yl isobutyrate (compound 113)



embedded image


Compound 113 was prepared in the same manner as described in Example 11, Step 2 to give the title compound as a white solid (98.9 mg, 83%): mp 69-71° C.; IR (neat) 3364, 2967, 2935, 2876, 1745, 1717, 1517, 1367, 1153, 1096 cm−1; 1H NMR (400 MHz, CDCl3) δ 5.34 (d, J=7.9 Hz, 1H), 5.12-4.99 (m, 1H), 4.93 (t, J=9.4 Hz, 1H), 4.71-4.63 (m, 1H), 3.94-3.85 (m, 2H), 3.77 (dd, J=11.7, 3.7 Hz, 1H), 3.59-3.45 (m, 2H), 3.30 (dt, J=9.1, 6.6 Hz, 1H), 3.17 (t, J=7.9 Hz, 1H), 2.53 (hept, J=7.0 Hz, 1H), 1.41 (s, 9H), 1.28 (d, J=6.3 Hz, 3H), 1.30-1.20 (m, 2H), 1.19-1.13 (m, 8H), 0.84 (t, J=7.3 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 175.77, 171.28, 155.23, 80.88, 80.29, 75.79, 75.70, 75.30, 71.49, 70.49, 54.10, 34.18, 32.00, 28.37, 19.30, 19.16, 18.84, 18.28, 13.94; HRMS-ESI (m/z) [M]+ calcd for C21H37NO8, 431.2519; found, 431.2524.


Compound 114 was prepared in the same manner as described in Example 16, Step 2 using compound III as starting material.


Example 16
Step 3: Preparation of (3S,6S,7S,8S)-3-amino-8-butoxy-6-methyl-4-oxo-1,5-dioxonan-7-yl isobutyrate hydrochloride (compound 180)



embedded image


Compound 180 was prepared in the same manner as described in Example 5, Step 7 to give the title compound as a light yellow solid (83.5 mg, quantitative): ESIMS m/z 332.8 ([M+H]+).


Compound 181 was prepared in the same manner as described in Example 16, Step 3 using compound 114 as starting material.


Example 16
Step 4: Preparation of (3S,6S,7S,8S)-8-butoxy-3-(3-hydroxy-4-methoxypicolinamido)-6-methyl-4-oxo-1,5-dioxonan-7-yl isobutyrate (compound 46)



embedded image


Compound 46 was prepared in the same manner as described in Example 5, Step 8 to give the title compound as a colorless oil (71.8 mg, 66%): IR (neat) 3367, 2935, 2875, 1739, 1649, 1528, 1481, 1242, 1182, 1145, 1093 cm−1; 1H NMR (400 MHz, CDCl3) δ 11.90 (s, 1H), 8.68 (d, J=8.1 Hz, 1H), 7.98 (d, J=5.2 Hz, 1H), 6.86 (d, J=5.2 Hz, 1H), 5.14 (dq, J=9.8, 6.4 Hz, 1H), 5.07 (ddd, J=8.1, 6.5, 4.2 Hz, 1H), 4.98 (t, J=9.4 Hz, 1H), 4.04 (dd, J=11.9, 6.5 Hz, 1H), 3.97 (dd, J=11.3, 1.1 Hz, 1H), 3.95-3.89 (m, 1H), 3.92 (s, 3H), 3.61 (dd, J=11.4, 7.6 Hz, 1H), 3.52 (dt, J=9.1, 6.6 Hz, 1H), 3.33 (dt, J=9.1, 6.6 Hz, 1H), 3.23 (ddd, J=8.9, 7.6, 1.3 Hz, 1H), 2.56 (hept, J=7.0 Hz, 1H), 1.49-1.38 (m, 2H), 1.32 (d, J=6.3 Hz, 3H), 1.32-1.24 (m, 2H), 1.19 (d, J=7.0 Hz, 3H), 1.17 (d, J=7.0 Hz, 3H), 0.86 (t, J=7.3 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 175.79, 170.21, 169.06, 155.46, 148.86, 140.77, 130.28, 109.71, 80.84, 75.91, 75.76, 74.72, 71.79, 70.55, 56.20, 52.63, 34.20, 32.02, 19.33, 19.18, 18.87, 18.31, 13.96; HRMS-ESI (m/z) [M]+ calcd for C23H34N2O9, 482.2264; found, 482.2266.


Compound 66 was prepared in the same manner as described in Example 16, Step 4 using compound 181 as starting material.


Example 17
Step 1: Preparation of tert-butyl N-[(3S,7S,8S,9S)-8-benzyloxy-7-butoxy-9-methyl-2-oxo-1,5-dioxonan-3-yl]-N-tert-butoxycarbonylcarbamate (compound 101)



embedded image


Compound 101 was prepared in the same manner as described in Example 7, Step 3 to give the title compound as a colorless oil (562 mg, 92%): IR (neat) 2932, 1766, 1709, 1367, 1256, 1147, 1122 cm−1; 1H NMR (400 MHz, CDCl3) δ 7.40-7.23 (m, 5H), 5.23 (dd, J=8.9, 4.1 Hz, 1H), 4.94 (d, J=10.9 Hz, 1H), 4.85 (dq, J=9.1, 6.3 Hz, 1H), 4.60 (d, J=10.9 Hz, 1H), 4.25 (dd, J=12.1, 4.1 Hz, 1H), 3.92 (dd, J=12.2, 8.9 Hz, 1H), 3.85 (d, J=10.7 Hz, 1H), 3.65-3.48 (m, 3H), 3.42-3.30 (m, 2H), 1.61-1.45 (m, 2H), 1.50 (s, 18H), 1.41 (d, J=6.3 Hz, 3H), 1.38-1.28 (m, 2H), 0.88 (t, J=7.4 Hz, 3H); HRMS-ESI (m/z) [M]+ calcd for C29H45NO9, 551.3094; found, 551.3109


Example 17
Step 2: Preparation of tert-butyl N-tert-butoxycarbonyl-N-[(3S,7S,8S,9S)-7-butoxy-8-hydroxy-9-methyl-2-oxo-1,5-dioxonan-3-yl]carbamate (compound 112)



embedded image


Compound 112 was prepared in the same manner as described in Example 7, Step 4 to give the title compound as a colorless oil (403.3 mg, 86%): IR (neat) 3536, 2979, 2934, 2875, 1764, 1747, 1706, 1366, 1246, 1147, 1121, 1088, 1049 cm−1; 1H NMR (400 MHz, CDCl3) δ 5.27 (dd, J=8.8, 2.4 Hz, 1H), 4.91 (dq, J=9.2, 6.3 Hz, 1H), 4.27 (dd, J=12.4, 2.4 Hz, 1H), 4.08 (dd, J=10.9, 0.8 Hz, 1H), 3.90 (dd, J=12.4, 8.8 Hz, 1H), 3.66 (dt, J=9.4, 6.6 Hz, 1H), 3.46-3.36 (m, 3H), 3.22-3.14 (m, 1H), 3.11 (d, J=1.1 Hz, 1H), 1.57-1.51 (m, 2H), 1.51 (s, 18H), 1.45 (d, J=6.3 Hz, 3H), 1.40-1.29 (m, 2H), 0.91 (t, J=7.4 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 168.42, 152.63, 82.95, 82.47, 76.64, 76.60, 74.41, 73.34, 69.79, 58.57, 31.80, 27.93, 19.25, 18.69, 13.81; HRMS-ESI (m/z) [M]+ calcd for C22H39NO9, 461.2625; found, 461.2632.


Example 17
Step 3: Preparation of tert-butyl N-tert-butoxycarbonyl-N-[(3S,7S,8S,9S)-7-butoxy-8-methoxy-9-methyl-2-oxo-1,5-dioxonan-3-yl]carbamate (compound 115)



embedded image


Compound 115 was prepared in the same manner as described in Example 12, Step 1 to give the title compound as a colorless oil (78.7 mg, 76%): IR (neat) 2979, 2933, 2875, 1765, 1747, 1707, 1367, 1243, 1106 cm−1; 1H NMR (400 MHz, CDCl3) δ 5.20 (dd, J=9.0, 4.1 Hz, 1H), 4.73 (dq, J=9.7, 6.3 Hz, 1H), 4.22 (dd, J=12.1, 4.1 Hz, 1H), 3.88 (dd, J=12.1, 9.0 Hz, 1H), 3.80 (dd, J=10.7, 0.6 Hz, 1H), 3.62-3.43 (m, 3H), 3.53 (s, 3H), 3.24-3.17 (m, 1H), 3.08-3.01 (m, 1H), 1.57-1.45 (m, 2H), 1.48 (s, 18H), 1.40 (d, J=6.3 Hz, 3H), 1.39-1.28 (m, 2H), 0.88 (t, J=7.4 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 169.12, 152.73, 86.80, 83.43, 83.12, 75.78, 72.79, 72.64, 70.71, 61.45, 57.97, 32.29, 28.03, 19.43, 18.69, 13.99; HRMS-ESI (m/z) [M]+ calcd for C23H41NO9, 475.2781; found, 475.2784.


Example 17
Steps 4 and 5: Preparation of N-((3S,7S,8S,9S)-7-butoxy-8-methoxy-9-methyl-2-oxo-1,5-dioxonan-3-yl)-3-hydroxy-4-methoxypicolinamide (compound 36)



embedded image


Compound 36 was prepared in two steps: Step 4 was performed in the same manner as described in Example 5, Step 7 to give compound 182; Step 5 was performed in the same manner as described in Example 5, Step 8, to give the title compound as a white solid (52.1 mg, 63%): mp 118-120° C.; IR (neat) 3366, 2933, 1742, 1650, 1529, 1244, 1103 cm−1; 1H NMR (400 MHz, CDCl3) δ 11.91 (s, 1H), 8.65 (d, J=8.1 Hz, 1H), 7.97 (d, J=5.2 Hz, 1H), 6.85 (d, J=5.2 Hz, 1H), 5.02 (ddd, J=8.1, 6.8, 5.1 Hz, 1H), 4.92 (dq, J=9.4, 6.3 Hz, 1H), 4.03 (dd, J=11.9, 6.8 Hz, 1H), 3.92 (s, 3H), 3.84-3.76 (m, 2H), 3.62-3.55 (m, 2H), 3.55 (s, 3H), 3.50 (dt, J=9.1, 6.6 Hz, 1H), 3.19 (ddd, J=8.4, 7.1, 1.3 Hz, 1H), 3.09 (t, J=9.0 Hz, 1H), 1.62-1.48 (m, 2H), 1.44 (d, J=6.3 Hz, 3H), 1.42-1.30 (m, 2H), 0.90 (t, J=7.4 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 170.38, 169.05, 155.42, 148.81, 140.77, 130.29, 109.68, 86.84, 83.62, 75.34, 74.02, 73.03, 70.82, 61.56, 56.19, 52.24, 32.25, 19.43, 18.64, 13.99; HRMS-ESI (m/z) [M]+ calcd for C20H30N2O8, 426.2002; found, 426.2039.


Example 18
Step 1: Preparation of tert-butyl N-[(3S,7S,8S,9S)-8-allyloxy-7-butoxy-9-methyl-2-oxo-1,5-dioxonan-3-yl]-N-tert-butoxycarbonyl-carbamate (compound 116)



embedded image


Compound 116 was prepared in the same manner as described in Example 7, Step 5 to give the title compound as a pale yellow oil (102.0 mg, 94%): IR (neat) 2979, 2933, 1765, 1708, 1367, 1244, 1121, 1098 cm−1; 1H NMR (400 MHz, CDCl3) δ 5.89 (ddt, J=16.2, 10.4, 5.7 Hz, 1H), 5.27-5.17 (m, 2H), 5.13 (dd, J=10.4, 1.7 Hz, 1H), 4.78 (dq, J=12.6, 6.2 Hz, 1H), 4.36 (ddt, J=12.1, 5.4, 1.3 Hz, 1H), 4.22 (dd, J=12.1, 4.1 Hz, 1H), 4.10-4.03 (m, 1H), 3.89 (dd, J=12.2, 9.0 Hz, 1H), 3.81 (d, J=10.8 Hz, 1H), 3.60-3.44 (m, 3H), 3.29-3.17 (m, 2H), 1.57-1.45 (m, 2H), 1.48 (s, 18H), 1.40 (d, J=6.3 Hz, 3H), 1.38-1.27 (m, 2H), 0.88 (t, J=7.4 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 169.13, 152.73, 135.04, 116.82, 84.57, 83.62, 83.13, 75.87, 74.70, 72.87, 72.72, 70.76, 58.00, 32.30, 28.05, 19.42, 18.85, 14.02; HRMS-ESI (m/z) [M]+ calcd for C25H43NO9, 501.2938; found, 501.2955.


Example 18
Steps 2 and 3: Preparation of N-((3S,7S,8S,9S)-8-(allyloxy)-7-butoxy-9-methyl-2-oxo-1,5-dioxonan-3-yl)-3-hydroxy-4-methoxypicolinamide (compound 43)



embedded image


Compound 43 was prepared in two steps: Step 2 was performed in the same manner as described in Example 5, Step 7 to give compound 183; Step 3 was performed in the same manner as described in Example 5, Step 8, to give the title compound as an off-white solid (77.4 mg, 60%): mp 101-103° C.; IR (neat) 3335, 2931, 1745, 1640, 1534, 1281, 1092 cm−1; 1H NMR (400 MHz, CDCl3) δ 11.92 (s, 1H), 8.66 (d, J=8.1 Hz, 1H), 7.98 (d, J=5.2 Hz, 1H), 6.85 (d, J=5.2 Hz, 1H), 5.91 (ddt, J=16.2, 10.4, 5.8 Hz, 1H), 5.25 (ddd, J=17.2, 3.2, 1.6 Hz, 1H), 5.15 (ddd, J=10.4, 2.7, 1.1 Hz, 1H), 5.02 (ddd, J=8.1, 6.8, 5.0 Hz, 1H), 4.99-4.92 (m, 1H), 4.38 (ddt, J=12.2, 5.5, 1.3 Hz, 1H), 4.13-4.05 (m, 1H), 4.03 (dd, J=11.9, 6.8 Hz, 1H), 3.92 (s, 3H), 3.86-3.76 (m, 2H), 3.64-3.54 (m, 2H), 3.49 (dt, J=9.2, 6.6 Hz, 1H), 3.31-3.19 (m, 2H), 1.59-1.48 (m, 2H), 1.44 (d, J=6.4 Hz, 3H), 1.40-1.28 (m, 2H), 0.89 (t, J=7.4 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 170.37, 169.05, 155.42, 148.81, 140.77, 134.92, 130.29, 117.01, 109.68, 84.56, 83.77, 75.44, 74.78, 74.08, 73.10, 70.87, 56.18, 52.25, 32.26, 19.42, 18.77, 14.02; HRMS-ESI (m/z) [M]+ calcd for C22H32N2O8, 452.2159; found, 452.2166.


Compound 171 was prepared in the same manner as described in Example 18, Step 2 using compound 187 as starting material.


Compound 9 was prepared in the same manner as described in Example 18, Step 3 using compound 171 as starting material.


Example 18
Step 4: Preparation of N-((3S,7S,8S,9S)-7-butoxy-9-methyl-2-oxo-8-propoxy-1,5-dioxonan-3-yl)-3-hydroxy-4-methoxypicolinamide (compound 44)



embedded image


Compound 44 was prepared in the same manner as described in Example 7, Step 6 to give the title compound as a white solid (64.4 mg, 99%): mp 110-112° C.; IR (neat) 3366, 2933, 1750, 1649, 1529, 1245, 1095 cm−1; 1H NMR (400 MHz, CDCl3) δ 11.93 (s, 1H), 8.66 (d, J=8.1 Hz, 1H), 7.99 (d, J=5.2 Hz, 1H), 6.86 (d, J=5.2 Hz, 1H), 5.02 (ddd, J=8.1, 6.9, 5.2 Hz, 1H), 4.95 (dq, J=12.6, 6.3 Hz, 1H), 4.04 (dd, J=11.9, 6.8 Hz, 1H), 3.93 (s, 3H), 3.86-3.76 (m, 3H), 3.64-3.54 (m, 2H), 3.49 (tt, J=8.7, 6.7 Hz, 2H), 3.24-3.16 (m, 2H), 1.65-1.49 (m, 4H), 1.45 (d, J=6.3 Hz, 3H), 1.41-1.30 (m, 2H), 0.92 (t, J=7.4 Hz, 3H), 0.91 (t, J=7.3 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 170.46, 169.08, 155.46, 148.85, 140.79, 130.34, 109.69, 85.05, 83.70, 75.72, 75.39, 74.01, 73.32, 70.90, 56.22, 52.23, 32.31, 23.64, 19.45, 18.71, 14.04, 10.79; HRMS-ESI (m/z) [M]+ calcd for C22H34N2O8, 454.2315; found, 454.2326.


Compound 10 was prepared in the same manner as described in Example 18, Step 4 using compound 9 as starting material.


Example 19
Step 1: Preparation of tert-butyl N-tert-butoxycarbonyl-N-[(3S,7S,8S,9S)-7-butoxy-9-methyl-8-(2-methylallyloxy)-2-oxo-1,5-dioxonan-3-yl]carbamate (compound 117)



embedded image


Compound 117 was prepared in the same manner as described in Example 7, Step 5 to give the title compound as a pale yellow oil (79.6 mg, 71%): IR (neat) 2978, 2933, 2874, 1765, 1709, 1456, 1367, 1244, 1147, 1120, cm−1; 1H NMR (400 MHz, CDCl3) δ 5.21 (dd, J=8.9, 4.1 Hz, 1H), 4.96-4.92 (m, 1H), 4.86-4.77 (m, 2H), 4.30 (d, J=11.6 Hz, 1H), 4.23 (dd, J=12.1, 4.1 Hz, 1H), 3.95-3.86 (m, 2H), 3.81 (d, J=10.8 Hz, 1H), 3.60-3.44 (m, 3H), 3.30-3.20 (m, 2H), 1.73 (s, 3H), 1.55-1.45 (m, 2H), 1.49 (s, 18H), 1.42 (d, J=6.3 Hz, 3H), 1.38-1.28 (m, 2H), 0.88 (t, J=7.4 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 169.17, 152.77, 142.55, 111.93, 84.92, 83.69, 83.17, 77.66, 75.85, 72.88, 72.75, 70.76, 58.03, 32.36, 28.08, 19.95, 19.47, 18.86, 14.06; HRMS-ESI (m/z) [M]+ calcd for C26H45NO9, 515.3094; found, 515.3101.


Example 19
Steps 2 and 3: Preparation of N-((3S,7S,8S,9S)-7-butoxy-8-(2-chloro-2-methylpropoxy)-9-methyl-2-oxo-1,5-dioxonan-3-yl)-3-hydroxy-4-methoxypicolinamide (compound 87) and N-((3S,7S,8S,9S)-7-butoxy-8-hydroxy-9-methyl-2-oxo-1,5-dioxonan-3-yl)-3-hydroxy-4-methoxypicolinamide (compound 42)



embedded image


Compounds 87 and 42 were prepared in two steps: Step 2 was performed in the same manner as described in Example 5, Step 7 to give compounds 184 and 185; Step 3 was performed in the same manner as described in Example 5, Step 8, to give the title compounds.


N-((3S,7S,8S,9S)-7-Butoxy-8-(2-chloro-2-methylpropoxy)-9-methyl-2-oxo-1,5-dioxonan-3-yl)-3-hydroxy-4-methoxypicolinamide (compound 87) was isolated as an amber solid (5.8 mg, 4.4%): mp 115-117° C.; IR (neat) 3364, 2932, 1751, 1650, 1529, 1244, 1094 cm−1; 1H NMR (400 MHz, CDCl3) δ 11.92 (s, 1H), 8.67 (d, J=8.1 Hz, 1H), 8.02-7.98 (m, 1H), 6.87 (d, J=5.2 Hz, 1H), 5.08-4.99 (m, 2H), 4.05 (dd, J=11.9, 6.8 Hz, 1H), 4.00 (d, J=9.3 Hz, 1H), 3.94 (s, 3H), 3.82 (dt, J=10.7, 5.4 Hz, 2H), 3.66-3.45 (m, 4H), 3.32-3.23 (m, 2H), 1.58 (s, 3H), 1.56 (s, 3H), 1.57-1.50 (m, 2H), 1.50 (d, J=6.3 Hz, 3H), 1.41-1.29 (m, 2H), 0.91 (t, J=7.3 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 170.36, 169.10, 155.50, 148.89, 140.81, 130.36, 109.73, 84.87, 83.89, 82.38, 75.30, 74.18, 73.05, 70.57, 68.04, 56.24, 52.31, 32.34, 29.65, 29.51, 19.51, 18.97, 14.08; HRMS-ESI (m/z) [M]+ calcd for C23H35ClN2O8, 502.2082; found, 502.2090.


N-((3S,7S,8S,9S)-7-Butoxy-8-hydroxy-9-methyl-2-oxo-1,5-dioxonan-3-yl)-3-hydroxy-4-methoxypicolinamide (compound 42) was isolated as an off-white oil (20.5 mg, 19%): IR (neat) 3370, 2933, 1750, 1648, 1529, 1244, 1088 cm−1; 1H NMR (400 MHz, CDCl3) δ 11.96-11.93 (m, 1H), 8.79 (d, J=7.8 Hz, 1H), 8.01 (d, J=5.2 Hz, 1H), 6.87 (d, J=5.2 Hz, 1H), 5.14 (dq, J=9.3, 6.3 Hz, 1H), 5.01 (ddd, J=7.9, 5.7, 2.2 Hz, 1H), 4.18-4.06 (m, 2H), 3.98-3.90 (m, 1H), 3.94 (s, 3H), 3.66 (dt, J=9.3, 6.6 Hz, 1H), 3.48-3.38 (m, 3H), 3.20 (s, 1H), 3.15-3.07 (m, 1H), 1.60-1.51 (m, 2H), 1.49 (d, J=6.3 Hz, 3H), 1.41-1.29 (m, 2H), 0.91 (t, J=7.4 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 169.62, 169.15, 155.48, 148.89, 140.83, 130.45, 109.71, 82.72, 77.79, 77.36, 76.62, 73.73, 70.15, 56.24, 53.63, 31.90, 19.44, 18.90, 13.96; HRMS-ESI (m/z) [M]+ calcd for C19H28N2O8, 412.1846; found, 412.1849.


Example 20
Step 1: Preparation of tert-butyl N-tert-butoxycarbonyl-N-[(3S,7S,8S,9S)-7-butoxy-8-(2-hydroxyethoxy)-9-methyl-2-oxo-1,5-dioxonan-3-yl]carbamate (compound 164)



embedded image


Compound 164 was prepared in the same manner as described in Example 8, Step 1 to give the title compound as a colorless oil (170 mg, 84%): IR (neat) 2934, 1745, 1707, 1457, 1367, 1254, 1120 cm−1; 1H NMR (400 MHz, CDCl3) δ 5.22 (dd, J=8.9, 3.9 Hz, 1H), 4.80 (dq, J=8.9, 6.3 Hz, 1H), 4.24 (dd, J=12.2, 3.9 Hz, 1H), 3.95-3.79 (m, 3H), 3.78-3.68 (m, 2H), 3.66-3.45 (m, 4H), 3.45-3.38 (m, 1H), 3.39-3.23 (m, 2H), 1.61-1.50 (m, 2H), 1.49 (s, 18H), 1.44 (d, J=6.3 Hz, 3H), 1.40-1.26 (m, 2H), 0.89 (t, J=7.4 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 169.06, 152.76, 85.77, 83.22, 83.05, 75.57, 75.51, 73.09, 73.00, 70.54, 62.93, 58.04, 31.86, 28.07, 19.32, 18.80, 13.99; HRMS-ESI (m/z) [M]+ calcd for C24H43NO10, 505.2887; found, 505.2900.


Example 20
Step 2: Preparation of tert-butyl N-tert-butoxycarbonyl-N-[(3S,7S,8S,9S)-7-butoxy-8-(2-methoxyethoxy)-9-methyl-2-oxo-1,5-dioxonan-3-yl]carbamate (compound 163)



embedded image


Compound 163 was prepared in the same manner as described in Example 12, Step 1 to give the title compound as a colorless oil (192.0 mg, 79%): IR (neat) 2933, 2875, 1764, 1747, 1708, 1456, 1367, 1243, 1099 cm−1; 1H NMR (400 MHz, CDCl3) δ 5.19 (dd, J=9.0, 4.1 Hz, 1H), 4.79 (dq, J=9.2, 6.3 Hz, 1H), 4.20 (dd, J=12.2, 4.1 Hz, 1H), 3.98 (ddd, J=10.6, 5.2, 3.8 Hz, 1H), 3.88 (dd, J=12.2, 9.0 Hz, 1H), 3.79 (d, J=10.7 Hz, 1H), 3.73-3.65 (m, 1H), 3.60-3.43 (m, 5H), 3.34 (s, 3H), 3.28-3.15 (m, 2H), 1.55-1.44 (m, 2H), 1.47 (s, 18H), 1.42 (d, J=6.3 Hz, 3H), 1.38-1.26 (m, 2H), 0.87 (t, J=7.4 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 169.06, 152.69, 85.55, 83.49, 83.10, 75.76, 72.96, 72.85, 72.70, 72.34, 70.62, 59.02, 57.95, 32.28, 28.02, 19.41, 18.67, 14.01; HRMS-ESI (m/z) [M]+ calcd for C25H45NO10, 519.3043; found, 519.3026.


Example 20
Step 3: Preparation of (3S,7S,8S,9S)-3-amino-7-butoxy-8-(2-methoxyethoxy)-9-methyl-1,5-dioxonan-2-one hydrochloride (compound 169)



embedded image


Compound 169 was prepared in the same manner as described in Example 5, Step 7 to give the title compound as a light yellow oil (130 mg, quantitative): ESIMS m/z 319 ([M]+).


Example 20
Step 4: Preparation of N-((3S,7S,8S,9S)-7-butoxy-8-(2-methoxyethoxy)-9-methyl-2-oxo-1,5-dioxonan-3-yl)-3-hydroxy-4-methoxypicolinamide (compound 52)



embedded image


Compound 52 was prepared in the same manner as described in Example 5, Step 8 to give the title compound as a white solid (107.0 mg, 62%): mp 75-77° C.; IR (neat) 3367, 2933, 1750, 1649, 1529, 1282, 1094 cm−1; 1H NMR (400 MHz, CDCl3) δ 11.92-11.89 (m, 1H), 8.65 (d, J=8.1 Hz, 1H), 7.97 (d, J=5.2 Hz, 1H), 6.85 (d, J=5.2 Hz, 1H), 5.04-4.94 (m, 2H), 4.06-3.96 (m, 2H), 3.92 (s, 3H), 3.84-3.77 (m, 2H), 3.75-3.68 (m, 1H), 3.61-3.44 (m, 5H), 3.36 (s, 3H), 3.27-3.19 (m, 2H), 1.58-1.48 (m, 2H), 1.46 (d, J=6.3 Hz, 3H), 1.40-1.27 (m, 2H), 0.89 (t, J=7.4 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 170.31, 169.04, 155.40, 148.79, 140.75, 130.28, 109.67, 85.60, 83.64, 75.38, 74.07, 73.09, 73.06, 72.34, 70.75, 59.04, 56.17, 52.23, 32.25, 19.41, 18.60, 14.01; HRMS-ESI (m/z) [M]+ calcd for C22H34N2O9, 470.2264; found, 470.2264.


Example 21
Step 1: Preparation of tert-butyl N-tert-butoxycarbonyl-N-[(3S,7S,8S,9S)-7-butoxy-9-methyl-2-oxo-8-(2-oxoethoxy)-1,5-dioxonan-3-yl]carbamate (compound 119)



embedded image


A mixture of tert-butyl N-[(3S,7S,8S,9S)-8-allyloxy-7-butoxy-9-methyl-2-oxo-1,5-dioxonan-3-yl]-N-tert-butoxycarbonylcarbamate (0.350 g, 0.698 mmol) and NaHCO3 (5.86 mg, 0.070 mmol) in MeOH (0.21 ml) and DCM (6.8 ml) was treated with ozone at −78° C. until the solution became light blue in color. The mixture was purged with nitrogen until colorless and quenched by the addition of DMS (0.10 ml, 1.40 mmol). The reaction mixture was slowly warmed to room temperature and stirred for 20 h. The mixture was concentrated and purified by flash chromatography on (SiO2, hexanes/EtOAc gradient) to yield the title compound as a colorless oil (320 mg, 91%): IR (neat) 2934, 2876, 1743, 1706, 1367, 1253, 1121, 1096 cm−1; 1H NMR (400 MHz, CDCl3) δ 9.63 (s, 1H), 5.18 (dd, J=8.9, 3.8 Hz, 1H), 4.84 (dq, J=9.4, 6.3 Hz, 1H), 4.39 (dd, J=17.9, 0.9 Hz, 1H), 4.22 (dd, J=17.8, 0.5 Hz, 1H), 4.19 (dd, J=12.2, 3.8 Hz, 1H), 3.91-3.75 (m, 2H), 3.57-3.42 (m, 2H), 3.37 (dt, J=9.2, 6.5 Hz, 1H), 3.29 (dd, J=7.9, 6.9 Hz, 1H), 3.21 (t, J=9.0 Hz, 1H), 1.52-1.40 (m, 2H), 1.45 (s, 18H), 1.41 (d, J=6.3 Hz, 3H), 1.30-1.19 (m, 2H), 0.83 (t, J=7.3 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 200.51, 168.79, 152.61, 86.19, 83.52, 83.08, 79.09, 75.35, 72.95, 71.99, 70.03, 57.92, 32.02, 27.94, 19.29, 18.84, 13.85; HRMS-ESI (m/z) [M]+ calcd for C24H41NO10, 503.2730; found, 503.2727.


Compound 95 was prepared in the same manner as described in Example 21, Step 1 using compound 94 as starting material.


Example 21
Step 2: Preparation of tert-butyl N-tert-butoxycarbonyl-N-[(3S,7S,8S,9S)-7-butoxy-8-(2,2-difluoroethoxy)-9-methyl-2-oxo-1,5-dioxonan-3-yl]carbamate (compound 120)



embedded image


To a solution of tert-butyl N-tert-butoxycarbonyl-N-[(3S,7S,8S,9S)-7-butoxy-9-methyl-2-oxo-8-(2-oxoethoxy)-1,5-dioxonan-3-yl]carbamate (0.130 g, 0.258 mmol) in DCM (1.50 mL) at 0° C. was added a solution of Deoxo-Fluor® (0.10 ml, 0.542 mmol) in DCM (1.0 mL) dropwise at 0° C., and the reaction mixture was then stirred at 0° C. for 1 h. The mixture was concentrated and purified by flash chromatography (SiO2, hexanes/EtOAc gradient) to yield the title compound as a colorless oil (89.0 mg, 66%): IR (neat) 2980, 2395, 2877, 1747, 1708, 1367, 1254, 1120 cm−1; 1H NMR (400 MHz, CDCl3) δ 5.81 (tdd, J=55.1, 4.7, 3.4 Hz, 1H), 5.21 (dd, J=9.0, 3.8 Hz, 1H), 4.80 (dq, J=12.6, 6.2 Hz, 1H), 4.23 (dd, J=12.2, 3.8 Hz, 1H), 4.13-3.99 (m, 1H), 3.92-3.71 (m, 3H), 3.56 (dt, J=9.1, 6.8 Hz, 1H), 3.52-3.40 (m, 2H), 3.29-3.19 (m, 2H), 1.56-1.45 (m, 2H), 1.48 (s, 18H), 1.41 (d, J=6.3 Hz, 3H), 1.38-1.26 (m, 2H), 0.89 (t, J=7.4 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 168.92, 152.72, 114.35 (t, J=241.7 Hz), 86.15, 83.55, 83.20, 75.56, 73.03, 72.78 (t, J=27.6 Hz), 72.17, 70.36, 58.01, 32.19, 28.04, 19.40, 18.71, 13.97; HRMS-ESI (m/z) [M]+ calcd for C24H41F2NO9, 525.2749; found, 525.2723.


Compound 96 was prepared in the same manner as described in Example 21, Step 2 using compound 95 as starting material.


Example 21
Step 3: Preparation of (3S,7S,8S,9S)-3-amino-7-butoxy-8-(2,2-difluoroethoxy)-9-methyl-1,5-dioxonan-2-one hydrochloride (compound 167)



embedded image


Compound 167 was prepared in the same manner as described in Example 5, Step 7 to give the title compound as a white solid (142 mg, quantitative): ESIMS m/z 326.7 ([M+H]+).


Example 21
Step 4: Preparation of N-((3S,7S,8S,9S)-7-butoxy-8-(2,2-difluoroethoxy)-9-methyl-2-oxo-1,5-dioxonan-3-yl)-3-hydroxy-4-methoxypicolinamide (compound 53)



embedded image


Compound 53 was prepared in the same manner as described in Example 5, Step 8 to give the title compound as a white solid (94.4 mg, 50%): mp 127-129° C.; IR (neat) 3356, 2958, 1736, 1643, 1536, 1262, 1091 cm−1; 1H NMR (400 MHz, CDCl3) δ 11.90 (s, 1H), 8.66 (d, J=8.0 Hz, 1H), 7.97 (d, J=5.2 Hz, 1H), 6.85 (d, J=5.2 Hz, 1H), 5.83 (tdd, J=55.1, 4.7, 3.3 Hz, 1H), 5.07-4.93 (m, 2H), 4.14-4.01 (m, 1H), 4.02 (dd, J=12.0, 6.7 Hz, 1H), 3.92 (s, 3H), 3.88-3.72 (m, 3H), 3.62-3.51 (m, 2H), 3.45 (dt, J=9.1, 6.6 Hz, 1H), 3.31-3.19 (m, 2H), 1.58-1.48 (m, 2H), 1.45 (d, J=6.3 Hz, 3H), 1.39-1.28 (m, 2H), 0.90 (t, J=7.4 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 170.17, 169.05, 155.44, 148.82, 140.78, 130.24, 114.30 (t, J=241.7 Hz), 109.69, 86.19, 83.72, 75.28, 74.31, 72.79 (t, J=27.6 Hz), 72.51, 70.45, 56.19, 52.33, 32.13, 19.39, 18.64, 13.96; HRMS-ESI (m/z) [M]+ calcd for C21H30F2N2O8, 476.1970; found, 476.1978.


Example 22
Step 1: Preparation of tert-butyl N-tert-butoxycarbonyl-N-[(3S,7S,8S,9S)-7-butoxy-8-isobutoxy-9-methyl-2-oxo-1,5-dioxonan-3-yl]carbamate (compound 118)



embedded image


Compound 118 was prepared in the same manner as described in Example 7, Step 6 to give the title compound as a colorless oil (112 mg, 70%): IR (neat) 3313, 1637, 1367 cm−1; 1H NMR (400 MHz, CDCl3) δ 5.20 (dd, J=8.9, 4.2 Hz, 1H), 4.78 (dq, J=9.4, 6.3 Hz, 1H), 4.23 (dd, J=12.1, 4.2 Hz, 1H), 3.90 (dd, J=12.1, 9.0 Hz, 1H), 3.80 (d, J=10.6 Hz, 1H), 3.66 (dd, J=8.4, 6.1 Hz, 1H), 3.60-3.42 (m, 3H), 3.26-3.18 (m, 2H), 3.18-3.10 (m, 1H), 1.87-1.74 (m, 1H), 1.56-1.44 (m, 2H), 1.49 (s, 18H), 1.40 (d, J=6.3 Hz, 3H), 1.39-1.28 (m, 2H), 0.93-0.84 (m, 9H); 13C NMR (101 MHz, CDCl3) δ 169.21, 152.77, 84.93, 83.58, 83.13, 80.65, 75.88, 72.92, 72.85, 70.74, 58.02, 32.36, 29.26, 28.08, 19.69, 19.51, 19.48, 18.83, 14.06; HRMS-ESI (m/z) [M]+ calcd for C26H47NO9, 517.3521; found, 517.3527.


Example 22
Steps 2 and 3: Preparation of N-((3S,7S,8S,9S)-7-butoxy-8-isobutoxy-9-methyl-2-oxo-1,5-dioxonan-3-yl)-3-hydroxy-4-methoxypicolinamide (compound 48)



embedded image


Compound 48 was prepared in two steps: Step 2 was performed in the same manner as described in Example 5, Step 7 to give compound 168; Step 3 was performed in the same manner as described in Example 5, Step 8 to give the title compound as a light yellow solid (61.5 mg, 62%): mp 104-106° C.; IR (neat) 3367, 2956, 1749, 1649, 1528, 1281, 1092 cm−1; 1H NMR (400 MHz, CDCl3) δ 11.92 (s, 1H), 8.65 (d, J=8.1 Hz, 1H), 7.97 (d, J=5.2 Hz, 1H), 6.85 (d, J=5.2 Hz, 1H), 5.01 (ddd, J=8.0, 6.9, 5.2 Hz, 1H), 4.94 (dq, J=12.6, 6.2 Hz, 1H), 4.03 (dd, J=11.9, 6.8 Hz, 1H), 3.91 (s, 3H), 3.82-3.75 (m, 2H), 3.66 (dd, J=8.4, 6.2 Hz, 1H), 3.64-3.44 (m, 3H), 3.24 (dd, J=8.4, 6.9 Hz, 1H), 3.21-3.13 (m, 2H), 1.88-1.74 (m, 1H), 1.57-1.47 (m, 2H), 1.43 (d, J=6.3 Hz, 3H), 1.40-1.29 (m, 2H), 0.94-0.83 (m, 9H); 13C NMR (101 MHz, CDCl3) δ 170.44, 169.04, 155.41, 148.80, 140.75, 130.29, 109.66, 84.93, 83.70, 80.71, 75.29, 73.92, 73.29, 70.79, 56.17, 52.18, 32.28, 29.21, 19.64, 19.48, 19.44, 18.71, 14.02; HRMS-ESI (m/z) [M]+ calcd for C23H36N2O8, 468.2472; found, 468.2497.


Example 23
Preparation of (2-((3S,7S,8S,9S)-7,8-diisobutoxy-9-methyl-2-oxo-1,5-dioxonan-3-ylcarbamoyl)-4-methoxypyridin-3-yloxy)methyl (compound 3)



embedded image


A mixture of N-((3S,7S,8S,9S)-7,8-diisobutoxy-9-methyl-2-oxo-1,5-dioxonan-3-yl)-3-hydroxy-4-methoxypicolinamide (58 mg, 0.124 mmol), Na2CO3 (17.06 mg, 0.161 mmol) and NaI (3.71 mg, 0.025 mmol) in acetone (1 mL) was stirred at room temperature. Bromomethyl acetate (0.016 mL, 0.155 mmol) was then added slowly. The resulting reaction mixture was stirred at 50° C. overnight. The solvent was removed and the crude residue was purified via flash chromatography (SiO2) to afford the title compound as a white foam (41 mg, 61%): 1H NMR (400 MHz, CDCl3) δ 8.53 (d, J=7.9 Hz, 1H), 8.29 (d, J=5.3 Hz, 1H), 6.95 (d, J=5.4 Hz, 1H), 5.79-5.69 (m, 2H), 5.13-5.01 (m, 1H), 5.01-4.88 (m, 1H), 4.04 (dd, J=7.9, 3.9 Hz, 1H), 3.91 (s, 3H), 3.83-3.74 (m, 2H), 3.71 (dd, J=8.4, 6.1 Hz, 1H), 3.65-3.56 (m, 1H), 3.37-3.13 (m, 5H), 2.07 (s, 3H), 1.91-1.73 (m, 2H), 1.45 (d, J=6.3 Hz, 3H), 0.97-0.87 (m, 12H); 13C NMR (101 MHz, CDCl3) δ 170.95, 170.30, 163.28, 160.25, 145.84, 143.97, 142.20, 109.73, 89.47, 84.86, 83.81, 80.60, 77.72, 75.07, 74.18, 73.03, 56.23, 52.49, 29.13, 28.90, 20.90, 19.61, 19.48, 19.39, 18.67; ESIMS m/z 540.5 ([M+H]+).


Compounds 2, 6, 7, 12, 13, 14, 17, 18, 23, 20, 24, 28, 29, 31, 51, 34, 35, 37, 40, 41, 45, 47, 50, 54, 55, 57, 60, 65, 64, 68, 69, 76, 77, 78, 80, 84, 85, 86, 214, 215, 216, 217, 218, 220, 221, 222, 223, 224, 226, 228, and 231 were prepared in the same manner as described in Example 23 from the corresponding 3-hydroxy picolinamides.


Example 24
Preparation of tert-butyl N-tert-butoxycarbonyl-N-[(3S,7S,8S,9S)-8-hydroxy-9-methyl-2-oxo-7-(4-trifluoromethylphenoxy)-1,5-dioxonan-3-yl]carbamate (compound 259) and tert-butyl N-tert-butoxycarbonyl-N-[(3S,7S,8R,9S)-7-hydroxy-9-methyl-2-oxo-8-(4-trifluoromethylphenoxy)-1,5-dioxonan-3-yl]carbamate (compound 260)



embedded image


To a stirred solution of tris(4-(trifluoromethyl)phenyl)bismuthine (1.67 g, 2.59 mmol) in DCM (3.5 mL) and THF (3.5 mL) cooled in an ice bath was added 32% peracetic acid in acetic acid, (0.61 mL, 2.94 mmol). The solution was warmed to room temperature and stirred for 20 min. To the reaction was added tert-butyl N-tert-butoxycarbonyl-N-[(3S,7S,8R,9S)-7,8-dihydroxy-9-methyl-2-oxo-1,5-dioxonan-3-yl]carbamate (0.70 g, 1.73 mmol) and diacetoxycopper (63 mg, 0.345 mmol). The reaction mixture was warmed to 45° C. and stirred for 18 h. The reaction was cooled to room temperature and filtered through Celite®, washing with DCM (5 mL). The filtrate was concentrated and purified by flash chromatography (SiO2; EtOAc/Hexanes) to provide the title compounds.


tert-butyl N-tert-butoxycarbonyl-N-[(3S,7S,8S,9S)-8-hydroxy-9-methyl-2-oxo-7-(4-trifluoromethylphenoxy)-1,5-dioxonan-3-yl]carbamate was isolated as a white solid (152 mg, 16%): 1H NMR (400 MHz, CDCl3) δ 7.59-7.52 (m, 2H), 7.03 (d, J=8.6 Hz, 2H), 5.39-5.28 (m, 1H), 5.06 (dq, J=8.9, 6.3 Hz, 1H), 4.34-4.21 (m, 2H), 4.06 (dd, J=11.2, 1.3 Hz, 1H), 3.94 (dd, J=12.7, 8.5 Hz, 1H), 3.80 (t, J=8.7 Hz, 1H), 3.64 (dd, J=11.2, 7.4 Hz, 1H), 2.87 (s, 1H), 1.53 (s, 21H); 13C NMR (101 MHz, CDCl3) δ 168.30, 159.10, 152.61, 127.21, 127.18, 127.14, 127.10, 125.55, 124.15, 123.82, 122.86, 115.66, 83.27, 80.62, 76.11, 75.90, 74.35, 73.36, 58.38, 27.99, 27.95, 18.69; ESIMS m/z 572 ([M+Na]+).


tert-butyl N-tert-butoxycarbonyl-N-[(3S,7S,8R,9S)-7-hydroxy-9-methyl-2-oxo-8-(4-trifluoromethylphenoxy)-1,5-dioxonan-3-yl]carbamate was isolated as a white solid (456 mg, 48%): 1H NMR (400 MHz, CDCl3) δ 7.59-7.52 (m, 2H), 7.13-7.06 (m, 2H), 5.26 (dd, J=8.5, 4.1 Hz, 1H), 5.09 (dq, J=8.7, 6.4 Hz, 1H), 4.37-4.29 (m, 2H), 4.09 (dd, J=12.1, 1.5 Hz, 1H), 4.00 (dd, J=12.2, 8.6 Hz, 1H), 3.91 (ddd, J=8.5, 7.3, 1.4 Hz, 1H), 3.72 (dd, J=11.1, 7.3 Hz, 1H), 2.33 (bs, 1H), 1.52 (s, 18H), 1.35 (d, J=6.4 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 168.72, 161.29, 152.63, 127.25, 127.21, 127.17, 127.13, 116.13, 84.48, 83.24, 77.25, 73.80, 73.68, 71.79, 58.08, 27.95, 18.90; ESIMS m/z 572 ([M+Na]+).


Compounds 267 and 268 were prepared in the same manner as described in Example 24 using tri(3-chlorophenyl)bismuth diacetate.


Example 25
Preparation of N-((3S,7S,8S,9S)-7,8-bis(isopentyloxy)-9-methyl-2-oxo-1,5-dioxonan-3-yl)-3-hydroxy-4-methoxypicolinamide (Compound 210)



embedded image


(3S,7S,8S,9S)-3-amino-7,8-bis(isopentyloxy)-9-methyl-1,5-dioxonan-2-one (130 mg, 0.376 mmol) and 3-hydroxy-4-methoxypicolinic acid (70.0 mg, 0.414 mmol) were diluted with DCM (3763 μl). PyBOP (215 mg, 0.414 mmol) was added, followed by N-ethyl-N-isopropylpropan-2-amine (216 μl, 1.242 mmol), and the mixture was stirred at room temperature until thin layer chromatography (TLC) indicated complete consumption of starting material. The reaction mixture was purified by column chromatography (SiO2; hexanes/EtOAc) to furnish the title compound (79.1 mg, 0.159 mmol, 42.3% yield) as a white solid: mp 61-70° C.; IR (thin film) 3530, 3371, 2955, 2873, 1750, 1649, 1529, 1262 cm−1; 1H NMR (400 MHz, CDCl3) δ 11.94 (s, 1H), 8.67 (d, J=8.1 Hz, 1H), 8.01-7.98 (m, 1H), 6.87 (d, J=5.2 Hz, 1H), 5.04 (ddd, J=8.2, 6.8, 5.0 Hz, 1H), 5.01-4.89 (m, 1H), 4.05 (dd, J=11.9, 6.8 Hz, 1H), 3.94 (s, 3H), 3.92-3.85 (m, 1H), 3.85-3.78 (m, 2H), 3.66-3.58 (m, 2H), 3.57-3.48 (m, 2H), 3.26-3.14 (m, 2H), 1.69 (dp, J=13.4, 6.7 Hz, 2H), 1.51-1.38 (m, 7H), 0.90 (dt, J=6.2, 2.7 Hz, 12H); 13C NMR (101 MHz, CDCl3) δ 170.30, 168.94, 155.32, 148.72, 140.66, 130.22, 109.56, 85.02, 83.63, 75.28, 73.94, 73.17, 72.48, 69.35, 56.09, 52.12, 39.23, 38.95, 24.96, 22.91, 22.67, 22.62, 22.50, 18.59; HRMS-ESI (m/z) [M+Na]+ calcd for C25H40N2NaO8, 519.2677, found 519.2687.


Compound 194 was prepared in the same manner as described in Example 25, starting from compound 288.


Compound 195 was prepared in the same manner as described in Example 25, starting from compound 287.


Compound 196 was prepared in the same manner as described in Example 25, starting from compound 286.


Compound 197 was prepared in the same manner as described in Example 25, starting from compound 285.


Compound 199 was prepared in the same manner as described in Example 25, starting from compound 283.


Compound 200 was prepared in the same manner as described in Example 25, starting from compound 282.


Compound 202 was prepared in the same manner as described in Example 25, starting from compound 280.


Compound 203 was prepared in the same manner as described in Example 25, starting from compound 279.


Compound 204 was prepared in the same manner as described in Example 25, starting from compound 278.


Compound 205 was prepared in the same manner as described in Example 25, starting from compound 277.


Compound 207 was prepared in the same manner as described in Example 25, starting from compound 275.


Compound 198 was prepared in the same manner as described in Example 25, starting from compound 284.


Compound 201 was prepared in the same manner as described in Example 25, starting from compound 281.


Compound 206 was prepared in the same manner as described in Example 25, starting from compound 276.


Compound 208 was prepared in the same manner as described in Example 25, starting from compound 274.


Compound 212 was prepared in the same manner as described in Example 25, starting from compound 271.


Example 26
Preparation of 2-(((3S,7S,8S,9S)-7,8-diisobutoxy-9-methyl-2-oxo-1,5-dioxonan-3-yl)carbamoyl)-4-methoxypyridin-3-yl 3-methoxypropanoate (compound 237)



embedded image


A reaction flask was charged with N-((3S,7S,8S,9S)-7,8-diisobutoxy-9-methyl-2-oxo-1,5-dioxonan-3-yl)-3-hydroxy-4-methoxypicolinamide (97 mg, 0.207 mmol), DMAP (40.1 mg, 0.328 mmol), and DCM. 3-Methoxypropanoyl chloride (22.5 μl, 0.207 mmol) was added and the colorless solution was stirred at room temperature under N2 overnight. The reaction mixture was concentrated and purified by column chromatography (SiO2, hexanes/EtOAc gradient) to afford the title compound (108.5 mg, 94% yield) as a sticky orange oil: IR (thin film) 3375, 2955, 2873, 1753, 1677, 1507, 1088 cm−1; 1H NMR (400 MHz, CDCl3) δ 8.67 (d, J=8.2 Hz, 1H), 8.38-8.30 (m, 1H), 7.00 (dd, J=5.7, 1.8 Hz, 1H), 5.08-4.98 (m, 1H), 4.93 (ddt, J=12.2, 8.4, 4.1 Hz, 1H), 4.00 (tt, J=7.2, 3.4 Hz, 1H), 3.93-3.84 (m, 3H), 3.85-3.64 (m, 5H), 3.64-3.55 (m, 1H), 3.41 (d, J=1.5 Hz, 3H), 3.33-3.12 (m, 5H), 2.97 (t, J=6.6 Hz, 2H), 1.82 (tt, J=12.9, 6.0 Hz, 2H), 1.43 (dd, J=6.3, 1.7 Hz, 3H), 0.97-0.85 (m, 12H); 13C NMR (101 MHz, CDCl3) δ 170.85, 169.37, 162.67, 159.42, 146.81, 141.19, 137.38, 109.88, 84.82, 83.75, 80.56, 77.70, 74.88, 74.07, 72.99, 67.58, 58.80, 56.32, 52.13, 34.61, 29.11, 28.87, 19.58, 19.46, 19.37, 18.63; ESIMS m/z 555 ([M+H]+).


Compounds 235 was prepared in the same manner as described in Example 26 from the corresponding 3-hydroxy picolinamides.


Example 27
Preparation of ((2-(((3S,7S,8S,9S)-8-(3-chlorophenoxy)-7-isobutoxy-9-methyl-2-oxo-1,5-dioxonan-3-yl)carbamoyl)-4-methoxypyridin-3-yl)oxy)methyl 2-ethoxyacetate



embedded image


To a solution of N-((3S,7S,8S,9S)-8-(3-chlorophenoxy)-7-isobutoxy-9-methyl-2-oxo-1,5-dioxonan-3-yl)-3-hydroxy-4-methoxypicolinamide (85 mg, 0.163 mmol) in acetone (2.0 mL) was added Na2CO3 (34.5 mg, 0.325 mmol), NaI (4.87 mg, 0.033 mmol), and chloromethyl 2-ethoxyacetate (37.2 mg, 0.244 mmol). The reaction was warmed to 45° C. and stirred for 16 h. The reaction was then concentrated and the residue purified by flash chromatography (SiO2; EtOAc/Hexanes) to give the title compound as a white foam (72.2 mg, 69.5%): 1H NMR (400 MHz, CDCl3) δ 8.56 (d, J=8.0 Hz, 1H), 8.29 (d, J=5.4 Hz, 1H), 7.17 (t, J=8.2 Hz, 1H), 7.04 (t, J=2.2 Hz, 1H), 6.96 (d, J=5.4 Hz, 1H), 6.95-6.87 (m, 2H), 5.82 (s, 2H), 5.23-5.06 (m, 2H), 4.25 (t, J=9.1 Hz, 1H), 4.10 (s, 2H), 3.91 (s, 4H), 3.82 (dd, J=11.8, 5.3 Hz, 1H), 3.71 (dd, J=11.1, 7.4 Hz, 1H), 3.59 (q, J=7.0 Hz, 2H), 3.37 (ddd, J=8.9, 7.4, 1.6 Hz, 1H), 3.29 (dd, J=8.8, 6.3 Hz, 1H), 3.15 (dd, J=8.8, 6.4 Hz, 1H), 1.67-1.51 (m, 2H), 1.39 (d, J=6.3 Hz, 3H), 1.23 (t, J=7.0 Hz, 3H), 0.68 (dd, J=18.4, 6.7 Hz, 6H); 13C NMR (101 MHz, CDCl3) δ 170.88, 170.06, 163.23, 160.17, 145.87, 143.98, 141.92, 134.59, 129.98, 121.38, 116.68, 114.41, 109.87, 89.44, 83.42, 82.64, 78.00, 74.36, 74.08, 72.30, 67.80, 67.20, 56.25, 52.32, 28.62, 19.16, 19.06, 18.72, 15.01; HRMS-FAB (m/z) [M+H]+ calcd for C30H39ClN2O11, 639.2315; found, 639.2320.


Compounds 219, 225, 227, and 230 were prepared in the same manner as described in Example 27 from the corresponding 3-hydroxy picolinamides.


Example 28
Preparation of 2-(((3S,7S,8S,9S)-7,8-bis(4-fluorophenoxy)-9-methyl-2-oxo-1,5-dioxonan-3-yl)carbamoyl)-4-methoxypyridin-3-yl acetate (compound 229)



embedded image


To a solution of N-((3S,7S,8S,9S)-7,8-bis(4-fluorophenoxy)-9-methyl-2-oxo-1,5-dioxonan-3-yl)-3-hydroxy-4-methoxypicolinamide (54 mg, 0.099 mmol) in DCM (0.5 mL) was added TEA (0.028 mL, 0.198 mmol), DMAP (6.1 mg, 0.050 mmol), and acetyl chloride (0.011 ml, 0.149 mmol). The reaction was warmed to 40° C. for and stirred for 14 h. The reaction was then concentrated and the crude residue purified by flash chromatography (SiO2, EtOAc/Hexanes) to give the title compound as a white foam (46.5 mg, 80%): IR (thin film) 3372, 2939, 1765, 1676 cm−1; 1H NMR (400 MHz, CDCl3) δ 8.78 (d, J=8.2 Hz, 1H), 8.37 (d, J=5.4 Hz, 1H), 7.03 (d, J=5.5 Hz, 1H), 6.98-6.86 (m, 6H), 6.74-6.61 (m, 2H), 5.33-5.24 (m, 1H), 5.14 (m, 1H), 4.36 (t, J=9.2 Hz, 1H), 4.30-4.22 (m, 1H), 4.10-3.99 (m, 2H), 3.92 (s, 3H), 3.92-3.87 (m, 1H), 3.79 (dd, J=11.2, 7.3 Hz, 1H), 2.40 (s, 3H), 1.48 (d, J=6.4 Hz, 3H); HRMS-FAB (m/z) [M+H]+ calcd for C29H28F2N2O9, 587.1836; found, 587.1838.


Compounds 232, 236, and 238 were prepared in the same manner as described in Example 28 from the corresponding 3-hydroxy picolinamides.


Example A
Evaluation of Fungicidal Activity: Leaf Blotch of Wheat (Mycosphaerella Graminicola; Anamorph: Septoria tritici; Bayer Code SEPTTR)

Technical grades of materials were dissolved in acetone, which were then mixed with nine volumes of water containing 110 ppm Triton X-100. The fungicide solutions were applied onto wheat seedlings using an automated booth sprayer to run-off. All sprayed plants were allowed to air dry prior to further handling.


Wheat plants (variety Yuma) were grown from seed in a greenhouse in 50% mineral soil/50% soil-less Metro mix until the first leaf was fully emerged, with 7-10 seedlings per pot. These plants were inoculated with an aqueous spore suspension of Septoria tritici either prior to or after fungicide treatments. After inoculation the plants were kept in 100% relative humidity (one day in a dark dew chamber followed by two to three days in a lighted dew chamber at 20° C.) to permit spores to germinate and infect the leaf. The plants were then transferred to a greenhouse set at 20° C. for disease to develop. When disease symptoms were fully expressed on the 1st leaves of untreated plants, infection levels were assessed on a scale of 0 to 100 percent disease severity. Percent disease control was calculated using the ratio of disease severity on treated plants relative to untreated plants.


Example B
Evaluation of Fungicidal Activity: Wheat Brown Rust (Puccinia Triticina; Synonym: Puccinia recondita f. Sp. Tritici; Bayer Code PUCCRT)

Wheat plants (variety Yuma) were grown from seed in a greenhouse in 50% mineral soil/50% soil-less Metro mix until the first leaf was fully emerged, with 7-10 seedlings per pot. These plants were inoculated with an aqueous spore suspension of Puccinia triticina either prior to or after fungicide treatments. After inoculation the plants were kept in a dark dew room at 22° C. with 100% relative humidity overnight to permit spores to germinate and infect the leaf. The plants were then transferred to a greenhouse set at 24° C. for disease to develop. Fungicide formulation, application and disease assessment followed the procedures as described in the Example A.


Example C
Evaluation of Fungicidal Activity: Wheat Glume Blotch (Leptosphaeria nodorum; Bayer Code LEPTNO)

Wheat plants (variety Yuma) were grown from seed in a greenhouse in 50% mineral soil/50% soil-less Metro mix until the first leaf was fully emerged, with 7-10 seedlings per pot. These plants were inoculated with an aqueous spore suspension of Leptosphaeria nodorum 24 hr after fungicide treatments. After inoculation the plants were kept in 100% relative humidity (one day in a dark dew chamber followed by two days in a lighted dew chamber at 20° C.) to permit spores to germinate and infect the leaf. The plants were then transferred to a greenhouse set at 20° C. for disease to develop. Fungicide formulation, application and disease assessment followed the procedures as described in the Example A.


Example D
Evaluation of Fungicidal Activity: Apple Scab (Venturia inaequalis; Bayer Code VENTIN)

Apple seedlings (variety McIntosh) were grown in soil-less Metro mix, with one plant per pot. Seedlings with two expanding young leaves at the top (older leaves at bottom of the plants were trimmed) were used in the test. Plants were inoculated with a spore suspension of Venturia inaequalis 24 hr after fungicide treatment and kept in a 22° C. dew chamber with 100% RH for 48 hr, and then moved to a greenhouse set at 20° C. for disease to develop. Fungicide formulation, application and disease assessment on the sprayed leaves followed the procedures as described in the Example A.


Example E
Evaluation of Fungicidal Activity: Grape Powdery Mildew (Uncinula necator; Bayer Code UNCINE)

Grape seedlings (variety Carignane) were grown in soil-less Metro mix, with one plant per pot, and used in the test when approximately one month old. Plants were inoculated 24 hr after fungicide treatment by shaking spores from infected leaves over test plants. Plants were maintained in a greenhouse set at 20° C. until disease was fully developed. Fungicide formulation, application and disease assessment on the sprayed leaves followed the procedures as described in the Example A.


Example F
Evaluation of Fungicidal Activity: Powdery Mildew of Cucumber (Erysiphe cichoracearum; Bayer Code ERYSCI)

Cucumber seedlings (variety Bush Pickle) were grown in soil-less Metro mix, with one plant per pot, and used in the test when 12 to 14 days old. Plants were inoculated with a spore suspension 24 hr following fungicide treatments. After inoculation the plants remained in the greenhouse set at 20° C. until disease was fully expressed. Fungicide formulation, application and disease assessment on the sprayed leaves followed the procedures as described in the Example A.


Example G
Evaluation of Fungicidal Activity: Leaf Spot of Sugar Beets (Cercospora beticola; Bayer Code CERCBE)

Sugar beet plants (variety HH88) were grown in soil-less Metro mix and trimmed regularly to maintain a uniform plant size prior to test. Plants were inoculated with a spore suspension 24 hr after fungicide treatments. Inoculated plants were kept in a dew chamber at 22° C. for 48 hr then incubated in a greenhouse set at 24° C. under a clear plastic hood with bottom ventilation until disease symptoms were fully expressed. Fungicide formulation, application and disease assessment on the sprayed leaves followed the procedures as described in the Example A.


Example H
Evaluation of Fungicidal Activity: Asian Soybean Rust (Phakopsora pachyrhizi; Bayer Code PHAKPA)

Technical grades of materials were dissolved in acetone, which were then mixed with nine volumes of water containing 0.011% Tween 20. The fungicide solutions were applied onto soybean seedlings using an automated booth sprayer to run-off. All sprayed plants were allowed to air dry prior to further handling.


Soybean plants (variety Williams 82) were grown in soil-less Metro mix, with one plant per pot. Two weeks old seedlings were used for testing. Plants were inoculated either 2 days prior to or 1 day after fungicide treatments. Plants were incubated for 24 h in a dark dew room at 22° C. and 100% RH then transferred to a growth room at 23° C. for disease to develop. Disease severity was assessed on the sprayed leaves.


Example I
Evaluation of Fungicidal Activity: Wheat Powdery Mildew (Blumeria graminis f.sp. tritici; Synonym: Erysiphe graminis f.sp. tritici; Bayer Code ERYSGT)

Wheat plants (variety Yuma) were grown from seed in a greenhouse in 50% mineral soil/50% soil-less Metro mix until the first leaf was fully emerged, with 7-10 seedlings per pot. These plants were inoculated by dusting with infected stock plants 24 hr after fungicide treatments. After inoculation the plants were kept in a greenhouse set at 20° C. for disease to develop. Fungicide formulation, application and disease assessment on the sprayed leaves followed the procedures as described in the Example A.


Example J
Evaluation of Fungicidal Activity: Barley Powdery Mildew (Blumeria graminis f.sp. hordei; Synonym: Erysiphe graminis f.sp. hordei; Bayer Code ERYSGH)

Barley seedlings (variety Harrington) were propagated in soil-less Metro mix, with each pot having 8 to 12 plants, and used in the test when first leaf was fully emerged. Test plants were inoculated by dusting with infected stock plants 24 hr after fungicide treatments. After inoculation the plants were kept in a greenhouse set at 20° C. for disease to develop. Fungicide formulation, application and disease assessment on the sprayed leaves followed the procedures as described in the Example A.


Example K
Evaluation of Fungicidal Activity: Barley Scald (Rhyncosporium secalis; Bayer Code RHYNSE)

Barley seedlings (variety Harrington) were propagated in soil-less Metro mix, with each pot having 8 to 12 plants, and used in the test when first leaf was fully emerged. Test plants were inoculated by an aqueous spore suspension of Rhyncosporium secalis 24 hr after fungicide treatments. After inoculation the plants were kept in a dew room at 20° C. with 100% relative humidity for 48 hr. The plants were then transferred to a greenhouse set at 20° C. for disease to develop. Fungicide formulation, application and disease assessment on the sprayed leaves followed the procedures as described in the Example A.


Example L
Evaluation of Fungicidal Activity: Rice Blast (Magnaporthe grisea; Anamorph: Pyricularia oryzae; Bayer Code PYRIOR)

Rice seedlings (variety Japonica) were propagated in soil-less Metro mix, with each pot having 8 to 14 plants, and used in the test when 12 to 14 days old. Test plants were inoculated with an aqueous spore suspension of Pyricularia oryzae 24 hr after fungicide treatments. After inoculation the plants were kept in a dew room at 22° C. with 100% relative humidity for 48 hr to permit spores to germinate and infect the leaf. The plants were then transferred to a greenhouse set at 24° C. for disease to develop. Fungicide formulation, application and disease assessment on the sprayed leaves followed the procedures as described in the Example A.


Example M
Evaluation of Fungicidal Activity: Tomato Early Blight (Alternaria solani; Bayer Code ALTESO)

Tomato plants (variety Outdoor girl) were propagated in soil-less Metro mix, with each pot having one plant, and used when 12 to 14 days old. Test plants were inoculated with an aqueous spore suspension of Alternaria solani 24 hr after fungicide treatments. After inoculation the plants were kept in 100% relative humidity (one day in a dark dew chamber followed by two to three days in a lighted dew chamber at 20° C.) to permit spores to germinate and infect the leaf. The plants were then transferred to a growth room at 22° C. for disease to develop. Fungicide formulation, application and disease assessment on the sprayed leaves followed the procedures as described in the Example A.


Example N
Evaluation of Fungicidal Activity: Cucumber Anthracnose (Glomerella lagenarium; Anamorph: Colletotrichum lagenarium; Bayer Code COLLLA)

Cucumber seedlings (variety Bush Pickle) were propagated in soil-less Metro mix, with each pot having one plant, and used in the test when 12 to 14 days old. Test plants were inoculated with an aqueous spore suspension of Colletotrichum lagenarium 24 hr after fungicide treatments. After inoculation the plants were kept in a dew room at 22° C. with 100% relative humidity for 48 hr to permit spores to germinate and infect the leaf. The plants were then transferred to a growth room set at 22° C. for disease to develop. Fungicide formulation, application and disease assessment on the sprayed leaves followed the procedures as described in the Example A.


Example O
Evaluation of Fungicide Mobility: Wheat Brown Rust (Puccinia triticina; Synonym: Puccinia recondita f. sp. tritici; Bayer Code PUCCRT)

“Yuma” wheat seedlings were used in the test. One mg of compound was dissolved in 9 μl of EC blank (emulsifiable concentrate) and 500 μl of acetone. Acetone was then evaporated overnight by leaving the vial open in a fume hood. Two milliliters of water containing 110 ppm Triton X-100 was added to each vial to prepare application solutions. A 2 μl drop of formulated material was applied to a marked line on the adaxial surface 5 cm from the leaf tip of the primary leaves. The primary leaves were kept in a horizontal position. Each treatment had 6 replicates. Plants were inoculated with PUCCRT 1-day after (1DPM) or 3-day prior to (3DCM) compound applications. When rust was fully expressed on primary leaves on control plants, the zone of treated leaves that was disease-free in the acropetal direction was measured with a ruler and converted to percent of the distance from marked line to leaf tip.









TABLE 1







Compound Structure and Appearance









Compound




Number
Appearance
Structure





 1
White Solid


embedded image







 2
Glassy Solid


embedded image







 3
Glassy Solid


embedded image







 4
White Solid


embedded image







 5
White Foam


embedded image







 6
White Sticky Solid


embedded image







 7
Sticky Solid


embedded image







 8
White Solid


embedded image







 9
White Solid


embedded image







 10
White Solid


embedded image







 11
White Solid


embedded image







 12
Colorless Oil


embedded image







 13
White Solid


embedded image







 14
Oil


embedded image







 15
Colorless Viscous Oil


embedded image







 16
Colorless Viscous Oil


embedded image







 17
Colorless Viscous Oil


embedded image







 18
Colorless Viscous Oil


embedded image







 19
Colorless Oil


embedded image







 20
Light Yellow Oil


embedded image







 21
White Solid


embedded image







 22
Colorless Oil


embedded image







 23
Light Yellow Oil


embedded image







 24
Colorless Oil


embedded image







 25
White Solid


embedded image







 26
White Solid


embedded image







 27
White Solid


embedded image







 28
White Solid


embedded image







 29
White Solid


embedded image







 30
Colorless Oil


embedded image







 31
Colorless Oil


embedded image







 32
White Solid


embedded image







 33
White Solid


embedded image







 34
Light Yellow Oil


embedded image







 35
Light Yellow Oil


embedded image







 36
White Solid


embedded image







 37
Light Yellow Oil


embedded image







 38
White Solid


embedded image







 39
White Solid


embedded image







 40
White Solid


embedded image







 41
White Solid


embedded image







 42
Off-White Oil


embedded image







 43
Off-White Solid


embedded image







 44
White Solid


embedded image







 45
Colorless Oil


embedded image







 46
Colorless Oil


embedded image







 47
Light Yellow Oil


embedded image







 48
Light Yellow Solid


embedded image







 49
Colorless Oil


embedded image







 50
Colorless Oil


embedded image







 51
Light Yellow Oil


embedded image







 52
White Solid


embedded image







 53
White Solid


embedded image







 54
Colorless Oil


embedded image







 55
Colorless Oil


embedded image







 56
White Solid


embedded image







 57
Colorless Oil


embedded image







 58
White Solid


embedded image







 59
Colorless Oil


embedded image







 60
Light Yellow Oil


embedded image







 61
White Solid


embedded image







 62
White Solid


embedded image







 63
White Solid


embedded image







 64
Thick Oil


embedded image







 65
Light Yellow Oil


embedded image







 66
Colorless Oil


embedded image







 67
White Solid


embedded image







 68
Little Yellow Oil


embedded image







 69
Colorless Oil


embedded image







 70
White Solid


embedded image







 71
White Solid


embedded image







 72
White Solid


embedded image







 73
White Solid


embedded image







 74
Thick Colorless Oil


embedded image







 75
White Solid


embedded image







 76
Colorless Oil


embedded image







 77
Colorless Oil


embedded image







 78
Colorless Oil


embedded image







 79
Colorless Oil


embedded image







 80
Colorless Oil


embedded image







 81
White Foam


embedded image







 82
White Solid


embedded image







 83
White Solid


embedded image







 84
Colorless Oil


embedded image







 85
Colorless Oil


embedded image







 86
Colorless Oil


embedded image







 87
Amber Solid


embedded image







 88
White Solid


embedded image







 89
Colorless Oil


embedded image







 90
Pale Yellow Oil


embedded image







 91
Pale Yellow Oil


embedded image







 92
Colorless Oil


embedded image







 93
Off-White Solid


embedded image







 94
Colorless Oil


embedded image







 95
Colorless Oil


embedded image







 96
Colorless Oil


embedded image







 97
Light Yellow Oil


embedded image







 98
Colorless Oil


embedded image







 99
White Solid


embedded image







100
Colorless Oil


embedded image







101
Colorless Oil


embedded image







102
White Gummy Solid


embedded image







103
Colorless, Thick Oil


embedded image







104
Colorless Oil


embedded image







105
Light Yellow Oil


embedded image







106
Light Yellow Oil


embedded image







107
Colorless Oil


embedded image







108
Colorless Oil


embedded image







109
Colorless Oil


embedded image







110
Colorless Oil


embedded image







111
Colorless Oil


embedded image







112
Colorless Oil


embedded image







113
White Solid


embedded image







114
White Solid


embedded image







115
Colorless Oil


embedded image







116
Light Yellow Oil


embedded image







117
Light Yellow Oil


embedded image







118
Colorless Oil


embedded image







119
Colorless Oil


embedded image







120
Colorless Oil


embedded image







121
Colorless Oil


embedded image







122
Light Yellow Oil


embedded image







123
Colorless Oil


embedded image







124
Off-White Oil


embedded image







125
White Solid


embedded image







126
White Solid


embedded image







127
White Solid


embedded image







128
White Foam


embedded image







129
Off-White Solid


embedded image







130
Colorless Oil


embedded image







131
Colorless Oil


embedded image







132
Colorless Solid


embedded image







133
Colorless Oil


embedded image







134
Colorless Oil


embedded image







135
White Foam


embedded image







136
Light Yellow Oil


embedded image







137
Colorless Oil


embedded image







138
Colorless Oil


embedded image







139
White Solid


embedded image







140
White Foam


embedded image







141
Colorless Oil


embedded image







142
Colorless Oil


embedded image







143
Yellow Solid


embedded image







144
Colorless Oil


embedded image







145
Colorless Oil


embedded image







146
Colorless Oil


embedded image







147
White Solid


embedded image







148
Colorless Oil


embedded image







149
Colorless Oil


embedded image







150
White Solid


embedded image







151
White Solid


embedded image







152
White Solid


embedded image







153
White Foam


embedded image







154
White Foam


embedded image







155
White Foam


embedded image







156
White Foam


embedded image







157
White Foam


embedded image







158
White Foam


embedded image







159
White Foam


embedded image







160
White Solid


embedded image







161



embedded image







162
White Solid


embedded image







163
Colorless Oil


embedded image







164
Colorless Oil


embedded image







165
White Solid


embedded image







166
White Solid


embedded image







167
White Solid


embedded image







168
Off-White Solid


embedded image







169
Light Yellow Oil


embedded image







170
Clear Oil


embedded image







171
Clear Oil


embedded image







172
Colorless Oil


embedded image







173
Off-White Solid


embedded image







174
Off-White Solid


embedded image







175
Crystalline Colorless Solid


embedded image







176
White Solid


embedded image







177
Light Yellow Solid


embedded image







178
White Solid


embedded image







179
Colorless Oil


embedded image







180
Light Yellow Solid


embedded image







181
White Solid


embedded image







182
White Solid


embedded image







183
Off-White Solid


embedded image







184
Off-White Solid


embedded image







185
Off-White Solid


embedded image







186
White Solid


embedded image







187
Clear Oil


embedded image







188



embedded image







189



embedded image







190



embedded image







191
White Foam


embedded image







192
Colorless Oil


embedded image







193



embedded image







194
White Foam


embedded image







195
White Foam


embedded image







196
White Solid


embedded image







197
White Foam


embedded image







198
White Foam


embedded image







199
White Foam


embedded image







200
Colorless Glass


embedded image







201
White Foam


embedded image







202
White Solid


embedded image







203
White Solid


embedded image







204
White Solid


embedded image







205
White Solid


embedded image







206
White Foam


embedded image







207
White Solid


embedded image







208
White Solid


embedded image







209
White Solid


embedded image







210
White Solid


embedded image







211
Pale Yellow Oil


embedded image







212
Pale Yellow Oil


embedded image







213
White Foam


embedded image







214
White Foam


embedded image







215
White Foam


embedded image







216
White Foam


embedded image







217
White Foam


embedded image







218
White Foam


embedded image







219
White Foam


embedded image







220
White Foam


embedded image







221
White Foam


embedded image







222
Light Yellow Foam


embedded image







223
White Foam


embedded image







224
White Foam


embedded image







225
White Foam


embedded image







226
White Foam


embedded image







227
Colorless Oil


embedded image







228
Clear Oil


embedded image







229
White Foam


embedded image







230
White Foam


embedded image







231
White Foam


embedded image







232
White Solid


embedded image







233
Colorless Oil


embedded image







234
White Solid


embedded image







235
Yellow- White Solid


embedded image







236
White Solid


embedded image







237
Sticky Orange Oil


embedded image







238
White Solid


embedded image







239
Light Amber Foam


embedded image







240
Colorless Oil


embedded image







241
Colorless Oil


embedded image







242
Colorless Oil


embedded image







243
Colorless Oil


embedded image







244
White Solid


embedded image







245
White Solid


embedded image







246
White Solid


embedded image







247
Colorless Oil


embedded image







248
Colorless Oil


embedded image







249
White Solid


embedded image







250
White Foam


embedded image







251
White Solid


embedded image







252
Colorless Oil


embedded image







253
Colorless Oil


embedded image







254
Colorless Oil


embedded image







255
Colorless Oil


embedded image







256
Colorless Oil


embedded image







257
White Solid


embedded image







258
White Solid


embedded image







259
White Solid


embedded image







260
White Solid


embedded image







261
Colorless Oil


embedded image







262
Colorless Oil


embedded image







263
White Solid.


embedded image







264
Yellow Oil


embedded image







265
Colorless Oil


embedded image







266
Colorless Oil


embedded image







267
Oil


embedded image







268
Oil


embedded image







269
Colorless Oil


embedded image







270
White Solid


embedded image







271
Yellow Oil


embedded image







272
Sticky Yellow Solid


embedded image







273
White Solid


embedded image







274
White Solid


embedded image







275
White Solid


embedded image







276
White Solid


embedded image







277
White Solid


embedded image







278
Clear Glass


embedded image







279
White Solid


embedded image







280
White Solid


embedded image







281
White Solid


embedded image







282
White Solid


embedded image







283
White Solid


embedded image







284
White Solid


embedded image







285
Off-White Solid


embedded image







286
White Solid


embedded image







287
White Solid


embedded image







288
White Solid


embedded image


















TABLE 2







Analytical Data












Com-







pound
MP
IR


Number
(° C.)
(cm−1)
MASS

1H NMR*


13C NMR*
















1
111-113

ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 469.4
11.95 (s, 1H), 8.68 (d, J = 8.0 Hz,
(CDCl3) δ





([M + H]+)
1H), 8.00 (d, J = 5.2 Hz,
170.33, 168.95,






1H), 6.87 (d, J = 5.2 Hz,
155.38, 148.76,






1H), 5.10-5.00 (m,
140.66, 130.23,






1H), 4.97 (dt, J = 12.6,
109.58, 84.84,






6.3 Hz, 1H),
83.75, 80.60,






4.10-4.01 (m, 1H), 3.94 (s, 3H),
77.74, 75.32,






3.87-3.78 (m, 2H),
73.97, 73.23,






3.71 (dd, J = 8.4, 6.1 Hz, 1H),
56.11, 52.19,






3.66-3.57 (m, 1H),
29.13, 28.89,






3.38-3.28 (m, 2H),
19.60, 19.48,






3.28-3.17 (m, 3H),
19.47, 19.39,






1.90-1.76 (m, 2H), 1.45 (t, J = 5.8 Hz,
18.66






3H), 0.98-0.88 (m,






12H)


2


ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 569.5
8.59 (d, J = 7.9 Hz, 1H),
(CDCl3) δ





([M + H]+)
8.27 (t, J = 4.6 Hz, 1H),
176.25, 170.96,






6.94 (d, J = 5.4 Hz, 1H),
163.23, 160.22,






5.76 (q, J = 6.4 Hz, 2H),
145.67, 144.18,






5.13-5.01 (m, 1H),
141.82, 109.66,






5.01-4.87 (m, 1H),
89.78, 84.82,






4.08-4.00 (m, 1H), 3.89 (s, 3H),
83.78, 80.57,






3.83-3.74 (m, 2H),
77.68, 74.91,






3.71 (dd, J = 8.4, 6.1 Hz, 1H),
74.09, 72.99,






3.67-3.57 (m, 1H),
56.14, 52.39,






3.37-3.27 (m, 2H),
33.85, 29.10,






3.27-3.14 (m, 3H), 2.54 (hept,
28.86, 19.57,






J = 7.0 Hz, 1H),
19.45, 19.44,






1.91-1.76 (m, 2H), 1.45 (d, J = 6.3 Hz,
19.36, 18.67,






3H), 1.14 (d, J = 7.0 Hz,
18.63






6H),






0.96-0.87 (m, 12H)


3


ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 540.5
8.53 (d, J = 7.9 Hz, 1H),
(CDCl3) δ





([M]+)
8.29 (d, J = 5.3 Hz, 1H),
170.95, 170.30,






6.95 (d, J = 5.4 Hz, 1H),
163.28, 160.25,






5.79-5.69 (m, 2H),
145.84, 143.97,






5.13-5.01 (m, 1H),
142.20, 109.73,






5.01-4.88 (m, 1H), 4.04 (dd, J = 7.9,
89.47, 84.86,






3.9 Hz, 1H), 3.91 (s,
83.81, 80.60,






3H), 3.83-3.74 (m, 2H),
77.72, 75.07,






3.71 (dd, J = 8.4, 6.1 Hz,
74.18, 73.03,






1H), 3.65-3.56 (m, 1H),
56.23, 52.49,






3.37-3.13 (m, 5H),
29.13, 28.90,






2.07 (s, 3H), 1.91-1.73 (m,
20.90, 19.61,






2H), 1.45 (d, J = 6.3 Hz,
19.48, 19.39,






3H), 0.97-0.87 (m, 12H)
18.67


4


ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 469.4
11.96 (d, J = 0.6 Hz, 1H),
(CDCl3) δ





([M + H]+)
8.68 (dd, J = 8.2, 5.1 Hz, 1H),
171.47, 168.93,






7.99 (d, J = 5.1 Hz, 1H),
155.30, 148.71,






6.87 (dd, J = 5.3, 1.3 Hz,
140.61, 130.24,






1H), 5.15-4.98 (m, 1H),
109.54, 84.89,






4.71 (dd, J = 11.5, 8.3 Hz,
80.90, 80.55,






1H), 4.20-4.14 (m,
80.39, 78.39,






1H), 4.12 (d, J = 7.1 Hz,
71.45, 64.45,






1H), 4.10-4.03 (m, 1H),
56.08, 52.21,






3.94 (s, 3H),
29.09, 28.84,






3.89-3.78 (m, 1H), 3.68-3.61 (m,
19.62, 19.43,






1H), 3.54 (dd, J = 8.5, 6.1 Hz,
19.37, 17.64






1H), 3.47 (ddd, J = 8.3,






7.0, 3.4 Hz, 1H),






3.36 (d, J = 6.5 Hz, 2H),






3.02 (dd, J = 8.3, 7.0 Hz, 1H),






1.91-1.75 (m, 2H),






1.24 (d, J = 6.2 Hz, 3H),






1.00-0.84 (m, 12H)


5


ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 524.1
11.90 (d, J = 0.6 Hz, 1H),
(CDCl3) δ





([M]+)
8.61 (d, J = 8.2 Hz, 1H),
170.83, 168.92,






8.49 (d, J = 5.2 Hz, 1H),
155.37, 148.76,






7.43-7.24 (m, 11H), 6.86 (d,
140.66, 137.97,






J = 5.2 Hz, 1H),
137.94, 130.17,






5.03 (ddd, J = 8.2, 6.8, 6.0 Hz,
128.48, 128.43,






1H), 4.80-4.62 (m, 5H),
127.91, 127.89,






4.21-4.07 (m, 2H),
127.87, 127.81,






3.93 (s, 3H), 3.85 (s, 1H),
109.61, 81.52,






3.79-3.65 (m, 2H),
79.29, 73.80,






3.55-3.47 (m, 1H)
73.44, 73.24,







72.97, 63.91,







56.10, 52.25


6


ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 623.4
8.54 (d, J = 7.9 Hz, 1H),
(CDCl3) δ





([M + H]+)
8.26 (d, J = 5.3 Hz, 1H),
176.27, 171.46,






7.44-7.24 (m, 10H), 6.94 (d,
163.14, 160.23,






J = 5.4 Hz, 1H), 5.75 (q,
145.63, 144.25,






J = 6.4 Hz, 2H),
141.69, 138.03,






5.15-5.01 (m, 1H),
138.01, 128.45,






4.84-4.59 (m, 5H), 4.22-4.05 (m,
128.40, 127.90,






2H), 3.89 (s, J = 7.2 Hz,
127.86, 127.85,






3H), 3.84 (dd, J = 10.9,
127.75, 109.68,






6.8 Hz, 2H),
89.76, 81.78,






3.78-3.61 (m, 2H), 3.50 (dd, J = 10.6,
79.45, 73.91,






4.0 Hz, 1H),
73.64, 73.08,






2.63-2.45 (m, 1H), 1.14 (d, J = 7.0 Hz,
72.99, 63.88,






6H)
56.15, 52.51,







33.85, 18.67


7


ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 569.7
8.60 (d, J = 7.9 Hz, 1H),
(CDCl3) δ





([M + H]+)
8.27 (d, J = 5.4 Hz, 1H),
176.24, 172.19,






7.27 (s, 1H), 6.94 (d, J = 5.5 Hz,
163.23, 160.24,






1H), 5.79-5.72 (m,
145.64, 144.20,






2H), 5.12-5.02 (m, 1H),
141.79, 109.64,






4.66 (dd, J = 11.4, 8.8 Hz,
89.83, 85.05,






1H), 4.17-4.04 (m,
81.04, 80.57,






1H), 3.89 (s, 3H),
80.02, 78.49,






3.80-3.74 (m, 1H), 3.66 (dd, J = 8.2,
71.51, 64.42,






6.2 Hz, 1H),
56.14, 52.40,






3.55 (dd, J = 8.4, 6.1 Hz, 1H),
33.86, 29.11,






3.47 (ddd, J = 8.8, 7.4,
28.87, 19.64,






3.5 Hz, 1H),
19.45, 19.43,






3.41-3.34 (m, 2H), 3.26-3.21 (m,
19.36, 18.68,






1H), 2.99 (dd, J = 8.3, 7.4 Hz,
17.38






1H), 2.54 (hept, J = 7.0 Hz,






1H),






1.89-1.75 (m, 2H), 1.22 (d, J = 6.2 Hz,






3H), 1.14 (d, J = 7.0 Hz,






6H), 0.96-0.86 (m,






12H)


8
 94-108

HRMS-ESI

1H NMR (CDCl3) δ







(m/z)
11.93 (s, 1H), 8.59 (d, J = 8.2 Hz,





[M + H]+
1H), 8.00 (d, J = 5.2 Hz,





calcd for
1H), 6.87 (d, J = 5.2 Hz,





C22H34N2O8,
1H), 5.13-4.87 (m,





455.2388;
1H), 4.67 (dd, J = 11.4,





found,
9.4 Hz, 1H),





455.2374
4.24-4.08 (m, 2H), 3.94 (s, 3H),






3.79-3.70 (m, 2H),






3.70-3.57 (m, 2H),






3.49-3.27 (m, 4H),






3.28-3.14 (m, 1H), 1.94-1.74 (m,






2H), 0.98-0.83 (m, 12H)


9
115-118

HRMS-ESI

1H NMR (CDCl3) δ







(m/z)
11.99 (s, 1H), 8.84 (d, J = 8.0 Hz,





[M + H]+
1H), 8.01 (d, J = 5.2 Hz,





calcd for
1H), 6.87 (d, J = 5.2 Hz,





C22H30N2O8,
1H), 5.16-5.03 (m,





451.2075;
2H), 5.03-4.84 (m, 4H),





found,
4.22-3.96 (m, 8H),





451.2089
3.94 (s, 3H), 3.89-3.79 (m,






1H), 3.75-3.65 (m, 1H),






3.50-3.40 (m, 1H),






1.76 (d, J = 6.5 Hz, 6H)


10
92-97

HRMS-ESI

1H NMR (CDCl3) δ







(m/z)
11.99 (s, 1H), 8.91-8.74 (m,





[M + H]+
1H), 8.04-7.97 (m, 1H),





calcd for
6.88-6.86 (m, 1H),





C22H34N2O8,
5.12-4.96 (m, 2H),





455.2388;
4.28-4.05 (m, 2H),





found,
4.03-3.88 (m, 2H), 3.94 (s, 3H),





455.2437
3.85-3.60 (m, 3H),






3.49-3.14 (m, 4H),






1.97-1.76 (m, 2H),






1.00-0.79 (m, 12H)


11
144-146
(Neat)
HRMS-ESI

1H NMR (CDCl3) δ


13C NMR





3363,
(m/z)
11.93 (s, 1H), 8.69 (d, J = 8.1 Hz,
(CDCl3) δ




2935,
[M]+
1H), 8.00 (d, J = 5.2 Hz,
170.31, 169.11,




1749,
calcd for
1H), 7.37-7.25 (m,
155.47, 148.87,




1648,
C29H32N2O8,
10H), 6.87 (d, J = 5.2 Hz,
140.82, 138.23,




1527,
536.2159;
1H), 5.13-5.02 (m, 2H),
138.06, 130.35,




1263,
found,
4.95 (d, J = 10.8 Hz, 1H),
128.56, 128.54,




1076
536.2150
4.70-4.61 (m, 2H),
128.11, 128.01,






4.62 (d, J = 10.8 Hz, 1H),
127.91, 109.72,






4.07 (dd, J = 11.9, 6.7 Hz,
84.84, 83.68,






1H), 4.02-3.96 (m, 1H),
75.95, 75.78,






3.94 (s, 3H), 3.87 (dd, J = 11.9,
74.38, 73.14,






4.8 Hz, 1H),
73.12, 56.23,






3.70 (dd, J = 11.3, 6.6 Hz,
52.40, 18.85






1H), 3.56-3.45 (m, 2H),






1.46 (d, J = 6.3 Hz, 3H)


12

(Neat)
HRMS-ESI

1H NMR (CDCl3) δ


13C NMR





3382,
(m/z)
8.55 (d, J = 7.9 Hz, 1H),
(CDCl3) δ




2920,
[M]+
8.29 (d, J = 5.4 Hz, 1H),
170.95, 170.39,




1753,
calcd for
7.38-7.21 (m, 10H), 6.95 (d,
163.42, 160.38,




1677,
C32H36N2O10,
J = 5.4 Hz, 1H),
145.96, 144.12,




1504,
608.2370;
5.79-5.67 (m, 2H),
142.31, 138.32,




1202,
found,
5.13-5.00 (m, 2H), 4.94 (d, J = 10.8 Hz,
138.14, 128.55,




1090
608.2374.
1H), 4.70-4.58 (m,
128.53, 128.10,






3H), 4.07 (dd, J = 11.9,
128.01, 127.88,






6.8 Hz, 1H), 3.98 (d, J = 10.7 Hz,
109.87, 89.60,






1H), 3.91 (s,
84.91, 83.78,






3H), 3.83 (dd, J = 11.9,
75.96, 75.49,






4.9 Hz, 1H), 3.70 (dd, J = 11.2,
74.58, 73.13,






6.7 Hz, 1H),
72.93, 56.34,






3.57-3.42 (m, 2H), 2.07 (s,
52.70, 21.02,






3H), 1.45 (d, J = 6.3 Hz,
18.87






3H)


13
58-64

HRMS-ESI

1H NMR (CDCl3) δ







(m/z)
8.46 (d, J = 8.0 Hz, 1H),





[M + H]+
8.28 (d, J = 5.3 Hz, 1H),





calcd for
6.96 (d, J = 5.4 Hz, 1H),





C25H38N2O10,
5.80-5.66 (m, 2H),





527.2599;
5.14-5.01 (m, 1H),





found,
4.69-4.58 (m, 1H), 4.20-4.05 (m,





527.2657
2H), 3.91 (s, 3H),






3.76-3.69 (m, 2H),






3.67-3.57 (m, 2H), 3.49-3.41 (m,






1H), 3.41-3.27 (m, 3H),






3.27-3.17 (m, 1H),






2.07 (s, 3H), 1.91-1.75 (m,






2H), 0.97-0.83 (m, 12H)


14


HRMS-ESI

1H NMR (CDCl3) δ







(m/z)
8.76-8.63 (m, 1H),





[M + H]+
8.33-8.24 (m, 1H),





calcd for
6.96-6.94 (m, 1H), 5.79-5.67 (m,





C25H38N2O10,
2H), 5.12-5.04 (m, 1H),





527.2599;
4.23-4.05 (m, 2H),





found,
4.02-3.85 (m, 2H), 3.91 (s,





527.2592
3H); 3.85-3.76 (m, 1H),






3.76-3.54 (m, 2H),






3.51-3.27 (m, 4H),






3.25-3.20 (m, 1H), 2.07 (s,






3H), 1.94-1.76 (m, 2H),






0.99-0.85 (m, 12H)


15


ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 541.4
12.00 (d, J = 0.7 Hz, 1H),
(CDCl3) δ





([M + H]+)
8.86 (d, J = 8.1 Hz, 1H),
169.72, 168.89,






8.01 (d, J = 5.2 Hz, 1H),
155.24, 148.66,






6.87 (dd, J = 5.2, 0.6 Hz, 1H),
140.64, 130.39,






5.33-5.23 (m, 1H),
109.47, 79.21,






5.09 (ddd, J = 7.9, 6.0, 1.7 Hz,
78.31, 76.84,






1H), 4.24-4.07 (m, 2H),
75.42, 73.40,






3.99 (dd, J = 11.7, 6.1 Hz,
72.61, 67.95,






1H), 3.93 (s, 3H),
56.05, 53.39,






3.92-3.86 (m, 1H),
28.84, 28.70,






3.82-3.67 (m, 3H),
28.47, 19.49,






3.46-3.39 (m, 2H), 3.34 (td, J = 9.1,
19.39






6.5 Hz, 2H),






3.27 (d, J = 6.6 Hz, 2H),






3.20 (dd, J = 8.9, 6.9 Hz, 1H),






1.97-1.79 (m, 3H),






0.96-0.87 (m, 18H)


16


ESIMS

1H NMR (400 MHz,


13C NMR






m/z 541.3
CDCl3) δ 12.00 (d, J = 0.6 Hz,
(CDCl3) δ





([M + H]+)
1H), 8.61 (d, J = 8.7 Hz,
168.47, 167.68,






1H), 7.95 (d, J = 5.2 Hz,
155.44, 148.87,






1H),
140.46, 140.42,






6.92-6.81 (m, 1H), 5.20 (td, J = 5.6,
130.31, 109.55,






3.1 Hz, 1H), 4.94 (ddd, J = 8.7,
79.11, 78.34,






6.2, 5.2 Hz, 1H),
78.30, 73.76,






4.30 (dd, J = 11.6, 6.3 Hz,
72.63, 68.03,






1H), 4.06-3.99 (m,
56.10, 54.44,






1H), 3.95 (s, 4H),
28.94, 28.70,






3.91-3.84 (m, 2H), 3.76 (qd, J = 10.2,
28.52, 19.37,






5.5 Hz, 2H),
19.35






3.58 (dd, J = 11.6, 5.1 Hz,






1H), 3.54-3.46 (m, 1H),






3.44 (dd, J = 8.9, 6.4 Hz,






1H), 3.34 (td, J = 8.8, 6.5 Hz,






2H), 3.29-3.24 (m,






2H), 3.24-3.16 (m, 1H),






1.87 (tt, J = 13.3, 6.6 Hz,






3H), 1.03-0.78 (m, 20H)


17


ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 613.4
8.73 (d, J = 7.9 Hz, 1H),
(CDCl3) δ





([M + H]+)
8.29 (d, J = 5.4 Hz, 1H),
170.32, 170.25,






6.94 (d, J = 5.4 Hz, 1H),
163.20, 160.19,






5.73 (d, J = 0.7 Hz, 2H),
145.81, 143.89,






5.25 (q, J = 4.6 Hz, 1H),
142.33, 109.60,






5.12 (ddd, J = 7.9, 6.1, 1.9 Hz,
89.50, 79.20,






1H), 4.22-4.06 (m, 2H),
78.31, 76.80,






3.97 (dd, J = 11.7, 6.1 Hz,
75.70, 73.26,






1H), 3.91 (s, 4H),
67.96, 56.17,






3.80-3.67 (m, 3H),
53.64, 28.85,






3.45-3.38 (m, 2H), 3.34 (dt, J = 9.0,
28.70, 28.48,






6.9 Hz, 2H),
20.88, 19.49,






3.26 (d, J = 6.6 Hz, 2H),
19.39, 19.37






3.20 (dd, J = 8.8, 6.9 Hz, 1H),






2.06 (s, 3H), 1.86 (tdd, J = 13.2,






6.6, 4.0 Hz, 3H),






0.98-0.83 (m, 18H)


18


ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 613.4
8.52 (d, J = 8.6 Hz, 1H),
(CDCl3) δ





([M + H]+)
8.23 (d, J = 5.3 Hz, 1H),
170.33, 168.22,






6.95 (d, J = 5.4 Hz, 1H),
162.66, 160.35,






5.73 (s, 2H), 5.19 (dt, J = 5.4,
145.55, 144.31,






2.7 Hz, 1H), 4.95 (ddd, J = 8.4,
142.16, 109.68,






6.3, 5.0 Hz, 1H),
89.55, 79.24,






4.29 (dd, J = 11.7, 6.3 Hz,
79.09, 78.26,






1H), 4.06-3.96 (m,
73.61, 72.90,






1H), 3.91 (s, 4H),
71.06, 68.05,






3.90-3.84 (m, 2H), 3.75 (ddt, J = 15.9,
56.21, 54.83,






10.2, 5.3 Hz, 3H),
28.93, 28.70,






3.55 (dd, J = 11.7, 5.0 Hz,
28.51, 20.87,






1H), 3.51-3.40 (m,
19.48, 19.40,






2H), 3.34 (td, J = 9.1, 6.4 Hz,
19.37, 19.35,






2H), 3.29-3.17 (m,
19.33






4H), 2.07 (s, 3H),






1.86 (dqd, J = 12.8, 6.6, 1.6 Hz,






3H), 1.01-0.78 (m,






18H)


19

(Neat)
HRMS-ESI

1H NMR (CDCl3) δ


13C NMR





3369,
(m/z)
12.02 (s, 1H), 8.86 (d, J = 8.0 Hz,
(CDCl3) δ




2956,
[M]+
1H), 8.00 (d, J = 5.2 Hz,
170.17, 169.05,




1751,
calcd for
1H), 6.86 (d, J = 5.2 Hz,
155.37, 148.79,




1650,
C24H38N2O8,
1H), 5.11-5.02 (m,
140.78, 130.57,




1528,
482.2628;
2H), 4.17 (dd, J = 11.9,
109.59, 79.37,




1242,
found,
3.6 Hz, 1H), 4.14 (dd, J = 11.7,
78.70, 78.33,




1082
482.2642
1.6 Hz, 1H),
75.53, 72.63,






3.97 (dd, J = 11.7, 5.9 Hz,
56.19, 53.59,






1H), 3.94 (s, 3H),
29.03, 28.85,






3.78-3.68 (m, 1H), 3.64 (dd, J = 11.8,
22.50, 19.60,






1.5 Hz, 1H),
19.53, 19.51,






3.35 (dtd, J = 26.6, 8.9, 6.6 Hz,
10.85






4H), 3.21 (dd, J = 8.7,






6.8 Hz, 1H),






1.93-1.79 (m, 3H),






1.78-1.65 (m, 1H), 1.02 (t, J = 7.4 Hz,






3H), 0.94-0.88 (m,






12H)


20

(Neat)
HRMS-ESI

1H NMR (CDCl3) δ


13C NMR





2956,
(m/z)
8.73 (d, J = 7.7 Hz, 1H),
(CDCl3) δ




1753,
[M]+
8.28 (d, J = 5.4 Hz, 1H),
170.79, 170.40,




1678,
calcd for
6.94 (d, J = 5.4 Hz, 1H),
163.40, 160.35,




1504,
C27H42N2O10,
6.01-5.44 (m, 2H),
145.96, 144.05,




1202,
554.2839;
5.09 (ddd, J = 7.7, 6.0, 1.6 Hz,
142.53, 109.74,




1082
found,
1H), 5.04 (dt, J = 9.9, 3.2 Hz,
89.68, 79.36,





554.2841
1H), 4.15 (dd, J = 11.9,
78.60, 78.53,






3.6 Hz, 1H),
76.96, 75.79,






4.11 (dd, J = 11.8, 1.7 Hz,
56.31, 53.84,






1H), 3.95 (dd, J = 11.7,
29.04, 28.85,






6.0 Hz, 1H), 3.90 (s, 3H),
21.02, 19.61,






3.80-3.71 (m, 1H),
19.53, 19.51,






3.63 (dd, J = 11.8, 1.6 Hz,
10.87






1H), 3.47-3.26 (m, 4H),






3.21 (dd, J = 8.7, 6.8 Hz,






1H), 2.06 (s, 3H),






1.94-1.76 (m, 3H),






1.77-1.62 (m, 1H), 1.02 (t, J = 7.4 Hz,






3H), 0.95-0.81 (m,






12H)


21
119-121

HRMS-ESI

1H NMR (CDCl3) δ


13C NMR (151 MHz,






(m/z)
11.95 (s, 1H), 8.73 (d, J = 8.0 Hz,
CDCl3) δ





[M]+
1H), 8.00 (d, J = 5.2 Hz,
170.53, 169.10,





calcd for
1H), 6.86 (d, J = 5.2 Hz,
155.49, 148.90,





C24H38N2O8,
1H), 5.03 (ddd, J = 8.0,
140.81, 130.47,





482.2628;
6.3, 4.2 Hz, 1H),
109.71, 84.19,





found,
4.93 (td, J = 8.8, 2.9 Hz, 1H),
83.34, 80.50,





482.2647
4.04 (dd, J = 12.0, 6.3 Hz,
77.84, 77.76,






1H), 3.94 (s, 3H),
76.80, 74.99,






3.89 (dd, J = 12.0, 4.0 Hz,
56.23, 52.79,






1H), 3.85 (d, J = 12.0 Hz,
29.26, 29.01,






1H), 3.71 (dd, J = 8.4,
25.30, 19.72,






6.2 Hz, 1H),
19.62, 19.60,






3.58 (dd, J = 11.6, 6.0 Hz,
19.53, 9.64






1H), 3.37-3.14 (m, 5H),






2.03 (dqd, J = 14.9, 7.5,






2.9 Hz, 1H), 1.81 (dp, J = 13.2,






6.6 Hz, 2H),






1.72-1.59 (m, 1H), 0.97 (t, J = 7.4 Hz,






3H),






0.93-0.86 (m, 12H)


22

(Neat)
HRMS-ESI

1H NMR (CDCl3) δ


13C NMR





2956,
(m/z)
12.00 (s, 1H), 8.60 (s, 1H),
(CDCl3) δ




1749,
[M]+
7.95 (d, J = 5.2 Hz, 1H),
168.56, 168.39,




1651,
calcd for
6.86 (d, J = 5.3 Hz, 1H),
155.59, 148.99,




1526,
C24H38N2O8,
4.99 (ddd, J = 9.3, 4.7, 2.8 Hz,
140.56, 130.37,




1262,
482.2628;
1H), 4.87 (dt, J = 8.8, 5.6 Hz,
109.63, 79.24,




1083
found,
1H), 4.23 (dd, J = 11.6,
79.17, 78.29,





482.2660
6.0 Hz, 1H),
77.39, 72.70,






3.97 (dd, J = 11.5, 4.2 Hz,
71.21, 56.22,






1H), 3.93 (s, 3H),
54.57, 29.11,






3.79 (dd, J = 11.5, 1.6 Hz,
28.80, 23.16,






1H), 3.65 (dd, J = 6.4, 2.5 Hz,
19.54, 19.47,






1H), 3.59 (dd, J = 11.6,
10.71






5.3 Hz, 1H),






3.46-3.37 (m, 2H), 3.31 (ddd, J = 21.1,






8.7, 6.5 Hz, 2H),






3.20 (dd, J = 8.8, 6.8 Hz,






1H), 1.94-1.72 (m, 4H),






1.00 (t, J = 7.4 Hz, 3H),






0.94 (d, J = 3.1 Hz, 3H),






0.92 (d, J = 3.1 Hz, 3H),






0.89 (d, J = 4.1 Hz, 3H),






0.87 (d, J = 4.1 Hz, 3H)


23

(Neat)
HRMS-ESI

1H NMR (CDCl3) δ


13C NMR





2956,
(m/z)
8.59 (d, J = 7.8 Hz, 1H),
(CDCl3) δ




1756,
[M]+
8.27 (d, J = 5.4 Hz, 1H),
171.06, 170.37,




1679,
calcd for
6.94 (d, J = 5.4 Hz, 1H),
163.38, 160.34,




1506,
C27H42N2O10,
5.82-5.57 (m, 2H),
145.93, 144.08,




1202,
554.2839;
5.05 (ddd, J = 7.7, 6.4, 4.3 Hz,
142.38, 109.82,




1097
found,
1H), 4.91 (td, J = 8.8, 2.9 Hz,
89.58, 84.23,





554.2863
1H), 4.02 (dd, J = 11.9,
83.32, 80.45,






6.4 Hz, 1H), 3.90 (s,
77.70, 77.52,






3H), 3.86 (dd, J = 11.9,
76.65, 75.27,






4.2 Hz, 1H), 3.84 (d, J = 11.7 Hz,
56.32, 53.07,






1H), 3.70 (dd, J = 8.4,
29.24, 28.98,






6.1 Hz, 1H),
25.29, 20.99,






3.56 (dd, J = 11.6, 6.1 Hz,
19.70, 19.60,






1H), 3.35-3.13 (m, 5H),
19.58, 19.50,






2.06 (s, 3H), 1.80 (dtd, J = 8.3,
9.59






6.6, 1.6 Hz, 2H),






1.64 (ddd, J = 21.8, 14.9,






7.6 Hz, 2H), 0.96 (t, J = 7.4 Hz,






3H),






0.93-0.84 (m, 12H)


24

(Neat)
HRMS-ESI (m/z)

1H NMR (CDCl3) δ


13C NMR





2956,
[M]+
8.49 (d, J = 8.6 Hz, 1H),
(CDCl3) δ




1755,
calcd for
8.25 (d, J = 5.4 Hz, 1H),
170.49, 168.91,




1680,
C27H42N2O10,
6.95 (d, J = 5.4 Hz, 1H),
162.84, 160.47,




1502,
554.2839;
5.73 (s, 2H), 4.98 (ddd, J = 9.5,
145.77, 144.39,




1203,
found,
4.3, 3.1 Hz, 1H),
142.38, 109.79,




1085
554.2842
4.90 (dt, J = 8.6, 5.5 Hz, 1H),
89.67, 79.20,






4.24 (dd, J = 11.6, 6.0 Hz,
79.17, 78.64,






1H), 3.96 (dd, J = 11.5,
77.33, 73.04,






4.0 Hz, 1H), 3.91 (s,
71.28, 56.35,






3H), 3.80 (dd, J = 11.4,
55.00, 29.12,






1.6 Hz, 1H), 3.68 (dd, J = 6.6,
28.84, 23.05,






2.8 Hz, 1H),
21.02, 19.60,






3.57 (dd, J = 11.7, 5.2 Hz,
19.52, 10.75






1H), 3.45-3.37 (m, 2H),






3.31 (ddd, J = 22.5, 8.8,






6.5 Hz, 2H), 3.20 (dd, J = 8.8,






6.9 Hz, 1H), 2.07 (s,






3H), 1.94-1.69 (m, 4H),






1.01 (t, J = 7.4 Hz, 3H),






0.93 (d, J = 3.1 Hz, 3H),






0.91 (d, J = 3.1 Hz, 3H),






0.90 (d, J = 4.8 Hz, 3H),






0.88 (d, J = 4.8 Hz, 3H)


25


ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 551.3
11.96 (s, 1H), 8.73 (d, J = 8.1 Hz,
(CDCl3) δ





([M + H]+)
1H), 8.00 (d, J = 5.2 Hz,
170.61, 168.98,






1H), 7.39-7.18 (m,
155.32, 148.73,






10H), 6.87 (d, J = 5.2 Hz,
140.66, 138.13,






1H), 5.16 (dq, J = 8.3, 6.4 Hz,
138.05, 130.26,






1H), 5.07 (ddd, J = 8.3,
128.41, 128.37,






6.9, 4.5 Hz, 1H),
128.28, 127.77,






4.85 (d, J = 11.1 Hz, 1H),
127.72, 127.67,






4.74 (d, J = 10.9 Hz, 1H),
109.56, 86.10,






4.61 (dd, J = 15.6, 11.0 Hz,
84.78, 81.83,






2H), 4.11 (dd, J = 12.0,
75.91, 75.18,






6.9 Hz, 1H), 3.94 (s, 3H),
73.38, 71.93,






3.89 (dd, J = 12.0, 4.5 Hz,
56.08, 52.28,






1H), 3.81 (t, J = 6.6 Hz,
18.64, 17.43






1H), 3.45 (t, J = 8.2 Hz,






1H), 3.37 (dd, J = 8.0,






6.9 Hz, 1H), 1.47 (d,






J = 6.5 Hz, 3H), 1.29 (d,






J = 6.4 Hz, 3H)


26


ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 483.7
11.97 (s, 1H), 8.71 (d, J = 8.2 Hz,
(CDCl3) δ





([M + H]+)
1H), 8.00 (d, J = 5.4 Hz,
170.69, 168.94,






1H), 6.87 (d, J = 5.3 Hz,
155.30, 148.71,






1H), 5.11-4.96 (m,
140.63, 130.29,






2H), 4.09 (dd, J = 12.0,
109.53, 86.09,






7.0 Hz, 1H), 3.94 (s, 3H),
85.32, 81.91,






3.84 (dd, J = 12.0, 4.6 Hz,
80.92, 80.25,






1H), 3.78-3.50 (m,
73.76, 71.72,






3H), 3.31-3.19 (m, 3H),
56.08, 52.25,






3.15 (t, J = 8.4 Hz, 1H),
29.22, 29.13,






3.06 (t, J = 7.5 Hz, 1H),
19.75, 19.64,






1.83 (dtd, J = 13.1, 6.9,
19.45, 19.37,






3.8 Hz, 2H), 1.45 (d, J = 6.4 Hz,
18.60, 17.21






3H), 1.21 (d, J = 6.4 Hz,






3H), 0.91 (dt, J = 14.6,






6.0 Hz, 12H)


27


ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 411.6
12.32-11.65 (m, 1H), 8.66 (d,
(CDCl3) δ





([M + H]+)
J = 8.6 Hz, 1H), 8.01 (d,
170.56, 168.82,






J = 5.2 Hz, 1H), 6.88 (d,
155.35, 148.78,






J = 5.2 Hz, 1H),
140.65, 130.29,






4.88-4.72 (m, 2H),
109.54, 109.30,






4.09-3.98 (m, 2H), 3.94 (s, 3H),
81.92, 80.88,






3.90-3.80 (m, 1H),
77.96, 77.36,






3.80-3.72 (m, 2H), 1.64 (d, J = 6.5 Hz,
77.04, 76.73,






3H), 1.37 (d, J = 3.7 Hz,
65.93, 56.08,






6H), 1.34 (d, J = 6.4 Hz,
54.07, 26.75,






3H)
26.57, 18.34,







16.73


28


ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 623.8
8.59 (d, J = 7.9 Hz, 1H),
(CDCl3) δ





([M + H]+)
8.28 (d, J = 5.4 Hz, 1H),
171.29, 170.26,






7.42-7.19 (m, 10H), 6.95 (d,
163.31, 160.24,






J = 5.4 Hz, 1H), 5.74 (s,
145.82, 143.96,






2H), 5.19-5.03 (m, 2H),
142.16, 138.18,






4.85 (d, J = 11.1 Hz, 1H),
138.11, 128.40,






4.75 (d, J = 10.8 Hz, 1H),
128.36, 127.76,






4.61 (dd, J = 13.2, 10.9 Hz,
127.70, 127.65,






2H), 4.12 (dd, J = 12.0,
127.50, 109.70,






7.1 Hz, 1H), 3.91 (s,
89.50, 86.21,






3H), 3.83 (dt, J = 12.6,
84.92, 81.30,






5.8 Hz, 2H), 3.45 (t, J = 8.4 Hz,
75.97, 75.27,






1H), 3.35 (t, J = 7.6 Hz,
73.22, 71.97,






1H), 2.07 (s, 3H),
56.20, 52.48,






1.47 (d, J = 6.3 Hz, 3H),
20.88, 18.69,






1.28 (d, J = 6.4 Hz, 3H)
17.30


29


ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 506.0
8.53 (d, J = 8.3 Hz, 1H),
(CDCl3) δ





([M + Na]+)
8.30 (d, J = 5.4 Hz, 1H),
171.10, 170.28,






6.96 (d, J = 5.4 Hz, 1H),
163.15, 160.26,






5.73 (s, 2H), 4.84 (dt, J = 8.3,
145.83, 144.06,






3.3 Hz, 1H), 4.74 (s, 1H),
142.28, 109.66,






4.08-3.97 (m, 2H),
109.28, 89.52,






3.91 (s, 3H), 3.86 (dd, J = 9.2,
81.83, 80.94,






6.8 Hz, 1H),
77.84, 66.10,






3.81-3.71 (m, 2H), 2.07 (s, 3H),
56.19, 54.46,






1.64 (d, J = 6.5 Hz, 3H),
26.77, 26.59,






1.37 (d, J = 4.1 Hz, 6H),
20.87, 18.38,






1.33 (d, J = 6.5 Hz, 3H)
16.71


30

(Neat)
HRMS-ESI

1H NMR (CDCl3) δ


13C NMR





3368,
(m/z)
11.98 (s, 1H), 8.86 (d, J = 8.0 Hz,
(CDCl3) δ




2933,
[M]+
1H), 8.01 (d, J = 5.2 Hz,
169.86, 169.07,




1748,
calcd for
1H), 7.41-7.27 (m,
155.41, 148.82,




1648,
C29H32N2O8,
10H), 6.86 (d, J = 5.2 Hz,
140.81, 138.27,




1527,
536.2159;
1H), 5.36 (qd, J = 6.7, 3.1 Hz,
138.10, 130.51,




1242,
found,
1H), 5.06 (ddd, J = 8.0,
128.58, 128.54,




1066
536.2162
6.1, 1.9 Hz, 1H),
128.14, 128.05,






4.71 (d, J = 11.4 Hz, 1H),
128.00, 127.85,






4.68 (d, J = 11.8 Hz, 1H),
109.64, 78.70,






4.60 (d, J = 11.3 Hz, 1H),
75.15, 74.37,






4.58 (d, J = 11.8 Hz, 1H),
72.35, 71.55,






4.16 (dd, J = 12.2, 3.6 Hz,
56.21, 53.37,






1H), 4.12 (dd, J = 9.4, 2.2 Hz,
15.28






2H), 3.98 (dd, J = 11.7,






6.1 Hz, 1H), 3.94 (s,






3H), 3.71 (dd, J = 11.9,






1.7 Hz, 1H),






3.57-3.50 (m, 1H), 1.38 (d, J = 6.8 Hz,






3H)


31

(Neat)
HRMS-ESI

1H NMR (CDCl3) δ


13C NMR





3380,
(m/z)
8.73 (d, J = 7.7 Hz, 1H),
(CDCl3) δ




2931,
[M]+
8.29 (d, J = 5.3 Hz, 1H),
170.43, 170.39,




1752,
calcd for
7.48-7.16 (m, 10H), 6.94 (d,
163.37, 160.33,




1677,
C32H36N2O10,
J = 5.4 Hz, 1H),
145.96, 144.03,




1504,
608.2370;
5.77-5.69 (m, 2H),
142.39, 138.33,




1203,
found,
5.41-5.30 (m, 1H), 5.09 (ddd, J = 7.8,
138.20, 128.53,




1068
608.2375
6.2, 1.9 Hz, 1H),
128.49, 128.07,






4.71 (d, J = 15.8 Hz, 1H),
127.97, 127.78,






4.68 (d, J = 16.1 Hz, 1H),
109.77, 89.61,






4.61 (d, J = 11.4 Hz, 1H),
78.63, 75.39,






4.58 (d, J = 11.8 Hz, 1H),
74.32, 72.36,






4.19-4.07 (m, 3H), 3.97 (dd,
71.33, 56.31,






J = 11.7, 6.1 Hz, 1H),
53.64, 21.01,






3.90 (s, 3H), 3.70 (dd, J = 11.8,
15.15






1.7 Hz, 1H),






3.58-3.49 (m, 1H), 2.06 (s,






3H), 1.37 (d, J = 6.8 Hz,






3H)


32
105-107
(Neat)
HRMS-ESI

1H NMR (CDCl3) δ


13C NMR





3347,
(m/z)
12.00-11.55 (m, 1H), 8.67 (d,
(CDCl3) δ




2957,
[M]+
J = 8.1 Hz, 1H), 8.00 (d,
170.40, 169.09,




1732,
calcd for
J = 5.2 Hz, 1H),
155.47, 148.87,




1642,
C26H34N2O8,
7.39-7.27 (m, 5H), 6.87 (d, J = 5.2 Hz,
140.81, 138.25,




1540,
502.2315;
1H), 5.04 (ddd, J = 8.1,
130.36, 128.52,




1206,
found,
6.8, 5.0 Hz, 1H),
127.89, 127.84,




1081
502.2324
4.99 (ddd, J = 15.8, 7.8,
109.71, 85.27,






4.6 Hz, 1H), 4.64 (s, 2H),
83.44, 75.66,






4.05 (dd, J = 11.9, 6.8 Hz,
74.20, 74.04,






1H), 3.94 (s, 3H),
73.32, 73.19,






3.94-3.84 (m, 2H),
56.23, 52.31,






3.83 (dd, J = 11.9, 5.0 Hz,
32.61, 19.50,






1H), 3.65 (dd, J = 11.2,
18.72, 14.12






7.1 Hz, 1H), 3.52 (dt, J = 8.8,






6.8 Hz, 1H),






3.42 (ddd, J = 8.4, 7.1, 1.3 Hz,






1H), 3.27 (t, J = 9.1 Hz,






1H), 1.59-1.49 (m, 2H),






1.47 (d, J = 6.3 Hz, 3H),






1.41-1.27 (m, 2H),






0.89 (t, J = 7.4 Hz, 3H)


33
117-119
(Neat)
HRMS-ESI

1H NMR (CDCl3) δ


13C NMR





3363,
(m/z)
11.93 (s, 1H), 8.67 (d, J = 8.1 Hz,
(CDCl3) δ




2933,
[M]+
1H), 8.00 (d, J = 5.2 Hz,
170.38, 169.10,




1749,
calcd for
1H), 7.42-7.26 (m,
155.47, 148.87,




1648,
C26H34N2O8,
5H), 6.87 (d, J = 5.2 Hz,
140.80, 138.40,




1528,
502.2315;
1H), 5.07-4.98 (m, 2H),
130.35, 128.53,




1243,
found,
4.95 (d, J = 10.9 Hz, 1H),
128.09, 127.89,




1091
502.2324
4.61 (d, J = 10.9 Hz, 1H),
109.71, 84.72,






4.06 (dd, J = 11.9, 6.8 Hz,
83.97, 75.89,






1H), 3.94 (s, 3H),
75.51, 74.18,






3.90-3.79 (m, 2H),
73.12, 70.86,






3.69-3.49 (m, 3H), 3.41 (t, J = 9.0 Hz,
56.23, 52.32,






1H), 3.32 (ddd,
32.34, 19.50,






J = 8.4, 6.9, 1.2 Hz, 1H),
18.86, 14.05






1.59-1.50 (m, 2H),






1.44 (d, J = 6.3 Hz, 3H),






1.41-1.29 (m, 2H), 0.89 (t, J = 7.4 Hz,






3H)


34

(Neat)
HRMS-ESI

1H NMR (CDCl3) δ


13C NMR





3373,
(m/z)
8.53 (d, J = 7.9 Hz, 1H),
(CDCl3) δ




2933,
[M]+
8.27 (d, J = 5.4 Hz, 1H),
171.01, 170.37,




1753,
calcd for
7.37-7.22 (m, 5H), 6.94 (d, J = 5.4 Hz,
163.38, 160.35,




1677,
C29H38N2O10,
1H),
145.93, 144.08,




1504,
574.2526;
5.88-5.54 (m, 2H), 5.06 (td, J = 6.9,
142.26, 138.29,




1201,
found,
5.2 Hz, 1H),
129.14, 128.48,




1093
574.2538
4.95 (dq, J = 9.5, 6.3 Hz, 1H),
127.86, 127.78,






4.63 (s, 2H), 4.04 (dd, J = 11.9,
109.84, 89.55,






6.9 Hz, 1H),
85.26, 83.50,






3.94-3.83 (m, 2H), 3.90 (s,
75.33, 74.35,






3H), 3.79 (dd, J = 11.8,
73.99, 73.13,






5.1 Hz, 1H), 3.64 (dd, J = 11.1,
73.08, 56.31,






7.2 Hz, 1H),
52.56, 32.58,






3.52 (dt, J = 8.7, 6.9 Hz, 1H),
20.97, 19.46,






3.40 (ddd, J = 7.9, 7.3,
18.69, 14.08






1.1 Hz, 1H), 3.26 (t, J = 9.1 Hz,






1H), 2.06 (s, 3H),






1.63-1.45 (m, 2H),






1.45 (d, J = 6.3 Hz, 3H),






1.41-1.26 (m, 2H), 0.88 (t, J = 7.4 Hz,






3H)


35

(Neat)
HRMS-ESI

1H NMR (CDCl3) δ


13C NMR





3373,
(m/z)
8.53 (d, J = 7.9 Hz, 1H),
(CDCl3) δ




2933,
[M]+
8.27 (d, J = 5.4 Hz, 1H),
170.97, 170.35,




1752,
calcd for
7.40-7.25 (m, 5H), 6.94 (d, J = 5.4 Hz,
163.37, 160.33,




1676,
C29H38N2O10,
1H),
145.91, 144.07,




1503,
574.2526;
5.92-5.45 (m, 2H), 5.06 (ddd, J = 7.7,
142.23, 138.43,




1200,
found,
6.9, 5.2 Hz, 1H),
128.48, 128.04,




1091
574.2529
4.99 (ddd, J = 9.8, 6.4,
127.82, 109.84,






3.3 Hz, 1H), 4.94 (d, J = 10.8 Hz,
89.53, 84.73,






1H), 4.60 (d, J = 10.9 Hz,
83.99, 75.85,






1H), 4.05 (dd, J = 11.9,
75.17, 74.32,






6.9 Hz, 1H),
72.88, 70.79,






3.90 (s, 3H), 3.84 (dd, J = 11.1,
56.31, 52.56,






1.0 Hz, 1H),
32.31, 20.97,






3.79 (dd, J = 11.8, 5.1 Hz,
19.46, 18.83,






1H), 3.69-3.48 (m, 3H),
14.01






3.40 (t, J = 9.0 Hz, 1H),






3.30 (ddd, J = 8.4, 7.1,






1.2 Hz, 1H), 2.06 (s, 3H),






1.60-1.49 (m, 2H),






1.42 (d, J = 6.3 Hz, 3H),






1.40-1.29 (m, 2H); 0.88 (t, J = 7.4 Hz,






3H)


36
118-120
(Neat)
HRMS-ESI

1H NMR (CDCl3) δ


13C NMR





3366,
(m/z)
11.91 (s, 1H), 8.65 (d, J = 8.1 Hz,
(CDCl3) δ




2933,
[M]+
1H), 7.97 (d, J = 5.2 Hz,
170.38, 169.05,




1742,
calcd for
1H), 6.85 (d, J = 5.2 Hz,
155.42, 148.81,




1650,
C20H30N2O8,
1H), 5.02 (ddd, J = 8.1,
140.77, 130.29,




1529,
426.2002;
6.8, 5.1 Hz, 1H),
109.68, 86.84,




1244,
found,
4.92 (dq, J = 9.4, 6.3 Hz, 1H),
83.62, 75.34,




1103
426.2039
4.03 (dd, J = 11.9, 6.8 Hz,
74.02, 73.03,






1H), 3.92 (s, 3H),
70.82, 61.56,






3.84-3.76 (m, 2H),
56.19, 52.24,






3.62-3.55 (m, 2H), 3.55 (s,
32.25, 19.43,






3H), 3.50 (dt, J = 9.1, 6.6 Hz,
18.64, 13.99






1H), 3.19 (ddd, J = 8.4,






7.1, 1.3 Hz, 1H),






3.09 (t, J = 9.0 Hz, 1H),






1.62-1.48 (m, 2H), 1.44 (d, J = 6.3 Hz,






3H),






1.42-1.30 (m, 2H), 0.90 (t, J = 7.4 Hz,






3H)


37

(Neat)
HRMS-ESI

1H NMR (CDCl3) δ


13C NMR





3371,
(m/z)
8.52 (d, J = 7.8 Hz, 1H),
(CDCl3) δ




2933,
[M]+
8.28 (d, J = 5.4 Hz, 1H),
171.04, 170.40,




1754,
calcd for
6.95 (d, J = 5.4 Hz, 1H),
163.39, 160.36,




1671,
C23H34N2O10,
5.85-5.57 (m, 2H), 5.06 (td, J = 7.0,
145.95, 144.11,




1505,
498.2213;
5.2 Hz, 1H),
142.25, 109.86,




1201,
found,
4.90 (dq, J = 9.4, 6.3 Hz, 1H),
89.58, 86.91,




1103
498.2218
4.04 (dd, J = 11.8, 6.9 Hz,
83.71, 75.10,






1H), 3.90 (s, 3H),
74.26, 72.87,






3.84-3.73 (m, 2H),
70.85, 61.60,






3.64-3.56 (m, 3H), 3.56 (s,
56.34, 52.56,






3H), 3.50 (dt, J = 9.2, 6.6 Hz,
32.30, 21.01,






1H), 3.19 (ddd, J = 8.5,
19.47, 18.68,






7.3, 1.2 Hz, 1H),
14.03






3.09 (t, J = 9.1 Hz, 1H),






2.06 (s, 2H), 1.60-1.49 (m,






2H), 1.44 (d, J = 6.3 Hz,






3H), 1.42-1.31 (m, 2H),






0.91 (t, J = 7.3 Hz, 3H)


38


ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 537.8.
11.98 (s, 1H), 8.86 (d, J = 8.0 Hz,
(CDCl3) δ





([M − H])
1H), 8.01 (d, J = 5.2 Hz,
169.86, 169.07,






1H), 7.41-7.27 (m,
155.41, 148.82,






10H), 6.86 (d, J = 5.2 Hz,
140.81, 138.27,






1H), 5.36 (qd, J = 6.7, 3.1 Hz,
138.10, 130.51,






1H), 5.06 (ddd, J = 8.0,
128.58, 128.54,






6.1, 1.9 Hz, 1H),
128.14, 128.05,






4.71 (d, J = 11.4 Hz, 1H),
128.00, 127.85,






4.68 (d, J = 11.8 Hz, 1H),
109.64, 78.70,






4.60 (d, J = 11.3 Hz, 1H),
75.15, 74.37,






4.58 (d, J = 11.8 Hz, 1H),
72.35, 71.55,






4.16 (dd, J = 12.2, 3.6 Hz,
56.21, 53.37,






1H), 4.12 (dd, J = 9.4, 2.2 Hz,
15.28






2H), 3.98 (dd, J = 11.7,






6.1 Hz, 1H), 3.94 (s,






3H), 3.71 (dd, J = 11.9,






1.7 Hz, 1H),






3.57-3.50 (m, 1H), 1.38 (d, J = 6.8 Hz,






3H)


39


HRMS-ESI

1H NMR (CDCl3) δ


13C NMR






(m/z)
11.96 (s, 1H), 8.51 (d, J = 8.6 Hz,
(CDCl3) δ





[M]+
1H), 7.93 (d, J = 5.2 Hz,
168.67, 168.06,





calcd for
1H), 7.38-7.27 (m,
155.61, 149.01,





C29H32N2O8,
10H), 6.87 (d, J = 5.2 Hz,
140.67, 138.24,





536.2159;
1H), 5.30 (qd, J = 6.7, 3.2 Hz,
138.22, 130.34,





found,
1H), 4.92 (dt, J = 8.8,
128.54, 127.99,





536.2165
6.1 Hz, 1H), 4.71 (d, J = 11.6 Hz,
127.93, 127.87,






1H), 4.69 (d, J = 11.8 Hz,
109.71, 79.48,






1H), 4.61 (d, J = 11.6 Hz,
77.33, 74.36,






1H), 4.58 (d, J = 11.9 Hz,
72.82, 72.29,






1H), 4.30 (dd, J = 11.5,
71.97, 71.81,






6.3 Hz, 1H),
56.26, 54.38,






4.05 (dd, J = 11.6, 3.9 Hz,
15.68






1H), 3.94 (s, 3H),






3.91-3.82 (m, 2H),






3.64-3.54 (m, 2H), 1.41 (d, J = 6.8 Hz,






3H)


40


ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 609.8
8.73 (d, J = 7.7 Hz, 1H),
(CDCl3) δ





([M + H]+)
8.29 (d, J = 5.3 Hz, 1H),
170.43, 170.39,






7.48-7.16 (m, 10H), 6.94 (d,
163.37, 160.33,






J = 5.4 Hz, 1H),
145.96, 144.03,






5.77-5.69 (m, 2H),
142.39, 138.33,






5.41-5.30 (m, 1H), 5.09 (ddd, J = 7.8,
138.20, 128.53,






6.2, 1.9 Hz, 1H),
128.49, 128.07,






4.71 (d, J = 15.8 Hz, 1H),
127.97, 127.78,






4.68 (d, J = 16.1 Hz, 1H),
109.77, 89.61,






4.61 (d, J = 11.4 Hz, 1H),
78.63, 75.39,






4.58 (d, J = 11.8 Hz, 1H),
74.32, 72.36,






4.19-4.07 (m, 3H), 3.97 (dd,
71.33, 56.31,






J = 11.7, 6.1 Hz, 1H),
53.64, 21.01,






3.90 (s, 3H), 3.70 (dd, J = 11.8,
15.15






1.7 Hz, 1H),






3.58-3.49 (m, 1H), 2.06 (s,






3H), 1.37 (d, J = 6.8 Hz,






3H)


41


ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 609.8
8.44 (d, J = 8.5 Hz, 1H),
(CDCl3) δ





([M + H]+)
8.20 (d, J = 5.4 Hz, 1H),
170.49, 168.56,






7.37-7.27 (m, 10H), 6.94 (d,
162.86, 160.47,






J = 5.4 Hz, 1H), 5.72 (s,
145.80, 144.42,






2H), 5.28 (qd, J = 6.7, 3.3 Hz,
142.18, 138.34,






1H), 4.93 (dt, J = 8.5,
128.52, 128.00,






5.9 Hz, 1H), 4.71 (d, J = 11.5 Hz,
127.89, 127.83,






1H), 4.69 (d, J = 11.8 Hz,
109.84, 89.66,






1H), 4.60 (d, J = 11.5 Hz,
79.49, 74.35,






1H), 4.58 (d, J = 11.9 Hz,
73.05, 72.28,






1H), 4.29 (dd, J = 11.6,
71.80, 71.64,






6.3 Hz, 1H),
56.36, 54.84,






4.02 (dd, J = 11.6, 3.8 Hz,
21.02, 15.65






1H), 3.91 (s, 3H),






3.90-3.82 (m, 2H),






3.62-3.59 (m, 1H), 3.56 (dd, J = 11.7,






5.7 Hz, 1H), 2.06 (s,






3H), 1.41 (d, J = 6.8 Hz,






3H)


42

(Neat)
HRMS-ESI

1H NMR (CDCl3) δ


13C NMR





3370,
(m/z)
11.96-11.93 (m, 1H), 8.79 (d,
(CDCl3) δ




2933,
[M]+
J = 7.8 Hz, 1H), 8.01 (d,
169.62, 169.15,




1750,
calcd for
J = 5.2 Hz, 1H), 6.87 (d,
155.48, 148.89,




1648,
C19H28N2O8,
J = 5.2 Hz, 1H), 5.14 (dq,
140.83, 130.45,




1529,
412.1846;
J = 9.3, 6.3 Hz, 1H),
109.71, 82.72,




1244,
found,
5.01 (ddd, J = 7.9, 5.7, 2.2 Hz,
77.79, 77.36,




1088
412.1849
1H), 4.18-4.06 (m, 2H),
76.62, 73.73,






3.98-3.90 (m, 1H),
70.15, 56.24,






3.94 (s, 3H), 3.66 (dt, J = 9.3,
53.63, 31.90,






6.6 Hz, 1H),
19.44, 18.90,






3.48-3.38 (m, 3H), 3.20 (s, 1H),
13.96






3.15-3.07 (m, 1H),






1.60-1.51 (m, 2H), 1.49 (d, J = 6.3 Hz,






3H),






1.41-1.29 (m, 2H), 0.91 (t, J = 7.4 Hz,






3H)


43
101-103
(Neat)
HRMS-ESI

1H NMR (CDCl3) δ


13C NMR





3335,
(m/z)
11.92 (s, 1H), 8.66 (d, J = 8.1 Hz,
(CDCl3) δ




2931,
[M]+
1H), 7.98 (d, J = 5.2 Hz,
170.37, 169.05,




1745,
calcd for
1H), 6.85 (d, J = 5.2 Hz,
155.42, 148.81,




1640,
C22H32N2O8,
1H), 5.91 (ddt, J = 16.2,
140.77, 134.92,




1534,
452.2159;
10.4, 5.8 Hz, 1H),
130.29, 117.01,




1281,
found,
5.25 (ddd, J = 17.2, 3.2,
109.68, 84.56,




1029
452.2166
1.6 Hz, 1H), ), 5.15 (ddd,
83.77, 75.44,






J = 10.4, 2.7, 1.1 Hz, 1H),
74.78, 74.08,






5.02 (ddd, J = 8.1, 6.8,
73.10, 70.87,






5.0 Hz, 1H),
56.18, 52.25,






4.99-4.92 (m, 1H), 4.38 (ddt, J = 12.2,
32.26, 19.42,






5.5, 1.3 Hz, 1H),
18.77, 14.02






4.13-4.05 (m, 1H),






4.03 (dd, J = 11.9, 6.8 Hz,






1H), 3.92 (s, 3H),






3.86-3.76 (m, 2H),






3.64-3.54 (m, 2H), 3.49 (dt, J = 9.2,






6.6 Hz, 1H),






3.31-3.19 (m, 2H), 1.59-1.48 (m,






2H), 1.44 (d, J = 6.4 Hz,






3H), 1.40-1.28 (m, 2H),






0.89 (t, J = 7.4 Hz, 3H)


44
110-112
(Neat)
HRMS-ESI

1H NMR (CDCl3) δ


13C NMR





3366,
(m/z)
11.93 (s, 1H), 8.66 (d, J = 8.1 Hz,
(CDCl3) δ




2933,
[M]+
1H), 7.99 (d, J = 5.2 Hz,
170.46, 169.08,




1750,
calcd for
1H), 6.86 (d, J = 5.2 Hz,
155.46, 148.85,




1649,
C22H34N2O8,
1H), 5.02 (ddd, J = 8.1,
140.79, 130.34,




1529,
454.2315;
6.9, 5.2 Hz, 1H),
109.69, 85.05,




1245,
found,
4.95 (dq, J = 12.6, 6.3 Hz,
83.70, 75.72,




1095
454.2326
1H), 4.04 (dd, J = 11.9,
75.39, 74.01,






6.8 Hz, 1H), 3.93 (s, 3H),
73.32, 70.90,






3.86-3.76 (m, 3H),
56.22, 52.23,






3.64-3.54 (m, 2H), 3.49 (tt, J = 8.7,
32.31, 23.64,






6.7 Hz, 2H),
19.45, 18.71,






3.24-3.16 (m, 2H),
14.04, 10.79






1.65-1.49 (m, 4H), 1.45 (d, J = 6.3 Hz,






3H), 1.41-1.30 (m,






2H), 0.92 (t, J = 7.4 Hz,






3H), 0.91 (t, J = 7.3 Hz,






3H)


45

(Neat)
HRMS-ESI

1H NMR (CDCl3) δ


13C NMR





3376,
(m/z)
8.52 (d, J = 7.9 Hz, 1H),
(CDCl3) δ




2933,
[M]+
8.28 (d, J = 5.4 Hz, 1H),
171.10, 170.41,




1754,
calcd for
6.94 (d, J = 5.4 Hz, 1H),
163.39, 160.37,




1678,
C25H38N2O10,
5.76-5.68 (m, 2H),
145.94, 144.11,




1506,
526.2526;
5.09-5.02 (m, 1H), 4.92 (dq, J = 12.6,
142.28, 109.84,




1202,
found,
6.3 Hz, 1H),
89.59, 85.09,




1099
526.2536
4.04 (dd, J = 11.8, 6.9 Hz,
83.76, 75.72,






1H), 3.91 (s, 3H),
75.11, 74.21,






3.87-3.72 (m, 3H),
73.13, 70.89,






3.64-3.54 (m, 2H), 3.49 (dq, J = 8.7,
56.34, 52.52,






6.8 Hz, 2H),
32.33, 23.66,






3.23-3.15 (m, 2H), 2.06 (s,
21.02, 19.47,






3H), 1.60-1.49 (m, 4H),
18.73, 14.06,






1.44 (d, J = 6.3 Hz, 3H),
10.80






1.41-1.30 (m, 2H),






0.92 (t, J = 7.4 Hz, 3H),






0.91 (t, J = 7.3 Hz, 3H)


46

(Neat)
HRMS-ESI

1H NMR (CDCl3) δ


13C NMR





3367,
(m/z)
11.90 (s, 1H), 8.68 (d, J = 8.1 Hz,
(CDCl3) δ




2935,
[M]+
1H), 7.98 (d, J = 5.2 Hz,
175.79, 170.21,




1739,
calcd for
1H), 6.86 (d, J = 5.2 Hz,
169.06, 155.46,




1649,
C23H34N2O9,
1H), 5.14 (dq, J = 9.8,
148.86, 140.77,




1528,
482.2264;
6.4 Hz, 1H),
130.28, 109.71,




1242,
found,
5.07 (ddd, J = 8.1, 6.5, 4.2 Hz,
80.84, 75.91,




1093
482.2266
1H), 4.98 (t, J = 9.4 Hz,
75.76, 74.72,






1H), 4.04 (dd, J = 11.9,
71.79, 70.55,






6.5 Hz, 1H), 3.97 (dd, J = 11.3,
56.20, 52.63,






1.1 Hz, 1H),
34.20, 32.02,






3.95-3.89 (m, 1H), 3.92 (s,
19.33, 19.18,






3H), 3.61 (dd, J = 11.4,
18.87, 18.31,






7.6 Hz, 1H), 3.52 (dt, J = 9.1,
13.96






6.6 Hz, 1H), 3.33 (dt,






J = 9.1, 6.6 Hz, 1H),






3.23 (ddd, J = 8.9, 7.6, 1.3 Hz,






1H), 2.56 (hept, J = 7.0 Hz,






1H), 1.49-1.38 (m,






2H), 1.32 (d, J = 6.3 Hz,






3H), 1.32-1.24 (m, 2H),






1.19 (d, J = 7.0 Hz, 3H),






1.17 (d, J = 7.0 Hz, 3H),






0.86 (t, J = 7.3 Hz, 3H)


47

(Neat)
HRMS-ESI

1H NMR (CDCl3) δ


13C NMR





3370,
(m/z)
8.56 (d, J = 7.8 Hz, 1H),
(CDCl3) δ




2935,
[M]+
8.28 (d, J = 5.4 Hz, 1H),
175.83, 170.85,




1739,
calcd for
6.95 (d, J = 5.4 Hz, 1H),
170.39, 163.39,




1676,
C26H38N2O11,
5.78-5.68 (m, 2H),
160.38, 145.92,




1505,
554.2476;
5.17-5.05 (m, 2H), 4.98 (t, J = 9.4 Hz,
144.17, 142.19,




1199,
found,
1H), 4.04 (dd, J = 11.9,
109.87, 89.57,




1093
554.2484
6.6 Hz, 1H),
75.82, 75.64,






3.96 (dd, J = 11.2, 0.8 Hz,
74.96, 71.60,






1H), 3.93-3.87 (m, 1H),
70.53, 56.34,






3.91 (s, 3H), 3.62 (dd, J = 11.3,
52.93, 34.23,






7.7 Hz, 1H),
32.05, 21.00,






3.53 (dt, J = 9.1, 6.6 Hz, 1H),
19.35, 19.22,






3.33 (dt, J = 9.1, 6.6 Hz,
18.90, 18.35,






1H), 3.27-3.18 (m, 1H),
13.99






2.56 (hept, J = 7.0 Hz,






1H), 2.06 (s, 3H),






1.50-1.40 (m, 2H), 1.32 (d, J = 6.3 Hz,






3H),






1.32-1.22 (m, 2H), 1.19 (d, J = 7.0 Hz,






3H), 1.18 (d, J = 7.0 Hz,






3H), 0.87 (t, J = 7.3 Hz,






3H)


48
104-106
(Neat)
HRMS-ESI

1H NMR (CDCl3) δ


13C NMR





3367,
(m/z)
11.92 (s, 1H), 8.65 (d, J = 8.1 Hz,
(CDCl3) δ




2956,
[M]+
1H), 7.97 (d, J = 5.2 Hz,
170.44, 169.04,




1749,
calcd for
1H), 6.85 (d, J = 5.2 Hz,
155.41, 148.80,




1649,
C23H36N2O8,
1H), 5.01 (ddd, J = 8.0,
140.75, 130.29,




1528,
468.2472;
6.9, 5.2 Hz, 1H),
109.66, 84.93,




1281,
found,
4.94 (dq, J = 12.6, 6.2 Hz,
83.70, 80.71,




1092
468.2497
1H), 4.03 (dd, J = 11.9,
75.29, 73.92,






6.8 Hz, 1H), 3.91 (s, 3H),
73.29, 70.79,






3.82-3.75 (m, 2H),
56.17, 52.18,






3.66 (dd, J = 8.4, 6.2 Hz, 1H),
32.28, 29.21,






3.64-3.44 (m, 3H),
19.64, 19.48,






3.24 (dd, J = 8.4, 6.9 Hz, 1H),
19.44, 18.71,






3.21-3.13 (m, 2H),
14.02






1.88-1.74 (m, 1H),






1.57-1.47 (m, 2H), 1.43 (d, J = 6.3 Hz,






3H),






1.40-1.29 (m, 2H), 0.94-0.83 (m,






9H)


49

(Neat)
HRMS-ESI

1H NMR (CDCl3) δ


13C NMR





3359,
(m/z)
11.96 (s, 1H), 8.51 (d, J = 8.6 Hz,
(CDCl3) δ




2929,
[M]+
1H), 7.93 (d, J = 5.2 Hz,
168.67, 168.06,




1745,
calcd for
1H), 7.38-7.27 (m,
155.61, 149.01,




1649,
C29H32N2O8,
10H), 6.87 (d, J = 5.2 Hz,
140.67, 138.24,




1525,
536.2159;
1H), 5.30 (qd, J = 6.7, 3.2 Hz,
138.22, 130.34,




1261,
found,
1H), 4.92 (dt, J = 8.8,
128.54, 127.99,




1065
536.2165
6.1 Hz, 1H), 4.71 (d, J = 11.6 Hz,
127.93, 127.87,






1H), 4.69 (d, J = 11.8 Hz,
109.71, 79.48,






1H), 4.61 (d, J = 11.6 Hz,
77.33, 74.36,






1H), 4.58 (d, J = 11.9 Hz,
72.82, 72.29,






1H), 4.30 (dd, J = 11.5,
71.97, 71.81,






6.3 Hz, 1H),
56.26, 54.38,






4.05 (dd, J = 11.6, 3.9 Hz,
15.68






1H), 3.94 (s, 3H),






3.91-3.82 (m, 2H),






3.64-3.54 (m, 2H), 1.41 (d, J = 6.8 Hz,






3H)


50

(Neat)
HRMS-ESI

1H NMR (CDCl3) δ


13C NMR





3372,
(m/z)
8.52 (d, J = 7.8 Hz, 1H),
(CDCl3) δ




2956,
[M]+
8.27 (d, J = 5.3 Hz, 1H),
171.09, 170.39,




1751,
calcd for
6.94 (d, J = 5.4 Hz, 1H),
163.38, 160.36,




1675,
C26H40N2O10,
5.76-5.68 (m, 2H), 5.05 (td, J = 7.0,
145.93, 144.10,




1505,
540.2683;
5.4 Hz, 1H),
142.27, 109.84,




1200,
found,
4.92 (dq, J = 12.7, 6.3 Hz,
89.58, 85.00,




1093 cm−1
540.2690
1H), 4.04 (dd, J = 11.8,
83.80, 80.75,






6.9 Hz, 1H), 3.90 (s, 3H),
75.09, 74.19,






3.81-3.73 (m, 2H),
73.14, 70.82,






3.68 (dd, J = 8.4, 6.2 Hz, 1H),
56.33, 52.52,






3.63-3.44 (m, 3H),
32.33, 29.26,






3.25 (dd, J = 8.4, 6.9 Hz, 1H),
21.01, 19.69,






3.23-3.12 (m, 2H),
19.53, 19.48,






2.06 (s, 3H), 1.88-1.75 (m,
18.77, 14.06






1H), 1.57-1.47 (m, 2H),






1.43 (d, J = 6.3 Hz, 3H),






1.40-1.29 (m, 2H),






0.96-0.85 (m, 9H)


51

(Neat)
HRMS-ESI

1H NMR (CDCl3) δ


13C NMR





3369,
(m/z)
8.44 (d, J = 8.5 Hz, 1H),
(CDCl3) δ




2925,
[M]+
8.20 (d, J = 5.4 Hz, 1H),
170.49, 168.56,




1749,
calcd for
7.37-7.27 (m, 10H), 6.94 (d,
162.86, 160.47,




1677,
C32H36N2O10,
J = 5.4 Hz, 1H), 5.72 (s,
145.80, 144.42,




1499,
608.2370;
2H), 5.28 (qd, J = 6.7, 3.3 Hz,
142.18, 138.34,




1202,
found,
1H), 4.93 (dt, J = 8.5,
128.52, 128.00,




1064
608.2377
5.9 Hz, 1H), 4.71 (d, J = 11.5 Hz,
127.89, 127.83,






1H), 4.69 (d, J = 11.8 Hz,
109.84, 89.66,






1H), 4.60 (d, J = 11.5 Hz,
79.49, 74.35,






1H), 4.58 (d, J = 11.9 Hz,
73.05, 72.28,






1H), 4.29 (dd, J = 11.6,
71.80, 71.64,






6.3 Hz, 1H),
56.36, 54.84,






4.02 (dd, J = 11.6, 3.8 Hz,
21.02, 15.65






1H), 3.91 (s, 3H),






3.90-3.82 (m, 2H),






3.62-3.59 (m, 1H), 3.56 (dd, J = 11.7,






5.7 Hz, 1H), 2.06 (s,






3H), 1.41 (d, J = 6.8 Hz,






3H)


52
75-77
(Neat)
HRMS-ESI

1H NMR (CDCl3) δ


13C NMR





3367,
(m/z)
11.92-11.89 (m, 1H), 8.65 (d,
(CDCl3) δ




2933,
[M]+
J = 8.1 Hz, 1H), 7.97 (d,
170.31, 169.04,




1750,
calcd for
J = 5.2 Hz, 1H), 6.85 (d,
155.40, 148.79,




1649,
C22H34N2O9,
J = 5.2 Hz, 1H),
140.75, 130.28,




1529,
470.2264;
5.04-4.94 (m, 2H),
109.67, 85.60,




1282,
found,
4.06-3.96 (m, 2H), 3.92 (s, 3H),
83.64, 75.38,




1094
470.2264
3.84-3.77 (m, 2H),
74.07, 73.09,






3.75-3.68 (m, 1H),
73.06, 72.34,






3.61-3.44 (m, 5H), 3.36 (s,
70.75, 59.04,






3H), 3.27-3.19 (m, 2H),
56.17, 52.23,






1.58-1.48 (m, 2H),
32.25, 19.41,






1.46 (d, J = 6.3 Hz, 3H),
18.60, 14.01






1.40-1.27 (m, 2H), 0.89 (t, J = 7.4 Hz,






3H)


53
127-129
(Neat)
HRMS-ESI

1H NMR (CDCl3) δ


13C NMR





3356,
(m/z)
11.90 (s, 1H), 8.66 (d, J = 8.0 Hz,
(CDCl3) δ




2958,
[M]+
1H), 7.97 (d, J = 5.2 Hz,
170.17, 169.05,




1736,
calcd for
1H), 6.85 (d, J = 5.2 Hz,
155.44, 148.82,




1643,
C21H30F2N2O8,
1H), 5.83 (tdd, J = 55.1 (H-F),
140.78, 130.24,




1536,
476.1970;
4.7, 3.3 Hz,
114.30 (t, J = 241.7 Hz),




1262,
found,
1H), 5.07-4.93 (m, 2H),
109.69, 86.19,




1091
476.1978
4.14-4.01 (m, 1H),
83.72, 75.28,






4.02 (dd, J = 12.0, 6.7 Hz,
74.31, 72.79 (t, J = 27.6 Hz),






1H), 3.92 (s, 3H),
72.51, 70.45,






3.88-3.72 (m, 3H),
56.19, 52.33,






3.62-3.51 (m, 2H), 3.45 (dt, J = 9.1,
32.13, 19.39,






6.6 Hz, 1H),
18.64, 13.96






3.31-3.19 (m, 2H), 1.58-1.48 (m,






2H), 1.45 (d, J = 6.3 Hz,






3H), 1.39-1.28 (m, 2H),






0.90 (t, J = 7.4 Hz, 3H)


54

(Neat)
HRMS-ESI

1H NMR (CDCl3) δ


13C NMR





3381,
(m/z)
8.51 (d, J = 7.9 Hz, 1H),
(CDCl3) δ




2953,
[M]+
8.26 (d, J = 5.3 Hz, 1H),
170.94, 170.34,




1755,
calcd for
6.93 (d, J = 5.4 Hz, 1H),
163.34, 160.31,




1678,
C25H38N2O11,
5.73-5.67 (m, 2H), 5.04 (td, J = 7.0,
145.90, 144.04,




1507,
542.2476;
5.2 Hz, 1H),
142.20, 109.82,




1202,
found,
4.95 (dq, J = 9.1, 6.2 Hz, 1H),
89.52, 85.62,




1095
542.2487
4.05-3.97 (m, 2H),
83.69, 75.05,






3.89 (s, 3H), 3.81-3.67 (m,
74.25, 73.05,






3H), 3.62-3.45 (m, 5H),
72.90, 72.35,






3.36 (s, 3H),
70.73, 59.03,






3.26-3.19 (m, 2H), 2.04 (s, 3H),
56.30, 52.50,






1.56-1.48 (m, 2H),
32.26, 20.96,






1.45 (d, J = 6.3 Hz, 3H),
19.41, 18.61,






1.39-1.27 (m, 2H), 0.89 (t, J = 7.4 Hz,
14.01






3H)


55

(Neat)
HRMS-ESI

1H NMR (CDCl3) δ


13C NMR





3372,
(m/z)
8.53 (d, J = 7.9 Hz, 1H),
(CDCl3) δ




2934,
[M]+
8.27 (d, J = 5.4 Hz, 1H),
170.80, 170.36,




1752,
calcd for
6.94 (d, J = 5.4 Hz, 1H),
163.37, 160.34,




1675,
C24H34F2N2O10,
5.83 (tdd, J = 55.7 (H-F), 4.7,
145.92, 144.09,




1505,
548.2182;
3.3 Hz, 1H),
142.17,




1201,
found,
5.74-5.68 (m, 2H), 5.08-5.01 (m,
114.31 (t, J = 240.8 Hz),




1094
548.2194.
1H), 4.96 (dq, J = 12.7,
109.86, 89.52,






6.3 Hz, 1H),
86.23, 83.77,






4.14-4.02 (m, 1H), 4.01 (dd, J = 11.9,
74.96, 74.51,






6.8 Hz, 1H), 3.89 (s,
72.81 (t, J = 27.8 Hz),






3H), 3.85-3.70 (m, 3H),
72.32,






3.60-3.52 (m, 2H),
70.44, 56.32,






3.45 (dt, J = 9.1, 6.6 Hz, 1H),
52.61, 32.15,






3.30-3.18 (m, 2H),
20.97, 19.40,






2.05 (s, 3H), 1.57-1.47 (m,
18.66, 13.97






2H), 1.44 (d, J = 6.3 Hz,






3H), 1.39-1.27 (m, 2H),






0.90 (t, J = 7.4 Hz, 3H)


56
111-113
(Neat)
HRMS-ESI

1H NMR (CDCl3) δ


13C NMR





3364,
(m/z)
11.85 (s, 1H), 8.64 (d, J = 8.3 Hz,
(CDCl3) δ




2974,
[M]+
1H), 7.98 (d, J = 5.2 Hz,
175.60, 175.50,




1738,
calcd for
1H), 6.86 (d, J = 5.2 Hz,
170.26, 169.09,




1649,
C23H32N2O10,
1H), 5.22-5.12 (m,
155.46, 148.85,




1529,
496.2057;
2H), 5.10 (ddd, J = 8.2,
140.83, 130.20,




1242,
found,
7.0, 5.4 Hz, 1H),
109.76, 74.87,




1140
496.2063
4.90 (ddd, J = 8.9, 6.5, 2.6 Hz,
74.19, 73.95,






1H), 4.07 (dd, J = 11.9,
73.35, 71.71,






6.9 Hz, 1H), 3.92 (s, 3H),
56.21, 52.03,






3.83 (dd, J = 11.9, 5.2 Hz,
34.08, 33.99,






1H), 3.81-3.72 (m,
19.09, 18.98,






2H), 2.57-2.39 (m, 2H),
18.81, 18.79,






1.33 (d, J = 5.9 Hz, 3H),
18.11






1.15 (d, J = 7.0 Hz, 3H),






1.13 (d, J = 7.0 Hz, 3H),






1.10 (d, J = 7.0 Hz, 3H),






1.09 (d, J = 7.0 Hz, 3H)


57

(Neat)
HRMS-ESI

1H NMR (CDCl3) δ


13C NMR





3374,
(m/z)
8.53 (d, J = 8.0 Hz, 1H),
(CDCl3) δ




2976,
[M]+
8.28 (d, J = 5.4 Hz, 1H),
175.65, 175.57,




1739,
calcd for
6.96 (d, J = 5.4 Hz, 1H),
170.89, 170.41,




1677,
C26H36N2O12,
5.79-5.64 (m, 2H),
163.41, 160.36,




1505,
568.2268;
5.18-5.08 (m, 2H), 4.91 (ddd, J = 9.1,
145.97, 144.12,




1197,
found,
7.0, 2.2 Hz, 1H),
142.10, 109.93,




1141
568.2272
4.07 (dd, J = 11.8, 7.0 Hz,
89.52, 74.66,






1H), 3.91 (s, 3H),
74.26, 74.20,






3.85-3.71 (m, 3H),
73.43, 71.51,






2.57-2.38 (m, 2H), 2.06 (s,
56.36, 52.37,






3H), 1.33 (d, J = 6.0 Hz,
34.12, 34.02,






3H), 1.16 (d, J = 7.0 Hz,
21.01, 19.13,






3H), 1.13 (d, J = 7.0 Hz,
19.01, 18.84,






3H), 1.11 (d, J = 7.0 Hz,
18.82, 18.15






4H), 1.10 (d, J = 7.0 Hz,






3H)


58


ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 442.1
11.92 (s, 1H), 8.56k (d, J = 8.2 Hz,
(CDCl3) δ





([M + H]+)
1H), 8.00 (d, J = 5.2 Hz,
170.33, 168.99,






1H), 6.87 (d, J = 5.2 Hz,
155.38, 148.79,






1H), 5.03 (ddd, J = 8.2,
140.66, 130.30,






6.8, 5.1 Hz, 1H),
109.60, 85.00,






4.99-4.89 (m, 1H), 4.07 (dd, J = 11.9,
83.58, 75.59,






6.8 Hz, 1H),
75.38, 73.96,






3.94 (s, 3H), 3.88-3.76 (m,
73.23, 72.74,






3H), 3.65-3.43 (m, 4H),
56.09, 52.17,






3.26-3.14 (m, 2H),
23.53, 23.30,






1.67-1.53 (m, 4H), 1.46 (d, J = 6.3 Hz,
18.60, 10.65,






3H), 0.92 (td, J = 7.4,
10.62






3.1 Hz, 6H);


59


ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 593.5
11.92 (d, J = 0.7 Hz, 1H),
(CDCl3) δ





([M + H]+)
8.66 (d, J = 8.1 Hz, 1H),
170.29, 168.97,






7.99 (d, J = 5.2 Hz, 1H),
155.36, 148.77,






7.37-7.21 (m, 4H),
141.89, 141.78,






7.21-7.10 (m, 6H), 6.86 (d, J = 5.2 Hz,
140.64, 130.27,






1H),
128.36, 128.34,






5.15-4.89 (m, 2H), 4.05 (dd, J = 11.9,
128.30, 125.83,






6.8 Hz, 1H),
125.81, 109.59,






3.99-3.86 (m, 4H),
85.12, 83.72,






3.85-3.75 (m, 2H), 3.69-3.45 (m,
75.23, 73.98,






4H), 3.27-3.18 (m, 2H),
73.35, 73.10,






2.78-2.56 (m, 4H),
70.15, 56.07,






2.02-1.79 (m, 4H), 1.46 (d, J = 6.3 Hz,
52.16, 32.50,






3H)
32.38, 31.97







31.65, 18.66


60


ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 665.5
8.51 (d, J = 7.9 Hz, 1H),
(CDCl3) δ





([M + H]+)
8.27 (d, J = 5.3 Hz, 1H),
170.94, 170.22,






7.36-7.21 (m, 4H),
163.28, 160.26,






7.21-7.11 (m, 6H), 6.94 (d, J = 5.4 Hz,
145.80, 143.99,






1H),
142.24, 141.94,






5.82-5.65 (m, 2H), 5.06 (ddd, J = 8.0,
141.83, 128.38,






6.8, 5.2 Hz, 1H),
128.35, 128.32,






4.95 (dq, J = 9.0, 6.0 Hz, 1H),
125.83, 125.81,






4.05 (dd, J = 11.8, 6.9 Hz,
109.73, 89.47,






1H), 3.97-3.85 (m,
85.15, 83.79,






4H), 3.85-3.70 (m, 2H),
74.94, 74.18,






3.67-3.54 (m, 3H),
73.37, 72.91,






3.50 (dt, J = 9.2, 6.4 Hz, 1H),
70.13, 56.20,






3.29-3.16 (m, 2H),
52.46, 32.52,






2.74-2.57 (m, 4H), 2.06 (s,
32.40, 32.00,






3H), 1.97-1.78 (m, 4H),
31.67, 20.85,






1.45 (d, J = 6.3 Hz, 3H)
18.69


61


ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 513.2
8.51 (d, J = 7.9 Hz, 1H),
(CDCl3) δ





([M + H]+)
8.28 (d, J = 5.3 Hz, 1H),
170.96, 170.27,






6.95 (d, J = 5.4 Hz, 1H),
163.26, 160.22,






5.83-5.62 (m, 2H),
145.81, 143.96,






5.06 (ddd, J = 8.0, 6.9, 5.2 Hz,
142.14, 109.72,






1H), 5.00-4.82 (m, 1H),
89.44, 84.95,






4.05 (dd, J = 11.8, 6.9 Hz,
83.60, 75.58,






1H), 3.91 (s, 3H),
75.00, 74.07,






3.88-3.72 (m, 3H),
72.99, 72.68,






3.64-3.42 (m, 4H),
56.20, 52.39,






3.26-3.17 (m, 2H), 2.06 (s,
23.51, 23.28,






3H), 1.58 (dddd, J = 10.9,
20.87, 18.59,






7.1, 3.9, 2.2 Hz, 4H),
10.65, 10.63






1.45 (d, J = 6.3 Hz, 3H),






0.92 (td, J = 7.4, 3.8 Hz, 6H)


62
89-91
(Neat)
HRMS-ESI

1H NMR (CDCl3) δ


13C NMR





3365,
(m/z)
11.93 (s, 1H), 8.65 (d, J = 8.1 Hz,
(CDCl3) δ




2931,
[M]+
1H), 7.98 (d, J = 5.2 Hz,
170.45, 169.07,




1751,
calcd for
1H), 6.86 (d, J = 5.2 Hz,
155.45, 148.84,




1646,
C25H40N2O8,
1H), 5.02 (ddd, J = 8.1,
140.78, 130.33,




1529,
496.2785;
6.9, 5.2 Hz, 1H),
109.69, 85.08,




1265,
found,
4.94 (dq, J = 12.5, 6.2 Hz,
83.69, 75.38,




1096
496.2791
1H), 4.04 (dd, J = 11.9,
74.19, 74.00,






6.8 Hz, 1H), 3.93 (s, 3H),
73.31, 71.22,






3.89-3.74 (m, 3H),
56.21, 52.22,






3.65-3.43 (m, 4H),
30.19, 29.93,






3.24-3.15 (m, 2H),
28.49, 28.48,






1.62-1.48 (m, 4H), 1.45 (d, J = 6.3 Hz,
22.73, 22.67,






3H), 1.38-1.21 (m,
18.71, 14.17






8H), 0.94-0.82 (m, 6H)


63
165-167
(Neat)
HRMS-ESI

1H NMR (CDCl3) δ


13C NMR





3365,
(m/z)
11.91 (s, 1H), 8.64 (s, 1H),
(CDCl3) δ




2982,
[M]+
7.98 (d, J = 5.2 Hz, 1H),
170.38, 169.06,




1733,
calcd for
6.86 (d, J = 5.2 Hz, 1H),
155.43, 148.82,




1643,
C17H24N2O8,
5.02 (ddd, J = 8.1, 6.8, 5.1 Hz,
140.78, 130.29,




1535,
384.1533;
1H), 4.94 (dq, J = 8.7, 6.3 Hz,
109.69, 86.83,




1285,
found,
1H), 4.05 (dd, J = 11.9,
85.33, 74.75,




1091
384.1532
6.8 Hz, 1H), 3.92 (s,
74.06, 72.92,






3H), 3.81 (d, J = 11.8 Hz,
61.35, 58.47,






1H), 3.80 (d, J = 11.9 Hz,
56.20, 52.23,






1H), 3.62-3.57 (m, 1H),
18.61






3.55 (s, 3H), 3.44 (s, 3H),






3.16-3.07 (m, 2H),






1.44 (d, J = 6.3 Hz, 3H)


64

(Neat)
HRMS-ESI

1H NMR (CDCl3) δ


13C NMR





3372,
(m/z)
8.52 (d, J = 7.9 Hz, 1H),
(CDCl3) δ




2931,
[M]+
8.28 (d, J = 5.4 Hz, 1H),
171.09, 170.40,




1753,
calcd for
6.94 (d, J = 5.4 Hz, 1H),
163.38, 160.36,




1677,
C28H44N2O10,
5.79-5.67 (m, 2H), 5.05 (td, J = 7.0,
145.94, 144.11,




1505,
568.2996;
5.3 Hz, 1H),
142.28, 109.84,




1201,
found,
4.91 (dq, J = 12.5, 6.2 Hz,
89.59, 85.12,




1096
568.3011
1H), 4.04 (dd, J = 11.8,
83.75, 75.10,






6.9 Hz, 1H), 3.90 (s, 3H),
74.20, 73.12,






3.89-3.72 (m, 3H),
71.21, 56.34,






3.63-3.45 (m, 4H),
52.52, 30.21,






3.23-3.14 (m, 2H), 2.06 (s,
29.95, 28.51,






3H), 1.62-1.49 (m, 4H),
28.50, 22.75,






1.44 (d, J = 6.3 Hz, 3H),
22.68, 21.01,






1.38-1.23 (m, 8H),
18.73, 14.18






0.95-0.81 (m, 6H)


65

(Neat)
HRMS-ESI

1H NMR (CDCl3) δ


13C NMR





3370,
(m/z)
8.51 (d, J = 7.9 Hz, 1H),
(CDCl3) δ




2935,
[M]+
8.26 (d, J = 5.4 Hz, 1H),
171.00, 170.36,




1752,
calcd for
6.94 (d, J = 5.4 Hz, 1H),
163.36, 160.33,




1676,
C20H28N2O10,
5.74-5.68 (m, 2H),
145.92, 144.07,




1506,
456.1744;
5.04 (ddd, J = 7.8, 6.9, 5.3 Hz,
142.20, 109.84,




1203,
found,
1H), 4.91 (dq, J = 8.9, 6.3 Hz,
89.53, 86.86,




1100
456.1752
1H), 4.04 (dd, J = 11.8,
85.39, 74.47,






6.9 Hz, 1H), 3.89 (s,
74.24, 72.72,






3H), 3.83-3.73 (m, 2H),
61.36, 58.45,






3.63-3.56 (m, 1H),
56.31, 52.51,






3.54 (s, 3H), 3.43 (s, 3H),
20.98, 18.61






3.15-3.05 (m, 2H), 2.05 (s,






3H), 1.43 (d, J = 6.3 Hz,






3H)


66

(Neat)
HRMS-ESI

1H NMR (CDCl3) δ


13C NMR





3366,
(m/z)
11.93-11.92 (m, 1H), 8.73 (d,
(CDCl3) δ




2934,
[M]+
J = 8.1 Hz, 1H),
170.26, 169.13,




1725,
calcd for
8.08-8.03 (m, 2H), 8.02 (d, J = 5.2 Hz,
165.59, 155.52,




1649,
C26H32N2O9,
1H),
148.93, 140.82,




1529,
516.2108;
7.61-7.56 (m, 1H), 7.49-7.43 (m,
133.34, 130.35,




1265,
found,
2H), 6.88 (d, J = 5.2 Hz,
129.98, 129.88,




1097 cm−1
516.2108
1H), 5.38-5.30 (m, 1H),
128.58, 109.75,






5.30-5.22 (m, 1H),
81.13, 76.95,






5.13 (ddd, J = 8.1, 6.4, 4.0 Hz,
76.33, 75.03,






1H), 4.16-3.97 (m, 3H),
71.87, 70.95,






3.95 (s, 3H), 3.69 (dd, J = 11.4,
56.25, 52.83,






7.7 Hz, 1H),
31.87, 19.14,






3.54 (dt, J = 9.2, 6.3 Hz, 1H),
18.50, 13.72






3.39 (ddd, J = 8.9, 7.8,






1.4 Hz, 1H), 3.30 (dt, J = 9.2,






6.6 Hz, 1H), 1.42 (d,






J = 6.2 Hz, 3H),






1.32-1.23 (m, 2H),






1.15-0.97 (m, 2H), 0.63 (t, J = 7.4 Hz,






3H)


67


ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 577.7
11.9 (m, 1H), 8.67 (d, J = 8.2 Hz,
(CDCl3) δ





([M + H]+)
1H), 8.00 (d, J = 5.2 Hz,
170.17, 168.97,






1H), 6.88 (d, J = 5.2 Hz,
155.36, 148.75,






1H), 5.15-4.78 (m,
140.70, 130.16,






2H), 4.05 (dd, J = 12.0,
127.2 (q, J = 276 Hz),






6.7 Hz, 1H), 3.94 (s, 3H),
127.1 (q, J = 276 Hz),






3.91-3.75 (m, 3H),
109.61, 85.01,






3.71-3.46 (m, 4H),
83.76, 75.10,






3.29-3.13 (m, 2H),
74.15, 72.71,






2.29-2.06 (m, 4H), 1.89-1.72 (m,
71.92, 68.67,






4H), 1.45 (d, J = 6.3 Hz,
56.09, 52.17,






3H)
30.72 (q, J = 29 Hz),







30.71 (q, J = 29 Hz),







23.0 (q, J = 3 Hz),







22.88 (q, J = 3 Hz),







18.59


68


ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 650.3
8.53 (d, J = 7.9 Hz, 1H),
(CDCl3) δ





([M + H]+)
8.29 (d, J = 5.4 Hz, 1H),
170.82, 170.29,






6.96 (d, J = 5.4 Hz, 1H),
163.29, 160.26,






5.89-5.61 (m, 2H),
145.84, 144.00,






5.06 (ddd, J = 7.9, 6.7, 5.0 Hz,
142.08, 127.1 (q,






1H), 4.94 (ddd, J = 12.3,
J = 275 Hz),






9.0, 6.0 Hz, 1H),
127.0 (q, J = 275 Hz),






4.04 (dd, J = 11.9, 6.8 Hz,
109.78,






1H), 3.91 (s, 3H),
89.42, 85.04,






3.87 (dt, J = 9.0, 6.2 Hz, 1H),
83.82, 74.80,






3.83-3.75 (m, 2H),
74.33, 72.53,






3.68-3.57 (m, 3H),
71.92, 68.65,






3.57-3.48 (m, 1H),
56.22, 52.47,






3.26-3.12 (m, 2H), 2.27-2.09 (m,
30.71, J = 28 Hz),






4H), 2.07 (s, 3H),
30.70 (q, J = 28 Hz),






1.89-1.76 (m, 4H), 1.44 (d, J = 6.3 Hz,
23.02 (q, J = 3 Hz),






3H)
22.79 (q, J = 3 Hz),







20.87,







18.62


69

(Neat)
HRMS-ESI

1H NMR (CDCl3) δ


13C NMR





3372,
(m/z)
8.59 (d, J = 7.8 Hz, 1H),
(CDCl3) δ




2934,
[M]+
8.28 (d, J = 5.3 Hz, 1H),
170.84, 170.37,




1725,
calcd for
8.09-8.00 (m, 2H),
165.54, 163.39,




1676,
C29H36N2O11,
7.60-7.54 (m, 1H),
160.35, 145.92,




1505,
588.2319;
7.48-7.41 (m, 2H), 6.95 (d, J = 5.4 Hz,
144.14, 142.17,




1266,
found,
1H), 5.77-5.69 (m,
133.26, 129.98,




1145
588.2329
2H), 5.30-5.21 (m, 2H),
129.82, 128.51,






5.14 (ddd, J = 7.8, 6.6,
109.87, 89.53,






4.2 Hz, 1H), 4.07 (dd, J = 11.9,
81.15, 76.94,






6.5 Hz, 1H),
75.92, 75.12,






4.02 (dd, J = 11.2, 1.1 Hz,
71.59, 70.83,






1H), 3.94 (dd, J = 11.8,
56.32, 53.04,






4.2 Hz, 1H), 3.90 (s, 3H),
31.83, 20.97,






3.68 (dd, J = 11.3, 7.8 Hz,
19.09, 18.45,






1H), 3.52 (dt, J = 9.2,
13.66






6.3 Hz, 1H),






3.39-3.34 (m, 1H), 3.28 (dt, J = 9.2,






6.6 Hz, 1H), 2.06 (s, 3H),






1.40 (d, J = 6.0 Hz, 3H),






1.31-1.17 (m, 2H),






1.16-0.94 (m, 2H), 0.60 (t, J = 7.4 Hz,






3H)


70


ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 413
11.95 (d, J = 0.6 Hz, 1H),
(CDCl3) δ





([M + H]+)
8.80 (d, J = 7.9 Hz, 1H),
169.47, 168.98,






8.01 (d, J = 5.2 Hz, 1H),
155.31, 148.71,






6.88 (dd, J = 5.3, 0.7 Hz, 1H),
140.69, 130.26,






5.15 (dq, J = 9.3, 6.3 Hz,
109.56, 82.64,






1H), 5.02 (ddd, J = 7.9,
77.56, 77.14,






5.6, 2.2 Hz, 1H),
76.90, 76.46,






4.21-4.07 (m, 2H),
73.57, 56.08,






4.01-3.90 (m, 4H), 3.52-3.37 (m,
53.47, 28.59,






3H), 3.28-3.16 (m, 2H),
19.31, 19.26,






3.11 (ddd, J = 9.1, 7.3,
18.73






1.1 Hz, 1H), 1.85 (dp, J = 13.3,






6.7 Hz, 1H),






1.49 (d, J = 6.3 Hz, 3H),






0.91 (dd, J = 6.7, 3.9 Hz, 6H)


71
138-140
(Neat)
HRMS-ESI

1H NMR (CDCl3) δ


13C NMR





3370,
(m/z)
11.98 (s, 1H), 8.73 (d, J = 8.0 Hz,
(CDCl3) δ




2926,
[M]+
1H), 8.01 (d, J = 5.2 Hz,
170.17, 169.09,




1750,
calcd for
1H), 6.87 (d, J = 5.2 Hz,
155.47, 148.89,




1650,
C24H38N2O8,
1H), 5.08 (dq, J = 9.1,
140.79, 130.47,




1529,
482.2628;
6.3 Hz, 1H),
109.68, 85.26,




1243,
found,
5.00 (ddd, J = 8.1, 6.1, 3.8 Hz,
81.29, 81.18,




1085
482.2631
1H), 4.00 (dd, J = 12.1,
77.82, 75.32,






6.1 Hz, 1H), 3.94 (s, 3H),
75.19, 73.37,






3.95-3.89 (m, 2H),
56.23, 53.07,






3.79 (dd, J = 8.6, 5.6 Hz, 1H),
35.01, 29.10,






3.56-3.45 (m, 2H),
25.16, 25.08,






3.07 (dt, J = 12.6, 8.4 Hz, 2H),
19.95, 19.60,






1.90-1.78 (m, 1H),
18.97, 9.06






1.56-1.43 (m, 2H), 1.45 (d, J = 6.4 Hz,






3H), 1.15 (s,






3H), 1.14 (s, 3H), 0.93 (d,






J = 6.6 Hz, 3H),






0.91-0.85 (m, 6H)


72
121-124

ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 413.1
11.92 (d, J = 0.7 Hz, 1H),
(CDCl3) δ





([M + H]+)
8.75 (d, J = 8.2 Hz, 1H),
169.65, 168.98,






7.98 (d, J = 5.2 Hz, 1H),
155.31, 148.70,






6.86 (d, J = 5.2 Hz, 1H),
140.69, 130.23,






5.12 (dq, J = 9.4, 6.4 Hz, 1H),
109.57, 86.44,






5.01 (ddd, J = 8.2, 5.4,
80.31, 79.27,






3.5 Hz, 1H), 4.12 (d, J = 11.0 Hz,
75.77, 74.17,






1H),
72.70, 56.07,






4.07-3.97 (m, 2H), 3.94 (s, 3H),
53.09, 29.04,






3.60-3.48 (m, 2H),
19.31, 19.21,






3.47-3.43 (m, 2H), 3.14 (dd,
18.68






J = 9.4, 8.4 Hz, 1H),






2.02-1.81 (m, 2H), 1.47 (d, J = 6.4 Hz,






3H), 0.97 (dd, J = 6.7,






4.0 Hz, 6H)


73
122-125

ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 495.6
12.17-11.64 (m, 1H), 8.67 (d,
(CDCl3) δ





([M + H]+)
J = 8.2 Hz, 1H), 8.00 (d,
170.33, 168.94,






J = 5.2 Hz, 1H), 6.87 (d,
155.33, 148.73,






J = 5.2 Hz, 1H),
140.65, 130.24,






5.04 (ddd, J = 8.2, 6.8, 4.9 Hz,
109.56, 84.91,






1H), 4.96 (dq, J = 9.3, 6.3 Hz,
80.88, 80.42,






1H), 4.04 (dd, J = 11.9,
78.13, 73.88,






6.9 Hz, 1H), 3.94 (s,
73.35, 56.09,






3H), 3.88-3.71 (m, 3H),
52.15, 33.29,






3.60 (dd, J = 10.9, 7.2 Hz,
32.39, 29.13,






1H), 3.48-3.31 (m,
25.73, 24.39,






2H), 3.26-3.11 (m, 2H),
24.32, 19.64,






2.08-1.67 (m, 5H),
19.41, 18.67






1.59-1.49 (m, 1H), 1.46 (d, J = 6.3 Hz,






3H),






1.36-1.09 (m, 5H), 0.91 (dd, J = 13.5,






6.7 Hz, 6H)


74


ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 461.9
11.96 (d, J = 0.7 Hz, 1H),
(CDCl3) δ





([M + Na]+)
8.80 (d, J = 7.8 Hz, 1H),
169.53, 168.98,






8.01 (d, J = 5.2 Hz, 1H),
155.33, 148.73,






6.88 (d, J = 5.2 Hz, 1H),
140.69, 130.28,






5.15 (dq, J = 9.2, 6.3 Hz, 1H),
109.56, 80.02,






5.02 (ddd, J = 7.9, 5.6,
79.09, 76.79,






2.2 Hz, 1H),
76.45, 73.62,






4.20-4.00 (m, 2H), 4.00-3.89 (m,
56.09, 53.50,






3H), 3.56-3.33 (m, 3H),
33.59, 31.75,






3.33-3.21 (m, 1H),
25.49, 24.29,






1.96 (d, J = 10.8 Hz, 1H),
24.12, 18.80






1.90-1.79 (m, 1H), 1.73 (dd,






J = 9.2, 4.0 Hz, 2H),






1.59-1.52 (m, 1H), 1.49 (d, J = 6.3 Hz,






3H),






1.38-1.09 (m, 5H)


75


ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 495.6
11.94 (d, J = 0.6 Hz, 1H),
(CDCl3) δ





([M + H]+)
8.67 (d, J = 8.1 Hz, 1H),
170.30, 168.95,






8.00 (d, J = 5.2 Hz, 1H),
155.32, 148.72,






6.87 (dd, J = 5.2, 0.7 Hz, 1H),
140.66, 130.24,






5.02 (ddd, J = 8.2, 6.7,
109.56, 84.40,






4.9 Hz, 1H), 4.94 (dq, J = 9.4,
80.64, 79.54,






6.4 Hz, 1H),
77.53, 75.43,






4.07 (dd, J = 11.9, 6.7 Hz,
74.08, 73.48,






1H), 3.94 (s, 3H),
56.08, 52.21,






3.87-3.76 (m, 2H), 3.64 (dd, J = 11.3,
33.57, 32.56,






6.5 Hz, 2H),
28.90, 25.72,






3.43 (dd, J = 9.4, 8.4 Hz, 1H),
24.74, 24.57,






3.37-3.25 (m, 2H),
19.50, 19.43,






3.19 (ddd, J = 8.2, 6.5, 1.3 Hz,
18.90






1H), 2.05-1.90 (m, 2H),






1.89-1.68 (m, 3H),






1.56 (d, J = 9.6 Hz, 1H),






1.45 (d, J = 6.4 Hz, 3H),






1.33-1.09 (m, 5H), 0.91 (dd,






J = 6.7, 3.7 Hz, 6H)


76


ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 567.8
8.53 (d, J = 7.9 Hz, 1H),
(CDCl3) δ





([M + H]+)
8.28 (d, J = 5.4 Hz, 1H),
170.96, 170.27,






6.95 (d, J = 5.4 Hz, 1H),
163.25, 160.22,






5.93-5.60 (m, 2H),
145.80, 143.96,






5.20-4.99 (m, 1H), 4.92 (dq, J = 9.5,
142.16, 109.70,






6.3 Hz, 1H),
89.45, 84.90,






4.03 (dd, J = 11.8, 7.0 Hz,
80.87, 80.48,






1H), 3.91 (s, 3H),
78.08, 76.45,






3.85-3.73 (m, 3H), 3.59 (dd, J = 10.9,
74.05, 73.15,






7.3 Hz, 1H),
56.19, 52.41,






3.48-3.30 (m, 2H),
33.30, 32.39,






3.26-3.09 (m, 2H), 2.07 (s,
29.13, 25.73,






3H), 2.01-1.87 (m, 2H),
24.40, 24.33,






1.87-1.77 (m, 1H),
20.87, 19.65,






1.77-1.68 (m, 2H),
19.41, 18.67






1.60-1.48 (m, 1H), 1.44 (d, J = 6.3 Hz,






3H),






1.35-1.13 (m, 5H), 0.91 (dd, J = 13.5,






6.7 Hz, 6H)


77


ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 568.4
8.53 (d, J = 7.9 Hz, 1H),
(CDCl3) δ





([M + H]+)
8.28 (d, J = 5.4 Hz, 1H),
170.91, 170.27,






6.95 (d, J = 5.4 Hz, 1H),
163.25, 160.21,






5.84-5.49 (m, 2H),
145.80, 143.94,






5.05 (ddd, J = 8.0, 6.8, 5.1 Hz,
142.16, 109.70,






1H), 4.91 (dq, J = 9.4, 6.4 Hz,
89.44, 84.45,






1H), 4.06 (dd, J = 11.9,
80.66, 79.54,






6.8 Hz, 1H), 3.91 (s,
77.51, 75.15,






3H), 3.78 (ddd, J = 11.9,
74.27, 73.25,






3.5, 2.1 Hz, 2H),
56.19, 52.49,






3.69-3.58 (m, 2H), 3.42 (dd, J = 9.5,
33.58, 32.58,






8.5 Hz, 1H),
28.90, 25.72,






3.36-3.25 (m, 2H), 3.17 (ddd, J = 8.3,
24.75, 24.57,






6.6, 1.3 Hz, 1H),
20.87, 19.49,






2.07 (s, 3H),
19.42, 18.91






2.04-1.90 (m, 2H), 1.88-1.69 (m,






3H), 1.56 (d, J = 10.4 Hz,






1H), 1.44 (d, J = 6.4 Hz,






3H), 1.29-1.09 (m, 5H),






0.90 (dd, J = 6.7, 3.6 Hz,






6H)


78

(Neat)
HRMS-ESI

1H NMR (CDCl3) δ


13C NMR





3377,
(m/z)
8.58 (d, J = 7.8 Hz, 1H),
(CDCl3) δ




2967,
[M]+
8.28 (d, J = 5.4 Hz, 1H),
170.77, 170.39,




1755,
calcd for
6.94 (d, J = 5.4 Hz, 1H),
163.38, 160.33,




1679,
C27H42N2O10,
5.75-5.68 (m, 2H),
145.94, 144.05,




1506,
554.2839;
5.10-4.95 (m, 2H), 3.98 (dd, J = 12.0,
142.39, 109.79,




1203,
found,
6.3 Hz, 1H),
89.58, 85.21,




1085
554.2837
3.90 (s, 3H), 3.90-3.85 (m,
81.16, 80.92,






2H), 3.78 (dd, J = 8.5, 5.6 Hz,
77.73, 75.35,






1H), 3.55-3.43 (m,
73.14, 56.31,






2H), 3.06 (dt, J = 14.7,
53.28, 35.00,






8.5 Hz, 2H), 2.05 (s, 3H),
29.07, 25.14,






1.90-1.76 (m, 1H),
25.04, 20.99,






1.55-1.44 (m, 2H), 1.43 (d, J = 6.4 Hz,
19.92, 19.57,






3H), 1.14 (s,
18.95, 9.03






3H), 1.12 (s, 3H), 0.92 (d,






J = 6.6 Hz, 3H),






0.90-0.83 (m, 6H)


79


ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 506.2
11.87 (d, J = 0.6 Hz, 1H),
(CDCl3) δ





([M + Na]+)
8.60-8.37 (m, 1H), 7.84 (d, J = 5.2 Hz,
169.91, 168.23,






1H), 6.71 (d, J = 5.3 Hz,
154.59, 148.00,






1H),
139.96, 139.86,






5.04-4.94 (m, 1H), 4.81 (dt, J = 8.2,
129.67, 108.79,






5.7 Hz, 1H),
82.49, 76.93,






4.07 (dd, J = 11.5, 5.9 Hz,
76.89, 75.23,






1H), 3.79 (s, 3H),
74.93, 72.99,






3.72-3.62 (m, 2H),
55.36, 51.90,






3.61-3.52 (m, 2H), 3.21-3.08 (m,
34.51, 28.01,






2H), 3.08-3.00 (m, 1H),
24.72, 24.67,






1.83-1.61 (m, 1H),
18.88, 18.77,






1.38 (qd, J = 7.4, 2.3 Hz, 2H),
18.15, 8.21






1.30 (d, J = 6.7 Hz, 3H),






1.01 (d, J = 4.9 Hz, 5H),






0.82-0.71 (m, 10H)


80


ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 556.4
8.38 (d, J = 7.9 Hz, 1H),
(CDCl3) δ





([M + H]+)
8.13 (d, J = 5.4 Hz, 1H),
171.21, 170.30,






6.80 (d, J = 5.4 Hz, 1H),
163.21, 160.21,






5.68-5.47 (m, 2H), 4.94 (t, J = 6.7 Hz,
145.81, 145.74,






1H), 4.84 (dt, J = 7.9,
143.94, 109.63,






5.8 Hz, 1H),
89.48, 83.23,






4.05 (dd, J = 11.5, 6.0 Hz,
77.59, 77.57,






1H), 3.84-3.71 (m, 3H),
75.84, 75.56,






3.72-3.58 (m, 2H),
74.09, 73.99,






3.58-3.49 (m, 1H),
56.17, 52.90,






3.25-3.06 (m, 2H),
35.30, 28.71,






3.06-2.97 (m, 1H), 1.92 (s, 3H),
25.49, 25.45,






1.70 (tt, J = 13.5, 6.7 Hz,
20.88, 19.61,






1H), 1.38 (qd, J = 7.5, 4.8 Hz,
19.47, 18.94,






2H), 1.29 (d, J = 6.8 Hz,
8.92






3H), 1.01 (d, J = 3.8 Hz,






6H), 0.83-0.67 (m,






10H)


81


ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 532.2
11.92 (s, 1H), 8.76 (d, J = 8.1 Hz,
(CDCl3) δ





([M + Na+)
1H), 8.02 (d, J = 5.2 Hz,
170.04, 169.04,






1H), 7.43-7.08 (m,
159.45, 157.21,






5H), 7.08-6.80 (m, 5H),
155.39, 148.79,






6.73 (dt, J = 7.8, 1.1 Hz,
140.77, 130.15,






2H), 5.56-5.24 (m, 1H),
129.49, 129.31,






5.16 (ddd, J = 8.1, 6.6,
121.62, 121.38,






4.5 Hz, 1H),
116.49, 115.59,






4.70-4.46 (m, 1H), 4.38 (ddd, J = 8.7,
109.68, 82.87,






7.2, 1.3 Hz, 1H),
80.51, 75.06,






4.17-4.03 (m, 1H),
74.46, 72.54,






4.02-3.95 (m, 1H), 3.93 (s,
56.11, 52.37,






3H), 3.83 (dd, J = 11.3,
18.88






7.2 Hz, 1H), 1.50 (d, J = 6.3 Hz,






3H)


82
117-119

ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 489.4
12.13-11.57 (m, 1H), 8.69 (d,
(CDCl3) δ





([M + H]+)
J = 8.2 Hz, 1H), 8.00 (d,
170.37, 168.98,






J = 5.2 Hz, 1H),
159.41, 155.35,






7.41-7.11 (m, 2H),
148.74, 140.70,






7.06-6.97 (m, 2H), 6.97-6.90 (m,
130.16, 129.24,






1H), 6.87 (d, J = 5.2 Hz,
121.20, 116.06,






1H), 5.19 (dq, J = 9.4, 6.3 Hz,
109.62, 83.01,






1H), 5.10 (ddd, J = 8.2,
82.67, 78.15,






6.9, 5.2 Hz, 1H),
74.80, 73.81,






4.31 (t, J = 9.1 Hz, 1H),
72.86, 56.09,






4.11 (dd, J = 11.9, 6.9 Hz,
52.05, 28.60,






1H), 3.94 (s, 3H), 3.91 (d,
19.19, 19.07,






J = 1.6 Hz, 1H), 3.86 (dd,
18.74






J = 11.8, 5.2 Hz, 1H),






3.74 (dd, J = 11.1, 7.3 Hz,






1H), 3.40 (ddd, J = 8.7,






7.2, 1.6 Hz, 1H),






3.34-3.24 (m, 1H), 3.19 (dd,






J = 8.9, 6.4 Hz, 1H),






1.59 (dp, J = 13.3, 6.6 Hz,






1H), 1.41 (d, J = 6.4 Hz,






3H), 0.70 (d, J = 6.7 Hz,






3H), 0.65 (d, J = 6.7 Hz,






3H)


83
112-113

ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 489.8
11.94 (d, J = 0.6 Hz, 1H),
(CDCl3) δ





([M + H]+)
8.73 (d, J = 8.1 Hz, 1H),
170.07, 168.99,






8.01 (d, J = 5.2 Hz, 1H),
157.34, 155.35,






7.41-7.15 (m, 2H),
148.75, 140.72,






7.06-6.62 (m, 4H),
130.18, 129.55,






5.27-4.89 (m, 2H), 4.23 (ddd, J = 8.5,
121.16, 115.58,






7.1, 1.3 Hz, 1H),
109.62, 84.42,






4.05 (dd, J = 12.0, 6.7 Hz,
81.11, 80.64,






1H), 3.99-3.86 (m, 5H),
75.35, 74.34,






3.76-3.62 (m, 2H),
72.87, 56.09,






3.45 (dd, J = 9.5, 8.7 Hz, 1H),
52.35, 28.98,






3.33 (dd, J = 8.4, 6.5 Hz,
19.41, 19.34,






1H), 1.73 (tt, J = 13.2, 6.8 Hz,
18.72






1H), 1.51 (d, J = 6.3 Hz,






3H), 0.84 (d, J = 6.7 Hz,






3H), 0.80 (d, J = 6.7 Hz,






3H)


84


ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 581.4
8.62 (d, J = 7.9 Hz, 1H),
(CDCl3) δ





([M + H]+)
8.32 (d, J = 5.4 Hz, 1H),
170.64, 170.29,






7.35-7.13 (m, 5H),
163.34, 160.26,






7.09-6.85 (m, 5H), 6.73 (dt, J = 7.8,
159.48, 157.25,






1.0 Hz, 2H),
145.87, 144.01,






5.85-5.69 (m, 2H),
142.08, 129.45,






5.41-5.24 (m, 1H), 5.18 (ddd, J = 7.8,
129.28, 121.55,






6.7, 4.6 Hz, 1H),
121.32, 116.48,






4.51 (t, J = 9.1 Hz, 1H),
115.59, 109.80,






4.37 (ddd, J = 8.7, 7.4, 1.3 Hz,
89.41, 82.88,






1H), 4.17-4.02 (m, 1H),
80.58, 74.71,






3.98-3.90 (m, 4H),
74.63, 72.36,






3.83 (dd, J = 11.2, 7.3 Hz,
56.23, 52.62,






1H), 2.08 (s, 3H), 1.49 (d,
20.88, 18.88






J = 6.3 Hz, 3H)


85


ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 561.1
8.55 (d, J = 7.9 Hz, 1H),
(CDCl3) δ





([M + H]+)
8.29 (d, J = 5.3 Hz, 1H),
170.98, 170.29,






7.29-7.21 (m, 2H),
163.28, 160.24,






7.03-6.90 (m, 4H),
159.45, 145.82,






5.83-5.66 (m, 2H), 5.21-5.04 (m,
143.99, 142.09,






2H), 4.30 (dd, J = 9.5, 8.7 Hz,
129.23, 121.14,






1H), 4.10 (dd, J = 11.9,
116.06, 109.76,






7.0 Hz, 1H),
89.42, 83.04,






3.95-3.88 (m, 4H), 3.82 (dd, J = 11.8,
82.72, 78.14,






5.3 Hz, 1H),
74.56, 74.03,






3.73 (dd, J = 11.0, 7.4 Hz,
72.67, 56.21,






1H), 3.38 (ddd, J = 8.8,
52.35, 28.60,






7.4, 1.6 Hz, 1H),
20.88, 19.19,






3.33-3.24 (m, 1H),
19.07, 18.76






3.24-3.13 (m, 1H), 2.07 (s, 3H),






1.58 (dp, J = 13.3, 6.6 Hz,






1H), 1.40 (d, J = 6.3 Hz,






3H), 0.70 (d, J = 6.7 Hz,






3H), 0.64 (d, J = 6.6 Hz,






3H)


86


ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 562.4
8.58 (d, J = 7.9 Hz, 1H),
(CDCl3) δ





([M + H]+)
8.30 (d, J = 5.4 Hz, 1H),
170.69, 170.28,






7.37-7.09 (m, 2H),
163.30, 160.23,






7.04-6.80 (m, 4H),
157.39, 145.85,






5.87-5.66 (m, 2H), 5.22-4.95 (m,
143.96, 142.14,






2H), 4.22 (ddd, J = 8.6,
129.52, 121.10,






7.2, 1.3 Hz, 1H),
115.60, 109.75,






4.04 (dd, J = 12.0, 6.8 Hz
89.42, 84.43,






1H), 4.00-3.82 (m, 5H),
81.18, 80.62,






3.78-3.63 (m, 2H),
74.99, 74.52,






3.44 (dd, J = 9.6, 8.7 Hz, 1H),
72.69, 56.21,






3.32 (dd, J = 8.4, 6.5 Hz,
52.61, 28.99,






1H), 2.07 (s, 3H),
20.87, 19.41,






1.84-1.67 (m, 1H), 1.50 (d, J = 6.3 Hz,
19.34, 18.72






3H), 0.83 (d, J = 6.7 Hz,






3H), 0.79 (d, J = 6.7 Hz,






3H)


87
115-117
(Neat)
HRMS-ESI

1H NMR (CDCl3) δ


13C NMR





3364,
(m/z)
11.92 (s, 1H), 8.67 (d, J = 8.1 Hz,
(CDCl3) δ




2932,
[M]+
1H), 8.02-7.98 (m,
170.36, 169.10,




1751,
calcd for
1H), 6.87 (d, J = 5.2 Hz,
155.50, 148.89,




1650,
C23H35ClN2O8,
1H), 5.08-4.99 (m, 2H),
140.81, 130.36,




1529,
502.2082;
4.05 (dd, J = 11.9, 6.8 Hz,
109.73, 84.87,




1244,
found,
1H), 4.00 (d, J = 9.3 Hz,
83.89, 82.38,




1094
502.2090
1H), 3.94 (s, 3H),
75.30, 74.18,






3.82 (dt, J = 10.7, 5.4 Hz,
73.05, 70.57,






2H), 3.66-3.45 (m, 4H),
68.04, 56.24,






3.32-3.23 (m, 2H),
52.31, 32.34,






1.58 (s, 3H), 1.56 (s, 3H),
29.65, 29.51,






1.57-1.50 (m, 2H), 1.50 (d, J = 6.3 Hz,
19.51, 18.97,






3H),
14.08






1.41-1.29 (m, 2H), 0.91 (t, J = 7.3 Hz,






3H)


88
108-110
3288,
ESIMS

1H NMR (CDCl3) δ


13C NMR





2925,
m/z 462.3
7.41-7.27 (m, 5H), 5.60 (d, J = 7.5 Hz,
(CDCl3) δ




2879,
([M + H]+)
1H), 5.10 (s,
171.00, 155.85,




1752,

2H), 4.98-4.88 (m, 3H),
142.43, 142.12,




1689,

4.88-4.81 (m, 2H),
136.25, 128.69,




1555,

4.74-4.64 (m, 1H), 4.33 (d, J = 11.8 Hz,
128.36, 128.23,




1330,

1H), 3.96 (s,
112.41, 112.00,




1197

2H), 3.95-3.80 (m, 4H),
83.44, 83.36,






3.53 (dd, J = 11.9, 6.0 Hz,
75.92, 74.66,






1H), 3.38-3.25 (m,
67.24, 54.84,






2H), 2.07-1.95 (m, 1H),
25.32, 19.91,






1.72 (d, J = 4.7 Hz, 6H),
19.78, 9.61






1.72-1.61 (m, 1H),






0.96 (t, J = 7.4 Hz, 3H)


89

(Neat)
HRMS-ESI

1H NMR (CDCl3) δ


13C NMR





2961,
(m/z)
7.39-7.27 (m, 5H), 5.76 (d, J = 7.3 Hz,
(CDCl3) δ




2926,
[M]+
1H), 5.10 (s,
170.52, 155.96,




1755,
calcd for
2H), 4.99-4.87 (m, 5H),
142.22, 141.86,




1721,
C26H37NO7,
4.74-4.67 (m, 1H),
136.45, 128.63,




1504,
475.2570;
4.19-3.74 (m, 8H), 3.68 (d, J = 12.7 Hz,
128.23, 128.17,




1455,
found,
1H), 3.50 (dd,
113.42, 112.76,




1334,
475.2593
J = 6.3, 4.6 Hz, 1H),
79.45, 77.69,




1244,

2.27-2.12 (m, 1H), 1.76 (s,
76.73, 75.73,




1200,

3H), 1.72 (s, 3H), 1.01 (d,
74.84, 73.31,




1062

J = 6.7 Hz, 3H), 0.98 (d,
70.03, 67.03,






J = 6.7 Hz, 3H)
55.78, 28.68,







19.83, 19.73,







19.63, 19.60


90

(Neat)
ESIMS

1H NMR (CDCl3) δ


13C NMR





3320,
m/z 462.2
7.41-7.26 (m, 5H), 5.74 (d, J = 7.5 Hz,
(CDCl3) δ




2969,
([M + H]+)
1H), 5.10 (s,
170.76, 155.95,




2935,

2H), 5.10-5.03 (m, 1H),
142.30, 142.06,




1754,

4.96 (dd, J = 7.9, 0.8 Hz,
136.40, 128.66,




1722,

2H), 4.89 (d, J = 7.8 Hz,
128.27, 128.15,




1506,

2H), 4.72 (t, J = 6.0 Hz,
113.07, 112.78,




1455,

1H), 4.67-4.63 (m, 1H),
78.09, 76.25,




1200

4.08-3.79 (m, 7H),
75.88, 73.94,






3.78-3.67 (m, 2H), 3.62 (d, J = 12.1 Hz,
71.73, 67.09,






1H),
55.51, 22.72,






3.45 (ddd, J = 6.9, 3.9, 1.4 Hz,
19.76, 19.67,






1H), 1.74 (s, 3H), 1.72 (s,
10.73






3H), 1.00 (t, J = 7.4 Hz,






3H)


91


ESIMS

1H NMR (CDCl3) δ






m/z 462.2
7.42-7.28 (m, 5H),





([M + H]+)
5.52-5.37 (m, 1H), 5.11 (s,






2H), 5.01 (ddd, J = 9.2,






4.8, 2.8 Hz, 1H),






4.98-4.93 (m, 2H), 4.88 (s,






2H), 4.53 (bs, 1H),






4.16-4.09 (m, 1H), 4.04 (d, J = 21.7 Hz,






1H), 4.01 (d, J = 22.0 Hz,






1H), 3.93 (dd, J = 12.2,






3.3 Hz, 2H),






3.87 (dd, J = 11.7, 4.1 Hz,






1H), 3.76 (dd, J = 11.8,






1.7 Hz, 1H), 3.70 (dd, J = 6.4,






2.7 Hz, 1H),






3.55-3.45 (m, 2H),






1.86-1.74 (m, 2H), 1.74 (s, 3H),






1.72 (s, 3H), 0.98 (t, J = 7.4 Hz,






3H)


92


ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 484.3
7.42-7.19 (m, 10H),
(CDCl3) δ





([M − H])
5.31-5.19 (m, 1H),
169.03, 154.68,






5.18-5.02 (m, 1H), 4.67 (dd, J = 16.0,
138.23, 138.17,






11.7 Hz, 2H),
128.54, 128.53,






4.60-4.52 (m, 1H),
128.12, 128.00,






4.51-4.40 (m, 1H), 4.18-4.08 (m,
127.97, 127.85,






2H), 3.92 (dd, J = 11.7,
77.97, 74.40,






3.9 Hz, 1H),
73.44, 72.31,






3.85-3.75 (m, 2H), 3.59-3.53 (m,
72.14, 71.61,






1H), 3.43 (dd, J = 11.5,
28.43, 15.64






5.5 Hz, 1H), 1.44 (s, 9H),






1.36 (d, J = 6.8 Hz, 3H)


93
69-71
(Neat)
ESIMS

1H NMR (CDCl3) δ


13C NMR





3349,
m/z 508.6
7.38-7.19 (m, 11H),
(CDCl3) δ




2978,
([M + Na]+)
5.38-5.20 (d, J = 7.9 Hz, 1H),
171.24, 155.11,




2933,

5.08-4.96 (dq, J = 8.2,
138.11, 137.93,




2876,

6.1 Hz, 1H),
128.40, 128.38,




1753,

4.96-4.88 (d, J = 10.8 Hz, 1H),
127.94, 127.86,




1710,

4.76-4.48 (m, 3H),
127.74, 84.76,




1497,

4.02-3.85 (dd, J = 11.8, 6.3 Hz,
83.57, 80.17,




1367,

2H), 3.77-3.55 (m,
75.79, 75.50,




1249,

2H), 3.52-3.34 (m, 2H),
74.90, 72.94,




1161,

1.48-1.36 (s, 12H)
72.70, 53.72,




1074,


28.28, 18.69




734,




697


94


ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 509.2
6.02-5.78 (m, 2H),
(CDCl3) δ





([M + Na]+)
5.30-5.10 (m, 5H), 4.81 (dq, J = 9.5,
169.00, 152.64,






6.3 Hz, 1H),
134.93, 134.80,






4.38 (ddd, J = 12.2, 5.5, 1.4 Hz,
116.95, 116.78,






1H), 4.24 (dd, J = 12.1,
84.63, 83.06,






4.1 Hz, 1H),
82.84, 75.93,






4.17-4.02 (m, 3H),
74.68, 72.85,






3.95-3.81 (m, 2H), 3.54 (dd, J = 10.9,
72.62, 71.85,






7.2 Hz, 1H),
57.94, 27.97,






3.41-3.21 (m, 2H), 1.50 (s,
18.74






18H), 1.42 (d, J = 6.3 Hz,






3H)


95

(Neat)
HRMS-ESI

1H NMR (CDCl3) δ


13C NMR





3440,
(m/z)
9.64 (s, 1H), 9.61 (s, 1H),
(CDCl3) δ




2980,
[M]+
5.22 (dd, J = 8.8, 3.8 Hz, 1H),
199.32, 198.53,




2935,
calcd for
4.97-4.86 (m, 1H),
168.72, 152.76,




1740,
C22H35NO11,
4.51 (d, J = 18.0 Hz, 1H),
86.24, 84.89,




1705,
489.2210;
4.34 (d, J = 18.1 Hz, 1H),
83.33, 79.40,




1367,
found,
4.29-4.19 (m, 2H), 3.91 (dd,
76.11, 75.14,




1253,
489.2210
J = 11.7, 8.1 Hz, 3H),
73.28, 72.00,




1120

3.58 (dd, J = 11.4, 7.1 Hz,
58.01, 28.09,






1H), 3.49-3.42 (m,
18.91






1H), 3.40-3.33 (m, 1H),






1.49 (s, 18H), 1.47 (d, J = 6.3 Hz,






3H)


96

(Neat)
HRMS-ESI

1H NMR (CDCl3) δ





2982,
(m/z)
6.01-5.66 (m, 2H), 5.24 (dd,




2938,
[M]+
J = 8.9, 3.7 Hz, 1H),




1743,
calcd for
4.84 (dq, J = 9.5, 6.3 Hz, 1H),




1705,
C22H35F4NO9,
4.27 (dd, J = 12.3, 3.7 Hz,




1367,
533.2248;
1H), 4.13-3.98 (m,




1246,
found,
1H), 3.96-3.87 (m, 2H),




1104
533.2252
3.86-3.67 (m, 3H),






3.55 (dd, J = 11.3, 7.3 Hz,






1H), 3.42-3.35 (m, 1H),






3.29 (t, J = 9.2 Hz, 1H),






1.50 (s, 18H), 1.44 (d, J = 6.3 Hz,






3H)


97

(Neat)
HRMS-ESI

1H NMR (CDCl3) δ


13C NMR





3351,
(m/z)
5.79-5.66 (m, 2H),
(CDCl3) δ




2978,
[M]+
5.60-5.48 (m, 2H), 5.20 (dd, J = 8.9,
169.19, 152.75,




2934,
calcd for
4.2 Hz, 1H),
129.10, 128.51,




1745,
C28H47NO9,
4.78 (dq, J = 9.4, 6.3 Hz, 1H),
125.64, 125.50,




1707,
541.3251;
4.31 (ddd, J = 11.1, 6.2,
84.48, 83.15,




1367,
found,
0.8 Hz, 1H), 4.22 (dd, J = 12.1,
82.72, 76.04,




1252,
541.3244
4.2 Hz, 1H),
74.65, 72.86,




1121

4.16-3.98 (m, 3H), 3.89 (dd, J = 12.1,
71.92, 58.03,






8.9 Hz, 1H),
28.08, 25.38,






3.83 (d, J = 10.9 Hz, 1H),
18.90, 13.42,






3.52 (dd, J = 10.9, 7.2 Hz,
13.39






1H), 3.35-3.28 (m, 1H),






3.24 (t, J = 9.0 Hz, 1H),






2.12-1.99 (m, 4H),






1.49 (s, 18H), 1.41 (d, J = 6.3 Hz,






3H), 1.02-0.95 (m,






6H)


98

(Neat)
HRMS-ESI

1H NMR (CDCl3) δ


13C NMR





2933,
(m/z)
5.20 (dd, J = 9.0, 4.1 Hz, 1H),
(CDCl3) δ




1766,
[M]+
4.76 (dq, J = 9.3, 6.3 Hz,
169.20, 152.76,




1710,
calcd for
1H), 4.22 (dd, J = 12.1,
85.05, 83.54,




1367,
C28H51NO9,
4.1 Hz, 1H),
83.14, 75.89,




1256,
545.3564;
3.93-3.76 (m, 3H), 3.60-3.43 (m,
74.07, 72.91,




1148,
found,
4H), 3.24-3.11 (m, 2H),
72.84, 71.11,




1122
545.3568
1.60-1.48 (m, 4H),
58.01, 30.21,






1.49 (s, 18H), 1.40 (d, J = 6.3 Hz,
29.97, 28.50,






3H), 1.37-1.21 (m,
28.07, 22.73,






8H), 0.93-0.81 (m, 6H)
22.68, 18.79,







14.16


99
51-54

ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 452.3
7.36-7.25 (m, 5H),
(CDCl3) δ





([M + H]+)
5.32-5.21 (m, 1H), 4.91 (dq, J = 9.5,
171.47, 155.24,






6.3 Hz, 1H),
138.27, 128.50,






4.68-4.60 (m, 1H), 4.62 (s,
127.88, 127.81,






2H), 3.96-3.81 (m, 3H),
85.31, 83.48,






3.67 (dd, J = 11.6, 4.8 Hz,
80.28, 75.53,






1H), 3.58 (dd, J = 10.8,
74.86, 74.01,






7.3 Hz, 1H),
73.14, 73.03,






3.50 (dd, J = 15.5, 6.9 Hz,
53.77, 32.60,






1H), 3.36 (dd, J = 12.0,
28.42, 19.49,






4.8 Hz, 1H), 3.23 (t, J = 9.1 Hz,
18.71, 14.11






1H),






1.60-1.44 (m, 2H), 1.44 (d, J = 5.8 Hz,






3H), 1.43 (s, 9H),






1.41-1.22 (m, 2H),






0.88 (t, J = 7.3 Hz, 3H)


100

(Neat)
HRMS-ESI

1H NMR (CDCl3) δ


13C NMR





3347,
(m/z)
7.38-7.24 (m, 5H),
(CDCl3) δ




2932,
[M]+
5.34-5.23 (m, 1H),
171.43, 155.22,




1754,
calcd for
5.02-4.91 (m, 1H), 4.93 (d, J = 10.8 Hz,
138.42, 128.49,




1714,
C24H37NO7,
1H), 4.68-4.60 (m,
128.04, 127.83,




1498,
451.2570;
1H), 4.59 (d, J = 10.9 Hz,
84.76, 83.99,




1367,
found,
1H), 3.92 (dd, J = 11.8,
80.24, 75.84,




1163,
451.2560
6.7 Hz, 1H), 3.81 (d, J = 11.1 Hz,
75.35, 74.81,




1094

1H), 3.68 (dd, J = 11.7,
72.82, 70.78,






4.9 Hz, 1H),
53.76, 32.31,






3.60 (t, J = 6.7 Hz, 1H),
28.40, 19.47,






3.58 (t, J = 6.8 Hz, 1H),
18.82, 14.02






3.51 (dt, J = 9.1, 6.6 Hz, 1H),






3.37 (t, J = 9.0 Hz, 1H),






3.26 (t, J = 7.4 Hz, 1H),






1.59-1.49 (m, 2H),






1.43 (s, 9H), 1.41 (d, J = 6.3 Hz,






3H), 1.40-1.30 (m,






2H), 0.88 (t, J = 7.4 Hz,






3H)


101

(Neat)
HRMS-ESI

1H NMR (CDCl3) δ






2932,
(m/z)
7.40-7.23 (m, 5H), 5.23 (dd,




1766,
[M]+
J = 8.9, 4.1 Hz, 1H),




1709,
calcd for
4.94 (d, J = 10.9 Hz, 1H),




1367,
C29H45NO9,
4.85 (dq, J = 9.1, 6.3 Hz, 1H),




1256,
551.3094;
4.60 (d, J = 10.9 Hz, 1H),




1147,
found,
4.25 (dd, J = 12.1, 4.1 Hz,




1122
551.3109
1H), 3.92 (dd, J = 12.2,






8.9 Hz, 1H),






3.85 (d, J = 10.7 Hz, 1H),






3.65-3.48 (m, 3H),






3.42-3.30 (m, 2H),






1.61-1.45 (m, 2H), 1.50 (s, 18H),






1.41 (d, J = 6.3 Hz, 3H),






1.38-1.28 (m, 2H),






0.88 (t, J = 7.4 Hz, 3H)


102

(Neat)
ESIMS

1H NMR (CDCl3) δ


13C NMR





3357,
m/z 304.2
5.52 (d, J = 7.9 Hz, 1H),
(CDCl3) δ




2979,
([M − H])
5.02 (dq, J = 12.7, 6.3 Hz,
171.04, 155.49,




1751,

1H), 4.67-4.58 (m, 1H),
80.40, 79.61,




1691,

4.10-4.01 (m, 1H),
78.32, 76.66,




1523,

3.93 (dd, J = 11.7, 2.6 Hz,
74.59, 73.06,




1368,

1H), 3.84 (dd, J = 11.7,
54.80, 28.44,




1163,

5.8 Hz, 1H),
18.74




1047

3.52-3.36 (m, 3H), 3.08 (bs, 1H),






2.90 (bs, 1H), 1.47 (d, J = 6.3 Hz,






3H), 1.43 (s, 9H)


103

(Neat)
HRMS-ESI

1H NMR (CDCl3) δ


13C NMR





3353,
(m/z)
5.41 (d, J = 8.2 Hz, 1H),
(CDCl3) δ




2976,
[M]+
5.21-5.12 (m, 1H),
175.57, 175.47,




1742,
calcd for
5.12-5.04 (m, 1H),
171.37, 155.18,




1519,
C21H35NO9,
4.92-4.83 (m, 1H), 4.74 (dd, J = 13.4,
80.34, 74.52,




1368,
445.2312;
6.9 Hz, 1H),
74.30, 74.15,




1251,
found,
3.95 (dd, J = 11.7, 7.0 Hz,
73.35, 71.34,




1155
445.2322
1H), 3.80-3.65 (m, 3H),
34.01, 33.91,






2.64-2.41 (m, 2H),
28.30, 19.01,






1.44 (s, 9H), 1.32 (d, J = 6.2 Hz,
18.88, 18.74,






3H), 1.20 (d, J = 7.0 Hz,
18.71, 18.03






3H), 1.16 (d, J = 7.0 Hz,






3H), 1.14 (d, J = 7.0 Hz,






3H), 1.10 (d, J = 7.0 Hz,






3H)


104

(Neat)
HRMS-ESI

1H NMR (CDCl3) δ


13C NMR





2980,
(m/z)
5.19 (dd, J = 8.9, 4.2 Hz, 1H),
(CDCl3) δ




2935,
[M]+
4.75 (dq, J = 9.4, 6.3 Hz,
169.10, 152.73,




1746,
calcd for
1H), 4.23 (dd, J = 12.1,
86.77, 85.12,




1707,
C20H35NO9,
4.2 Hz, 1H), 3.89 (dd, J = 12.1,
83.13, 75.07,




1367,
433.2312;
9.0 Hz, 1H),
72.76, 72.52,




1254,
found,
3.80 (d, J = 10.6 Hz, 1H),
61.21, 58.43,




1106
433.2317
3.56-3.48 (m, 1H), 3.52 (s,
57.94, 28.03,






3H), 3.42 (s, 3H),
18.65






3.17-3.11 (m, 1H), 3.06 (t, J = 9.0 Hz,






1H), 1.48 (s,






18H), 1.40 (d, J = 6.3 Hz,






3H)


105


ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 496.7
5.81 (dd, J = 17.7, 10.6 Hz,
(CDCl3) δ





([M + Na]+)
1H), 5.17-5.14 (m, 1H),
169.43, 152.53,






4.99-4.86 (m, 2H),
143.20, 115.09,






4.19 (dd, J = 11.6, 9.1 Hz,
83.16, 77.26,






1H), 4.13-4.02 (m, 2H),
76.60, 75.75,






3.83-3.71 (m, 2H),
74.16, 73.32,






3.55-3.47 (m, 2H), 2.78 (d, J = 5.3 Hz,
71.73, 58.07,






1H), 1.48 (s,
28.00, 26.74,






18H), 1.38 (d, J = 6.8 Hz,
26.30, 19.31






3H), 1.27 (s, 3H), 1.23 (s,






3H)


106


ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 496.7
5.79 (dd, J = 17.8, 10.5 Hz,
(CDCl3) δ





([M + Na]+)
1H), 5.18 (dd, J = 8.2, 3.4 Hz,
169.01, 152.64,






1H), 5.15 (s, 1H),
142.56, 115.33,






5.11 (dd, J = 5.6, 0.7 Hz,
83.07, 79.83,






1H), 4.95 (dq, J = 12.9,
77.47, 76.46,






6.4 Hz, 1H), 4.14 (dd, J = 12.4,
74.46, 74.35,






3.4 Hz, 1H),
74.01, 58.56,






3.96-3.84 (m, 2H), 3.45 (dd, J = 10.6,
28.04, 26.82,






7.6 Hz, 1H),
25.82, 18.56






3.41-3.32 (m, 2H), 3.05 (d, J = 1.3 Hz,






1H), 1.47 (s,






18H), 1.42 (d, J = 6.4 Hz,






3H), 1.29 (s, 3H), 1.26 (s,






3H)


107


ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 550.8
5.90 (dd, J = 17.9, 10.5 Hz,
(CDCl3) δ





([M + Na]+)
1H), 5.17 (dd, J = 8.6, 4.1 Hz,
169.08, 152.57,






1H), 5.07-5.05 (m,
144.07, 142.26,






1H) 5.03 (dd, J = 4.9, 1.1 Hz,
114.06, 111.66,






1H), 4.96-4.89 (m,
84.32, 83.01,






1H), 4.85-4.77 (m, 2H),
79.73, 77.43,






4.33 (d, J = 12.1 Hz, 1H),
77.12, 76.01,






4.13 (dd, J = 12.2, 4.1 Hz,
73.04, 72.85,






1H), 3.86 (dd, J = 12.3,
58.13, 28.01,






8.6 Hz, 1H), 3.81 (t,
27.04, 25.68,






J = 11.8 Hz, 2H),
19.95, 18.83






3.48 (dd, J = 10.7, 7.2 Hz,






1H), 3.41 (t, J = 7.5 Hz,






1H), 3.11 (t, J = 8.8 Hz,






1H), 1.70 (s, 3H), 1.46 (s,






18H), 1.38 (d, J = 6.3 Hz,






3H), 1.26 (s, 3H), 1.22 (s,






3H)


108


ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 553.4
5.18 (dd, J = 8.6, 3.8 Hz, 1H),
(CDCl3) δ





([M + Na]+)
4.87-4.77 (m, 1H),
169.10, 152.63,






4.15 (dd, J = 12.3, 3.9 Hz,
84.90, 83.01,






1H), 3.87 (dd, J = 12.3,
81.02, 80.20,






8.6 Hz, 1H), 3.81 (dd, J = 10.0,
77.56, 75.09,






4.3 Hz, 1H),
73.14, 73.07,






3.75 (dd, J = 8.5, 5.6 Hz, 1H),
58.27, 35.03,






3.54-3.43 (m, 2H),
29.04, 28.04,






3.10-2.99 (m, 2H),
25.12, 25.00,






1.91-1.72 (m, 1H), 1.48 (s,
19.89, 19.53,






18H), ), 1.47-1.41 (m,
18.97, 9.00






2H), 1.39 (d, J = 6.3 Hz,






3H), 1.13 (s, 3H), 1.10 (s,






3H), 0.90 (d, J = 6.6 Hz,






3H), 0.85 (t, J = 7.5 Hz,






3H), 0.84 (d, J = 6.7 Hz,






3H)


109


ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 550.8
5.92 (dd, J = 17.6, 10.8 Hz,
(CDCl3) δ





([M + Na]+)
1H), 5.14-5.06 (m, 2H),
169.59, 152.73,






5.06-5.00 (m, 1H),
152.62, 144.07,






4.97-4.91 (m, 2H),
142.20, 114.19,






4.89-4.81 (m, 1H), 4.16 (dd, J = 12.1,
112.54, 83.00,






8.1 Hz, 1H),
80.59, 77.04,






4.03 (dd, J = 11.6, 7.0 Hz,
76.10, 75.42,






1H), 3.99-3.94 (m, 1H),
74.38, 73.22,






3.93-3.81 (m, 2H),
58.15, 28.06,






3.73-3.67 (m, 1H),
26.69, 26.52,






3.56-3.51 (m, 1H), 3.21 (td, J = 6.6,
19.77, 18.71






1.6 Hz, 1H),






1.72 (s, 3H), 1.52-1.45 (m,






21H), 1.39 (d, J = 6.7 Hz,






3H), 1.27 (s, 3H)


110


ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 555.5
5.05 (t, J = 7.3 Hz, 1H),
(CDCl3) δ





([M + Na]+)
4.94-4.84 (m, 1H), 4.17 (dd, J = 11.6,
169.70, 152.68,






7.5 Hz, 1H),
83.00, 82.98,






4.04 (dd, J = 11.6, 7.1 Hz,
75.49, 75.39,






1H), 3.88 (dd, J = 12.3,
73.27, 73.13,






5.9 Hz, 1H),
58.15, 35.30,






3.69-3.61 (m, 2H), 3.27 (d, J = 6.7 Hz,
28.79, 28.07,






2H), 3.19-3.12 (m,
25.59, 25.53,






1H), 1.92-1.74 (m, 1H),
19.70, 19.63,






1.52-1.47 (m, 20H),
18.86, 8.99






1.41 (d, J = 6.7 Hz, 3H),






1.13 (s, 3H), 1.12 (s, 3H),






0.92-0.84 (m, 9H)


111

(Neat)
HRMS-ESI

1H NMR (CDCl3) δ






3323,
(m/z)
5.41 (d, J = 7.1 Hz, 1H),




2960,
[M]+
5.08 (dq, J = 9.3, 6.3 Hz, 1H),




2933,
calcd for
4.66-4.56 (m, 1H),




2874,
C17H31NO7,
4.07 (d, J = 12.0 Hz, 1H),




1755,
361.2101;
4.02 (d, J = 13.5 Hz, 1H),




1710,
found,
3.81 (dd, J = 11.9, 5.6 Hz,




1521,
361.2107
1H), 3.65 (dt, J = 9.3, 6.6 Hz,




1367,

1H), 3.44-3.34 (m,




1248,

3H), 3.17 (s, 1H),




1164,

3.08-3.01 (m, 1H), ),




1084

1.59-1.49 (m, 2H), 1.46 (d, J = 6.3 Hz,






3H), 1.44 (s, 9H),






1.41-1.31 (m, 2H),






0.91 (t, J = 7.4 Hz, 3H)


112

(Neat)
HRMS-ESI (m/z)

1H NMR (CDCl3) δ


13C NMR





3536,
[M]+
5.27 (dd, J = 8.8, 2.4 Hz, 1H),
(CDCl3) δ




2979,
calcd for
4.91 (dq, J = 9.2, 6.3 Hz,
168.42, 152.63,




2934,
C22H39NO9,
1H), 4.27 (dd, J = 12.4,
82.95, 82.47,




2875,
461.2625;
2.4 Hz, 1H), 4.08 (dd, J = 10.9,
76.64, 76.60,




1764,
found,
0.8 Hz, 1H),
74.41, 73.34,




1747,
461.2632
3.90 (dd, J = 12.4, 8.8 Hz,
69.79, 58.57,




1706,

1H), 3.66 (dt, J = 9.4, 6.6 Hz,
31.80, 27.93,




1366,

1H), 3.46-3.36 (m,
19.25, 18.69,




1246,

3H), 3.22-3.14 (m, 1H),
13.81




1147,

3.11 (d, J = 1.1 Hz, 1H),




1121,

1.57-1.51 (m, 2H),




1088,

1.51 (s, 18H), 1.45 (d, J = 6.3 Hz,




1049

3H), 1.40-1.29 (m,






2H), 0.91 (t, J = 7.4 Hz,






3H)


113
69-71
(Neat)
HRMS-ESI

1H NMR (CDCl3) δ


13C NMR





3364,
(m/z)
5.34 (d, J = 7.9 Hz, 1H),
(CDCl3) δ




2967,
[M]+
5.12-4.99 (m, 1H), 4.93 (t, J = 9.4 Hz,
175.77, 171.28,




2935,
calcd for
1H),
155.23, 80.88,




2876,
C21H37NO8,
4.71-4.63 (m, 1H),
80.29, 75.79,




1745,
431.2519;
3.94-3.85 (m, 2H), 3.77 (dd, J = 11.7,
75.70, 75.30,




1717,
found,
3.7 Hz, 1H),
71.49, 70.49,




1517,
431.2524
3.59-3.45 (m, 2H), 3.30 (dt, J = 9.1,
54.10, 34.18,




1367,

6.6 Hz, 1H),
32.00, 28.37,




1153,

3.17 (t, J = 7.9 Hz, 1H),
19.30, 19.16,




1096

2.53 (hept, J = 7.0 Hz, 1H),
18.84, 18.28,






1.41 (s, 9H), 1.28 (d, J = 6.3 Hz,
13.94






3H),






1.30-1.20 (m, 2H), 1.19-1.13 (m,






8H), 0.84 (t, J = 7.3 Hz,






3H)


114
97-99
(Neat)
HRMS-ESI

1H NMR (CDCl3) δ


13C NMR





3339,
(m/z)
8.13-7.98 (m, 2H),
(CDCl3) δ




2959,
[M]+
7.59-7.51 (m, 1H),
171.27, 165.48,




2933,
calcd for
7.47-7.40 (m, 2H), 5.41 (d, J = 7.8 Hz,
155.23, 133.46,




1716,
C24H35NO8,
1H), 5.30-5.16 (m,
133.23, 130.17,




1513,
465.2363;
2H), 4.78-4.66 (m, 1H),
129.92, 129.77,




1367,
found,
4.02-3.90 (m, 2H),
128.47, 81.09,




1257,
465.2380
3.83 (dd, J = 11.7, 3.7 Hz,
80.27, 76.90,




1162,

1H), 3.62 (dd, J = 11.0,
75.94, 75.45,




1095,

7.9 Hz, 1H), 3.50 (dt, J = 9.2,
71.48, 70.78,




710

6.3 Hz, 1H), 3.32 (t,
54.20, 31.78,






J = 7.8 Hz, 1H), 3.26 (dt,
28.35, 19.04,






J = 9.1, 6.6 Hz, 1H),
18.39, 13.62






1.43 (s, 9H), 1.37 (d, J = 6.0 Hz,






3H), 1.29-1.18 (m,






2H), 1.12-0.93 (m, 2H),






0.59 (t, J = 7.4 Hz, 3H)


115

(Neat)
HRMS-ESI

1H NMR (CDCl3) δ


13C NMR





2979,
(m/z)
5.20 (dd, J = 9.0, 4.1 Hz, 1H),
(CDCl3) δ




2933,
[M]+
4.73 (dq, J = 9.7, 6.3 Hz,
169.12, 152.73,




2875,
calcd for
1H), 4.22 (dd, J = 12.1,
86.80, 83.43,




1765, 1747,
C23H41NO9,
4.1 Hz, 1H), 3.88 (dd, J = 12.1,
83.12, 75.78,




1707,
475.2781;
9.0 Hz, 1H),
72.79, 72.64,




1367,
found,
3.80 (dd, J = 10.7, 0.6 Hz,
70.71, 61.45,




1243,
475.2784
1H), 3.62-3.43 (m, 3H),
57.97, 32.29,




1106

3.53 (s, 3H),
28.03, 19.43,






3.24-3.17 (m, 1H), 3.08-3.01 (m,
18.69, 13.99






1H), 1.57-1.45 (m, 2H),






1.48 (s, 18H), 1.40 (d, J = 6.3 Hz,






3H),






1.39-1.28 (m, 2H), 0.88 (t, J = 7.4 Hz,






3H)


116

(Neat)
HRMS-ESI

1H NMR (CDCl3) δ


13C NMR





2979,
(m/z)
5.89 (ddt, J = 16.2, 10.4, 5.7 Hz,
(CDCl3) δ




2933,
[M]+
1H), 5.27-5.17 (m,
169.13, 152.73,




1765,
calcd for
2H), 5.13 (dd, J = 10.4,
135.04, 116.82,




1708,
C25H43NO9,
1.7 Hz, 1H), 4.78 (dq, J = 12.6,
84.57, 83.62,




1367,
501.2938;
6.2 Hz, 1H),
83.13, 75.87,




1244,
found,
4.36 (ddt, J = 12.1, 5.4, 1.3 Hz,
74.70, 72.87,




1121,
501.2955
1H), 4.22 (dd, J = 12.1,
72.72, 70.76,




1098

4.1 Hz, 1H),
58.00, 32.30,






4.10-4.03 (m, 1H), 3.89 (dd, J = 12.2,
28.05, 19.42,






9.0 Hz, 1H),
18.85, 14.02






3.81 (d, J = 10.8 Hz, 1H),






3.60-3.44 (m, 3H),






3.29-3.17 (m, 2H),






1.57-1.45 (m, 2H), 1.48 (s, 18H),






1.40 (d, J = 6.3 Hz, 3H),






1.38-1.27 (m, 2H),






0.88 (t, J = 7.4 Hz, 3H)


117

(Neat)
HRMS-ESI

1H NMR (CDCl3) δ


13C NMR





2978,
(m/z)
5.21 (dd, J = 8.9, 4.1 Hz, 1H),
(CDCl3) δ




2933,
[M]+
4.96-4.92 (m, 1H),
169.17, 152.77,




2874,
calcd for
4.86-4.77 (m, 2H), 4.30 (d, J = 11.6 Hz,
142.55, 111.93,




1765,
C26H45NO9,
1H), 4.23 (dd,
84.92, 83.69,




1709,
515.3094;
J = 12.1, 4.1 Hz, 1H),
83.17, 77.66,




1456,
found,
3.95-3.86 (m, 2H),
75.85, 72.88,




1367,
515.3101
3.81 (d, J = 10.8 Hz, 1H),
72.75, 70.76,




1244,

3.60-3.44 (m, 3H),
58.03, 32.36,




1147,

3.30-3.20 (m, 2H), 1.73 (s,
28.08, 19.95,




1120,

3H), 1.55-1.45 (m, 2H),
19.47, 18.86,






1.49 (s, 18H), 1.42 (d, J = 6.3 Hz,
14.06






3H),






1.38-1.28 (m, 2H), 0.88 (t, J = 7.4 Hz,






3H)


118

(Neat)
HRMS-ESI

1H NMR (CDCl3) δ


13C NMR





3313,
(m/z)
5.20 (dd, J = 8.9, 4.2 Hz, 1H),
(CDCl3) δ




1637,
[M]+
4.78 (dq, J = 9.4, 6.3 Hz,
169.21, 152.77,




1367
calcd for
1H), 4.23 (dd, J = 12.1,
84.93, 83.58,





C26H47NO9,
4.2 Hz, 1H), 3.90 (dd, J = 12.1,
83.13, 80.65,





517.3521;
9.0 Hz, 1H),
75.88, 72.92,





found,
3.80 (d, J = 10.6 Hz, 1H),
72.85, 70.74,





517.3527
3.66 (dd, J = 8.4, 6.1 Hz, 1H),
58.02, 32.36,






3.60-3.42 (m, 3H),
29.26, 28.08,






3.26-3.18 (m, 2H),
19.69, 19.51,






3.18-3.10 (m, 1H),
19.48, 18.83,






1.87-1.74 (m, 1H), 1.56-1.44 (m,
14.06






2H), 1.49 (s, 18H),






1.40 (d, J = 6.3 Hz, 3H),






1.39-1.28 (m, 2H),






0.93-0.84 (m, 9H)


119

(Neat)
HRMS-ESI

1H NMR (CDCl3) δ


13C NMR





2934,
(m/z)
9.63 (s, 1H), 5.18 (dd, J = 8.9,
(CDCl3) δ




2876,
[M]+
3.8 Hz, 1H), 4.84 (dq, J = 9.4,
200.51, 168.79,




1743,
calcd for
6.3 Hz, 1H),
152.61, 86.19,




1706,
C24H41NO10,
4.39 (dd, J = 17.9, 0.9 Hz,
83.52, 83.08,




1367,
503.2730;
1H), 4.22 (dd, J = 17.8,
79.09, 75.35,




1253,
found,
0.5 Hz, 1H), 4.19 (dd, J = 12.2,
72.95, 71.99,




1121,
503.2727
3.8 Hz, 1H),
70.03, 57.92,




1096

3.91-3.75 (m, 2H),
32.02, 27.94,






3.57-3.42 (m, 2H), 3.37 (dt, J = 9.2,
19.29, 18.84,






6.5 Hz, 1H), 3.29 (dd, J = 7.9,
13.85






6.9 Hz, 1H), 3.21 (t,






J = 9.0 Hz, 1H),






1.52-1.40 (m, 2H), 1.45 (s,






18H), 1.41 (d, J = 6.3 Hz,






3H), 1.30-1.19 (m, 2H),






0.83 (t, J = 7.3 Hz, 3H)


120

(Neat)
HRMS-ESI

1H NMR (CDCl3) δ


13C NMR





2980,
(m/z)
5.81 (tdd, J = 55.1 (H-F), 4.7,
(CDCl3) δ




2395,
[M]+
3.4 Hz, 1H), 5.21 (dd, J = 9.0,
168.92, 152.72,




2877,
calcd for
3.8 Hz, 1H),
114.35 (t, J = 241.7 Hz),




1747,
C24H41F2NO9,
4.80 (dq, J = 12.6, 6.2 Hz,
86.15, 83.55,




1708,
525.2749;
1H), 4.23 (dd, J = 12.2,
83.20, 75.56,




1367,
found,
3.8 Hz, 1H),
73.03, 72.78 (t, J = 27.6 Hz),




1254,
525.2723
4.13-3.99 (m, 1H), 3.92-3.71 (m,




1120

3H), 3.56 (dt, J = 9.1, 6.8 Hz,






1H), 3.52-3.40 (m,
72.17, 70.36,






2H), 3.29-3.19 (m, 2H),
58.01, 32.19,






1.56-1.45 (m, 2H),
28.04, 19.40,






1.48 (s, 18H), 1.41 (d, J = 6.3 Hz,
18.71, 13.97






3H), 1.38-1.26 (m,






2H),, 0.89 (t, J = 7.4 Hz,






3H)


121

(Neat)
HRMS-ESI

1H NMR (CDCl3) δ





3364,
(m/z)
4.79 (td, J = 8.8, 3.1 Hz, 1H),




2954,
[M]+
3.92 (dd, J = 11.7, 6.8 Hz,




2873,
calcd for
1H), 3.78 (t, J = 6.4 Hz,




1742,
C17H33NO5,
1H), 3.68 (dd, J = 8.4,




1467,
331.2359;
6.1 Hz, 1H), 3.62 (d,




1183,
found,
J = 3.7 Hz, 2H), 3.45 (dd,




1094
331.2350
J = 11.7, 6.0 Hz, 1H),






3.36-3.13 (m, 5H),






2.08-1.95 (m, 1H),






1.88-1.74 (m, 2H),






1.72-1.58 (m, 3H), 0.97 (t, J = 7.4 Hz,






3H), 0.92-0.86 (m,






12H)


122

(Neat)
HRMS-ESI

1H NMR (CDCl3) δ






2955,
(m/z)
4.96 (dt, J = 10.1, 3.6 Hz, 1H),




2872,
[M]+
4.07 (dd, J = 11.7, 3.5 Hz,




1745,
calcd for
1H), 3.90-3.77 (m,




1467,
C17H33NO5,
3H), 3.68 (dd, J = 7.1, 3.0 Hz,




1180,
331.2359;
1H), 3.63 (dd, J = 11.7,




1081
found,
1.7 Hz, 1H),





331.2373
3.42-3.25 (m, 4H), 3.20 (dd, J = 8.8,






6.8 Hz, 1H),






1.91-1.76 (m, 3H),






1.76-1.59 (m, 3H), 1.00 (t, J = 7.4 Hz,






3H), 0.89 (ddd, J = 6.9,






4.0, 1.6 Hz, 12H)


123

(Neat)
HRMS-ESI

1H NMR (CDCl3) δ






2955,
(m/z)
4.99-4.94 (m, 1H),




2873,
[M]+
4.17-4.08 (m, 2H), 3.92 (dd, J = 11.8,




1744,
calcd for
3.8 Hz, 1H),




1228,
C17H33NO5,
3.88-3.80 (m, 1H), 3.77 (d, J = 10.4 Hz,




1084
331.2359;
1H), 3.65 (dt,





found,
J = 8.0, 4.0 Hz, 1H),





331.2367
3.67-3.54 (m, 2H),






3.44-3.36 (m, 2H), 3.28 (ddd, J = 13.3,






8.8, 6.6 Hz, 2H),






3.19 (dd, J = 8.8, 6.8 Hz,






1H), 1.92-1.72 (m, 4H),






1.02 (t, J = 7.4 Hz, 3H),






0.95-0.83 (m, 12H)


124

(Neat)
HRMS-ESI

1H NMR (CDCl3) δ






3365,
(m/z)
8.76 (bs, 2H), 7.35-7.20 (m,




1636,
[M]+
10H), 5.30 (s, 1H),




1235,
calcd for
4.69-4.45 (m, 5H), 4.20 (d, J = 9.1 Hz,




1063
C22H27NO5,
2H),





385.1889;
3.89-3.75 (m, 2H), 3.59 (d, J = 11.1 Hz,





found,
1H), 3.47 (d, J = 7.1 Hz,





385.1890
1H), 1.32 (d, J = 6.8 Hz,






3H)


125
174-177

ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 352.2
8.71 (bs, 1H), 7.36-7.25 (m,
(CDCl3) δ





([M + H]+)
5H), 5.04-4.90 (m, 1H),
168.62, 138.39,






4.92 (d, J = 10.8 Hz, 1H),
128.50, 128.06,






4.63-4.47 (m, 2H),
127.85, 84.55,






4.39-4.21 (m, 1H),
83.65, 76.01,






4.16-3.97 (m, 1H),
75.84, 73.82,






3.94-3.79 (m, 1H), 3.64-3.42 (m,
71.16, 70.82,






3H), 3.40-3.22 (m, 2H),
53.59, 32.36,






1.57-1.45 (m, 2H),
19.50, 18.76,






1.44-1.21 (m, 7H), 0.86 (t, J = 7.3 Hz,
14.08






3H)


126
90-91

ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 470.3
7.40-7.28 (m, 5H), 5.55 (d, J = 7.7 Hz,
(CDCl3) δ





([M + Na]+)
1H), 5.10 (s,
170.85, 155.71,






2H), 5.01-4.91 (m, 3H),
142.26, 142.02,






4.85 (d, J = 1.2 Hz, 2H),
136.10, 128.57,






4.69 (dd, J = 12.1, 6.7 Hz,
128.25, 128.11,






1H), 4.32 (d, J = 11.7 Hz,
112.33, 112.02,






1H), 3.99-3.89 (m,
84.95, 83.01,






4H), 3.85 (d, J = 11.3 Hz,
77.63, 75.87,






1H), 3.74 (dd, J = 11.9,
74.89, 74.66,






4.5 Hz, 1H),
72.86, 67.14,






3.60-3.51 (m, 1H), 3.33-3.23 (m,
54.26, 19.81,






2H), 1.72 (d, J = 6.2 Hz,
19.66, 18.63,






6H), 1.44 (d, J = 6.3 Hz,
0.03






3H)


127
79-81

ESIMS

1H NMR (CDCl3) δ







m/z 471.1
7.40-7.29 (m, 5H), 5.57 (d, J = 7.9 Hz,





([M + Na]+)
1H), 5.10 (s,






2H), 5.02-4.92 (m, 3H),






4.91-4.83 (m, 2H),






4.82-4.65 (m, 2H),






4.17-3.87 (m, 5H),






3.84-3.77 (m, 1H), 3.68-3.59 (m,






1H), 3.56 (td, J = 7.0, 3.3 Hz,






1H), 3.12 (dd, J = 8.2,






6.6 Hz, 1H),






1.85-1.66 (m, 6H), 1.23 (d, J = 6.2 Hz,






3H)


128


ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 506.3
7.37-7.24 (m, 15H), 5.54 (d,
(CDCl3) δ





([M + H]+)
J = 8.0 Hz, 1H), 5.11 (s,
171.66, 155.61,






2H), 4.80-4.61 (m, 6H),
138.01, 137.98,






4.09 (dd, J = 11.5, 3.9 Hz,
136.10, 128.59,






1H), 3.99 (dd, J = 11.5,
128.50, 128.45,






6.7 Hz, 1H),
128.28, 128.15,






3.78 (dt, J = 8.4, 3.8 Hz, 2H),
127.91, 127.89,






3.72-3.63 (m, 1H),
127.82, 81.63,






3.56 (dd, J = 11.5, 6.0 Hz,
79.43, 73.96,






1H), 3.49-3.39 (m, 1H)
73.80, 73.26,







72.96, 67.17,







63.80, 54.10


129


ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 372.9
7.79-6.92 (m, 10H),
(CDCl3) δ





([M + H]+)
4.79-4.53 (m, 6H), 4.14 (dd, J = 11.4,
175.95, 138.09,






3.6 Hz, 1H),
138.04, 128.46,






3.97 (dd, J = 11.4, 7.2 Hz,
128.40, 128.00,






1H), 3.87-3.74 (m, 3H),
127.88, 127.85,






3.73-3.56 (m, 2H),
127.74, 81.49,






3.45 (ddd, J = 7.8, 6.0, 1.8 Hz,
79.46, 75.01,






1H), 3.25 (dd, J = 11.5,
73.66, 72.75,






7.9 Hz, 1H)
71.53, 63.47,







54.33


130


ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 506.8
7.44-7.12 (m, 10H),
(CDCl3) δ





([M + Na]+)
5.24 (qd, J = 6.7, 3.3 Hz, 1H),
168.91, 154.56,






5.20-5.06 (m, 1H),
138.04, 137.96,






4.76-4.52 (m, 4H),
128.36, 128.34,






4.21-4.06 (m, 1H), 3.92 (dd, J = 11.8,
127.95, 127.82,






4.0 Hz, 1H),
127.79, 127.67,






3.85-3.76 (m, 2H), 3.56 (dd,
77.72, 74.18,






J = 4.7, 2.1 Hz, 1H),
73.11, 72.11,






3.43 (dd, J = 11.6, 5.8 Hz,
71.87, 71.35,






1H), 1.43 (s, 9H), 1.36 (d,
55.72, 28.25






J = 6.7 Hz, 3H)


131


ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 487.1
7.40-7.23 (m, 10H), 5.48 (d,
(CDCl3) δ





([M + H]+)
J = 7.7 Hz, 1H), 5.31 (qd,
170.72, 155.29,






J = 7.0, 3.3 Hz, 1H),
138.20, 137.98,






4.73-4.62 (m, 2H),
128.43, 128.39,






4.61-4.50 (m, 2H),
128.03, 127.91,






4.14-4.05 (m, 1H), 4.00 (dd, J = 11.6,
127.78, 127.69,






2.0 Hz, 1H),
79.90, 78.53,






3.84 (dd, J = 11.6, 5.9 Hz,
76.59, 75.54,






2H), 3.65 (dd, J = 12.0,
74.15, 72.07,






1.9 Hz, 1H),
71.06, 54.80,






3.54-3.45 (m, 1H), 1.43 (s, 9H),
28.34






1.34 (d, J = 6.8 Hz, 3H)


132


ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 260.1
4.92 (dq, J = 9.3, 6.4 Hz, 1H),
(CDCl3) δ





([M + H]+)
4.03 (dd, J = 10.3, 4.4 Hz,
174.41, 108.61,






1H), 3.78 (dd, J = 9.3,
83.25, 81.95,






6.7 Hz, 1H),
79.84, 74.17,






3.70-3.52 (m, 3H), 3.39 (dd, J = 10.3,
71.40, 57.27,






6.3 Hz, 1H),
26.77, 26.49,






1.65 (s, 2H), 1.53 (d, J = 6.5 Hz,
18.48, 17.89






3H), 1.35 (s, 6H),






1.29 (d, J = 6.0 Hz, 3H)


133


ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 386.9
8.77 (s, 3H), 7.54-6.95 (m,
(CDCl3) δ





([M + H]+)
10H), 5.29 (d, J = 7.4 Hz,
167.90, 137.94,






1H), 4.63-4.47 (m, 5H),
137.75, 128.45,






4.44 (s, 1H),
128.39, 128.13,






4.21-4.09 (m, 1H), 3.92-3.84 (m,
127.92, 127.80,






1H), 3.80-3.73 (m, 1H),
161.65, 54.29,






3.68-3.53 (m, 2H),
42.92, 20.91






3.49-3.37 (m, 1H), 1.29 (d, J = 6.6 Hz,






3H)


134


ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 386.3
8.89 (s, 3H), 7.41-7.10 (m,
(CDCl3) δ





([M + H]+)
10H), 5.21 (d, J = 7.9 Hz,
165.18, 137.87,






1H), 4.66 (d, J = 11.4 Hz,
137.53, 128.49,






1H), 4.60-4.44 (m, 3H),
128.40, 128.27,






4.23-4.11 (m, 1H),
128.05, 127.85,






4.03 (t, J = 10.3 Hz, 2H),
127.78, 74.35,






3.86 (d, J = 6.9 Hz, 1H),
72.80, 72.47,






3.79-3.72 (m, 1H),
72.25, 71.77,






3.68-3.52 (m, 2H), 1.37 (d, J = 6.6 Hz,
71.12, 61.69,






3H)
54.70, 15.32


135


ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 661.8
7.43-7.15 (m, 10H),
(CDCl3) δ





([M + Na]+)
6.65-6.51 (m, 2H), 6.29 (dtd, J = 16.1,
169.03, 152.65,






6.0, 4.2 Hz, 2H),
132.35, 132.15,






5.23 (dd, J = 8.9, 4.2 Hz,
128.53, 127.64,






1H), 4.93-4.77 (m, 1H),
126.53, 126.51,






4.56 (ddd, J = 12.3, 6.0,
126.20, 126.07,






1.5 Hz, 1H),
84.59, 83.07,






4.41-4.17 (m, 4H), 4.01-3.84 (m,
82.96, 74.28,






2H), 3.60 (dd, J = 11.0,
72.85, 72.66,






7.2 Hz, 1H), 3.45 (ddd, J = 8.5,
71.54, 57.92,






7.1, 1.4 Hz, 1H),
27.96, 18.81






3.40-3.31 (m, 1H),






1.50 (s, 18H), 1.47 (d, J = 6.3 Hz,






3H)


136


ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 644.2
6.48-6.28 (m, 2H),
(CDCl3) δ





([M + Na]+)
5.87 (dddt, J = 15.4, 8.7, 6.5,
168.72, 152.68,






2.0 Hz, 2H), 5.24 (dd, J = 8.9,
136.51-136.07 (q, J = 6.1 Hz),






3.7 Hz, 1H),
136.27 (q, J = 6.1 Hz),






4.97-4.75 (m, 1H),
122.99 (q, J = 269.1 Hz),






4.52-4.38 (m, 1H), 4.32-4.13 (m,
122.92 (q, J = 269.1 Hz),






4H), 3.98-3.82 (m, 2H),
118.80 (q, J = 34.3 Hz),






3.56 (dd, J = 11.2, 7.2 Hz,
118.51 (q, J = 34.3 Hz).






1H), 3.49-3.35 (m,
85.42, 83.62,






1H), 3.35-3.25 (m, 1H),
83.20, 75.78,






1.51 (s, 18H), 1.43 (d, J = 6.3 Hz,
73.19, 72.03,






3H)
71.34, 68.35,







57.97, 27.98,







18.67


137


ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 513.3
5.21 (dd, J = 8.9, 4.2 Hz, 1H),
(CDCl3) δ





([M + Na]+)
4.77 (dq, J = 9.3, 6.2 Hz,
169.04, 152.59,






1H), 4.26 (dd, J = 12.1,
84.88, 83.40,






4.2 Hz, 1H), 3.92 (dd, J = 12.1,
82.95, 75.71,






8.9 Hz, 1H),
75.41, 72.78,






3.86-3.77 (m, 2H),
72.65, 72.55,






3.60-3.41 (m, 4H), 3.29-3.12 (m,
57.88, 27.91,






2H), 1.67-1.52 (m, 2H),
23.48, 23.27,






1.49 (s, 19H), 1.42 (d, J = 6.4 Hz,
18.62, 10.59,






3H), 0.92 (td, J = 7.4,
10.57






2.8 Hz, 7H)


138


ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 664.2
7.34-7.20 (m, 4H),
(CDCl3) δ





([M + Na]+)
7.20-7.11 (m, 6H), 5.21 (dd, J = 8.9,
169.07, 152.66,






4.3 Hz, 1H),
141.97, 141.89,






4.80 (dq, J = 9.1, 6.3 Hz, 1H),
128.38, 128.34,






4.23 (dd, J = 12.1, 4.3 Hz,
128.32, 125.81,






1H), 4.00-3.84 (m,
125.79, 85.06,






2H), 3.80 (dd, J = 11.1,
83.59, 83.04,






1.4 Hz, 1H),
75.51, 73.25,






3.65-3.44 (m, 4H), 3.30-3.15 (m,
72.73, 72.68,






2H), 2.73-2.58 (m, 4H),
70.07, 57.90,






1.95-1.77 (m, 4H),
32.53, 32.43,






1.50 (s, 18H), 1.43 (d, J = 6.3 Hz,
32.02, 31.72,






3H)
27.97, 18.75


139


ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 290.7
8.67 (s, 3H), 4.91 (dq, J = 8.7,
(CDCl3) δ





([M + H]+)
6.2 Hz, 1H), 4.55 (dd, J = 6.7,
168.56, 84.88,






4.1 Hz, 1H),
83.28, 76.08,






4.28 (dd, J = 12.8, 4.1 Hz,
75.58, 73.93,






1H), 4.05 (dd, J = 12.8,
72.69, 70.96,






6.7 Hz, 1H),
53.41, 23.50,






3.90-3.73 (m, 2H), 3.58-3.38 (m,
23.31, 18.50,






4H), 3.23-3.09 (m, 2H),
10.63






1.56 (dddd, J = 8.6, 7.0,






5.2, 2.4 Hz, 4H), 1.44 (d,






J = 6.3 Hz, 3H), 0.91 (td,






J = 7.4, 1.6 Hz, 6H)


140


ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 442.9
8.72 (s, 3H), 7.36-7.19 (m,
(CDCl3) δ





([M + H]+)
4H), 7.19-7.06 (m, 6H),
168.44, 141.83,






5.04-4.85 (m, 1H),
128.36, 128.30,






4.53 (s, 1H), 4.29 (d, J = 12.3 Hz,
125.84, 85.03,






1H), 4.04 (dd, J = 12.7,
83.43, 73.88,






6.3 Hz, 1H),
73.44, 71.17,






3.94-3.80 (m, 2H),
70.21, 61.74,






3.81-3.73 (m, 1H), 3.68-3.61 (m,
53.48, 32.49,






1H), 3.61-3.42 (m, 3H),
32.43, 31.96,






3.27-3.09 (m, 2H),
31.74, 18.59






2.73-2.55 (m, 3H),






2.07-1.73 (m, 4H), 1.44 (d, J = 6.2 Hz,






3H)


141


ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 647.4
5.21 (dd, J = 8.8, 4.1 Hz, 1H),
(CDCl3) δ





([M + Na]+)
4.87-4.71 (m, 1H),
168.91, 152.66,






4.25 (dd, J = 12.2, 4.1 Hz,
127.14 (q, J = 275.5 Hz),






1H), 3.91 (dd, J = 12.2,
127.11 (d, J = 276.8 Hz),






8.8 Hz, 1H),
84.94, 83.56,






3.88-3.76 (m, 2H), 3.67-3.48 (m,
83.13, 75.36,






4H), 3.29-3.22 (m, 1H),
72.87, 72.34,






3.22-3.13 (m, 1H),
71.79, 68.58,






2.29-2.06 (m, 4H),
57.86, 30.76 (q,






1.88-1.73 (m, 4H), 1.50 (s,
J = 29.4 Hz),






18H), 1.41 (d, J = 6.3 Hz,
30.73 (q, J = 28.3 Hz),






3H)
27.95,







23.02 (q, J = 3.0 Hz),







22.80 (q,







J = 3.0 Hz),







18.68


142


ESIMS

1H NMR (400 MHz,


13C NMR (101 MHz,






m/z 563.5
CDCl3, as mixture of
CDCl3 as





([M + Na]+)
diastereomers) δ
mixture of






5.92-5.64 (m, 2H), 5.24 (ddd, J = 9.0,
diastereomers,)






3.9, 2.4 Hz, 1H),
δ 169.05,






5.01-4.90 (m, 1H),
152.62, 152.60,






4.90-4.77 (m, 2H), 4.37 (dd,
142.27, 131.12,






J = 11.8, 5.2 Hz, 1H),
130.82, 128.00,






4.24 (ddd, J = 12.2, 4.0,
127.54, 111.66,






3.2 Hz, 1H),
111.41, 84.99,






4.12-4.00 (m, 1H), 4.00-3.82 (m,
84.44, 83.03,






4H), 3.55 (ddd, J = 10.6,
81.30, 81.00,






7.6, 6.4 Hz, 1H),
77.61, 77.57,






3.46 (dddd, J = 8.8, 7.5, 3.2,
73.66, 72.84,






1.2 Hz, 1H), 3.23 (ddd, J = 9.7,
72.78, 72.75,






8.5, 4.8 Hz, 1H),
72.73, 72.28,






2.18-1.83 (m, 2H),
57.94, 28.91,






1.80-1.70 (m, 6H), 1.51 (s,
28.25, 27.94,






18H), 1.43 (d, J = 6.3 Hz,
25.24, 25.19,






3H)
19.84, 19.81,







19.08, 18.90,







18.76, 18.74


143


ESIMS

1H NMR (CDCl3) δ







m/z 426.04
8.65 (s, 3H), 4.93 (s, 1H),





([M + H]+)
4.57 (s, 1H), 4.32 (s, 1H),






4.21-3.96 (m, 1H),






3.96-3.80 (m, 2H),






3.67-3.42 (m, 4H), 3.18 (dt, J = 14.7,






4.4 Hz, 2H),






2.31-2.04 (m, 4H),






1.93-1.68 (m, 4H), 1.43 (d, J = 5.4 Hz,






3H)


144


ESIMS

1H NMR (400 MHz,







m/z 562.8
CDCl3 as mixture of





([M + Na]+)
diastereomers) δ






5.88-5.74 (m, 2H), 5.21 (dt, J = 8.6,






4.3 Hz, 1H),






4.96 (tt, J = 1.8, 1.0 Hz, 1H),






4.91-4.74 (m, 2H),






4.28 (s, 1H), 4.26-4.17 (m,






1H), 4.02-3.89 (m, 3H),






3.81 (ddd, J = 21.8, 11.3,






1.3 Hz, 1H), 3.60 (ddd, J = 13.4,






11.3, 6.7 Hz, 1H),






3.46 (ddd, J = 21.6, 9.5,






8.5 Hz, 1H),






3.36-3.25 (m, 1H), 2.09-1.85 (m,






2H), 1.84-1.67 (m, 6H),






1.53-1.47 (m, 18H),






1.45 (dd, J = 6.3, 4.5 Hz,






3H)


145


ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 567.5
5.22 (dd, J = 9.0, 4.0 Hz, 1H),
(CDCl3) δ





([M + Na]+)
4.78 (dq, J = 9.7, 6.3 Hz,
169.10, 152.62,






1H), 4.22 (dd, J = 12.2,
84.78, 83.00,






4.0 Hz, 1H), 3.90 (dd, J = 12.2,
80.77, 80.32,






9.0 Hz, 1H),
77.75, 72.95,






3.83-3.71 (m, 2H), 3.52 (dd, J = 10.8,
72.64, 57.92,






7.3 Hz, 1H),
33.39, 32.33,






3.46-3.35 (m, 2H),
29.12, 27.94,






3.23-3.07 (m, 2H),
25.75, 24.43,






2.02-1.86 (m, 2H), 1.86-1.76 (m,
24.33, 19.65,






1H), 1.76-1.60 (m, 3H),
19.41, 18.75






1.50 (s, 18H), 1.42 (d, J = 6.3 Hz,






3H),






1.31-1.10 (m, 5H), 0.90 (dd, J = 13.8,






6.7 Hz, 6H)


146


ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 566.8
5.21 (dd, J = 8.8, 4.3 Hz, 1H),
(CDCl3) δ





([M + Na]+)
4.75 (dq, J = 9.5, 6.3 Hz,
169.07, 152.61,






1H), 4.22 (dd, J = 12.1,
84.32, 83.01,






4.3 Hz, 1H), 3.92 (dd, J = 12.2,
80.53, 79.44,






8.8 Hz, 1H),
77.42, 73.11,






3.77 (dd, J = 11.1, 1.3 Hz,
72.68, 57.86,






1H), 3.71-3.61 (m, 2H),
44.51, 39.23,






3.57 (dd, J = 11.2, 6.7 Hz,
33.59, 32.62,






1H), 3.40 (dd, J = 9.5,
29.73, 28.92,






8.5 Hz, 2H),
28.28, 27.94,






3.35-3.24 (m, 3H),
25.73, 24.75,






3.24-3.14 (m, 1H), 2.95-2.84 (m,
24.58, 19.50,






1H), 2.76-2.64 (m, 1H),
19.44, 18.99






2.03-1.89 (m, 2H),






1.87-1.59 (m, 4H), 1.50 (s,






18H), 1.46-1.38 (m,






3H), 1.28-1.09 (m, 5H),






0.90 (dd, J = 6.7, 3.9 Hz,






6H)


147


ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 559.0
7.31-7.20 (m, 2H),
(CDCl3) δ





([M + H]+)
7.20-7.12 (m, 2H),
168.79, 159.50,






7.02-6.81 (m, 4H), 6.73 (dt, J = 7.8,
157.39, 152.59,






1.1 Hz, 2H), 5.34 (dd, J = 9.0,
129.37, 129.24,






3.6 Hz, 1H),
121.47, 121.23,






5.16 (dq, J = 9.4, 6.3 Hz, 1H),
116.49, 115.72,






4.58-4.45 (m, 1H),
83.25, 82.80,






4.41 (ddd, J = 8.7, 7.3, 1.3 Hz,
80.62, 75.45,






1H), 4.32 (dd, J = 12.3,
73.18, 72.36,






3.6 Hz, 1H), 4.08 (dd, J = 11.1,
57.95, 28.00,






1.3 Hz, 1H),
18.97






3.98 (dd, J = 12.4, 8.9 Hz,






1H), 3.77 (dd, J = 11.1,






7.3 Hz, 1H), 1.54 (s,






18H), 1.46 (d, J = 6.3 Hz,






3H)


148


ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 538.8
7.30-7.18 (m, 2H), 6.99 (dt, J = 7.9,
(CDCl3) δ





([M + H]+)
1.0 Hz, 2H),
169.05, 159.48,






6.96-6.87 (m, 1H), 5.27 (dd, J = 9.0,
152.64, 129.18,






4.1 Hz, 1H),
121.04, 116.07,






5.10-4.93 (m, 1H),
83.12, 83.01,






4.37-4.21 (m, 2H), 4.05-3.88 (m,
82.48, 78.05,






2H), 3.64 (dd, J = 10.9,
75.56, 72.81,






7.5 Hz, 1H), 3.41 (ddd, J = 8.9,
72.45, 57.89,






7.4, 1.5 Hz, 1H),
28.61, 27.96,






3.32-3.23 (m, 1H),
19.19, 19.07,






3.23-3.12 (m, 1H),
18.81






1.60-1.51 (m, overlapping, m, 1H),






1.52 (s, 18H), 1.37 (d, J = 6.3 Hz,






3H), 0.66 (dd, J = 21.7,






6.7 Hz, 6H)


149


ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 538.8
7.32-7.21 (m, 2H),
(CDCl3) δ





([M + H]+)
6.98-6.88 (m, 3H), 5.28 (dd, J = 8.9,
168.87, 157.52,






3.7 Hz, 1H),
152.59, 129.44,






4.92 (dq, J = 9.7, 6.2 Hz, 1H),
128.49, 121.02,






4.30-4.21 (m, 2H),
115.72, 84.32,






4.00-3.85 (m, 2H),
83.14, 81.24,






3.72-3.60 (m, 2H), 3.43 (dd, J = 9.7,
80.56, 75.61,






8.7 Hz, 1H),
73.01, 72.67,






3.30 (dd, J = 8.4, 6.6 Hz, 1H),
57.94, 28.98,






1.75-1.65 (m, 1H),
27.97, 19.42,






1.52 (s, 18H), 1.48 (d, J = 6.3 Hz,
19.33, 18.80






3H), 0.82 (d, J = 6.7 Hz,






3H), 0.78 (d, J = 6.7 Hz,






3H)


150
227-229

ESIMS

1H NMR (400 MHz,







m/z 358.7
MeOD) δ 7.30-7.21 (m,





([M + H]+)
2H), 7.21-7.12 (m, 2H),






7.04-6.84 (m, 4H),






6.67 (dt, J = 7.8, 1.0 Hz, 2H),






5.53-5.32 (m, 1H),






4.70 (t, J = 9.2 Hz, 1H),






4.55 (dd, J = 4.2, 3.1 Hz, 1H),






4.29 (ddd, J = 9.1, 6.7,






1.0 Hz, 1H),






4.20-4.09 (m, 3H), 4.01-3.83 (m,






1H), 1.50 (d, J = 6.3 Hz,






3H)


151


ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 338.9
8.73 (s, 3H), 7.28-7.16 (m,
(CDCl3) δ





([M + H]+)
2H), 7.01-6.87 (m, 3H),
168.69, 159.26,






5.17 (dt, J = 15.8, 6.2 Hz,
129.25, 121.24,






1H), 4.67 (t, J = 5.3 Hz,
115.99, 82.76,






1H), 4.44-4.31 (m, 1H),
82.29, 78.11,






4.27 (t, J = 9.0 Hz, 1H),
75.46, 73.58,






4.22-4.07 (m, 1H),
70.86, 53.43,






3.97 (d, J = 10.8 Hz, 1H),
28.60, 19.18,






3.70-3.58 (m, 1H), 3.40 (t, J = 8.2 Hz,
19.05, 18.67






1H), 3.27 (dd, J = 8.8,






6.3 Hz, 1H),






3.16 (dd, J = 8.8, 6.3 Hz, 1H),






1.54 (dt, J = 13.1, 6.6 Hz,






1H), 1.41 (d, J = 6.3 Hz,






3H), 0.67 (d, J = 6.7 Hz,






3H), 0.61 (d, J = 6.7 Hz,






3H)


152


ESIMS







m/z 338.7





([M + H]+)


153


ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 541.3
7.42-7.27 (m, 6H), 5.74 (d, J = 7.7 Hz,
(CDCl3) δ





([M + Na]+)
1H),
170.29, 155.78,






5.36-5.25 (m, 1H), 5.10 (d, J = 1.6 Hz,
142.14, 141.92,






2H),
141.86, 141.74,






5.00-4.84 (m, 6H), 4.80-4.71 (m,
136.23, 128.56,






1H), 4.12 (dd, J = 12.0,
128.51, 128.14,






3.5 Hz, 1H),
128.00, 112.95,






4.09-3.78 (m, 9H), 3.77-3.65 (m,
112.71, 112.41,






2H), 3.57-3.45 (m, 1H),
77.22, 76.30,






1.78-1.68 (m, 9H)
76.19, 75.77,







75.19, 75.22,







73.82, 67.08,







66.96, 55.29,







19.61, 19.52,







19.45


154


ESIMS

1H NMR (CDCl3) δ







m/z 541.2
7.44-7.28 (m, 6H), 5.49 (d, J = 9.0 Hz,





([M + Na]+)
1H), 5.24 (td, J = 5.7,






3.2 Hz, 1H),






5.09 (s, 2H), 5.00-4.83 (m,






6H), 4.60-4.52 (m, 1H),






4.19 (dd, J = 11.6, 6.0 Hz,






1H) 4.04 (t, J = 12.7 Hz,






1H), 4.00-3.85 (m,






6H), 3.83-3.77 (m, 1H),






3.76-3.61 (m, 2H),






3.55 (ddd, J = 7.0, 3.9, 1.6 Hz,






1H), 3.51-3.38 (m, 1H),






1.74-1.72 (m, 9H)


155


ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 484.2
7.40-7.28 (m, 5H), 5.57 (d, J = 8.0 Hz,
(CDCl3) δ





([M + Na]+)
1H), 5.11 (s,
170.10, 155.51,






2H), 4.94 (qd, J = 2.1, 1.0 Hz,
142.15, 142.10,






2H), 4.85 (td, J = 2.3,
136.09, 128.55,






1.3 Hz, 2H), 4.67 (s, 1H),
128.25, 128.13,






4.52 (t, J = 4.0 Hz, 1H),
112.17, 112.07,






4.21 (d, J = 11.8 Hz, 2H),
82.31, 81.16,






3.98 (dd, J = 11.2, 4.9 Hz,
78.80, 76.94,






1H), 3.86 (dd, J = 11.9,
67.42, 67.12,






10.5 Hz, 2H),
55.95, 19.82,






3.75 (dq, J = 8.7, 6.4 Hz, 1H),
19.75, 18.58,






3.63 (dd, J = 11.2, 2.8 Hz,
16.50






1H), 3.50 (t, J = 7.6 Hz,






1H), 3.26 (dd, J = 8.8,






5.8 Hz, 1H), 1.72 (dt,






J = 2.4, 1.1 Hz, 6H),






1.62 (d, J = 6.7 Hz, 3H),






1.26 (d, J = 6.4 Hz, 3H)


156


ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 400.2
7.37-7.19 (m, 10H), 5.31 (d,
(CDCl3) δ





([M + H]+)
J = 8.0 Hz, 1H), 5.08 (dq,
171.73, 155.17,






J = 8.4, 6.4 Hz, 1H),
138.15, 138.08,






4.83 (d, J = 11.2 Hz, 1H),
128.40, 128.35,






4.76-4.70 (m, 1H), 4.67 (td, J = 7.4,
128.34, 128.26,






4.7 Hz, 1H),
128.13, 127.76,






4.58 (t, J = 11.7 Hz, 2H),
127.75, 127.71,






4.05-3.92 (m, 1H),
127.66, 127.53,






3.79-3.67 (m, 2H), 3.41 (t, J = 8.3 Hz,
86.14, 84.87,






1H),
81.40, 80.11,






3.36-3.25 (m, 1H), 1.47-1.41 (m,
75.90, 75.19,






12H), 1.27 (d, J = 6.2 Hz,
73.13, 72.46,






3H)
53.66, 28.30,







18.65, 17.34


157


ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 416.8
7.50-7.27 (m, 5H), 5.60 (d, J = 8.5 Hz,
(CDCl3) δ





([M + Na]+)
1H), 5.11 (d, J = 2.7 Hz,
171.27, 155.59,






2H), 4.76 (d, J = 8.7 Hz,
136.12, 128.54,






1H), 4.46 (d, J = 8.6 Hz,
128.24, 128.13,






1H),
109.33, 80.62,






4.00-3.85 (m, 2H),
77.57, 67.11,






3.85-3.75 (m, 1H), 3.75-3.54 (m,
65.67, 56.15,






2H), 1.59 (d, J = 6.5 Hz,
26.73, 26.52,






3H), 1.35 (d, J = 2.7 Hz,
18.29, 16.53






6H), 1.31 (d, J = 6.4 Hz,






3H)


158


ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 559.3
7.30-7.20 (m, 2H),
(CDCl3) δ





([M + Na]+)
6.99-6.87 (m, 3H), 5.29 (dd, J = 8.9,
168.81, 157.35,






3.7 Hz, 1H),
152.57, 142.17,






5.02-4.90 (m, 1H), 4.87 (dq, J = 2.2,
129.48, 121.14,






1.2 Hz, 1H),
115.75, 112.41,






4.83-4.74 (m, 1H),
84.29, 83.14,






4.39-4.20 (m, 3H), 4.02-3.87 (m,
81.39, 77.76,






3H), 3.67 (dd, J = 11.0,
75.44, 72.98,






7.3 Hz, 1H), 3.52 (dd, J = 9.7,
72.49, 57.90,






8.7 Hz, 1H), 1.65 (t,
27.96, 19.79,






J = 1.2 Hz, 3H), 1.52 (s,
18.84






18H), 1.49 (d, J = 6.3 Hz,






3H)


159


ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 559.4
7.31-7.19 (m, 2H),
(CDCl3) δ





([M + Na]+)
7.05-6.97 (m, 2H), 6.93 (tt, J = 7.4,
169.03, 159.37,






1.1 Hz, 1H),
152.63, 141.86,






5.27 (dd, J = 8.9, 4.1 Hz, 1H),
129.29, 121.18,






5.04 (dq, J = 9.5, 6.3 Hz,
116.06, 112.66,






1H), 4.79-4.69 (m, 2H),
83.15, 83.03,






4.37-4.24 (m, 2H),
81.47, 75.52,






4.03-3.82 (m, 4H), 3.68 (dd,
74.93, 72.82,






J = 11.0, 7.3 Hz, 1H),
72.46, 57.86,






3.51 (ddd, J = 8.7, 7.3,
27.96, 19.41,






1.4 Hz, 1H), 1.52 (s,
18.80






18H), 1.49 (s, 3H),






1.37 (d, J = 6.3 Hz, 3H)


160
m

ESIMS

1H NMR (CDCl3) δ


13C NMR




144-146° C.

m/z 318.8
4.82 (dq, J = 8.5, 6.3 Hz, 1H),
(CDCl3) δ





([M + H]+)
3.97-3.84 (m, 1H),
175.66, 84.70,






3.78 (t, J = 7.0 Hz, 1H),
83.85, 80.55,






3.72-3.53 (m, 3H),
77.57, 74.90,






3.44-3.29 (m, 2H), 3.29-3.12 (m,
72.72, 72.70,






4H), 1.82 (ttd, J = 13.4,
29.11, 28.87,






6.5, 2.5 Hz, 2H), 1.42 (d,
19.58, 19.48,






J = 6.3 Hz, 3H),
19.45, 19.38,






0.99-0.78 (m, 12H)
18.61


161




1H NMR (CDCl3) δ








4.84 (dq, J = 8.8, 6.4 Hz, 1H),






3.99-3.86 (m, 1H),






3.78 (dd, J = 7.4, 6.1 Hz, 1H),






3.68 (dd, J = 7.2, 6.1 Hz,






1H), 3.61 (dd, J = 8.3, 5.8 Hz,






1H), 3.55 (dd, J = 8.5,






5.9 Hz, 1H),






3.42 (dd, J = 11.8, 6.2 Hz,






1H), 3.22 (ddd, J = 8.5,






7.3, 2.0 Hz, 2H),






3.15-3.06 (m, 1H), 2.98 (dd, J = 8.2,






7.4 Hz, 1H),






1.81 (p, J = 6.8 Hz, 4H),






1.42 (d, J = 6.4 Hz, 3H),






1.19 (d, J = 6.4 Hz, 3H),






0.90 (ddd, J = 15.4, 6.7, 3.7 Hz,






12H).


162


ESIMS

1H NMR (300 MHz,







m/z 318.8
CDCl3) δ 4.53 (dd, J = 11.2,





([M + H]+)
9.0 Hz, 1H),






4.10 (dd, J = 11.2, 3.6 Hz,






1H), 3.75-3.49 (m, 2H),






3.47-3.10 (m, 5H),






2.96 (t, J = 7.8 Hz, 1H),






1.81 (dt, J = 13.3, 6.6 Hz, 2H),






1.22 (d, J = 5.9 Hz, 3H),






1.04-0.77 (m, 16H)


163

(Neat)
HRMS-ESI

1H NMR (CDCl3) δ


13C NMR





2933,
(m/z)
5.19 (dd, J = 9.0, 4.1 Hz, 1H),
(CDCl3) δ




2875,
[M]+
4.79 (dq, J = 9.2, 6.3 Hz,
169.06, 152.69,




1764,
calcd for
1H), 4.20 (dd, J = 12.2,
85.55, 83.49,




1747,
C25H45NO10,
4.1 Hz, 1H), 3.98 (ddd, J = 10.6,
83.10, 75.76,




1708,
519.3043;
5.2, 3.8 Hz, 1H),
72.96, 72.85,




1456,
found,
3.88 (dd, J = 12.2, 9.0 Hz,
72.70, 72.34,




1367,
519.3026
1H), 3.79 (d, J = 10.7 Hz,
70.62, 59.02,




1243,

1H), 3.73-3.65 (m,
57.95, 32.28,




1099

1H), 3.60-3.43 (m, 5H),
28.02, 19.41,






3.34 (s, 3H),
18.67, 14.01






3.28-3.15 (m, 2H), 1.55-1.44 (m,






2H), 1.47 (s, 18H),






1.42 (d, J = 6.3 Hz, 3H),






1.38-1.26 (m, 2H), 0.87 (t, J = 7.4 Hz,






3H)


164

(Neat)
HRMS-ESI

1H NMR (CDCl3) δ


13C NMR





2934,
(m/z)
5.22 (dd, J = 8.9, 3.9 Hz, 1H),
(CDCl3) δ




1745,
[M]+
4.80 (dq, J = 8.9, 6.3 Hz,
169.06, 152.76,




1707,
calcd for
1H), 4.24 (dd, J = 12.2,
85.77, 83.22,




1457,
C24H43NO10,
3.9 Hz, 1H),
83.05, 75.57,




1367,
505.2887;
3.95-3.79 (m, 3H), 3.78-3.68 (m,
75.51, 73.09,




1254,
found,
2H), 3.66-3.45 (m, 4H),
73.00, 70.54,




1120
505.2900
3.45-3.38 (m, 1H),
62.93, 58.04,






3.39-3.23 (m, 2H),
31.86, 28.07,






1.61-1.50 (m, 2H), 1.49 (s,
19.32, 18.80,






18H), 1.44 (d, J = 6.3 Hz,
13.99






3H), 1.40-1.26 (m, 2H),






0.89 (t, J = 7.4 Hz, 3H)


167


ESIMS







m/z 326.7





([M + H]+)


169


ESIMS







m/z 319





([M]+)


170


ESIMS







m/z 304.6





([M + H]+)


172


ESIMS







m/z 386.2





([M − Boc + 2H]+)


177


ESIMS

1H NMR (CDCl3) δ







m/z 346.7
8.83 (bs, 1H), 5.24-5.12 (m,





([M + H]+)
2H), 4.88-4.80 (m, 1H),






4.71-4.63 (m, 1H),






4.45 (dd, J = 12.9, 3.3 Hz,






1H), 4.12 (dd, J = 12.7,






6.5 Hz, 1H), 3.85 (d, J = 10.8 Hz,






1H), 3.73 (dd, J = 11.9,






7.9 Hz, 1H),






2.57-2.39 (m, 2H),






1.82-1.52 (m, 2 H), 1.35 (d, J = 5.7 Hz,






3H), 1.16 (d, J = 7.0 Hz,






3H), 1.13 (d, J = 7.0 Hz,






3H), 1.10 (d, J = 7.0 Hz,






3H), 1.09 (d, J = 7.0 Hz,






3H)


180


ESIMS







m/z 332.8





([M + H]+)


186
66-68

ESIMS

1H NMR (CDCl3) δ







m/z 456.19
7.42-7.29 (m, 5H), 5.48 (d, J = 7.9 Hz,





([M + Na]+)
1H), 5.10 (s,






2H), 4.96 (s, 2H), 4.89 (s,






2H), 4.69 (dd, J = 11.5,






8.8 Hz, 2H), 4.12 (dd, J = 11.5,






3.8 Hz, 1H),






4.09-3.96 (m, 5H), 3.69 (ddt, J = 12.4,






8.7, 4.5 Hz, 3H),






3.56 (dd, J = 11.5, 6.0 Hz,






1H), 3.33 (t, J = 6.2 Hz,






1H), 1.73 (s, 6H)


187


ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 422.22
5.46 (d, J = 7.7 Hz, 1H),
(CDCl3) δ





([M + Na]+)
5.05-4.94 (m, 3H), 4.90 (d, J = 12.7 Hz,
170.89, 155.22,






2H),
142.05, 141.87,






4.71-4.61 (m, 2H),
112.88, 112.66,






4.14-4.07 (m, 2H), 4.05-3.92 (m,
79.94, 78.02,






4H), 3.87 (td, J = 10.9,
77.22, 75.78,






6.1 Hz, 1H), 3.78 (td, J = 6.6,
75.67, 74.69,






2.6 Hz, 1H),
73.73, 71.35,






3.65 (dd, J = 12.1, 1.3 Hz,
62.99, 54.95,






1H), 3.44-3.38 (m, 1H),
28.30, 19.55






1.74 (d, J = 8.7 Hz, 6H),






1.43 (s, 9H)


188




1H NMR (CDCl3) δ








8.66 (s, 2H), 7.35-7.15 (m,






10H), 5.16 (t, J = 7.0 Hz,






1H), 4.77 (d, J = 11.1 Hz,






1H), 4.67 (d, J = 10.9 Hz,






1H), 4.62-4.50 (m, 3H),






4.32 (d, J = 12.7 Hz, 1H),






4.09 (dd, J = 13.0, 6.6 Hz,






1H), 3.81-3.60 (m,






1H), 3.36 (dt, J = 22.9,






7.6 Hz, 2H), 1.43 (d, J = 6.3 Hz,






3H), 1.26 (d, J = 6.1 Hz,






3H).


189




1H NMR (CDCl3) δ








5.18 (td, J = 5.5, 3.3 Hz, 1H),






4.14-4.05 (m, 1H),






3.92-3.80 (m, 2H),






3.76-3.66 (m, 3H),






3.46-3.30 (m, 4H), 3.25 (d, J = 6.6 Hz,






2H), 3.23-3.14 (m,






2H), 1.93-1.77 (m, 4H),






0.97-0.83 (m, 19H)


190




1H NMR (CDCl3) δ








5.16 (td, J = 5.3, 3.6 Hz, 1H),






4.20 (dd, J = 10.8, 6.8 Hz,






1H), 3.81 (dd, J = 7.5,






3.6 Hz, 1H),






3.77-3.62 (m, 4H),






3.44-3.35 (m, 2H), 3.35-3.28 (m,






2H), 3.25 (dd, J = 6.6, 0.8 Hz,






2H), 3.22-3.13 (m,






2H), 1.94-1.77 (m, 4H),






0.95-0.83 (m, 19H)


191


ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 428.5
5.25 (dd, J = 8.7, 2.8 Hz, 1H),
(CDCl3) δ





([M + Na]+)
4.94-4.76 (m, 1H),
168.63, 152.70,






4.26 (dd, J = 12.3, 2.9 Hz,
83.18, 79.34,






1H), 4.06 (dd, J = 10.7,
77.96, 74.40,






1.3 Hz, 1H), 3.91 (dd, J = 12.3,
74.25, 73.02,






8.7 Hz, 1H),
58.54, 27.98,






3.62-3.54 (m, 1H),
18.60






3.54-3.38 (m, 2H), 3.15 (d, J = 4.0 Hz,






1H), 2.96 (d, J = 3.5 Hz,






1H), 1.51 (s, 18H),






1.46 (d, J = 6.3 Hz, 3H)


192


ESIMS

1H NMR (CDCl3) δ







m/z 609.6
7.38-7.23 (m, 10H),





([M + Na]+)
5.24 (dd, J = 8.9, 3.9 Hz, 1H),






4.98-4.82 (m, 2H),






4.70-4.54 (m, 3H), 4.26 (dd,






J = 12.2, 3.9 Hz, 1H),






4.03-3.88 (m, 2H),






3.63 (dd, J = 10.9, 7.2 Hz,






1H), 3.58-3.50 (m, 1H),






3.50-3.42 (m, 1H),






1.50 (s, 18H), 1.43 (d, J = 6.3 Hz,






3H)


194

(Thin
HRMS-FAB

1H NMR (CDCl3) δ


13C NMR





Film)
(m/z)
11.91 (d, J = 0.7 Hz, 1H),
(CDCl3) δ




3364,
[M + H]+
8.68 (d, J = 8.2 Hz, 1H),
170.27, 168.98,




2955,
calcd for
8.01 (d, J = 5.2 Hz, 1H),
160.14, 155.37,




2874,
C25H31ClN2O8,
7.17 (t, J = 8.1 Hz, 1H), 7.04 (t,
148.76, 140.70,




1752,
523.1842;
J = 2.2 Hz, 1H), 6.93 (ddd,
134.61, 130.16,




1649
found,
J = 8.0, 2.0, 0.9 Hz, 1H),
129.99, 121.43,





523.1848
6.91-6.86 (m, 2H),
116.66, 114.42,






5.18 (dq, J = 9.6, 6.3 Hz, 1H),
109.63, 83.40,






5.10 (ddd, J = 8.2, 6.8, 5.1 Hz,
82.59, 78.02,






1H), 4.25 (t, J = 9.1 Hz,
74.66, 73.92,






1H), 4.16-4.05 (m,
72.49, 56.10,






1H), 4.00-3.89 (m, 4H),
52.06, 28.62,






3.87 (dd, J = 11.9, 5.1 Hz,
19.16, 19.05,






1H), 3.72 (dd, J = 11.1,
18.72






7.4 Hz, 1H), 3.38 (ddd, J = 8.8,






7.3, 1.5 Hz, 1H),






3.30 (dd, J = 8.8, 6.4 Hz, 1H),






3.16 (dd, J = 8.8, 6.4 Hz,






1H), 1.67-1.50 (m, 1H),






1.41 (d, J = 6.3 Hz, 3H),






0.69 (dd, J = 17.9, 6.7 Hz,






6H)


195

(Thin
HRMS-FAB

1H NMR (CDCl3) δ


13C NMR





Film)
(m/z)
11.90 (d, J = 0.6 Hz, 1H),
(CDCl3) δ




3369,
[M + H]+
8.68 (d, J = 8.2 Hz, 1H),
170.25, 168.99,




2957,
calcd for
8.01 (d, J = 5.2 Hz, 1H),
161.79, 155.38,




2876,
C26H31F3N2O8,
7.58-7.44 (m, 2H), 7.07 (dd, J = 8.8,
148.77, 140.71,




1752,
557.2105;
0.9 Hz, 2H), 6.88 (dd,
130.14, 126.73,




1650
found,
J = 5.3, 0.7 Hz, 1H),
126.69, 115.91,





557.2115
5.21 (dq, J = 9.4, 6.3 Hz, 1H),
109.64, 83.01,






5.11 (ddd, J = 8.2, 6.9, 5.1 Hz,
82.57, 78.02,






1H), 4.35 (t, J = 9.1 Hz,
74.65, 73.96,






1H), 4.11 (dd, J = 11.9,
72.38, 56.11,






6.9 Hz, 1H),
52.06, 28.56,






4.00-3.91 (m, 4H), 3.88 (dd, J = 11.9,
19.10, 18.98,






5.1 Hz, 1H),
18.69






3.73 (dd, J = 11.2, 7.3 Hz, 1H),






3.40 (ddd, J = 8.8, 7.4, 1.5 Hz,






1H), 3.29 (dd, J = 8.9,






6.3 Hz, 1H), 3.13 (dd, J = 8.9,






6.4 Hz, 1H),






1.54 (hept, J = 6.6 Hz, 1H),






1.40 (d, J = 6.3 Hz, 3H),






0.67 (d, J = 6.7 Hz, 3H),






0.62 (d, J = 6.7 Hz, 3H)


196

(Thin
HRMS-FAB

1H NMR (CDCl3) δ


13C NMR





Film)
(m/z)
11.90 (s, 1H), 8.68 (d, J = 8.2 Hz,
(CDCl3) δ




3331,
[M + H]+
1H), 8.01 (d, J = 5.2 Hz,
170.31, 169.00,




2944,
calcd for
1H), 7.60-7.47 (m,
161.84, 155.39,




2884,
C25H29F3N2O8,
2H), 7.08 (d, J = 8.6 Hz,
148.78, 140.71,




1737,
543.1949;
2H), 6.88 (d, J = 5.2 Hz,
130.14, 126.79,




1646
found,
1H), 5.20 (dq, J = 9.5, 6.3 Hz,
126.75, 126.71,





543.1957
1H), 5.11 (ddd, J = 8.2,
115.98, 109.64,






6.9, 5.3 Hz, 1H),
83.22, 82.34,






4.35 (t, J = 9.1 Hz, 1H),
74.57, 73.80,






4.11 (dd, J = 11.8, 7.0 Hz, 1H),
72.99, 72.38,






3.97-3.89 (m, 4H),
56.10, 51.98,






3.86 (dd, J = 11.8, 5.3 Hz, 1H),
22.92, 18.69,






3.74 (dd, J = 11.1, 7.4 Hz,
10.27






1H), 3.52-3.38 (m, 2H),






3.31 (dt, J = 9.1, 6.6 Hz,






1H), 1.40 (d, J = 6.3 Hz,






3H), 1.38-1.24 (m, 2H),






0.66 (t, J = 7.4 Hz, 3H)


197

(Thin
HRMS-FAB

1H NMR (CDCl3) δ


13C NMR





Film)
(m/z)
11.91 (s, 1H), 8.75 (d, J = 8.1 Hz,
(CDCl3) δ




3365,
[M + H]+
1H), 8.03 (d, J = 5.2 Hz,
169.89, 169.00,




2939,
calcd for
1H), 7.62-7.46 (m,
159.91, 155.39,




2879,
C25H29F3N2O8,
2H), 6.99 (dd, J = 8.8, 0.9 Hz,
148.79, 140.73,




1751,
543.1949;
2H), 6.89 (d, J = 5.2 Hz,
130.16, 127.07,




1649
found,
1H), 5.19-5.04 (m,
127.03, 126.99,





543.1957
2H), 4.27 (ddd, J = 8.5,
126.95, 115.41,






7.0, 1.2 Hz, 1H), 4.05 (dd,
109.63, 84.47,






J = 12.1, 6.5 Hz, 1H),
81.33, 77.22,






4.01-3.91 (m, 5H),
75.76, 75.74,






3.85-3.68 (m, 2H),
74.77, 72.70,






3.59-3.42 (m, 2H), 1.52 (d, J = 6.3 Hz,
56.11, 52.46,






3H), 1.51-1.42 (m,
23.36, 18.63,






2H), 0.82 (t, J = 7.4 Hz,
10.56






3H)


198

(Thin
HRMS-FAB

1H NMR (CDCl3) δ


13C NMR





Film)
(m/z)
11.93 (d, J = 0.6 Hz, 1H),
(CDCl3) δ




3363,
[M + H]+
8.74 (d, J = 8.2 Hz, 1H),
170.13, 169.01,




2919,
calcd for
8.02 (d, J = 5.2 Hz, 1H),
159.55, 157.31,




1753,
C31H36N2O8,
6.88 (d, J = 5.2 Hz, 1H),
155.39, 148.80,




1649
565.2544;
6.61 (d, J = 1.3 Hz, 3H),
140.73, 139.17,





found,
6.59-6.53 (m, 1H),
138.92, 130.19,





565.2549
6.41-6.29 (m, 2H), 5.29 (dq, J = 9.4,
123.37, 123.15,






6.3 Hz, 1H), 5.15 (ddd, J = 8.3,
114.47, 113.45,






6.8, 4.7 Hz, 1H),
109.64, 82.89,






4.46 (t, J = 9.0 Hz, 1H),
80.39, 74.62,






4.32 (ddd, J = 8.7, 7.2, 1.4 Hz,
74.16, 72.78,






1H), 4.11 (dd, J = 11.9,
56.11, 52.22,






6.9 Hz, 1H), 4.03 (dd, J = 11.3,
21.42, 21.40,






1.3 Hz, 1H), 3.94 (s,
18.92






3H), 3.95-3.91 (m, 1H),






3.81 (dd, J = 11.2, 7.3 Hz,






1H), 2.27 (s, 6H), 2.23 (s,






6H), 1.50 (d, J = 6.3 Hz,






3H)


199

(Thin
HRMS-FAB

1H NMR (CDCl3) δ


13C NMR





Film)
(m/z)
11.89 (d, J = 0.7 Hz, 1H),
(CDCl3) δ




3335,
[M + H]+
8.69 (d, J = 8.3 Hz, 1H),
175.56, 170.14,




2938,
Calcd for
8.01 (d, J = 5.2 Hz, 1H),
169.00, 155.33,




2838,
C26H32N2O10,
6.92-6.85 (m, 3H),
154.30, 152.98,




1745,
533.213;
6.84-6.78 (m, 2H), 5.25 (dq, J = 9.4,
148.71, 140.74,




1644,
found,
6.3 Hz, 1H), 5.11 (ddd, J = 8.3,
130.09, 116.58,




1506
533.2142
6.9, 5.4 Hz, 1H),
114.54, 109.65,






5.05 (ddd, J = 8.8, 6.6, 2.0 Hz,
81.64, 75.01,






1H), 4.39 (t, J = 9.1 Hz,
74.81, 73.81,






1H), 4.12 (dd, J = 11.9,
72.83, 56.09,






6.9 Hz, 1H), 3.94 (s, 3H),
55.70, 51.90,






3.90-3.78 (m, 3H),
33.79, 18.76,






3.77 (s, 3H), 2.23 (hept, J = 7.0 Hz,
18.64, 18.44






1H), 1.44 (d, J = 6.4 Hz,






3H), 0.96 (d, J = 7.0 Hz,






3H), 0.88 (d, J = 7.0 Hz,






3H)


200

(Thin
HRMS-FAB

1H NMR (CDCl3) δ


13C NMR





Film)
(m/z)
11.91 (s, 1H), 8.75 (d, J = 8.1 Hz,
(CDCl3) δ




3364,
[M + H]+
1H), 8.02 (d, J = 5.2 Hz,
175.85, 169.89,




2939,
calcd for
1H), 6.89 (d, J = 5.2 Hz,
168.99, 155.39,




2838,
C26H32N2O10,
1H), 6.87-6.73 (m,
154.26, 151.07,




1740,
533.213;
4H), 5.35-5.20 (m, 2H),
148.80, 140.71,




1506
found,
5.14 (ddd, J = 8.1, 6.1, 3.9 Hz,
130.17, 116.33,





533.2138
1H), 4.23-3.99 (m,
114.75, 109.64,






4H), 3.95 (s, 3H), 3.75 (s,
78.98, 75.80,






3H), 3.74-3.70 (m, 1H),
75.15, 75.07,






2.47 (hept, J = 7.0 Hz,
71.35, 56.11,






1H), 1.40 (d, J = 5.8 Hz,
55.68, 52.71,






3H), 1.10 (dd, J = 15.3,
34.04, 18.91,






7.0 Hz, 6H)
18.23


201

(Thin
HRMS-FAB

1H NMR (CDCl3) δ


13C NMR





Film)
(m/z)
11.92 (s, 1H), 8.73 (d, J = 8.2 Hz,
(CDCl3) δ




3364,
[M + H]+
1H), 8.01 (d, J = 5.2 Hz,
170.10, 169.01,




2938,
calcd for
1H), 7.05-6.91 (m,
155.36, 154.36,




2835,
C29H32N2O10,
2H), 6.87 (d, J = 5.2 Hz,
154.34, 153.74,




1751,
569.2130;
1H), 6.83-6.70 (m, 6H),
151.45, 148.77,




1649
found,
5.30 (dq, J = 9.3, 6.3 Hz,
140.73, 130.15,





569.2133
1H), 5.13 (ddd, J = 8.2,
117.64, 116.97,






6.7, 4.7 Hz, 1H), 4.35 (t, J = 9.1 Hz,
114.64, 114.38,






1H), 4.23 (ddd, J = 8.7,
109.65, 84.13,






7.0, 1.3 Hz, 1H),
81.78, 74.75,






4.16-4.00 (m, 2H),
74.21, 72.64,






3.95-3.91 (m, 4H), 3.80 (dd, J = 11.3,
56.10, 55.65,






7.1 Hz, 1H),
52.24, 18.93






3.76 (s, 3H), 3.72 (s, 3H),






1.50 (d, J = 6.3 Hz, 3H)


202


HRMS-FAB

1H NMR (CDCl3) δ


13C NMR






(m/z)
11.92 (d, J = 0.6 Hz, 1H),
(CDCl3) δ





[M + H]+
8.68 (d, J = 8.2 Hz, 1H),
170.42, 168.98,





calcd for
8.00 (d, J = 5.2 Hz, 1H),
159.47, 155.35,





C24H30N2O8,
7.33-7.20 (m, 2H),
148.74, 140.69,





475.2075;
7.07-6.98 (m, 2H), 6.95 (tt, J = 7.4,
130.16, 129.27,





found,
1.1 Hz, 1H),
121.26, 116.14,





475.2088
6.87 (dd, J = 5.2, 0.7 Hz, 1H),
109.62, 83.24,






5.18 (dq, J = 9.5, 6.3 Hz,
82.45, 74.74,






1H), 5.10 (ddd, J = 8.2,
73.68, 73.12,






7.0, 5.4 Hz, 1H),
72.85, 56.09,






4.31 (dd, J = 9.5, 8.6 Hz, 1H),
51.96, 22.99,






4.11 (dd, J = 11.8, 7.0 Hz,
18.75, 10.34






1H), 3.94 (s, 3H),






3.90 (dd, J = 11.0, 1.6 Hz,






1H), 3.83 (dd, J = 11.8,






5.4 Hz, 1H),






3.74 (dd, J = 11.1, 7.3 Hz,






1H), 3.49 (dt, J = 9.0, 6.6 Hz,






1H), 3.44-3.33 (m,






2H), 1.42 (d, J = 6.3 Hz,






3H), 1.40-1.29 (m, 2H),






0.69 (t, J = 7.4 Hz, 3H)


203


HRMS-FAB

1H NMR (CDCl3) δ


13C NMR






(m/z)
11.93 (s, 1H), 8.72 (d, J = 8.1 Hz,
(CDCl3) δ





[M + H]+
1H), 8.02 (d, J = 5.2 Hz,
170.04, 168.99,





calcd for
1H), 7.38-7.20 (m,
157.43, 155.35,





C24H30N2O8,
2H), 7.04-6.89 (m, 3H),
148.76, 140.71,





475.2075;
6.88 (d, J = 5.2 Hz, 1H),
130.20, 129.56,





found,
5.16-5.04 (m, 2H),
121.20, 115.62,





475.2085
4.22 (ddd, J = 8.7, 7.1, 1.3 Hz,
109.61, 84.52,






1H), 4.05 (dd, J = 12.0,
81.17, 75.64,






6.7 Hz, 1H),
75.35, 74.37,






4.00-3.89 (m, 5H), 3.85 (dt, J = 8.8,
72.85, 56.10,






6.6 Hz, 1H), 3.71 (dd, J = 11.3,
52.33, 23.41,






7.1 Hz, 1H), 3.54 (dt,
18.68, 10.60






J = 8.8, 6.7 Hz, 1H),






3.46 (dd, J = 9.6, 8.8 Hz, 1H),






1.59-1.41 (m, 5H),






0.83 (t, J = 7.4 Hz, 3H)


204


HRMS-FAB

1H NMR (CDCl3) δ


13C NMR






(m/z)
11.92 (s, 1H), 8.68 (d, J = 8.2 Hz,
(CDCl3) δ





[M + H]+
1H), 8.01 (d, J = 5.2 Hz,
170.14, 168.99,





calcd for
1H), 7.36-7.15 (m,
157.40, 155.35,





C26H32N2O8,
2H), 7.04-6.98 (m, 2H),
148.75, 140.71,





501.2231;
6.93 (tt, J = 7.2, 1.1 Hz,
130.20, 129.56,





found,
1H), 6.88 (d, J = 5.2 Hz,
121.14, 115.59,





501.2246
1H), 5.23-5.14 (m, 1H),
109.61, 84.26,






5.14-5.06 (m, 1H),
82.20, 81.24,






4.28 (t, J = 9.1 Hz, 1H),
75.47, 74.34,






4.11 (dd, J = 11.8, 7.1 Hz, 1H),
73.27, 56.10,






4.03 (ddd, J = 8.6, 5.0, 3.6 Hz,
52.32, 32.96,






1H), 3.94 (s, 3H),
32.32, 23.13,






3.88 (dd, J = 11.1, 1.7 Hz, 1H),
18.80






3.83 (dd, J = 11.8, 5.5 Hz,






1H), 3.73 (dd, J = 11.0,






7.5 Hz, 1H), 3.48 (ddd, J = 8.9,






7.3, 1.6 Hz, 1H),






1.63-1.49 (m, 2H),






1.46-1.35 (m, 7H),






1.37-1.26 (m, 2H)


205


HRMS-FAB

1H NMR (CDCl3) δ


13C NMR






(m/z)
11.93 (d, J = 0.6 Hz, 1H),
(CDCl3) δ





[M + H]+
8.72 (d, J = 8.1 Hz, 1H),
170.14, 168.99,





calcd for
8.01 (d, J = 5.2 Hz, 1H),
157.40, 155.35,





C26H32N2O8,
7.32-7.24 (m, 2H),
148.75, 140.71,





501.2231;
6.99-6.90 (m, 3H), 6.88 (dd, J = 5.3,
130.20, 129.56,





found,
0.6 Hz, 1H),
121.14, 115.59,





501.2243
5.13-5.01 (m, 2H), 4.41-4.32 (m,
109.61, 84.26,






1H), 4.18 (ddd, J = 8.4,
82.20, 81.24,






6.8, 1.2 Hz, 1H), 4.06 (dd,
75.47, 74.34,






J = 12.0, 6.7 Hz, 1H),
73.27, 56.10,






3.94 (m, 4H), 3.89 (dd, J = 12.0,
52.32, 32.96,






4.6 Hz, 1H),
32.32, 23.13,






3.73 (dd, J = 11.4, 6.8 Hz, 1H),
18.80






3.60 (dd, J = 9.5, 8.6 Hz,






1H), 1.74-1.57 (m, 6H),






1.52 (m, J = 6.4 Hz, 4H),






1.48-1.40 (m, 1H)


206

(Thin
HRMS-FAB

1H NMR (CDCl3) δ


13C NMR





Film)
(m/z)
11.92 (d, J = 0.6 Hz, 1H),
(CDCl3) δ




3361,
[M + H]+
8.74 (d, J = 8.1 Hz, 1H),
170.07, 169.02,




2938,
calcd for
8.02 (d, J = 5.2 Hz, 1H),
157.50, 155.38,




1750,
C29H32N2O8,
7.08-7.02 (m, 2H),
155.23, 148.78,




1648,
537.2231;
7.02-6.97 (m, 2H), 6.94-6.85 (m,
140.74, 130.86,




1577,
found,
3H), 6.69-6.64 (m, 2H),
130.69, 130.17,




1506
537.2243.
5.31 (dq, J = 9.4, 6.3 Hz,
129.93, 129.76,






1H), 5.14 (ddd, J = 8.1,
116.44, 115.65,






6.7, 4.6 Hz, 1H), 4.43 (t, J = 9.1 Hz,
109.65, 83.30,






1H), 4.30 (ddd, J = 8.6,
80.89, 74.88,






7.1, 1.3 Hz, 1H),
74.32, 72.68,






4.13-4.02 (m, 2H),
56.11, 52.29,






3.97-3.91 (m, 4H), 3.80 (dd, J = 11.3,
20.53, 20.48,






7.2 Hz, 1H),
18.90






2.28 (s, 3H), 2.24 (s, 3H),






1.49 (d, J = 6.3 Hz, 3H)


207
127
(Thin
HRMS-FAB

1H NMR (CDCl3) δ






Film)
(m/z)
11.92 (d, J = 0.6 Hz, 1H),




3376,
[M + H]+
8.72 (d, J = 8.1 Hz, 1H),




2955,
calcd for
8.02 (d, J = 5.2 Hz, 1H),




1733,
C25H31F1N2O8,
7.05-6.91 (m, 2H),




1642,
507.2137;
6.91-6.80 (m, 3H), 5.19-5.03 (m,




1506
found,
2H), 4.17-4.08 (m, 1H),





507.2147
4.05 (dd, J = 12.1, 6.6 Hz,






1H), 4.00-3.91 (m, 5H),






3.75-3.62 (m, 2H),






3.43 (t, J = 9.2 Hz, 1H),






3.32 (dd, J = 8.4, 6.5 Hz, 1H),






1.73 (hept, J = 6.7 Hz,






1H), 1.51 (d, J = 6.3 Hz,






3H), 0.82 (dd, J = 15.4,






6.7 Hz, 6H)


208
170-172
(Thin
HRMS-FAB

1H NMR (CDCl3) δ






Film)
(m/z)
11.89 (d, J = 0.6 Hz, 1H),




3150.6,
[M + H]+
8.74 (d, J = 8.1 Hz, 1H),




3097.8,
calcd for
8.04 (d, J = 5.2 Hz, 1H),




2932.5,
C27H26F2N2O8,
7.03-6.82 (m, 7H),




2886.2,
545.173;
6.76-6.62 (m, 2H), 5.33 (dq, J = 9.4,




1755.4,
found,
6.3 Hz, 1H), 5.14 (m, 1H),




1650.2
545.1729
4.38 (t, J = 9.1 Hz, 1H),






4.27 (ddd, J = 8.7, 7.1, 1.3 Hz,






1H), 4.15-4.02 (m,






2H), 3.99 (d, J = 4.4 Hz,






1H), 3.96 (s, 3H),






3.81 (dd, J = 11.4, 7.1 Hz, 1H),






1.50 (d, J = 6.4 Hz, 3H)


209
114-117

ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 465
11.72 (s, 1H), 8.46 (d, J = 8.2 Hz,
(CDCl3) δ





([M + H]+)
1H), 7.78 (d, J = 5.2 Hz,
170.26, 168.93,






1H), 6.66 (d, J = 5.2 Hz,
155.28, 148.67,






1H), 4.83 (ddd, J = 8.3,
140.65, 130.14,






6.9, 5.1 Hz, 1H),
109.56, 84.60,






4.80-4.75 (m, 1H), 3.83 (dd, J = 11.9,
83.26, 78.74,






6.9 Hz, 1H),
75.81, 75.36,






3.73 (s, 3H), 3.67-3.53 (m,
73.81, 73.11,






3H), 3.40 (dd, J = 11.1,
56.06, 52.05,






6.7 Hz, 1H),
18.59, 11.07,






3.27-3.14 (m, 3H), 3.10-3.00 (m,
10.91, 3.21, 3.15,






2H), 1.27 (d, J = 6.3 Hz,
2.93, 2.84






3H), 0.95-0.78 (m, 2H),






0.40-0.28 (m, 4H),






0.08-−0.06 (m, 4H)


210
61-70
(Thin
HRMS-ESI

1H NMR (CDCl3) δ


13C NMR





Film)
(m/z)
11.94 (s, 1H), 8.67 (d, J = 8.1 Hz,
(CDCl3) δ




3530,
[M + Na]+
1H), 8.01-7.98 (m,
170.30, 168.94,




3371, 2955,
calcd for
1H), 6.87 (d, J = 5.2 Hz,
155.32, 148.72,




2873,
C25H40N2NaO8,
1H), 5.04 (ddd, J = 8.2,
140.66, 130.22,




1750,
519.2677,
6.8, 5.0 Hz, 1H),
109.56, 85.02,




1649,
found,
5.01-4.89 (m, 1H), 4.05 (dd, J = 11.9,
83.63, 75.28,




1529,
519.2687
6.8 Hz, 1H), 3.94 (s,
73.94, 73.17,




1262

3H), 3.92-3.85 (m, 1H),
72.48, 69.35,






3.85-3.78 (m, 2H),
56.09, 52.12,






3.66-3.58 (m, 2H),
39.23, 38.95,






3.57-3.48 (m, 2H),
24.96, 22.91,






3.26-3.14 (m, 2H), 1.69 (dp, J = 13.4,
22.67, 22.62,






6.7 Hz, 2H),
22.50, 18.59






1.51-1.38 (m, 7H), 0.90 (dt, J = 6.2,






2.7 Hz, 12H)


211

(Thin
ESIMS

1H NMR (CDCl3) δ






Film)
m/z 433.1
11.94 (s, 1H), 8.83 (d, J = 7.9 Hz,




3364,
([M + H]+)
1H), 8.04 (d, J = 5.2 Hz,




2926,

1H), 7.37-7.27 (m,




1750,

2H), 7.01 (t, J = 7.4 Hz,




1649,

1H), 6.97-6.87 (m, 3H),




1530,

5.31-5.21 (m, 1H),




1482,

5.09 (ddd, J = 8.0, 5.9, 2.5 Hz,




1242

1H), 4.22-4.06 (m, 4H),






3.99 (dd, J = 12.2, 5.9 Hz,






1H), 3.95 (s, 3H), 3.78 (t,






J = 9.1 Hz, 1H), 3.58 (dd,






J = 11.9, 7.1 Hz, 1H),






1.56 (d, J = 6.4 Hz, 3H);


212

(Thin
ESIMS

1H NMR (CDCl3) δ






Film)
m/z 541.2
11.93 (s, 1H), 8.73 (t, J = 7.0 Hz,




3367,
([M + H]+)
1H), 8.02 (dd, J = 5.2, 2.1 Hz,




2925,

1H), 7.32-7.25 (m,




1752,

2H), 6.99-6.86 (m, 4H),




1650,

5.16-5.04 (m, 2H),




1530,

4.30-4.00 (m, 4H),




1242

4.00-3.82 (m, 2H), 3.95 (s, 3H),






3.80-3.59 (m, 2H),






3.55-3.38 (m, 1H),






2.17-2.01 (m, 2H),






2.01-1.77 (m, 2H), 1.73-1.38 (m,






9H)


213

(Thin
HRMS-FAB

1H NMR (CDCl3) δ


13C NMR





Film)
(m/z)
8.56 (d, J = 8.0 Hz, 1H),
(CDCl3) δ




3375,
[M + H]+
8.29 (d, J = 5.4 Hz, 1H),
170.88, 170.06,




2956,
calcd for
7.17 (t, J = 8.2 Hz, 1H), 7.04 (t,
163.23, 160.17,




2875,
C30H39ClN2O11,
J = 2.2 Hz, 1H), 6.96 (d, J = 5.4 Hz,
145.87, 143.98,




1753,
639.2315;
1H),
141.92, 134.59,




1677
found,
6.95-6.87 (m, 2H), 5.82 (s, 2H),
129.98, 121.38,





639.232
5.23-5.06 (m, 2H), 4.25 (t, J = 9.1 Hz,
116.68, 114.41,






1H), 4.10 (s, 2H),
109.87, 89.44,






3.91 (s, 4H), 3.82 (dd, J = 11.8,
83.42, 82.64,






5.3 Hz, 1H),
78.00, 74.36,






3.71 (dd, J = 11.1, 7.4 Hz, 1H),
74.08, 72.30,






3.59 (q, J = 7.0 Hz, 2H),
67.80, 67.20,






3.37 (ddd, J = 8.9, 7.4, 1.6 Hz,
56.25, 52.32,






1H), 3.29 (dd, J = 8.8,
28.62, 19.16,






6.3 Hz, 1H), 3.15 (dd, J = 8.8,
19.06, 18.72,






6.4 Hz, 1H),
15.01






1.67-1.51 (m, 2H), 1.39 (d, J = 6.3 Hz,






3H), 1.23 (t, J = 7.0 Hz,






3H), 0.68 (dd, J = 18.4,






6.7 Hz, 6H)


214

(Thin
HRMS-FAB

1H NMR (CDCl3) δ


13C NMR





Film)
(m/z)
8.55 (d, J = 7.9 Hz, 1H),
(CDCl3) δ




3376,
[M + H]+
8.29 (d, J = 5.4 Hz, 1H),
170.90, 170.27,




2955,
calcd for
7.17 (t, J = 8.1 Hz, 1H), 7.04 (t,
163.27, 160.25,




2874,
C28H35ClN2O10,
J = 2.2 Hz, 1H), 6.96 (d, J = 5.4 Hz,
160.18, 145.82,




1753,
595.2053;
1H),
144.03, 142.05,




1677
found,
6.94-6.87 (m, 2H), 5.78-5.70 (m,
134.59, 129.98,





595.2066
2H), 5.21-5.08 (m, 2H),
121.37, 116.68,






4.25 (t, J = 9.1 Hz, 1H),
114.41, 109.77,






4.16-4.05 (m, 1H),
89.43, 83.41,






3.94-3.88 (m, 4H), 3.83 (dd, J = 11.8,
82.64, 77.99,






5.3 Hz, 1H),
74.35, 74.09,






3.72 (dd, J = 11.0, 7.4 Hz, 1H),
72.28, 56.21,






3.37 (ddd, J = 8.8, 7.5, 1.6 Hz,
52.34, 28.62,






1H), 3.29 (dd, J = 8.8,
20.87, 19.16,






6.3 Hz, 1H), 3.15 (dd, J = 8.9,
19.05, 18.73






6.4 Hz, 1H), 2.07 (s,






3H), 1.59 (dq, J = 13.2,






6.6 Hz, 1H), 1.39 (d, J = 6.3 Hz,






3H), 0.68 (dd, J = 18.2,






6.7 Hz, 6H)


215

(Thin
HRMS-FAB

1H NMR (CDCl3) δ






Film)
(m/z)
8.55 (d, J = 7.9 Hz, 1H),




3377,
[M + H]+
8.30 (d, J = 5.3 Hz, 1H),




2956,
calcd for
7.56-7.47 (m, 2H), 7.07 (d, J = 8.6 Hz,




2876,
C29H35F3N2O10,
2H), 6.97 (d, J = 5.4 Hz,




1754,
629.2317;
1H),




1678
found,
5.78-5.70 (m, 2H), 5.24-5.09 (m,





629.2327
2H), 4.34 (t, J = 9.1 Hz,






1H), 4.10 (dd, J = 11.8,






7.0 Hz, 1H),






3.96-3.88 (m, 4H), 3.83 (dd, J = 11.8,






5.3 Hz, 1H),






3.77-3.69 (m, 1H), 3.39 (ddd, J = 8.9,






7.3, 1.4 Hz, 1H),






3.28 (dd, J = 8.8, 6.3 Hz,






1H), 3.12 (dd, J = 8.9, 6.4 Hz,






1H), 2.08 (s, 3H),






1.61-1.47 (m, 1H), 1.39 (d, J = 6.3 Hz,






3H), 0.64 (dd, J = 22.7,






6.7 Hz, 6H)


216

(Thin
HRMS-FAB

1H NMR (CDCl3) δ


13C NMR





Film)
(m/z)
8.54 (d, J = 8.0 Hz, 1H),
(CDCl3) δ




3376,
[M + H]+
8.29 (d, J = 5.3 Hz, 1H),
170.95, 170.26,




2937,
calcd for
7.56-7.47 (m, 2H), 7.09 (dd, J = 7.8,
163.28, 161.89,




2879,
C28H33F3N2O10,
1.6 Hz, 2H), 6.97 (d, J = 5.4 Hz,
160.26, 145.81,




1754,
615.216;
1H),
144.05, 142.02,




1677
found,
5.78-5.70 (m, 2H), 5.23-5.09 (m,
126.77, 126.73,





615.2167
2H), 4.34 (dd, J = 9.6, 8.6 Hz,
126.69, 115.98,






1H), 4.11 (dd, J = 11.8,
109.79, 89.42,






7.0 Hz, 1H),
83.23, 82.40,






3.94-3.87 (m, 4H), 3.82 (dd, J = 11.8,
74.25, 73.95,






5.5 Hz, 1H),
72.95, 72.17,






3.73 (dd, J = 11.0, 7.5 Hz, 1H),
56.21, 52.25,






3.48 (dt, J = 9.1, 6.6 Hz,
22.92, 20.86,






1H), 3.41 (ddd, J = 8.9,
18.69, 10.27






7.5, 1.6 Hz, 1H), 3.30 (dt,






J = 9.1, 6.6 Hz, 1H),






2.08 (s, 3H), 1.39 (d, J = 6.3 Hz,






3H), 1.36-1.22 (m,






2H), 0.65 (t, J = 7.4 Hz,






3H)


217

(Thin
HRMS-FAB

1H NMR (CDCl3) δ


13C NMR





Film)
(m/z)
8.61 (d, J = 7.9 Hz, 1H),
(CDCl3) δ




3374,
[M + H]+
8.31 (d, J = 5.3 Hz, 1H),
170.52, 170.25,




2938,
calcd for
7.54 (d, J = 9.0 Hz, 2H),
163.32, 160.25,




2879,
C28H33F3N2O10,
7.03-6.94 (m, 3H), 5.74 (d, J = 1.0 Hz,
159.97, 145.86,




1753,
615.216;
2H),
144.00, 142.08,




1677
found,
5.19-5.05 (m, 2H), 4.26 (ddd, J = 8.6,
127.00, 126.96,





615.2156
7.1, 1.2 Hz, 1H),
115.42, 109.78,






4.04 (dd, J = 12.0, 6.6 Hz, 1H),
89.40, 84.46,






3.99-3.88 (m, 5H),
81.40, 75.71,






3.83-3.68 (m, 2H), 3.53 (dt, J = 8.8,
75.36, 74.89,






6.6 Hz, 1H), 3.46 (t,
72.51, 56.22,






J = 9.2 Hz, 1H), 2.07 (s,
52.71, 23.36,






3H), 1.51 (d, J = 6.3 Hz,
20.86, 18.63,






3H), 1.49-1.37 (m, 2H),
10.55






0.81 (t, J = 7.4 Hz, 3H)


218

(Thin
ESIMS

1H NMR (CDCl3) δ






Film)
m/z 637
8.59 (d, J = 8.0 Hz, 1H),




3373,
([M + H]+)
8.32 (d, J = 5.4 Hz, 1H),




2921,

6.97 (d, J = 5.4 Hz, 1H),




1753,

6.61 (d, J = 1.1 Hz, 3H),




1678

6.56 (tt, J = 1.6, 0.7 Hz, 1H),






6.41-6.30 (m, 2H),






5.76-5.73 (d, J = 1.2 Hz, 2H),






5.25 (dq, J = 9.4, 6.3 Hz,






1H), 5.17 (ddd, J = 7.8,






6.9, 4.9 Hz, 1H), 4.45 (t, J = 9.1 Hz,






1H), 4.31 (ddd, J = 8.6,






7.4, 1.4 Hz, 1H),






4.16-4.06 (m, 1H),






4.01 (dt, J = 11.2, 2.2 Hz, 1H),






3.92 (s, 3H),






3.92-3.85 (m, 1H), 3.85-3.77 (m,






1H), 2.27 (s,, 6H), 2.22 (s,






6H), 2.08 (s, 3H), 1.49 (d,






J = 6.3 Hz, 3H)


219

(Thin
HRMS-FAB

1H NMR (CDCl3) δ


13C NMR





Film)
(m/z)
8.60 (d, J = 7.9 Hz, 1H),
(CDCl3) δ




3375,
[M + H]+
8.30 (d, J = 5.4 Hz, 1H),
170.70, 170.05,




2937,
calcd for
7.02-6.91 (m, 3H),
163.26, 160.17,




1751,
C34H40N2O13,
6.86-6.67 (m, 6H), 5.82 (s, 2H),
154.33, 154.31,




1677,
685.2603;
5.27 (dq, J = 9.4, 6.3 Hz, 1H),
153.78, 151.51,




1503
found,
5.14 (ddd, J = 7.9, 6.8, 4.9 Hz,
145.90, 143.96,





685.261
1H), 4.34 (t, J = 9.1 Hz,
141.93, 117.63,






1H), 4.23 (ddd, J = 8.7,
116.98, 114.62,






7.2, 1.3 Hz, 1H),
114.38, 109.90,






4.17-4.05 (m, 3H), 4.02 (dd, J = 11.3,
89.41, 84.14,






1.4 Hz, 1H),
81.85, 74.43,






3.91 (s, 3H), 3.88 (dd, J = 11.9,
74.37, 72.46,






4.9 Hz, 1H), 3.80 (dd, J = 11.2,
67.79, 67.20,






7.2 Hz, 1H), 3.76 (s,
56.26, 55.66,






3H), 3.73 (s, 3H), 3.59 (q,
52.48, 18.94,






J = 7.0 Hz, 2H), 1.50 (s,
15.01






3H), 1.23 (t, J = 7.0 Hz,






3H)


220

(Thin
HRMS-FAB

1H NMR (CDCl3) δ


13C NMR





Film)
(m/z)
8.59 (d, J = 7.9 Hz, 1H),
(CDCl3) δ




3375,
[M + H]+
8.31 (d, J = 5.4 Hz, 1H),
170.72, 170.27,




2938,
calcd for
7.02-6.91 (m, 3H),
163.31, 160.25,




2835,
C32H36N2O12,
6.85-6.68 (m, 6H), 5.74 (d, J = 1.3 Hz,
154.33, 154.30,




1752,
641.2341;
2H), 5.27 (dq, J = 9.3,
153.79, 151.52,




1677,
found,
6.3 Hz, 1H), 5.16 (ddd, J = 8.0,
145.85, 144.02,




1502
641.2349
6.8, 4.9 Hz, 1H),
142.07, 117.64,






4.34 (t, J = 9.1 Hz, 1H),
116.98, 114.63,






4.23 (ddd, J = 8.7, 7.2, 1.3 Hz,
114.38, 109.79,






1H), 4.09 (dd, J = 12.0,
89.42, 84.14,






6.9 Hz, 1H), 4.02 (dd, J = 11.2,
81.85, 74.42,






1.4 Hz, 1H), 3.92 (s,
74.39, 72.46,






3H), 3.88 (dd, J = 11.9,
56.22, 55.67,






4.9 Hz, 1H), 3.80 (dd, J = 11.2,
52.50, 20.88,






7.3 Hz, 1H), 3.77 (s,
18.95






3H), 3.73 (s, 3H), 2.07 (s,






3H), 1.49 (d, J = 6.3 Hz,






3H)


221

(Thin
HRMS-FAB

1H NMR (CDCl3) δ


13C NMR





Film)
(m/z)
8.55 (d, J = 8.0 Hz, 1H),
(CDCl3) δ




3374,
[M + H]+
8.29 (d, J = 5.4 Hz, 1H),
171.04, 170.27,




2935,
calcd for
7.31-7.20 (m, 2H),
163.27, 160.25,




2877,
C27H34N2O10,
7.07-6.99 (m, 2H), 6.99-6.90 (m,
159.52, 145.81,




1751,
547.2286;
2H), 5.78-5.69 (m, 2H),
144.02, 142.06,




1676,
found,
5.21-5.08 (m, 2H),
129.26, 121.20,




1492
547.2312
4.30 (dd, J = 9.6, 8.5 Hz, 1H),
116.14, 109.76,






4.17-4.06 (m, 1H),
89.43, 83.27,






3.91 (s, 3H), 3.89 (dd, J = 11.1,
82.51, 74.46,






1.7 Hz, 1H), 3.77 (ddd, J = 22.7,
73.87, 73.10,






11.4, 6.5 Hz, 2H),
72.65, 56.21,






3.48 (dt, J = 9.0, 6.6 Hz,
52.24, 22.98,






1H), 3.44-3.32 (m, 2H),
20.87, 18.76,






2.07 (s, 3H), 1.41 (d, J = 6.3 Hz,
10.34






3H),






1.38-1.29 (m, 2H), 0.68 (t, J = 7.4 Hz,






3H)


222

(Thin
HRMS-FAB

1H NMR (CDCl3) δ


13C NMR





Film)
(m/z)
8.59 (d, J = 7.9 Hz, 1H),
(CDCl3) δ




3374,
[M + H]+
8.30 (d, J = 5.4 Hz, 1H),
170.69, 170.27,




2920,
calcd for
7.32-7.23 (m, 2H),
163.29, 160.24,




2877,
C27H34N2O10,
7.01-6.89 (m, 4H), 5.74 (d, J = 1.2 Hz,
157.49, 145.85,




1751,
547.2286;
2H), 5.17-5.03 (m,
143.99, 142.13,




1676,
found,
2H), 4.21 (ddd, J = 8.6,
129.54, 121.15,




1494
547.2301
7.3, 1.3 Hz, 1H), 4.04 (dd,
115.64, 109.75,






J = 12.0, 6.8 Hz, 1H),
89.44, 84.52,






3.94 (d, J = 11.1, 1H), 3.92 (s,
81.24, 75.62,






3H), 3.90-3.80 (m, 2H),
74.95, 74.50,






3.71 (dd, J = 11.1, 7.3 Hz,
72.66, 56.21,






1H), 3.54 (dt, J = 8.7, 6.7 Hz,
52.58, 23.41,






1H), 3.46 (dd, J = 9.6,
20.87, 18.68,






8.7 Hz, 1H), 2.07 (s, 3H),
10.59






1.57-1.43 (m, 5H),






0.83 (t, J = 7.4 Hz, 3H)


223

(Thin
HRMS-FAB

1H NMR (CDCl3) δ


13C NMR





Film)
(m/z)
8.55 (d, J = 7.9 Hz, 1H),
(CDCl3) δ




3375,
[M + H]+
8.29 (d, J = 5.3 Hz, 1H),
171.06, 170.27,




2943,
calcd for
7.30-7.19 (m, 2H),
163.26, 160.25,




1751,
C29H37N2O10,
7.05-6.98 (m, 2H), 6.98-6.90 (m,
159.48, 145.80,




1675,
573.2443;
2H), 5.79-5.70 (m, 2H),
144.02, 142.07,




1587,
found,
5.20-5.08 (m, 2H),
129.16, 121.00,




1492
573.2463
4.27 (dd, J = 9.6, 8.6 Hz, 1H),
115.92, 109.75,






4.10 (dd, J = 11.8, 7.1 Hz,
89.44, 82.68,






1H), 4.02 (ddd, J = 8.6,
81.65, 80.05,






5.1, 3.6 Hz, 1H), 3.92 (s,
74.87, 73.79,






3H), 3.86 (dd, J = 10.8,
72.72, 56.21,






1.6 Hz, 1H), 3.79 (dd, J = 11.8,
52.21, 32.94,






5.6 Hz, 1H),
31.70, 23.31,






3.73 (dd, J = 10.8, 7.5 Hz, 1H),
22.99, 20.88,






3.47 (ddd, J = 9.0, 7.5, 1.6 Hz,
18.81






1H), 2.07 (s, 3H),






1.61-1.51 (m, 2H),






1.47-1.35 (m, 7H), 1.29 (m,






2H)


224

(Thin
HRMS-FAB

1H NMR (CDCl3) δ


13C NMR





Film)
(m/z)
8.58 (d, J = 7.9 Hz, 1H),
(CDCl3) δ




3375,
[M + H]+
8.30 (d, J = 5.3 Hz, 1H),
170.77, 170.26,




2946,
calcd for
7.34-7.21 (m, 3H),
163.28, 160.23,




2874,
C29H36N2O10,
7.00-6.86 (m, 4H), 5.74 (d, J = 1.4 Hz,
157.44, 145.83,




1751,
573.2443;
2H), 5.11 (ddd, J = 7.9,
143.98, 142.12,




1676,
found,
6.7, 4.8 Hz, 1H),
129.52, 121.07,




1494
573.2469
5.03 (dq, J = 9.4, 6.4 Hz, 1H),
115.60, 109.74,






4.35 (m, 1H), 4.17 (ddd, J = 8.4,
89.43, 84.23,






6.8, 1.3 Hz, 1H),
82.20, 81.30,






4.06 (dd, J = 12.0, 6.8 Hz,
75.08, 74.48,






1H), 3.95-3.89 (m, 4H),
73.07, 56.21,






3.85 (dd, J = 12.0, 4.8 Hz,
52.56, 32.96,






1H), 3.73 (dd, J = 11.2,
32.32, 23.13,






6.9 Hz, 1H), 3.59 (dd, J = 9.5,
20.87, 18.82






8.6 Hz, 1H), 2.07 (s,






3H), 1.72-1.56 (m, 6H),






1.51 (d, J = 6.4 Hz, 3H),






1.47-1.39 (m, 1H)


225


HRMS-FAB

1H NMR (CDCl3) δ


13C NMR






(m/z)
8.61 (d, J = 7.9 Hz, 1H),
(CDCl3) δ





[M + H]+
8.30 (d, J = 5.4 Hz, 1H),
170.68, 170.06,





calcd for
7.10-7.02 (m, 2H),
163.27, 160.18,





C34H40N2O11,
7.02-6.94 (m, 3H), 6.94-6.87 (m,
157.53, 155.27,





653.2705;
2H), 6.72-6.62 (m, 2H),
145.91, 143.98,





found,
5.82 (s, 2H), 5.28 (dq, J = 9.4,
141.94, 130.80,





653.2727
6.3 Hz, 1H),
130.63, 129.90,






5.15 (ddd, J = 8.0, 6.8, 4.8 Hz,
129.74, 116.43,






1H), 4.42 (t, J = 9.1 Hz,
115.66, 109.89,






1H), 4.30 (ddd, J = 8.7,
89.43, 83.30,






7.3, 1.3 Hz, 1H),
80.95, 74.53,






4.14-4.05 (m, 3H), 4.03 (dd, J = 11.3,
74.45, 72.49,






1.3 Hz, 1H),
67.80, 67.21,






3.95-3.86 (m, 4H), 3.81 (dd, J = 11.2,
56.26, 52.52,






7.3 Hz, 1H), 3.59 (q,
20.52, 20.46,






J = 7.0 Hz, 2H), 2.28 (s,
18.90, 15.02






3H), 2.23 (s, 3H), 1.48 (d,






J = 6.3 Hz, 3H), 1.23 (t, J = 7.0 Hz,






3H)


226


HRMS-FAB

1H NMR (CDCl3) δ


13C NMR






(m/z)
8.60 (d, J = 7.9 Hz, 1H),
(CDCl3) δ





[M + H]+
8.31 (d, J = 5.4 Hz, 1H),
170.70, 170.27,





calcd for
7.09-7.02 (m, 2H),
163.31, 160.25,





C32H36N2O10,
7.02-6.94 (m, 3H), 6.94-6.87 (m,
157.53, 155.27,





609.2443;
2H), 6.71-6.62 (m, 2H),
145.85, 144.02,





found,
5.74 (d, J = 1.2 Hz, 2H),
142.08, 130.79,





609.2469
5.28 (dq, J = 9.4, 6.3 Hz,
130.62, 129.89,






1H), 5.16 (ddd, J = 8.0,
129.73, 116.43,






6.8, 4.8 Hz, 1H), 4.42 (t, J = 9.1 Hz,
115.65, 109.78,






1H), 4.30 (ddd, J = 8.7,
89.42, 83.30,






7.3, 1.3 Hz, 1H),
80.95, 74.52,






4.14-4.05 (m, 1H),
74.47, 72.49,






4.03 (dd, J = 11.2, 1.3 Hz, 1H),
56.22, 52.54,






3.95-3.86 (m, 4H),
20.88, 20.51,






3.81 (dd, J = 11.2, 7.3 Hz, 1H),
20.46, 18.89






2.28 (s, 3H), 2.23 (s, 3H),






2.07 (s, 3H), 1.48 (d, J = 6.3 Hz,






3H)


227

(Thin
HRMS-FAB

1H NMR (CDCl3) δ


13C NMR





Film)
(m/z)
8.59 (d, J = 7.9 Hz, 1H),
(CDCl3) δ




3377,
[M + H]+
8.30 (d, J = 5.4 Hz, 1H),
170.62, 170.04,




2927,
calcd for
7.04-6.91 (m, 3H),
163.24, 160.16,




1750,
C30H39F1N2O11,
6.92-6.79 (m, 2H), 5.81 (s, 2H),
158.66, 156.28,




1676,
623.2611;
5.16-5.03 (m, 2H),
153.57, 153.55,




1502
found,
4.17-4.08 (m, 3H), 4.03 (dd, J = 12.0,
145.89, 143.94,





623.2626
6.7 Hz, 1H),
141.97, 116.79,






3.96-3.89 (m, 4H), 3.87 (dd J = 12.0,
116.71, 116.00,






4.6 Hz, 1H),
115.77, 109.85,






3.75-3.63 (m, 2H), 3.59 (q, J = 7.0 Hz,
89.42, 84.44,






2H), 3.42 (dd, J = 9.6,
82.22, 80.67,






8.8 Hz, 1H), 3.32 (dd,
75.06, 74.61,






J = 8.4, 6.5 Hz, 1H),
72.63, 67.79,






1.73 (hept, J = 6.6 Hz, 1H),
67.19, 56.25,






1.50 (d, J = 6.3 Hz, 3H),
52.59, 29.00,






1.23 (t, J = 7.0 Hz, 3H),
19.40, 19.35,






0.82 (dd, J = 15.7, 6.7 Hz,
18.69, 15.00






6H)


228

(Thin
HRMS-FAB

1H NMR (CDCl3) δ


13C NMR





Film)
(m/z)
8.58 (d, J = 7.9 Hz, 1H),
(CDCl3) δ




3376,
[M + H]+
8.30 (d, J = 5.4 Hz, 1H),
170.64, 170.26,




2956,
calcd for
7.04-6.91 (m, 3H),
163.29, 160.24,




1753,
C28H35F1N2O10,
6.91-6.81 (m, 2H), 5.74 (d, J = 1.1 Hz,
145.84, 143.99,




1678,
579.2349;
2H), 5.18-5.00 (m,
142.10, 116.79,




1503
found,
2H), 4.12 (ddd, J = 8.6,
116.71, 116.00,





579.2366
7.1, 1.2 Hz, 1H), 4.04 (dd,
115.77, 109.75,






J = 12.0, 6.7 Hz, 1H),
89.42, 84.43,






3.97-3.83 (m, 5H),
82.22, 80.67,






3.74-3.62 (m, 2H), 3.42 (dd, J = 9.6,
75.04, 74.62,






8.7 Hz, 1H), 3.32 (dd,
72.62, 56.21,






J = 8.4, 6.5 Hz, 1H),
52.61, 29.00,






2.07 (s, 3H), 1.73 (hept, J = 6.6 Hz,
20.87, 19.40,






1H), 1.50 (d, J = 6.3 Hz,
19.35, 18.70






3H), 0.82 (dd, J = 15.6,






6.7 Hz, 6H)


229

(Thin
HRMS-FAB

1H NMR (CDCl3) δ






Film)
(m/z)
8.78 (d, J = 8.2 Hz, 1H),




3372,
[M + H]+
8.37 (d, J = 5.4 Hz, 1H),




2939,
calcd for
7.03 (d, J = 5.5 Hz, 1H),




1765,
C29H28F2N2O9,
6.98-6.86 (m, 6H),




1676
587.1836;
6.74-6.61 (m, 2H), 5.33-5.24 (m,





found,
1H), 5.14 (m, 1H), 4.36 (t,





587.1838
J = 9.2 Hz, 1H),






4.30-4.22 (m, 1H),






4.10-3.99 (m, 2H), 3.92 (s, 3H),






3.92-3.87 (m, 1H), 3.79 (dd, J = 11.2,






7.3 Hz, 1H),






2.40 (s, 3H), 1.48 (d, J = 6.4 Hz,






3H)


230

(Thin
HRMS-FAB

1H NMR (CDCl3) δ






Film)
(m/z)
8.61 (d, J = 7.9 Hz, 1H),




3372,
[M + H]+
8.31 (d, J = 5.4 Hz, 1H),




2926,
calcd for
7.01-6.86 (m, 7H),




1753,
C32H34F2N2O11,
6.72-6.64 (m, 2H), 5.82 (s, 2H),




1676
661.2203;
5.30 (dq, J = 9.4, 6.4 Hz, 1H),





found,
5.19-5.12 (m, 1H),





661.2217
4.38 (t, J = 9.2 Hz, 1H), 4.26 (t,






J = 7.9 Hz, 1H),






4.14-4.05 (m, 3H), 4.02 (d, J = 11.3 Hz,






1H),






3.97-3.88 (m, 4H), 3.81 (dd, J = 11.3,






7.2 Hz, 1H), 3.59 (q,






J = 7.0 Hz, 2H), 1.49 (d, J = 6.3 Hz,






3H), 1.24 (t, J = 7.0 Hz,






3H)


231

(Thin
HRMS-FAB

1H NMR (CDCl3) δ






Film)
(m/z)
8.61 (d, J = 7.9 Hz, 1H),




2928,
[M + H]+
8.31 (d, J = 5.4 Hz, 1H),




1752,
calcd for
7.03-6.84 (m, 7H),




1676,
C30H30F2N2O10,
6.74-6.62 (m, 2H), 5.74 (d, J = 1.1 Hz,




1500
617.1941;
2H), 5.29 (m, 1H),





found,
5.17 (ddd, J = 7.9, 6.7, 4.7 Hz,





617.1929
1H), 4.38 (t, J = 9.1 Hz,






1H), 4.31-4.22 (m,






1H), 4.09 (dd, J = 12.0,






6.8 Hz, 1H), 4.02 (dd, J = 11.3,






1.3 Hz, 1H),






3.99-3.87 (m, 4H), 3.81 (dd, J = 11.3,






7.3 Hz, 1H), 2.08 (s,






3H), 1.49 (d, J = 6.3 Hz,






3H)


232
54-60

ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 507
8.68 (d, J = 8.2 Hz, 1H),
(CDCl3) δ





([M + H]+)
8.31 (d, J = 5.4 Hz, 1H),
170.80, 168.81,






6.99 (d, J = 5.5 Hz, 1H),
162.72, 159.40,






5.03 (ddd, J = 8.3, 7.1, 5.3 Hz,
146.77, 141.09,






1H), 4.92 (dq, J = 9.0, 6.3 Hz,
137.51, 109.91,






1H), 3.99 (dd, J = 11.8,
84.63, 83.30,






7.0 Hz, 1H), 3.88 (s,
78.75, 75.85,






3H), 3.83-3.69 (m, 3H),
74.95, 73.94,






3.57 (dd, J = 10.9, 7.0 Hz,
72.94, 56.29,






1H), 3.45-3.33 (m, 3H),
52.05, 20.70,






3.28-3.17 (m, 2H),
18.59, 11.08,






2.37 (s, 3H), 1.44 (d, J = 6.3 Hz,
10.92, 3.21, 3.16,






3H), 1.13-0.95 (m,
2.93, 2.84






2H), 0.59-0.45 (m, 4H),






0.26-0.12 (m, 4H)


233


ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 537
8.31 (d, J = 7.9 Hz, 1H),
(CDCl3) δ





([M + H]+)
8.06 (d, J = 5.3 Hz, 1H),
170.88, 170.22,






6.75 (d, J = 5.4 Hz, 1H),
163.23, 160.19,






5.55-5.47 (m, 2H), 4.85 (td, J = 7.3,
145.79, 143.91,






5.2 Hz, 1H), 4.73 (dq,
142.06, 109.73,






J = 8.4, 6.3 Hz, 1H),
89.38, 84.61,






3.82 (dd, J = 11.8, 7.0 Hz, 1H),
83.31, 78.72,






3.70 (s, 3H),
75.79, 75.03,






3.64-3.53 (m, 3H), 3.39 (dd, J = 10.9,
73.98, 72.90,






6.8 Hz, 1H),
56.19, 52.31,






3.25-3.13 (m, 3H),
20.84, 18.59,






3.10-2.98 (m, 2H), 1.85 (s, 3H),
11.07, 10.91,






1.26 (d, J = 6.3 Hz, 3H),
3.20, 3.14, 2.92,






0.93-0.77 (m, 2H),
2.83






0.39-0.25 (m, 4H), −0.01 (ddt, J = 9.2,






6.0, 4.7 Hz, 4H)


234
68-75
(Thin
HRMS-ESI

1H NMR (CDCl3) δ


13C NMR





Film)
(m/z)
8.67 (d, J = 6.5 Hz, 1H),
(CDCl3) δ




3372,
[M + H]+
8.36 (s, 1H), 7.27-7.09 (m,
176.27, 170.59,




2978,
calcd for
4H), 7.08-6.82 (m, 5H),
159.46, 157.24,




2938,
C32H37N2O10,
6.82-6.64 (m, 2H),
129.44, 129.27,




1750,
609.2443;
5.79 (s, 2H), 5.36-5.27 (m,
121.55, 121.31,




1678,
found,
1H), 5.21-5.13 (m, 1H),
116.48, 115.59,




1493,
609.2450
4.51 (t, J = 9.1 Hz, 1H),
89.70, 82.86,




1227

4.37 (t, J = 7.9 Hz, 1H),
80.56, 74.64,






4.14-4.00 (m, 2H),
74.56, 72.38,






3.99-3.89 (m, 4H), 3.83 (dd, J = 11.1,
56.42, 52.67,






7.3 Hz, 1H),
33.85, 18.88,






2.56 (p, J = 7.0 Hz, 1H),
18.69






1.49 (d, J = 6.3 Hz, 3H),






1.14 (d, J = 6.9 Hz, 6H)


235
58-66
(Thin
HRMS-ESI

1H NMR (CDCl3) δ


13C NMR





Film)
(m/z)
8.77 (d, J = 8.1 Hz, 1H),
(CDCl3) δ




3372,
[M + H]+
8.37 (d, J = 5.2 Hz, 1H),
176.27, 170.59,




2934,
calcd for
7.36-7.15 (m, 4H),
159.46, 157.24,




1758,
C31H35N2O10,
7.05-6.86 (m, 5H), 6.73 (d, J = 7.8 Hz,
129.44, 129.27,




1678,
595.2286;
2H), 5.31 (dq, J = 9.5,
121.55, 121.31,




1587,
found,
6.3 Hz, 1H), 5.15 (ddd, J = 8.2,
116.48, 115.59,




1492,
595.2297
6.8, 4.7 Hz, 1H),
89.70, 82.86,




1200

4.50 (t, J = 9.1 Hz, 1H),
80.56, 74.64,






4.37 (ddd, J = 8.8, 7.4, 1.3 Hz,
74.56, 72.38,






1H), 4.14-4.00 (m, 2H),
56.42, 52.67,






3.91 (s, 3H),
33.85, 18.88,






3.90-3.86 (m, 1H), 3.85-3.78 (m,
18.69






3H), 3.41 (s, 3H), 2.98 (t,






J = 6.5 Hz, 2H), 1.48 (d, J = 6.3 Hz,






3H)


236
85-95
(Thin
HRMS-ESI

1H NMR (CDCl3) δ


13C NMR





Film)
(m/z)
8.79 (s, 1H), 8.38 (s, 1H),
(CDCl3) δ




3371,
[M + H]+
7.34-7.15 (m, 4H),
170.53, 168.85,




2940,
calcd for
7.06-6.86 (m, 5H),
159.47, 157.24,




1769,
C29H31N2O9,
6.76-6.69 (m, 2H), 5.37-5.25 (m,
146.83, 129.45,




1678,
551.2024;
1H), 5.15 (td, J = 7.2, 4.6 Hz,
129.27, 121.54,




1493
found,
1H), 4.50 (t, J = 9.1 Hz,
121.31, 116.49,





551.2033
1H), 4.37 (dd, J = 8.8,
115.58, 110.00,






7.1 Hz, 1H),
99.99, 82.87,






4.12-4.01 (m, 2H), 3.92 (s, 3H),
80.54, 74.57,






3.92-3.86 (m, 1H), 3.82 (dd, J = 11.2,
72.36, 56.34,






7.4 Hz, 1H),
52.34, 20.73,






2.40 (s, 3H), 1.48 (d, J = 6.3 Hz,
18.88






3H)


237

(Thin
ESIMS

1H NMR (CDCl3) δ


13C NMR





Film)
m/z 555
8.67 (d, J = 8.2 Hz, 1H),
(CDCl3) δ




3375,
([M + H]+)
8.38-8.30 (m, 1H), 7.00 (dd, J = 5.7,
170.85, 169.37,




2955,

1.8 Hz, 1H),
162.67, 159.42,




2873,

5.08-4.98 (m, 1H), 4.93 (ddt, J = 12.2,
146.81, 141.19,




1753,

8.4, 4.1 Hz, 1H),
137.38, 109.88,




1677,

4.00 (tt, J = 7.2, 3.4 Hz,
84.82, 83.75,




1507,

1H), 3.93-3.84 (m, 3H),
80.56, 77.70,




1088

3.85-3.64 (m, 5H),
74.88, 74.07,






3.64-3.55 (m, 1H), 3.41 (d, J = 1.5 Hz,
72.99, 67.58,






3H),
58.80, 56.32,






3.33-3.12 (m, 5H), 2.97 (t, J = 6.6 Hz,
52.13, 34.61,






2H), 1.82 (tt, J = 12.9,
29.11, 28.87,






6.0 Hz, 2H), 1.43 (dd, J = 6.3,
19.58, 19.46,






1.7 Hz, 3H),
19.37, 18.63






0.97-0.85 (m, 12H)


238
118-120
(Thin
HRMS-ESI

1H NMR (CDCl3) δ


13C NMR





Film)
(m/z)
8.70 (d, J = 8.2 Hz, 1H),
(CDCl3) δ




3384,
[M + H]+
8.34 (d, J = 5.4 Hz, 1H),
170.82, 168.83,




2954,
calcd for
7.00 (d, J = 5.5 Hz, 1H),
162.73, 159.41,




2873,
C25H39N2O9,
5.09-4.87 (m, 2H), 4.02 (dd, J = 11.9,
146.76, 141.17,




1760,
511.2650;
6.9 Hz, 1H), 3.91 (s,
137.53, 109.89,




1748,
found,
3H), 3.84-3.66 (m, 3H),
84.83, 83.75,




1675,
511.2652
3.65-3.52 (m, 1H),
80.57, 77.71,




1512,

3.37-3.12 (m, 5H), 2.39 (s,
74.95, 74.10,




1092

3H), 1.82 (dh, J = 13.2,
73.00, 56.29,






6.6 Hz, 2H), 1.44 (d, J = 6.3 Hz,
52.17, 29.11,






3H),
28.88, 20.72,






0.97-0.84 (m, 12H)
19.58, 19.46,







19.45, 19.37,







18.64


239

(Thin
HRMS-FAB

1H NMR (CDCl3) δ


13C NMR





Film)
(m/z)
7.29-7.21 (m, 2H),
(CDCl3) δ




2931,
[M + H]+
6.97-6.90 (m, 3H), 5.29 (dd, J = 8.9,
168.83, 157.55,




1765,
calcd for
3.8 Hz, 1H),
152.56, 145.41,




1708,
C32H47NO9,
5.24-5.17 (m, 1H), 4.97-4.86 (m,
129.46, 121.08,




1367,
589.3251;
1H), 4.36 (dd, J = 10.8,
117.47, 115.76,




1240
found,
7.1 Hz, 1H),
83.20, 83.13,





589.3265
4.32-4.21 (m, 2H), 4.15 (dd, J = 10.9,
81.41, 75.57,






7.6 Hz, 1H),
72.96, 72.65,






4.00-3.87 (m, 2H), 3.66 (dd, J = 11.0,
69.01, 57.88,






7.3 Hz, 1H),
37.04, 28.86,






3.50 (dd, J = 9.7, 8.8 Hz, 1H),
28.27, 27.73,






2.17-1.99 (m, 4H),
26.66, 18.87






1.59-1.38 (m, 6H), 1.51 (s,






18H), 1.49 (d, J = 6.3 Hz,






3H)


240


ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 464
5.41-5.22 (m, 3H), 4.88 (dq, J = 8.8,
(CDCl3) δ





([M + Na]+)
6.2 Hz, 1H), 4.64 (q, J = 6.8 Hz,
171.39, 137.14,






1H), 4.37 (dd, J = 10.8,
136.86, 121.12,






7.1 Hz, 1H),
121.00, 84.38,






4.13-3.99 (m, 3H),
82.85, 80.13,






3.98-3.83 (m, 1H), 3.80 (d, J = 11.0 Hz,
77.02, 76.71,






1H), 3.69-3.62 (m,
75.24, 74.51,






1H), 3.55 (dd, J = 11.1,
72.90, 70.29,






6.3 Hz, 1H),
67.43, 60.39,






3.29-3.17 (m, 2H), 1.78-1.72 (m,
53.53, 28.28,






6H), 1.71-1.64 (m, 6H),
25.79, 25.78,






1.46-1.41 (m, 12H)
18.64, 18.03,







17.99, 14.21


241

(Thin
HRMS-ESI

1H NMR (CDCl3) δ


13C NMR





Film)
(m/z) [M + H]+
5.33 (t, J = 7.2 Hz, 1H),
(CDCl3) δ




3352,
calcd for
4.87 (dq, J = 9.4, 6.1 Hz, 1H),
171.38, 155.09,




2956,
C23H44NO7,
4.64 (td, J = 7.1, 4.7 Hz,
85.06, 83.68,




2930,
446.3112;
1H), 3.98-3.79 (m, 2H),
80.13, 74.60,




2872,
found,
3.76 (d, J = 11.0 Hz, 1H),
72.88, 72.45,




1754,
446.3212
3.72-3.45 (m, 4H),
69.29, 53.56,




1715,

3.19-3.11 (m, 2H),
39.22, 38.93,




1367,

1.75-1.58 (m, 2H),
28.28, 25.00,




1164,

1.47-1.39 (m, 16H), 1.32-1.19 (m,
24.94, 22.90,




1095

1H), 0.92-0.86 (m, 12H)
22.65, 22.61,







22.58, 22.49,







18.58


242


ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 436
5.26 (d, J = 8.8 Hz, 1H),
(CDCl3) δ





([M + Na]+)
4.88 (dq, J = 8.9, 6.2 Hz, 1H),
171.35, 155.08,






4.62 (td, J = 7.3, 5.2 Hz,
84.65, 83.29,






1H), 3.88 (dd, J = 11.8,
80.09, 78.71,






6.7 Hz, 1H), 3.74 (dt, J = 9.8,
75.78, 75.15,






7.5 Hz, 2H), 3.62 (dd,
74.43, 72.84,






J = 11.8, 5.1 Hz, 1H),
53.47, 28.25,






3.58-3.48 (m, 1H),
18.53, 11.06,






3.44-3.29 (m, 3H),
10.90, 3.19, 3.14,






3.25-3.12 (m, 2H), 1.45-1.37 (m,
2.92, 2.82






12H), 1.11-0.94 (m, 2H),






0.56-0.45 (m, 4H),






0.17 (ddt, J = 9.3, 6.0, 4.7 Hz,






4H)


243


ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 522
7.02-6.93 (m, 2H),
(CDCl3) δ





([M + Na]+)
6.93-6.86 (m, 2H), 5.31 (dd, J = 8.6,
168.35, 152.62,






2.4 Hz, 1H), 5.04 (dq, J = 8.9,
117.17, 117.09,






6.3 Hz, 1H), 4.27 (dd,
116.26, 116.03,






J = 12.6, 2.4 Hz, 1H),
83.19, 81.37,






4.17-4.05 (m, 2H), 3.93 (dd, J = 12.6,
76.29, 75.89,






8.6 Hz, 1H),
74.32, 73.33,






3.75 (td, J = 8.8, 2.1 Hz, 1H),
58.41, 27.99,






3.58 (dd, J = 11.1, 7.6 Hz,
18.72






1H), 2.94 (d, J = 2.1 Hz,






1H), 1.52 (s, 21H)


244


ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 522
7.03-6.91 (m, 4H), 5.25 (dd, J = 8.5,
(CDCl3) δ





([M + Na]+)
4.0 Hz, 1H),
168.70, 159.08,






5.12-5.02 (m, 1H), 4.31 (dd, J = 12.2,
156.68, 155.09,






4.0 Hz, 1H),
155.06, 152.63,






4.20-4.07 (m, 2H), 3.99 (dd, J = 12.1,
117.59, 117.51,






8.5 Hz, 1H), 3.87 (td,
116.27, 116.04,






J = 6.2, 5.1, 3.4 Hz, 1H),
85.69, 83.19,






3.68 (dd, J = 11.2, 7.4 Hz,
73.85, 71.99,






1H), 2.38 (d, J = 3.3 Hz,
58.17, 27.96,






1H), 1.52 (d, J = 2.6 Hz,
19.01






18H), 1.35 (d, J = 6.4 Hz,






3H)


245


ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 616
6.98-6.82 (m, 6H),
(CDCl3) δ





([M + Na]+)
6.72-6.65 (m, 2H), 5.33 (dd, J = 8.9,
168.69, 156.38,






3.6 Hz, 1H), 5.13 (dq, J = 9.2,
155.54, 153.44,






6.3 Hz, 1H),
153.41, 152.61,






4.45-4.26 (m, 3H), 4.05 (dd, J = 11.2,
117.54, 117.46,






1.0 Hz, 1H),
116.92, 116.84,






3.98 (dd, J = 12.4, 8.9 Hz, 1H),
115.91, 115.76,






3.75 (dd, J = 11.1, 7.0 Hz,
115.68, 115.53,






1H), 1.53 (s, 18H),
83.76, 83.28,






1.46 (d, J = 6.3 Hz, 3H)
81.62, 75.41,







73.22, 72.11,







57.91, 27.98,







18.95


246
108

ESIMS

1H NMR (CDCl3) δ







m/z 578
6.98-6.90 (m, 2H),





([M + Na]+)
6.91-6.83 (m, 2H), 5.27 (dd, J = 8.8,






3.6 Hz, 1H), 4.91 (dq, J = 9.8,






6.2 Hz, 1H), 4.26 (dd,






J = 12.3, 3.6 Hz, 1H),






4.15 (dd, J = 8.7, 7.2 Hz, 1H),






3.98-3.87 (m, 2H),






3.69-3.60 (m, 2H), 3.40 (t, J = 9.2 Hz,






1H), 3.30 (dd, J = 8.4,






6.6 Hz, 1H),






1.78-1.65 (m, 1H), 1.51 (s,






18H), 1.47 (d, J = 6.3 Hz,






3H), 0.82 (d, J = 6.7 Hz,






3H), 0.78 (d, J = 6.7 Hz,






3H)


247


ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 518
7.12-7.05 (m, 2H),
(CDCl3) δ





([M + Na]+)
6.95-6.88 (m, 2H), 5.25 (dd, J = 8.5,
168.70, 156.86,






3.9 Hz, 1H), 5.06 (dq, J = 8.9,
152.61, 131.56,






6.4 Hz, 1H), 4.30 (dd,
130.20, 116.13,






J = 12.2, 3.9 Hz, 1H),
84.88, 83.16,






4.19 (t, J = 8.8 Hz, 1H),
73.91, 72.23,






4.16-4.08 (m, 1H), 3.99 (dd, J = 12.2,
58.24, 27.96,






8.5 Hz, 1H),
20.48, 19.00






3.90-3.81 (m, 1H), 3.67 (dd, J = 11.1,






7.4 Hz, 1H), 2.42 (d,






J = 2.9 Hz, 1H), 2.29 (s,






3H), 1.52 (s, 18H),






1.34 (d, J = 6.4 Hz, 3H)


248


ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 440
7.11-7.05 (m, 2H),
(CDCl3) δ





([M − C4H9+ 2H]+)
6.87-6.80 (m, 2H), 5.32 (dd, J = 8.8,
168.44, 154.46,






2.5 Hz, 1H), 5.03 (dq, J = 9.0,
152.59, 131.27,






6.3 Hz, 1H), 4.26 (dd,
130.15, 115.75,






J = 12.5, 2.5 Hz, 1H),
83.17, 80.57,






4.18-4.07 (m, 2H), 3.92 (dd, J = 12.6,
76.35, 75.86,






8.8 Hz, 1H),
74.19, 73.40,






3.75 (td, J = 8.8, 2.0 Hz, 1H),
58.40, 27.99,






3.57 (dd, J = 11.0, 7.7 Hz,
20.48, 18.71






1H), 2.98 (d, J = 1.9 Hz,






1H), 2.28 (s, 3H), 1.52 (s,






21H)


249
110-112

ESIMS

1H NMR (CDCl3) δ







m/z 504
7.33-7.27 (m, 2H),





([M + Na]+)
7.04-6.97 (m, 3H), 5.26 (dd, J = 8.5,






3.9 Hz, 1H), 5.08 (dq, J = 8.9,






6.4 Hz, 1H), 4.31 (dd,






J = 12.2, 4.0 Hz, 1H),






4.26 (t, J = 8.7 Hz, 1H),






4.14-4.11 (m, 1H), 3.99 (dd, J = 12.2,






8.5 Hz, 1H),






3.88 (dddd, J = 8.6, 7.5, 3.1, 1.3 Hz,






1H), 3.68 (dd, J = 11.0,






7.4 Hz, 1H), 2.42 (d,






J = 3.1 Hz, 1H), 1.52 (s,






18H), 1.35 (d, J = 6.4 Hz,






3H)


250


ESIMS

1H NMR (CDCl3) δ







m/z 504
7.33-7.26 (m, 2H),





([M + Na]+)
7.04-6.92 (m, 3H), 5.32 (dd, J = 8.7,






2.4 Hz, 1H), 5.05 (dq, J = 9.0,






6.3 Hz, 1H), 4.27 (dd,






J = 12.5, 2.4 Hz, 1H),






4.23-4.16 (m, 1H),






4.16-4.08 (m, 1H), 3.93 (dd, J = 12.6,






8.7 Hz, 1H), 3.77 (td,






J = 8.8, 2.0 Hz, 1H),






3.59 (dd, J = 11.0, 7.7 Hz, 1H),






2.97 (d, J = 2.0 Hz, 1H),






1.53 (s, 18H), 1.52 (d, J = 1.9 Hz,






3H)


251


ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 608
7.07-7.01 (m, 2H),
(CDCl3) δ





([M + Na]+)
7.00-6.95 (m, 2H), 6.93-6.86 (m,
168.86, 157.56,






2H), 6.70-6.64 (m, 2H),
155.41, 152.59,






5.33 (dd, J = 8.9, 3.8 Hz,
130.69, 130.51,






1H), 5.12 (dq, J = 9.4, 6.3 Hz,
129.82, 129.70,






1H), 4.41 (t, J = 9.1 Hz,
116.45, 115.75,






1H), 4.37-4.26 (m,
83.23, 83.21,






2H), 4.05 (dd, J = 11.0,
80.98, 77.38,






1.3 Hz, 1H), 3.97 (dd, J = 12.3,
77.06, 76.74,






8.9 Hz, 1H),
75.31, 73.04,






3.75 (dd, J = 11.0, 7.3 Hz, 1H),
72.47, 57.92,






2.27 (s, 3H), 2.23 (s, 3H),
27.99, 20.52,






1.53 (s, 18H), 1.45 (d, J = 6.3 Hz,
20.46, 18.98






3H)


252


ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 572
7.31-7.22 (m, 2H),
(CDCl3) δ





([M + Na]+)
6.97-6.89 (m, 3H), 5.33-5.23 (m,
168.93, 157.56,






1H), 4.86 (dq, J = 9.5, 6.3 Hz,
152.57, 129.44,






1H), 4.35 (ddd, J = 7.4,
120.99, 115.70,






4.2, 2.0 Hz, 1H),
84.14, 83.10,






4.28-4.18 (m, 2H),
82.04, 81.39,






3.98-3.87 (m, 2H), 3.69 (dd, J = 11.2,
75.62, 73.09,






6.9 Hz, 1H),
72.91, 57.88,






3.58 (dd, J = 9.6, 8.6 Hz, 1H),
32.96, 32.32,






1.73-1.54 (m, 5H),
27.96, 23.12,






1.51 (s, 20H), 1.48 (d, J = 6.3 Hz,
18.89






3H), 1.46-1.33 (m,






1H)


253


ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 572
7.27-7.19 (m, 2H), 6.98 (m,
(CDCl3) δ





([M + Na]+)
2H), 6.95-6.87 (m, 1H),
169.11, 159.51,






5.27 (dd, J = 9.1, 4.2 Hz,
152.62, 129.10,






1H), 5.01 (dq, J = 9.7, 6.3 Hz,
120.90, 115.92,






1H), 4.40-4.21 (m,
83.09, 82.64,






2H), 4.02 (td, J = 5.1, 2.6 Hz,
81.36, 79.83,






1H), 3.96 (dd, J = 12.2,
75.97, 72.60,






9.2 Hz, 1H),
72.47, 57.80,






3.92-3.86 (m, 1H),
32.97, 31.66,






3.78-3.72 (m, 1H), 3.64 (dd, J = 10.8,
27.95, 23.34,






7.5 Hz, 1H),
23.00, 18.86






3.54-3.45 (m, 1H), 1.85 (m,






1H), 1.52 (s, 18H),






1.47-1.33 (m, 6H),






1.32-1.24 (m, 3H)


254


ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 546
7.30-7.22 (m, 2H),
(CDCl3) δ





([M + Na]+)
6.98-6.89 (m, 3H), 5.29 (dd, J = 8.9,
168.85, 157.62,






3.7 Hz, 1H), 4.91 (dq, J = 9.7,
152.57, 129.45,






6.2 Hz, 1H),
121.06, 115.75,






4.30-4.22 (m, 2H),
84.42, 83.12,






3.99-3.88 (m, 2H), 3.82 (dt, J = 8.8,
81.31, 75.60,






6.6 Hz, 1H), 3.66 (dd, J = 11.0,
75.54, 73.00,






7.2 Hz, 1H), 3.52 (dt,
72.65, 57.92,






J = 8.7, 6.7 Hz, 1H),
27.97, 23.41,






3.44 (dd, J = 9.7, 8.7 Hz, 1H),
18.76, 10.59






1.52 (s, 18H),






1.50-1.43 (m, 5H), 0.81 (t, J = 7.4 Hz,






3H)


255


ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 546
7.29-7.20 (m, 2H),
(CDCl3) δ





([M + Na]+)
7.03-6.98 (m, 2H), 6.93 (tt, J = 7.3,
169.07, 159.54,






1.0 Hz, 1H), 5.27 (dd, J = 9.0,
152.64, 129.20,






4.2 Hz, 1H), 5.02 (dq,
121.09, 116.13,






J = 9.6, 6.3 Hz, 1H),
83.25, 83.09,






4.34-4.24 (m, 2H),
82.29, 75.59,






4.02-3.88 (m, 2H), 3.65 (dd, J = 10.9,
73.01, 72.72,






7.4 Hz, 1H),
72.40, 57.84,






3.52-3.40 (m, 2H), 3.36 (dt, J = 9.0,
27.95, 22.99,






6.6 Hz, 1H), 1.52 (s,
18.81, 10.33






18H), 1.38 (d, J = 6.3 Hz,






3H), 1.36-1.24 (m, 2H),






0.67 (t, J = 7.4 Hz, 3H)


256


ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 534
6.96-6.84 (m, 2H),
(CDCl3) δ





([M + Na]+)
6.84-6.76 (m, 2H), 5.31 (dd, J = 8.7,
168.43, 154.66,






2.5 Hz, 1H), 5.02 (dq, J = 9.1,
152.58, 150.61,






6.3 Hz, 1H), 4.26 (dd,
117.16, 114.80,






J = 12.5, 2.5 Hz, 1H),
83.11, 81.43,






4.15-4.03 (m, 2H), 3.91 (dd, J = 12.6,
76.35, 75.78,






8.7 Hz, 1H),
74.15, 73.33,






3.81-3.69 (m, 4H), 3.55 (dd, J = 10.8,
58.40, 55.67,






7.6 Hz, 1H), 3.10 (d,
27.97, 18.72






J = 2.0 Hz, 1H), 1.52 (s,






21H)


257


ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 534
6.98-6.91 (m, 2H),
(CDCl3) δ





([M + H]+)
6.85-6.78 (m, 2H), 5.24 (dd, J = 8.5,
168.70, 154.68,






4.0 Hz, 1H), 5.05 (dq, J = 8.8,
153.06, 152.59,






6.3 Hz, 1H), 4.30 (dd,
117.42, 114.76,






J = 12.2, 4.0 Hz, 1H),
85.73, 83.10,






4.16-4.06 (m, 2H), 3.98 (dd, J = 12.2,
77.55, 73.86,






8.5 Hz, 1H),
73.83, 72.19,






3.84 (dddd, J = 8.6, 7.4, 3.1, 1.3 Hz,
58.21, 55.64,






1H), 3.76 (s, 3H),
27.94, 19.02






3.66 (dd, J = 11.0, 7.4 Hz, 1H),






2.61 (d, J = 3.1 Hz, 1H),






1.51 (s, 18H), 1.34 (d, J = 6.4 Hz,






3H)


258


ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 640
6.97-6.91 (m, 2H),
(CDCl3) δ





([M + Na]+)
6.81-6.76 (m, 2H), 6.73 (s, 4H),
168.87, 154.27,






5.32 (dd, J = 8.9, 3.8 Hz, 1H),
154.25, 153.80,






5.11 (dq, J = 9.3, 6.3 Hz,
152.59, 151.65,






1H), 4.38-4.22 (m, 3H),
117.63, 117.10,






4.08-4.02 (m, 1H),
114.54, 114.34,






3.97 (dd, J = 12.3, 9.0 Hz, 1H),
84.06, 83.20,






3.78-3.74 (m, 4H),
81.88, 75.20,






3.72 (s, 3H), 1.53 (s, 18H),
72.96, 72.42,






1.47 (d, J = 6.3 Hz, 3H)
57.87, 55.65,







27.98, 19.02.


259


ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 572
7.59-7.52 (m, 2H), 7.03 (d, J = 8.6 Hz,
(CDCl3) δ





([M + Na]+)
2H),
168.30, 159.10,






5.39-5.28 (m, 1H), 5.06 (dq, J = 8.9,
152.61, 127.21,






6.3 Hz, 1H),
127.18, 127.14,






4.34-4.21 (m, 2H), 4.06 (dd, J = 11.2,
127.10, 125.55,






1.3 Hz, 1H),
124.15, 123.82,






3.94 (dd, J = 12.7, 8.5 Hz, 1H),
122.86, 115.66,






3.80 (t, J = 8.7 Hz, 1H),
83.27, 80.62,






3.64 (dd, J = 11.2, 7.4 Hz,
76.11, 75.90,






1H), 2.87 (s, 1H), 1.53 (s,
74.35, 73.36,






21H)
58.38, 27.99,







27.95, 18.69


260


ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 572
7.59-7.52 (m, 2H),
(CDCl3) δ





([M + Na]+)
7.13-7.06 (m, 2H), 5.26 (dd, J = 8.5,
168.72, 161.29,






4.1 Hz, 1H), 5.09 (dq, J = 8.7,
152.63, 127.25,






6.4 Hz, 1H),
127.21, 127.17,






4.37-4.29 (m, 2H), 4.09 (dd, J = 12.1,
127.13, 116.13,






1.5 Hz, 1H),
84.48, 83.24,






4.00 (dd, J = 12.2, 8.6 Hz, 1H),
77.25, 73.80,






3.91 (ddd, J = 8.5, 7.3, 1.4 Hz,
73.68, 71.79,






1H), 3.72 (dd, J = 11.1,
58.08, 27.95,






7.3 Hz, 1H),
18.90, −0.01






2.33 (bs, 1H), 1.52 (s, 18H),






1.35 (d, J = 6.4 Hz, 3H)


261


ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 426
6.78 (s, 4H), 5.33 (dd, J = 8.9,
(CDCl3) δ





([M − C4H9 + 2H]+)
3.1 Hz, 1H), 5.24 (dd, J = 9.9,
175.92, 168.72,






9.1 Hz, 1H), 5.08 (dq,
154.18, 152.56,






J = 9.9, 6.2 Hz, 1H),
151.32, 116.51,






4.30 (dd, J = 12.3, 3.1 Hz, 1H),
114.63, 83.20,






4.18 (ddd, J = 9.1, 7.8, 1.3 Hz,
79.10, 75.91,






1H), 4.09 (dd, J = 11.1,
75.13, 73.63,






1.3 Hz, 1H),
71.19, 58.19,






3.96 (dd, J = 12.4, 8.9 Hz, 1H),
55.68, 34.04,






3.75 (s, 3H), 3.68 (dd, J = 11.0,
27.98, 18.91,






7.8 Hz, 1H), 2.44 (p,
18.87, 18.27






J = 7.0 Hz, 1H), 1.53 (s,






18H), 1.36 (d, J = 6.2 Hz,






3H), 1.09 (d, J = 7.0 Hz,






3H), 1.05 (d, J = 7.0 Hz,






3H)


262


ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 526
6.90-6.83 (m, 2H),
(CDCl3) δ





([M − C4H9 + 2H]+)
6.82-6.76 (m, 2H), 5.29 (dd, J = 8.8,
175.52, 168.89,






4.4 Hz, 1H),
154.21, 153.01,






5.14-5.01 (m, 2H), 4.38 (t, J = 9.2 Hz,
152.51, 116.57,






1H), 4.28 (dd, J = 12.1,
114.50, 83.29,






4.4 Hz, 1H),
81.55, 75.11,






3.97 (dd, J = 12.2, 8.9 Hz, 1H),
72.50, 57.59,






3.85-3.77 (m, 2H),
55.69, 33.78,






3.76 (s, 3H), 2.20 (hept, J = 7.0 Hz,
27.95, 18.78,






1H), 1.52 (s, 18H),
18.73, 18.44






1.41 (d, J = 6.3 Hz, 3H),






0.94 (d, J = 7.0 Hz, 3H),






0.86 (d, J = 7.0 Hz, 3H)


263


ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 636
6.60 (m, 3H), 6.55 (m, 1H),
(CDCl3) δ





([M + Na]+)
6.40-6.31 (m, 2H),
168.88, 159.63,






5.35 (dd, J = 9.1, 3.7 Hz, 1H),
157.44, 152.57,






5.11 (dq, J = 9.4, 6.3 Hz,
139.04, 138.85,






1H), 4.44 (t, J = 9.1 Hz,
123.26, 122.97,






1H), 4.38-4.27 (m, 2H),
114.52, 113.46,






4.04 (dd, J = 11.0, 1.3 Hz,
83.23, 82.83,






1H), 3.97 (dd, J = 12.3,
80.46, 75.29,






9.1 Hz, 1H), 3.75 (dd, J = 11.0,
73.05, 72.49,






7.3 Hz, 1H), 2.26 (s,
57.90, 28.01,






6H), 2.20 (s, 6H), 1.54 (s,
21.42, 21.36,






18H), 1.46 (d, J = 6.3 Hz,
19.00






3H)


264


ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 614
7.55-7.48 (m, 2H),
(CDCl3) δ





([M + Na]+)
7.03-6.97 (m, 2H), 5.29 (dd, J = 8.7,
168.66, 160.10,






3.4 Hz, 1H), 4.93 (dq, J = 9.6,
152.60, 128.48,






6.2 Hz, 1H),
126.91, 126.87,






4.37-4.25 (m, 2H),
115.50, 84.34,






4.00-3.88 (m, 2H), 3.76 (dt, J = 8.7,
83.19, 81.40,






6.5 Hz, 1H), 3.68 (dd, J = 11.2,
75.99, 75.62,






7.2 Hz, 1H),
73.37, 72.58,






3.57-3.40 (m, 2H), 1.52 (s,
57.99, 27.97,






18H), 1.48 (d, J = 6.2 Hz,
23.36, 18.72,






3H), 1.48-1.39 (m, 2H),
10.55






0.80 (t, J = 7.4 Hz, 3H)


265


ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 614
7.54-7.47 (m, 2H), 7.07 (dd, J = 8.8,
(CDCl3) δ





([M + Na]+)
0.9 Hz, 2H), 5.28 (dd,
168.98, 161.92,






J = 9.1, 4.1 Hz, 1H),
152.65, 126.68,






5.04 (dq, J = 9.6, 6.2 Hz, 1H),
126.64, 115.98,






4.36-4.28 (m, 2H),
83.23, 83.18,






4.03-3.90 (m, 2H) 3.64 (dd, J = 11.0,
82.15, 75.40,






7.6 Hz, 1H),
72.87, 72.81,






3.52-3.40 (m, 2H), 3.29 (dt, J = 9.0,
71.95, 57.83,






6.6 Hz, 1H), 1.52 (s,
27.95, 22.93,






18H), 1.36 (d, J = 6.3 Hz,
18.75, 10.27






3H), 1.28 (td, J = 7.6, 6.7 Hz,






2H), 0.64 (t, J = 7.4 Hz,






3H)


266


ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 550
7.58-7.45 (m, 2H), 7.06 (dd, J = 8.8,
(CDCl3) δ





([M − C4H9 + 2H]+)
0.9 Hz, 2H), 5.29 (dd,
168.93, 161.87,






J = 9.0, 4.0 Hz, 1H),
152.64, 142.04,






5.05 (dq, J = 9.6, 6.3 Hz, 1H),
128.41, 128.39,






4.38-4.25 (m, 2H),
126.70, 126.66,






4.03-3.92 (m, 2H), 3.64 (dd, J = 11.0,
126.62, 126.59,






7.5 Hz, 1H),
125.83, 115.92,






3.43 (ddd, J = 8.8, 7.5, 1.5 Hz,
83.17, 83.02,






1H), 3.28 (dd, J = 8.9, 6.3 Hz,
82.36, 77.89,






1H), 3.11 (dd, J = 8.9,
75.37, 72.90,






6.4 Hz, 1H),
71.97, 57.88,






1.57-1.47 (m, 19H), 1.36 (d, J = 6.2 Hz,
39.24, 32.05,






3H), 0.66 (d, J = 6.7 Hz,
28.56, 27.95,






3H), 0.60 (d, J = 6.7 Hz,
19.10, 18.97,






3H)
18.75


267


ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 538
7.20 (t, J = 8.2 Hz, 1H), 7.03 (t,
(CDCl3) δ





([M + Na]+)
J = 2.2 Hz, 1H), 6.97 (ddd,
168.72, 159.69,






J = 8.0, 1.9, 0.9 Hz, 1H),
152.58, 135.01,






6.90 (ddd, J = 8.4, 2.6, 0.9 Hz,
130.46, 122.20,






1H), 5.25 (dd, J = 8.5,
116.82, 114.51,






4.1 Hz, 1H), 5.04 (dq, J = 8.9,
84.76, 83.17,






6.4 Hz, 1H), 4.30 (dd,
73.73, 73.61,






J = 12.2, 4.1 Hz, 1H),
71.89, 58.07,






4.22 (t, J = 8.7 Hz, 1H),
27.98, 27.92,






4.06 (dd, J = 11.1, 1.5 Hz, 1H),
18.88






3.98 (dd, J = 12.2, 8.6 Hz,






1H), 3.85 (ddd, J = 8.6,






7.4, 1.4 Hz, 1H), 3.68 (dd,






J = 11.1, 7.4 Hz, 1H),






2.77 (bs, 1H), 1.51 (s, 18H),






1.34 (d, J = 6.5 Hz, 3H)


268


ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 538
7.19 (t, J = 8.1 Hz, 1H),
(CDCl3) δ





([M + Na]+)
7.00-6.93 (m, 2H), 6.84 (ddd, J = 8.5,
168.34, 157.39,






2.5, 0.9 Hz, 1H),
152.55, 135.12,






5.33 (dd, J = 8.7, 2.4 Hz,
130.50, 122.07,






1H), 5.04 (dq, J = 9.0, 6.3 Hz,
116.31, 114.05,






1H), 4.27 (dd, J = 12.6,
83.25, 80.82,






2.4 Hz, 1H),
76.14, 75.77,






4.20-4.09 (m, 1H), 4.06 (dd, J = 11.0,
74.27, 73.27,






1.3 Hz, 1H),
58.33, 28.00,






3.93 (dd, J = 12.6, 8.7 Hz, 1H),
27.95, 18.70






3.77 (t, J = 8.8 Hz, 1H),






3.60 (dd, J = 11.1, 7.6 Hz,






1H), 1.57-1.49 (m, 21H)


269


ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 594
7.15 (t, J = 8.1 Hz, 1H), 7.03 (t,
(CDCl3) δ





([M + Na]+)
J = 2.2 Hz, 1H),
168.93, 160.20,






6.89 (dddd, J = 12.5, 8.4, 2.2,
152.61, 134.53,






0.9 Hz, 2H), 5.28 (dd, J = 9.0,
129.92, 121.25,






4.0 Hz, 1H), 5.02 (dq,
116.63, 114.44,






J = 9.5, 6.3 Hz, 1H),
83.39, 83.10,






4.31 (dd, J = 12.1, 4.0 Hz, 1H),
82.39, 77.88,






4.23 (dd, J = 9.6, 8.7 Hz,
75.38, 72.87,






1H), 3.96 (dd, J = 11.9,
72.05, 57.88,






9.4 Hz, 2H), 3.63 (dd, J = 11.0,
28.61, 27.94,






7.5 Hz, 1H),
19.15, 19.04,






3.40 (ddd, J = 8.9, 7.5, 1.5 Hz,
18.76






1H), 3.29 (dd, J = 8.8, 6.4 Hz,






1H), 3.14 (dd, J = 8.8,






6.3 Hz, 1H),






1.61-1.55 (m, 1H), 1.52 (s, 18H),






1.36 (d, J = 6.3 Hz, 3H),






0.69 (d, J = 6.7 Hz, 3H),






0.65 (d, J = 6.7 Hz, 3H)


270


ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 502
7.39-7.30 (m, 5H), 5.51 (d, J = 8.0 Hz,
(CDCl3) δ





([M + Na]+)
1H), 5.10 (s, 2H),
170.96, 155.67,






4.89 (dd, J = 9.0, 6.0 Hz,
136.08, 128.53,






1H), 4.69 (q, J = 6.5 Hz,
128.47, 128.21,






1H), 3.99-3.90 (m, 1H),
128.07, 85.03,






3.86 (q, J = 7.9 Hz, 1H),
83.64, 75.37,






3.78 (d, J = 11.2 Hz, 1H),
74.53, 73.00,






3.74-3.66 (m, 1H),
72.44, 69.29,






3.66-3.45 (m, 4H),
67.09, 54.05,






3.18-3.10 (m, 2H),
39.22, 38.93,






1.77-1.59 (m, 2H), 1.45-1.39 (m,
24.94, 22.89,






7H), 0.89 (ddd, J = 6.4,
22.65, 22.60,






3.7, 2.4 Hz, 12H)
22.49, 18.56


271

(Thin
ESIMS

1H NMR (CDCl3) δ






Film)
m/z 390.2
7.69-6.69 (m, 5H), 5.39 (t, J = 8.0 Hz,




3387,
([M + H]+)
1H),




2932,

5.18-5.06 (m, 1H), 4.11 (d, J = 8.0 Hz,




1753,

2H), 3.94-3.48 (m,




1587,

7H), 2.26-1.94 (m, 4H),




1493,

1.80-1.37 (m, 9H)




1230


272

(Thin
HRMS-ESI (m/z)

1H NMR (CD3OD) δ


13C NMR





Film)
[M + H]+
5.06-4.93 (m, 1H), 4.45 (t, J = 4.1 Hz,
(CD3OD) δ




2955,
calcd for
1H), 4.05 (d, J = 4.1 Hz,
167.82, 84.87,




2928,
C18H36NO5,
2H), 3.99 (dd, J = 11.8,
83.77, 78.27,




2870,
346.2588;
1.1 Hz, 1H),
73.16, 72.01,




2185,
found,
3.94-3.86 (m, 1H),
71.93, 68.68,




1753,
346.2604;
3.72-3.37 (m, 6H), 3.31 (p, J = 1.7 Hz,
53.80, 38.99,




1214,

1H), 3.22 (t, J = 9.1 Hz,
38.75, 24.78,




1103

1H), 3.12 (ddd, J = 9.0,
24.68, 21.90,






6.6, 1.1 Hz 1H),
21.68, 21.52,






1.75-1.63 (m, 2H), 1.45 (dd, J = 6.6,
17.47






3.4 Hz, 6H),






0.91 (ddd, J = 6.7, 4.4, 2.2 Hz,






12H)


273
181-185

ESIMS

1H NMR (CDCl3) δ


13C NMR






m/z 314
8.47 (s, 3H), 4.78-4.64 (m,
(CDCl3) δ





([M]+)
1H), 4.38 (s, 1H), 4.06 (d,
168.53, 84.43,






J = 11.8 Hz, 1H), 3.87 (s,
82.98, 78.67,






1H), 3.66 (d, J = 12.0 Hz,
75.75, 73.74,






1H), 3.56 (dd, J = 9.9, 6.7 Hz,
70.74, 67.05,






1H), 3.37-3.26 (m,
53.24, 18.49,






1H), 3.19 (pd, J = 8.6, 7.0,
11.05, 10.92,






5.2 Hz, 3H),
3.24, 3.13, 2.95,






3.10-2.94 (m, 2H), 1.26 (d, J = 6.1 Hz,
2.80






3H), 0.84 (dqd, J = 14.7,






7.9, 2.4 Hz, 2H),






0.42-0.24 (m, 4H),






0.09-−0.06 (m, 4H)


274


ESIMS

1H NMR (CD3OD) δ







m/z 394
6.99 (s, 2H), 6.97 (d, J = 1.1 Hz,





([M + H]+)
2H), 6.96-6.89 (m,






2H), 6.73-6.65 (m, 2H),






5.41 (dq, J = 9.2, 6.3 Hz,






1H), 4.62 (t, J = 9.2 Hz,






1H), 4.53 (dd, J = 4.5, 2.9 Hz,






1H), 4.23 (dd, J = 9.2,






6.4 Hz, 1H),






4.19-4.08 (m, 3H), 3.90 (dd, J = 12.3,






6.6 Hz, 1H), 1.50 (d,






J = 6.4 Hz, 3H)


275
197-200

ESIMS

1H NMR (CD3OD) δ







m/z 356
7.04-6.96 (m, 2H),





([M + H]+)
6.93-6.87 (m, 2H), 5.17 (dq, J = 9.3,






6.3 Hz, 1H), 4.46 (t, J = 3.7 Hz,






1H),






4.12-4.02 (m, 4H), 3.78-3.67 (m,






2H), 3.52 (t, J = 9.3 Hz,






1H), 3.35 (dd, J = 8.5, 6.4 Hz,






1H), 1.70 (m, 1H),






1.52 (d, J = 6.3 Hz, 3H),






0.83 (dd, J = 13.8, 6.7 Hz,






6H)


276
213-216

ESIMS

1H NMR (CD3OD) δ







m/z 386
7.10-7.02 (m, 2H),





([M + H]+)
7.01-6.96 (m, 2H),






6.91-6.85 (m, 2H), 6.62-6.56 (m,






2H), 5.39 (dq, J = 9.2, 6.3 Hz,






1H), 4.58 (t, J = 9.2 Hz,






1H), 4.52 (dd, J = 4.9,






2.7 Hz, 1H),






4.26-4.18 (m, 1H), 4.18-4.08 (m,






3H), 3.87 (dd, J = 12.1,






6.6 Hz, 1H), 2.26 (s, 3H),






2.21 (s, 3H), 1.49 (d, J = 6.4 Hz,






3H)


277
217-219

ESIMS

1H NMR (CD3OD) δ







m/z 350
7.35-7.17 (m, 2H),





([M + H]+)
7.03-6.84 (m, 3H), 5.09 (dq, J = 9.1,






6.3 Hz, 1H), 4.40 (dq,






J = 5.4, 3.2, 2.5 Hz, 2H),






4.21-3.96 (m, 4H),






3.76 (dd, J = 12.1, 6.2 Hz, 1H),






3.67 (t, J = 9.1 Hz, 1H),






1.76-1.67 (m, 2H),






1.66-1.56 (m, 4H), 1.52 (m,






4H), 1.50-1.43 (m, 1H)


278


ESIMS

1H NMR (CD3OD) δ







m/z 350
7.27-7.19 (m, 2H),





([M + H]+)
7.01-6.96 (m, 2H), 6.91 (tt, J = 7.3,






1.0 Hz, 1H), 5.23 (dq,






J = 9.3, 6.3 Hz, 1H),






4.46 (dd, J = 5.9, 2.9 Hz, 1H),






4.36 (t, J = 9.1 Hz, 1H),






4.14-3.97 (m, 4H),






3.71 (dd, J = 11.7, 7.3 Hz, 1H),






3.40 (ddd, J = 8.7, 7.3, 1.3 Hz,






1H), 1.53 (tt, J = 9.0,






4.6 Hz, 2H),






1.45-1.27 (m, 9H)


279
217-219

ESIMS

1H NMR (CD3OD) δ







m/z 324
7.30-7.22 (m, 2H),





([M + H]+)
6.98-6.88 (m, 3H), 5.14 (dq, J = 9.3,






6.3 Hz, 1H), 4.43 (dd,






J = 5.0, 2.8 Hz, 1H),






4.19-4.11 (m, 1H),






4.10-4.00 (m, 3H), 3.89 (dt, J = 8.8,






6.5 Hz, 1H), 3.74 (dd,






J = 12.1, 6.6 Hz, 1H),






3.62-3.50 (m, 2H), 1.52 (d, J = 6.3 Hz,






3H),






1.50-1.42 (m, 2H), 0.84 (t, J = 7.4 Hz,






3H)


280


ESIMS

1H NMR (CD3OD) δ







m/z 324
7.29-7.19 (m, 2H),





([M + H]+)
7.05-6.97 (m, 2H), 6.92 (tt, J = 7.5,






1.0 Hz, 1H), 5.25 (dq,






J = 9.2, 6.4 Hz, 1H),






4.46 (dd, J = 5.7, 2.8 Hz, 1H),






4.40 (t, J = 9.1 Hz, 1H),






4.15-3.99 (m, 3H),






3.72 (dd, J = 11.8, 7.1 Hz, 1H),






3.52-3.42 (m, 1H),






3.40-3.32 (m, 2H), 1.41 (d, J = 6.4 Hz,






3H),






1.34-1.23 (m, 2H), 0.66 (t, J = 7.4 Hz,






3H)


281


ESIMS

1H NMR (CD3OD) δ







m/z 418
7.01-6.88 (m, 2H),





([M + H]+)
6.86-6.71 (m, 4H),






6.71-6.61 (m, 2H), 5.43-5.31 (m,






1H), 4.57-4.43 (m, 2H),






4.22-4.06 (m, 4H),






3.85 (dd, J = 12.3, 6.8 Hz, 1H),






3.74 (d, J = 2.0 Hz, 3H),






3.70 (s, 3H), 1.50 (d, J = 6.3 Hz,






3H)


282
197-198

ESIMS

1H NMR (CD3OD) δ







m/z 382
6.85-6.75 (m, 4H), 5.36 (dq, J = 9.6,





([M + H]+)
6.3 Hz, 1H), 5.22 (t,






J = 9.5 Hz, 1H), 4.53 (dd,






J = 5.3, 2.5 Hz, 1H),






4.20-4.02 (m, 4H), 3.79 (dd, J = 12.2,






6.9 Hz, 1H),






3.73 (s, 3H), 2.47 (m, 1H),






1.40 (d, J = 6.3 Hz, 3H),






1.10 (d, J = 7.0 Hz, 3H),






1.05 (d, J = 7.0 Hz, 3H)


283
207-208

ESIMS

1H NMR (CD3OD) δ







m/z 383
6.93-6.88 (m, 2H),





([M + H]+)
6.86-6.80 (m, 2H), 5.32 (dq,






J = 9.2, 6.3 Hz, 1H),






4.97-4.89 (m, 1H),






4.60-4.47 (m, 2H),






4.13-4.09 (m, 2H), 3.99 (dd, J = 12.2,






1.3 Hz, 1H),






3.90 (dd, J = 12.2, 6.9 Hz,






1H), 3.73 (s, 3H),






2.16 (hept, J = 7.0 Hz, 1H),






1.43 (d, J = 6.3 Hz, 3H),






0.91 (d, J = 7.0 Hz, 3H),






0.82 (d, J = 6.9 Hz, 3H)


284
212

ESIMS

1H NMR (CD3OD) δ







m/z 414
6.66-6.52 (m, 4H),





([M + H]+)
6.28-6.24 (m, 2H), 5.37 (dq, J = 9.1,






6.3 Hz, 1H), 4.61 (t, J = 9.2 Hz,






1H), 4.54 (dd, J = 4.7,






3.0 Hz, 1H),






4.22 (dd, J = 9.1, 6.7 Hz, 1H),






4.18-4.10 (m, 3H),






3.86 (dd, J = 12.1, 6.8 Hz, 1H),






2.25 (d, J = 0.8 Hz, 6H),






2.18 (d, J = 0.8 Hz, 6H),






1.49 (d, J = 6.3 Hz, 3H)


285


ESIMS

1H NMR (CD3OD) δ


13C NMR






m/z 392
7.62-7.55 (m, 2H),
(CD3OD) δ





([M + H]+)
7.11-7.03 (m, 2H), 5.19 (dq, J = 9.3,
169.17, 161.65,






6.3 Hz, 1H), 4.52 (dd,
129.46, 129.44,






J = 4.7, 2.5 Hz, 1H),
128.06, 128.02,






4.24 (dd, J = 9.2, 6.1 Hz, 1H),
127.98, 116.66,






4.18-4.04 (m, 2H),
85.58, 82.73,






3.82 (ddt, J = 12.3, 11.2, 6.4 Hz,
79.75, 76.72,






2H), 3.76-3.70 (m,
74.36, 73.98,






1H), 3.63-3.52 (m, 2H),
68.88, 68.15,






3.31 (p, J = 1.6 Hz, 2H),
55.54, 54.83,






1.53 (d, J = 6.3 Hz, 3H),
26.51, 24.43,






1.51-1.38 (m, 2H),
18.78, 10.96






0.82 (t, J = 7.4 Hz, 3H)


286


ESIMS

1H NMR (CD3OD) δ


13C NMR






m/z 392
7.58-7.51 (m, 2H),
(CD3OD) δ





([M + H]+)
7.20-7.13 (m, 2H), 5.29 (dq, J = 9.2,
169.26, 163.46,






6.3 Hz, 1H),
127.70, 127.66,






4.61-4.49 (m, 2H),
127.63, 117.26,






4.14-4.05 (m, 3H), 3.79-3.71 (m,
83.95, 83.64,






1H), 3.47 (dt, J = 8.9, 6.3 Hz,
78.96, 73.92,






1H), 3.41-3.24 (m,
73.81, 73.36,






4H), 1.42 (d, J = 6.3 Hz,
68.15, 55.24,






3H), 1.31-1.18 (m, 2H),
54.83, 24.03,






0.61 (t, J = 7.4 Hz, 3H)
18.79, 10.74


287


ESIMS

1H NMR (CD3OD) δ


13C NMR






m/z 406
7.57-7.51 (m, 2H), 7.15 (d, J = 8.6 Hz,
(CD3OD) δ





([M + H]+)
2H), 5.30 (dq, J = 9.2,
169.24, 163.41,






6.3 Hz, 1H), 4.58 (t,
129.46, 129.35,






J = 9.2 Hz, 1H), 4.52 (t, J = 4.0 Hz,
127.66, 127.63,






1H),
127.59, 126.71,






4.16-4.05 (m, 2H), 3.81-3.70 (m,
117.20, 84.21,






1H), 3.38-3.24 (m, 3H),
83.40, 78.91,






3.11 (dd, J = 8.8, 6.2 Hz,
78.84, 73.93,






1H), 1.52-1.40 (m, 4H),
73.44, 55.30,






0.63 (d, J = 6.7 Hz, 3H),
54.84, 40.49,






0.59 (d, J = 6.7 Hz, 3H)
29.82, 19.49,







19.37, 18.78


288
168-169

ESIMS

1H NMR (CD3OD) δ







m/z 372
7.21 (dd, J = 8.5, 7.9 Hz, 1H),





([M + H]+)
7.05 (t, J = 2.2 Hz, 1H),






6.97-6.89 (m, 2H),






5.26 (dq, J = 9.2, 6.3 Hz, 1H),






4.48 (dd, J = 5.2, 2.9 Hz,






1H), 4.43 (t, J = 9.2 Hz,






1H), 4.15-4.02 (m, 3H),






3.73 (dd, J = 12.0, 7.0 Hz,






1H), 3.34-3.27 (m, 2H),






3.14 (dd, J = 8.8, 6.1 Hz,






1H), 1.50 (hept, 6.6 Hz,






1H), 1.41 (d, J = 6.4 Hz,






3H), 0.67 (d, J = 6.7 Hz,






3H), 0.64 (d, J = 6.7 Hz,






3H)





*1H NMR were run at 400 MHz unless noted otherwise


*13C NMR were run at 101 MHz unless noted otherwise













TABLE 3







Biological Testing Rating Scale


Rating Table for Fungal Pathogens










% Control
Rating







80-100
A



More than 0-Less than 80
B



Not Tested
C



No activity noticed in this bioassay
D

















TABLE 4







Biological Activity - Disease Control at 100 ppm











Compound
PUCCRT*

SEPTTR*












Number
1DP*
3DC*
1DP
3DC














1
A
A
A
A


2
A
A
A
A


3
A
A
A
A


4
A
C
A
A


5
B
B
B
B


6
A
C
B
B


7
A
C
A
A


8
B
A
B
B


9
B
B
B
B


10
B
B
B
B


11
A
A
A
B


12
A
A
A
A


13
A
A
A
C


14
A
B
B
C


15
D
B
B
C


16
B
B
B
C


17
B
B
B
C


18
B
B
B
C


19
D
D
B
B


20
D
D
B
B


21
A
A
A
B


22
D
D
B
B


23
A
A
A
A


24
B
B
B
B


25
A
B
A
B


26
A
A
A
B


27
B
B
B
B


28
A
A
A
A


29
B
B
B
B


30
B
B
B
B


31
B
B
B
B


32
A
A
A
B


33
A
A
A
B


34
A
A
A
A


35
A
A
A
A


36
A
A
B
B


37
A
A
B
B


38
A
B
B
B


40
A
B
B
B


41
B
D
B
B


42
A
A
B
B


43
A
A
A
B


44
A
A
A
A


45
A
A
A
A


46
A
A
A
A


47
A
A
A
A


48
A
A
A
A


49
B
B
B
B


50
A
A
A
A


51
B
B
B
B


52
D
A
B
B


53
A
A
B
B


54
A
A
B
B


55
A
A
A
A


56
A
A
B
A


57
A
A
A
A


58
A
A
B
B


59
A
A
A
B


60
A
A
A
B


61
A
A
A
A


62
C
A
C
A


63
C
D
C
B


64
A
A
A
A


65
C
B
C
B


66
A
A
A
B


67
A
B
B
B


68
A
A
A
A


69
A
A
A
A


70
B
B
B
B


71
A
B
A
B


72
B
B
B
B


73
A
A
A
A


74
B
B
B
B


75
A
A
A
B


76
A
A
A
A


77
A
A
A
A


78
A
A
A
A


79
A
A
A
A


81
A
A
A
A


82
A
A
A
B


83
A
A
A
A


84
A
A
A
A


85
A
A
A
A


86
A
A
A
A


87
C
C
C
C


194
A
A
C
C


195
A
D
C
C


196
C
C
C
C


197
A
D
C
C


198
B
D
A
D


199
A
D
B
D


200
D
D
B
D


201
A
D
A
B


202
A
A
A
A


203
A
A
A
A


204
A
A
A
A


205
A
A
A
A


206
A
A
A
A


207
A
A
A
A


208
A
D
A
B


209
B
B
D
B


210
C
C
C
C


211
B
C
D
B


212
A
B
A
B


213
C
C
C
C


214
C
C
C
C


215
C
C
C
C


216
C
C
C
C


217
C
C
C
C


218
C
C
C
C


219
A
A
A
B


220
A
A
A
A


221
A
A
A
A


222
A
A
A
A


223
A
A
A
A


224
A
A
A
A


225
A
A
A
A


226
A
A
A
A


227
A
A
A
A


228
A
A
A
A


229
C
C
C
C


230
A
A
A
A


231
C
C
C
C


232
A
A
A
B


233
A
A
A
B


234
A
A
A
A


235
A
A
A
A


236
A
A
A
A


237
A
A
A
A


238
A
A
A
A





*PUCCRT—Wheat Brown Rust (Puccinia triticina)


*SEPTTR—Wheat Leaf Blotch (Septoria tritici)


*1DP—1 Day Protectant


*3DC—3 Day Curative













TABLE 5







Dropline Mobility Test at 1 ug/leaf









Compound
PUCCRT*










Number
1DPM*
3DCM*












1
A
A


2
A
A


3
A
A


11
B
B


12
B
B


26
B
D


34
B
A


58
A
B


59
D
D


60
B
D


61
A
B


62
B
D


63
B
D


64
B
B


65
B
B


66
B
B


67
B
B


68
B
B


69
B
B


70
B
B


72
B
B


73
B
B


74
B
B


75
B
B


76
A
B


77
A
B


78
B
B


81
A
B


82
A
B


83
A
B


84
A
D


85
A
A


86
A
B


87
B
A


210
C
C


221
C
C


234
A
D


235
B
D


236
B
D


237
A
A


238
A
A





*PUCCRT—Wheat Brown Rust (Puccinia triticina)


*1DPM—1 Day Protectant Mobility


*3DCM—3 Day Curative Mobility













TABLE 6







Biological Activity - Disease Control at 100 ppm












Com-







pound.
ALTESO*
CERCBE*
COLLLA*
ERYSCI*
ERYSGH*








Number
1DP*















2
C
B
C
A
A


3
B
A
A
B
A


6
C
C
C
C
C


12
B
A
A
D
B


34
C
C
C
C
C


35
C
C
C
C
C


45
C
C
C
C
C


47
C
C
C
C
C


54
D
B
A
D
B


55
D
A
A
D
D


57
B
A
A
B
B


60
B
A
A
D
D


65
D
B
B
D
D


68
B
A
A
B
B


77
B
A
A
B
B


78
B
B
A
A
B


84
B
A
A
B
B


85
B
A
A
B
B


86
A
A
A
B
B


221
D
A
A
D
C


222
B
A
A
D
C


228
C
B
C
C
B


229
B
A
A
B
B


231
B
B
A
B
B





*ALTESO—Tomato Early Blight (Alternaria solani)


*CERCBE—Leaf Spot of Sugar Beets (Cercospora beticola)


*COLLLA—Cucumber Anthracnose (Glomerella lagenarium; Anamorph: Colletotricum lagenarium)


*ERYSCI—Powdery Mildew of Cucumber (Erysiphe cichoracearum)


*ERYSGH—Barley Powdery Mildew (Blumeria graminis f.sp. hordei; Synonym: Erysiphe graminis f.sp. hordei)


*1DP—1 Day Protectant













TABLE 7







Biological Activity - Disease Control at 100 ppm













Compound.
ERYSGT*
LEPTNO*
PYRIOR*
RHYNSE*
UNCINE*
VENTIN*








Number
1 DP*
















2
C
C
C
C
C
C


3
A
A
A
C
A
B


6
C
C
C
C
B
B


12
B
A
A
C
B
B


34
C
C
C
C
A
A


35
C
C
C
C
B
B


45
C
C
C
C
A
B


47
C
C
A
C
B
A


54
B
A
B
C
B
D


55
B
A
A
C
B
C


57
B
B
A
C
B
C


60
B
A
A
C
D
B


65
D
B
D
C
B
D


68
B
A
A
C
B
B


77
B
A
A
C
A
B


78
A
A
A
C
A
A


84
B
A
A
A
B
B


85
B
A
A
C
A
B


86
A
A
A
C
A
B


221
C
C
A
A
C
C


222
C
C
A
A
C
C


228
C
A
C
C
C
C


229
C
A
A
A
A
D


231
C
A
A
A
A
B





*ERYSGT—Wheat Powdery Mildew (Blumeria graminis f. sp. tritici; Synonym: Erysiphe graminis f. sp. tritici)


*LEPTNO—Wheat Glume Blotch (Leptosphaeria nodorum)


*PYRIOR—Rice Blast (Magnaporthe grisea; Anamorph: Pyricularia oryzae)


*RHYNSE—Barley Scald (Rhyncosporium secalis)


*UNCINE—Grape Powdery Mildew (Uncinula necator)


*VENTIN—Apple Scab (Venturia inaequalis)


*1 DP—1 Day Protectant













TABLE 8







Biological Activity - Disease Control at 25 ppm









Compound
PHAKPA*










Number
1DP*
3DC*












3
A
C


77
B
C


78
A
C


84
A
A


86
A
A


222
A
A


221
A
A





*PHAKPA—Asian Soybean Rust (Phakopsora pachyrhizi)


*1DP—1 Day Protectant


*3DC—3 Day Curative





Claims
  • 1. A compound of Formula I:
  • 2. A compound according to claim 1, wherein: wherein, R is H or C(O)R6;R1 is C(O)R6;R2 is independently or separately H, alkyl, alkenyl, aryl, each substituted with 0, 1 or multiple R5;R3 is independently or separately H, methyl;R5 is alkyl, alkoxy, halo, haloalkyl, or aryl; andR6 is alkoxy or benzyloxy.
  • 3. The compound according to claim 1, wherein: wherein, R is H;R1 is Q, wherein Q is,
  • 4. The compound of claim 1, wherein R1 is C(O)R6.
  • 5. The compound of claim 4, wherein R6 is alkoxy.
  • 6. The compound of claim 4, wherein R6 is benzyloxy.
  • 7. The compound of claim 4, wherein R is C(O)R6.
  • 8. The compound of claim 1, wherein the compound is:
  • 9. A compound of Formula I:
  • 10. The compound of claim 1, wherein R1 is Q.
  • 11. The compound of claim 10, where R7 is H.
  • 12. The compound of claim 10, where R7 is —C(O)R4.
  • 13. The compound of claim 10, where R7 is —CH2OC(O)R4.
  • 14. A composition for treating plants, comprising a compound of Formula I:
  • 15. The compositions according to claim 14, wherein the plant pathogen is least one pathogen selected from the group consisting of: Mycosphaerella graminicola, Septoria tritici, Puccinia triticina, Puccinia striiformis, Venturia inaequalis, Ustilago maydis, Uncinula necator, Rhynchosporium secalis, Magnaporthe grisea, Pseudoperonospora cubensis, Phakopsora pachyrhizi, Leptosphaeria nodorum, Blumeria graminis, forma specialis tritici, Blumeria graminis, forma specialis hordei, Erysiphe cichoracearum, Glomerella lagenarium, Cercospora beticola, Alternaria solani, and Pyrenophora teres.
  • 16. The composition according to claim 15, wherein the fungal pathogen is at least one of Septoria tritici, Puccinia triticina, and Phakopsora pachyrhizi.
  • 17. A method for treating a plant, comprising the steps of: applying a agriculturally effective amount of at least one of the compounds of Formula I:
  • 18. The method according to claim 17, wherein the compound is applied in a mixture with at least one additional compound selected from the group consisting of: phytologically acceptable carrier materials, pesticides, fungicides, insecticides, nematocides, miticides, arthropodicides, and bactericides, wherein said compound is effective for the control of a plant pathogen.
  • 19. The method according to claim 17, wherein the plant is infected with or at risk for becoming infected with a fungal pathogen.
  • 20. The method according to claim 18, wherein the plant pathogen is least one pathogen selected from the group consisting of: Mycosphaerella graminicola, Septoria tritici, Puccinia triticina, Puccinia striiformis, Venturia inaequalis, Ustilago maydis, Uncinula necator, Rhynchosporium secalis, Magnaporthe grisea, Pseudoperonospora cubensis, Phakopsora pachyrhizi, Leptosphaeria nodorum, Blumeria graminis, forma specialis tritici, Blumeria graminis, forma specialis hordei, Erysiphe cichoracearum, Glomerella lagenarium, Cercospora beticola, Alternaria solani, and Pyrenophora teres.
CROSS REFERENCE TO RELATED APPLICATIONS

This Application is a continuation application of U.S. patent application Ser. No. 13/888,084, filed May 6, 2010, now U.S. Pat No. 8,785,479, issued Jul. 22, 2014, which claims the benefit of U.S. Provisional Patent Application Ser. No. 61/643,753 filed on May 7, 2012, the disclosures of which are expressly incorporated by reference herein.

US Referenced Citations (12)
Number Name Date Kind
6355660 Ricks et al. Mar 2002 B1
6521622 Ricks et al. Feb 2003 B1
6706740 Ricks et al. Mar 2004 B2
6861390 Meyer et al. Mar 2005 B2
7250389 Sakanaka et al. Jul 2007 B1
8785479 Meyer et al. Jul 2014 B2
20040171838 Meyer et al. Sep 2004 A1
20040186296 Niyaz et al. Sep 2004 A1
20040192924 Meyer et al. Sep 2004 A1
20070060579 Wachendorff-Neumann et al. Mar 2007 A1
20070066629 Blasco et al. Mar 2007 A1
20110082160 Owen et al. Apr 2011 A1
Foreign Referenced Citations (2)
Number Date Country
1 516 874 Mar 2005 EP
WO 2012070015 May 2012 WO
Non-Patent Literature Citations (2)
Entry
International Searching Authority, International Search Report for PCT/US2013/039732, dated Oct. 18, 2013., 3 pages.
Anonymous, Synergistic Fungicidal Compositions of Heterocyclic Aromatic Amides and Triazoles, IP.COM, Electronic Publication, 2004, 1-10.
Related Publications (1)
Number Date Country
20140275171 A1 Sep 2014 US
Provisional Applications (1)
Number Date Country
61643753 May 2012 US
Divisions (1)
Number Date Country
Parent 13888084 May 2013 US
Child 14288933 US